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A B S T R A C T
Background
Treatment of cancer is increasingly more effective but is associated with short and long term side effects. Oral side effects remain a
major source of illness despite the use of a variety of agents to prevent them. One of these side effects is oral mucositis (mouth ulcers).
Objectives
To evaluate the effectiveness of prophylactic agents for oral mucositis in patients with cancer receiving treatment, compared with other
potentially active interventions, placebo or no treatment.
Search methods
Electronic searches of Cochrane Oral Health Group and PaPaS Trials Registers (to 16 February 2011), CENTRAL (The Cochrane
Library 2011, Issue 1), MEDLINE via OVID (1950 to 16 February 2011), EMBASE via OVID (1980 to 16 February 2011), CINAHL
via EBSCO (1980 to 16 February 2011), CANCERLIT via PubMed (1950 to 16 February 2011), OpenSIGLE (1980 to 2005) and
LILACS via the Virtual Health Library (1980 to 16 February 2011) were undertaken. Reference lists from relevant articles were searched
and the authors of eligible trials were contacted to identify trials and obtain additional information.
Selection criteria
Randomised controlled trials of interventions to prevent oral mucositis in patients receiving treatment for cancer.
Data collection and analysis
Information regarding methods, participants, interventions, outcome measures, results and risk of bias were independently extracted,
in duplicate, by two review authors. Authors were contacted for further details where these were unclear. The Cochrane Collaboration
statistical guidelines were followed and risk ratios calculated using random-effects models.
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Main results
A total of 131 studies with 10,514 randomised participants are now included. Overall only 8% of these studies were assessed as being
at low risk of bias. Ten interventions, where there was more than one trial in the meta-analysis, showed some statistically significant
evidence of a benefit (albeit sometimes weak) for either preventing or reducing the severity of mucositis, compared to either a placebo
or no treatment. These ten interventions were: aloe vera, amifostine, cryotherapy, granulocyte-colony stimulating factor (G-CSF),
intravenous glutamine, honey, keratinocyte growth factor, laser, polymixin/tobramycin/amphotericin (PTA) antibiotic pastille/paste
and sucralfate.
Authors’ conclusions
Ten interventions were found to have some benefit with regard to preventing or reducing the severity of mucositis associated with
cancer treatment. The strength of the evidence was variable and implications for practice include consideration that benefits may be
specific for certain cancer types and treatment. There is a need for further well designed, and conducted trials with sufficient numbers
of participants to perform subgroup analyses by type of disease and chemotherapeutic agent.
P L A I N L A N G U A G E S U M M A R Y
Interventions for preventing oral mucositis for patients with cancer receiving treatment
Treatment for cancer (including bone marrow transplant) can cause oral mucositis (severe ulcers in the mouth). This painful condition
can cause difficulties in eating, drinking and swallowing, and may also be associated with infections which may require the patient
to stay longer in hospital. Different strategies are used to try and prevent this condition, and the review of trials found that some of
these are effective. Two interventions, cryotherapy (ice chips) and keratinocyte growth factor (palifermin®) showed some benefit in
preventing mucositis. Sucralfate is effective in reducing the severity of mucositis, and a further seven interventions, aloe vera, amifostine,
intravenous glutamine, granulocyte-colony stimulating factor (G-CSF), honey, laser and antibiotic lozenges containing polymixin/
tobramycin/amphotericin (PTA) showed weaker evidence of benefit. These were evaluated in patients with different types of cancer,
undergoing different types of cancer treatment. Benefits may be restricted to the disease and treatment combinations evaluated.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cryotherapy versus no treatment for preventing oral mucositis for patients with cancer receiving treatment
Patient or population: preventing oral mucositis for patients with cancer receiving treatment
Settings:
Intervention: Cryotherapy versus no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Cryotherapy versus no
treatment
Mucositis (any)
0-4 scale
Follow-up: median 28
days
Low risk population1 RR 0.74
(0.57 to 0.95)
472
(5 studies)
⊕⊕©©
low2,3
600 per 1000 444 per 1000
(342 to 570)
High risk population1
950 per 1000 703 per 1000
(541 to 902)
Mucositis (severe)
0-4 scale
Follow-up: median 28
days
Low risk population4 RR 0.36
(0.17 to 77)
472
(5 studies)
⊕⊕©©
low2,5
300 per 1000 108 per 1000
(51 to 1000)
High risk population4
650 per 1000 234 per 1000
(111 to 1000)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control
groups of the included studies.
2 3 studies at high risk of bias and 2 unclear
3 Substantial heterogeneity Chi squared = 14.77, df=4, P=0.005, I squared =73%,
4 Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the
control groups of the included studies.
5 Substantial heterogeneity Chi squared=14.31, df=4, P=0.006, I squared =72%.
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B A C K G R O U N D
Treatment for malignancies with cytotoxic chemotherapy or ra-
diotherapy or both are becoming increasingly effective but are as-
sociated with short and long term side effects. Among the clini-
cally important acute side effects is the disruption in the function
and integrity of the mouth. The consequences of this include se-
vere ulceration (mucositis) and fungal infection of themouth (oral
candidiasis, thrush). These disease and treatment induced compli-
cations may also produce oral discomfort or pain, poor nutrition,
delays in cancer treatment, increased hospital stays and costs and,
in some patients, life threatening infection (septicaemia).
Oral complications remain a major source of illness despite the
use of a plethora of prophylactic agents, many of which are not
evidence based. Individual cancer centres use different mouth care
regimens to prevent mucositis (Glenny 2004), frequently with
scant evidence of efficacy.Mucositis presents a particular challenge
due to its complex biological nature and the range of interventions
tested have included mucosal surface protectants, anti-inflamma-
tory formulations, antimicrobials, growth factors and a plethora
of other miscellaneous agents. Given the costs to patients and
their clinicians of mucositis-related morbidity it is surprising that
a uniform approach to mucositis prevention, backed by a strong
evidence base, is lacking. There are variations in usage between
cancer centres in terms of the mouth care regimen used. Compli-
ance with recommended use of product is variable and there are
conflicting reports of the effectiveness of prophylactic agents. The
qualitative and quantitative benefits, side effects and costs of oral
therapies are of importance to the cancer teams responsible for the
treatment of patients.
There have been several traditional reviews published and most
of these present a general discussion for both chemotherapy and
radiotherapy induced oral side effects (Andreassen 2003; Chang
2003; De Pauw 1997; Denning 1992; Duncan 2003; Lortholary
1997; Savarese 2003; Stevens 1995; Symonds 1998; Verdi 1993;
White 1993). The conclusions drawn and recommendationsmade
vary from advocating a particular therapy to recommending oral
care procedures that have not been systematically investigated.
Three systematic reviews have focused on the prevention of oral
mucositis in patients with cancer (Kowanko 1998; Stokman 2006;
Sunderland 2001). Kowanko and colleagues concluded that for
most strategies reviewed there was insufficient evidence to draw
any conclusions regarding their effectiveness (Kowanko 1998).
Sunderland and colleagues focused exclusively on patients with
head and neck cancer. Their main analysis combined all the in-
terventions in one meta-analysis and found a beneficial effect of
prophylactic interventions (Sunderland 2001). The most recent
published review (Stokman 2006) considered eight different in-
terventions and found four which showed a statistically signifi-
cant effect in preventing the development or severity of mucosi-
tis. Since the previous update of this review the most significant
development in this field have been the publication of a review
of evidence and the development of clinical practice guidelines
by the Mucositis Study Section of the Multinational Association
of Supportive Care in Cancer and the International Society for
Oral Oncology (Keefe 2007; Rubenstein 2004; Sonis 2004). The
development of clinical practice guidelines highlights the fact that
preventing and managing mucositis in cancer patients worldwide
is imperative. However, given the large number of clinical trials
identified in this systematic review, it is important that researchers
work co-operatively to maintain up to date systematic reviews,
which can then be used to provide the evidence base for clinical
guidelines, which can be adapted at the local level to take account
of policy and resources.
A previous versionof thisCochrane review looked at the use of pro-
phylactic agents for the prevention of oral mucositis and oral can-
didiasis in patients with cancer treated by chemotherapy (Clarkson
2000). The review concluded that there was some evidence that
using ice chips during the chemotherapy treatment was effective in
preventing mucositis. The review was updated in 2003 (Clarkson
2003a) and this update broadened the oral mucositis part of the
initial review and looked at the prevention of oral mucositis in pa-
tients receiving any treatment for cancer, including patients with
all types of cancer, as well as head and neck cancer, and includ-
ing comparisons between any interventions for prevention. A sec-
ond review update was carried out in 2006 (Worthington 2006)
and reviews on the prevention of oral candidiasis have also been
published inThe Cochrane Library (Clarkson 2007a;Worthington
2004a). The third prevention review update was carried out in
2007 (Worthington 2007).These reviews form part of a series of
Cochrane reviews on the prevention and treatment of oral mucosi-
tis, oral candidiasis (Clarkson 2007b;Worthington 2007a); xeros-
tomia (Tavender 2004) and herpes simplex in patients receiving
cancer therapy (Glenny 2009).
O B J E C T I V E S
To evaluate the effectiveness of interventions (which may include
placebo or no treatment) for the prevention of oral mucositis in
patients with cancer receiving radiotherapy, chemotherapy or tar-
geted therapies.
We also investigated the following secondary outcomes for benefits
or harms provided there were three or more trials or one trial
with more than 100 participants, otherwise we recorded outcomes
reported:
• Oral hygiene measures
• Relief of pain/use of analgesia
• Duration or severity of dysphagia
• Use of parenteral nutrition or feeding tube
• Incidence of systemic infection or use of antibiotics
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• Febrile episodes
• Blood changes
• Treatment interruption
• Days of stay in hospital
• Toxicity (nausea/vomiting/constipation/diarrhoea)
• Toxicity - skin changes
• Toxicity - unspecific
• Xerostomia
• Cost of care
• Patient quality of life
• Death
• Weight loss/gain
• Caloric intake by oral nutrition
• Eating/drinking difficulty
• Overall health
• Recurrence of cancer.
The following subgroup analyses were proposed:
• Cancer type (leukaemia, head and neck, other solid
tumours and mixed)
• Cancer treatment (specific, for example 5-fluorouracil (5-
FU))
• Age group (adults, children or both).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCTs) were eligible for inclu-
sion in this review, including both cross-over and parallel group
studies.
Types of participants
Anyone with cancer who received radiotherapy, chemotherapy or
targeted therapies.
Types of interventions
(This review did not include studies of different cancer treatments
when the primary outcome was survival or cure with mucositis as
a toxicity.)
Active agents: any agent prescribed as prophylaxis for oral mucosi-
tis.
Control: may be placebo or no treatment, or another active inter-
vention.
Types of outcome measures
Primary outcome
• Mucositis (at all levels of severity) (ulcers). Mucositis
measured on a 0 to 4 point scale (none to severe) was used and
this was dichotomised as any mucositis (0 versus 1+), moderate
plus severe mucositis (0 to 1 versus 2+), severe mucositis (0 to 2
versus 3+).
• Trials where mucositis is measured using a scale which
individually grades multiple components of oral health such as
teeth or plaque (Eilers 1988), are excluded. It is acknowledged
that these oral effects are important, but it is not possible to
separate the ’mucositis only’ score, from the total score, so this
review will not include studies which evaluate mucositis using
such component scores.
Secondary outcomes
• Oral hygiene measures
• Relief of pain/use of analgesia
• Duration or severity of dysphagia
• Use of parenteral nutrition or feeding tube
• Incidence of systemic infection or use of antibiotics
• Febrile episodes
• Blood changes
• Treatment interruption
• Days of stay in hospital
• Toxicity (nausea/vomiting/constipation/diarrhoea)
• Toxicity - skin changes
• Toxicity - unspecific
• Xerostomia
• Cost of care
• Patient quality of life
• Death
• Weight loss/gain
• Caloric intake by oral nutrition
• Eating/drinking difficulty
• Overall health
• Recurrence of cancer.
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Search methods for identification of studies
This review is part of a series of four reviews on the prevention
and treatment of oral candidiasis and oral mucositis in patients
with cancer, and the same search strategies were used for all four
reviews.
The searches attempted to identify all relevant trials irrespective of
language. Papers not in English were translated bymembers of The
Cochrane Collaboration. Sensitive search strategies were devel-
oped for each database using a combination of free text andMeSH
terms. TheMEDLINE and CANCERLIT searches combined the
subject search with the Cochrane Highly Sensitive Search Strat-
egy (CHSSS) for identifying randomised trials in MEDLINE:
sensitivity maximising version (2009 revision) as referenced in
Chapter 6.4.11.1 and detailed in boxes 6.4.a and 6.4.c of the
Cochrane Handbook for Systematic Reviews of Interventions version
5.0.2 (updated September 2009) (Higgins 2009). The EMBASE
and CINAHL searches were combined with sensitive search strate-
gies developed by theCochrane OralHealthGroup for identifying
randomised controlled trials (RCTs). The LILACs subject search
was combined with the Brazilian Cochrane Centre search strategy
for identifying RCTs in LILACS.
Electronic searching - the databases searched were:
• Cochrane Oral Health Group Trials Register (to 16
February 2011) (Appendix 1)
• Cochrane Pain, Palliative and Supportive Care (PaPaS)
Group Trials Register (to 16 February 2011) (Appendix 1)
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2011, Issue 1) (Appendix 2)
• MEDLINE via OVID (1950 to 16 February 2011)
(Appendix 3)
• EMBASE via OVID (1980 to 16 February 2011)
(Appendix 4)
• CANCERLIT via PubMed (1950 to 16 February 2011)
(Appendix 5)
• OpenSIGLE (1980 to 2005) (Appendix 6)
• LILACS via The Virtual Health Library (to 16 February
2011) (Appendix 7)
• CINAHL via EBSCO (1980 to 16 February 2011)
(Appendix 8).
Only handsearching carried out by The Cochrane Collaboration
was included in the search (see master list www.cochrane.org).
The controlled trials database (www.controlled-trials.com) was
also searched to identify ongoing and completed trials and to con-
tact trialists for further information about these trials.
The reference list of related review articles and all articles obtained
were checked for further trials. Authors of trial reports and spe-
cialists in the field known to the review authors were written to
concerning further published and unpublished trials.
The review will be updated every 2 years using the Cochrane
OralHealth Group Trials Register, CENTRAL,MEDLINE, EM-
BASE, CINAHL, CANCERLIT and LILACS. The search of
OpenSIGLE was discontinued as this database ceased being up-
dated in 2005.
Data collection and analysis
Selection of studies
The titles and abstracts (when available) of all reports identified
through the electronic searches were scanned independently by
two review authors. For studies appearing to meet the inclusion
criteria, or for which there were insufficient data in the title and
abstract to make a clear decision, the full report was obtained. The
full reports, containing names of the authors, institutions, journal
of publication and results, obtained from all the electronic and
other methods of searching were assessed independently by two
authors with expertise in this content area, to establish whether
the studies met the inclusion criteria or not. Disagreements were
resolved by discussion. Where resolution was not possible, a third
review author was consulted. All studies meeting the inclusion
criteria then underwent validity assessment and data extraction.
Studies rejected at this or subsequent stages were recorded in the
’Characteristics of excluded studies’ table, and reasons for exclusion
recorded.
Data extraction and management
Data were extracted by two review authors independently using
specially designed data extraction forms. The characteristics of the
trial participants, interventions andoutcomes in the included trials
are presented in the study tables. Mucositis may be dichotomised
at different levels of severity. In order to maximise the availability
of similar outcome data we recorded the number of patients in
each category of mucositis. We planned to form three dichotomies
of mucositis: absent versus present (0 versus 1+), mild versus mod-
erate/severe (0 to 1 versus 2+) and moderate versus severe (0 to 2
versus 3+). Pain was assessed on visual analogue scales (0 to 100),
the means and standard deviations for each group were recorded.
The duration of trials and timing of assessments were recorded in
order to make a decision about which to include for commonality.
We also recorded the country where the trial was conducted and
whether a dentist was involved in the investigation. Some of the
authors were contacted for clarification or for further information.
Assessment of risk of bias in included studies
For any relevant studies identified, two review authors indepen-
dently graded the relevant trials following the domain-based eval-
uation described in the Cochrane Handbook for Systematic Reviews
of Interventions 5.0.2 (updated September 2009) (Higgins 2009).
The review authors then compared evaluations, discussed and re-
solved any disagreements and reported their assessments in a risk
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of bias in included studies table in Review Manager (RevMan)
software.
An assessment of the overall risk of bias involved the consideration
of the relative importance of different domains and studies were
to be categorised as low, high or unclear risk of bias.
The review authors were to assess the following domains as ’Yes’
(i.e. low risk of bias), ’Unclear’ (i.e. uncertain risk of bias) or ’No’
(i.e. high risk of bias):
1. adequate sequence generation;
2. allocation concealment;
3. blinding (of participants, carers and outcome assessors);
4. incomplete outcome data addressed;
5. free of selective outcome reporting;
6. free of other bias.
These risk of bias assessments were then for each study across all
domains. Adequate allocation concealment and blinding of out-
come assessors were designated as key domains for this assessment.
Overall risk of bias was categorised according to the following:
• Low risk of bias (plausible bias unlikely to seriously alter the
results) for all key domains;
• Unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more key domains were assessed as
unclear; or
• High risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more key domains were
assessed to be at high risk of bias.
Measures of treatment effect
For dichotomous outcomes, the estimate of effect of an interven-
tion was expressed as risk ratios (RR) together with 95% confi-
dence intervals (CIs). For continuous outcomes, mean differences
and standard deviations were used to summarise the data for each
group usingmean differences and 95%CIs. Appropriate data were
extracted from the cross-over studies and the generic inverse vari-
ance method was used to enter this into RevMan.
Unit of analysis issues
The patient was the unit of analysis in all trials.
Dealing with missing data
All authors were contacted to retrieve missing data from authors
of trials.
The analysis will generally include only the available data (ignoring
missing data) however methods for estimating missing standard
deviations in Section7.7.3 of theCochrane Handbook for Systematic
Reviews of Interventions 5.0.2 (Higgins 2009) were to be used.
Otherwise we do not intend to undertake any imputations nor to
use statistical methods to allow for missing data.
Assessment of heterogeneity
The significance of any discrepancies in the estimates of the treat-
ment effects from the different trials was to be assessed by means
of Cochran’s test for heterogeneity and heterogeneity would have
been considered significant if P < 0.1 (Higgins 2009).
The I2 statistic, which describes the percentage total variation
across studies that is due to heterogeneity rather than chance, was
used to quantify heterogeneity with I2 over 50% being considered
substantial heterogeneity (Higgins 2009; Section 9.5.2). In order
to assist in the readers in the interpretation of heterogeneity we
would still have included the pooled meta-analysis in the forest
plot because the I2 and Chi2 statistics are helpful.With substantial
heterogeneity pooling the data may not be appropriate and this
will be considered in the results for each intervention.
Assessment of reporting biases
If there had been sufficient numbers of trials (more than 10) in any
meta-analysis, publicationbiaswould have been assessed according
to the recommendations on testing for funnel plot asymmetry
(Egger 1997) as described in theCochrane Handbook for Systematic
Reviews of Interventions 5.0.2 (Higgins 2009). If asymmetry were
identified we would have examined possible causes.
Data synthesis
A meta-analysis would have only be conducted if there were stud-
ies of similar comparisons reporting the same mucositis outcome
measures. Single studies would not be entered into forest plots.
Risk ratios were to be combined for dichotomous data, and mean
differences for continuous data, using random-effect models pro-
vided there were more than three studies in the meta-analysis.
It is possible to conduct cross-over trials in this area as patients may
be receiving several chemotherapy sessions, any mucositis com-
pletely healing in the periods between the sessions. The treatment
effects from cross-over trials were combined with those from par-
allel group trials where appropriate, using the data from both peri-
ods of the cross-over studies (Elbourne 2002). The generic inverse
variancemethod incorporated inRevManwas used for all analyses.
Where data for the cross-tabulation of pairs were not available, all
possible paired comparisons for each study were calculated, giving
rise to the same risk ratios values with different confidence inter-
vals. The widest confidence interval was used in the analysis.
Subgroup analysis and investigation of heterogeneity
Clinical heterogeneity was to be assessed by examining the types
of participants and interventions for all outcomes in each study.
We proposed a priori to conduct subgroup analyses for different
cancer types (leukaemia, head and neck, other solid tumours and
mixed), cancer treatment (for example 5-fluorouracil (5-FU)) and
age groups (children, adults and both). However, there were in-
sufficient trials by intervention type to do this.
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Sensitivity analysis
It was planned to undertake sensitivity analyses to examine the
effect of the study quality assessment on the overall estimates of
effect. In addition, the effect of including unpublished literature
on the review’s findings was also to be examined. There were too
few trials to undertake these analyses.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Characteristics of the trial settings and investigators
Three hundred and eighty-three reports of trials were initially
identified as eligible according to the defined inclusion criteria for
this review with regard to study design, participants, interventions
and outcomes. From this list, the total number of included trials
was 131, there were 10 duplicate reports and 176 studies were
excluded.
See Characteristics of excluded studies table for further informa-
tion on each excluded study. In summary, studies were excluded
for the following reasons.
• Abstracts only available, insufficient information to include
study in the review (36 studies: Antonadou 1998; Buentzel 1999;
Castro 2009; Clarke 2001; Collova 2004; Colombat 1995;
Costa 1999; Gabison 1995; Goldberg 2003; Gordon 1993;
Harris 1995; He 2004; Kante 1995; Klocke 2006; Lavendag
1998; Le 2008; Leong 1995; Lozada 1998; Marcial 1994; Merte
1999; Papas 1984; Pouli 1999; Radmard 2002; Robustelli 1999;
Schwerkoske 1999; Sharma 2009; Shea 2007; Shidfar 2008;
Spadaro 1991; Spielberger 2001; Throuvalas 1995; Valcárcel
1997; Vesole 1999; Villar 2009; Vitello 2000; Wagner 2002).
• Comparing different cancer treatments including
radiotherapy regimens (29 trial reports: Andersen 1987;
Ardizzoni 2002; Awada 2002; Awwad 2002; Bensadoun 2006;
Bentzen 2001; Bleehen 1996; Bourhis 2006; Calais 2000;
Cassidy 2002; Cunningham 1995; Damon 2004; De Boer 2002;
Denham 1999; Dobrowsky 1998; Doroshow 1987; Erkisi 1996;
Erlichman 1988; Ezzat 2005; Falcone 2001; Giles 2003a; Giles
2003b; Gladkov 2007; Lee 1989; Levi 1997; Mahmoud 1996;
Pyrhonen 1995; Rabinovitch 2006; Rocci 2005).
• Not a randomised controlled trial (64 study reports: Aisa
2005; Altmann 1999; Arora 2008; Awada 2004; Baydar 2005;
Calais 2004; Cheng 2001; Cheng 2002; Colella 2010; Costa
2003; Dreicer 1997; Edelman 1998; Eisen 2003; El-Sayed
2002a; Fahlke 1999; Fay 1994; Foncuberta 2001; Gandara
1997; Gutierrez 1996; Horsley 2007; Hu 2003; Hunter 2007;
Inagaki 2006; Ito 2002; Johnson 2002; Ju 2009; Karacetin 2004;
Khouri 2009; Kuriakose 2002; Labbate 2003; Luglié 2002;
Maddocks-Jennings 2009; Madero 1999; Malaker 1991;
Mantovani 2003; Martin 2006; Matejka 1990; Mills 1995; Mori
2006; Nicolatou-Galitis 2006; Okutomi 2000; Papadeas 2007;
Penpattanagul 2007; Peters 1993; Phillips 2002; Putwatana
2009; Sato 1997; Sato 2006; Schuster 2008; Shabanloei 2009;
Simoes 2009; Stokman 2004; Thieblemont 2002; Tiemann
2006; Toubai 2003; Uchiyama 2005; Wang 2002a; Ward 2007;
Weiss 1990; Whelan 2002; Whelan 2004; Wollina 2002;
Wymenga 1999; Yokomizo 2004).
• Multicomponent oral assessment instruments (which
included voice, teeth etc) - specifically excluded in methods
section of review (16 trial reports: Aquino 2005; Cowen 1997;
Dudjak 1987; Epstein 1992; Etiz 2000; Feber 1995; Feber 1996;
Grotz 2001; Jebb 1995; Kenny 1990; McIlroy 1996; Nikoletti
2005; Piccirillo 2003; Pytlik 2002; Rothwell 1990; Verdi 1995).
• Some mucositis present at baseline (12 trial reports:
Anderson 1998b; Barasch 1995; Djuric 2006; Ferretti 1990;
Genot-Klastersky 2008; Kuhn 2009; Lanzos 2010; Loo 2010;
Masucci 2005; Prada 1985; Ryu 2007; Valcarcel 2002).
• Mucositis prevention not purpose of study (one trial report:
Jham 2007).
• Data presented as episodes rather than patients, where
patients were re-entered into the study, so data not independent
(seven trial reports: Abramoff 2008; Awidi 2001; Hickey 1982;
Karthaus 1998; Lorusso 2003; Rojas 2001; van Zaanen 1994).
• Major change to protocol half way through study, blinded
and unblinded patient data combined (one trial report: Okuno
1997).
• Unclear if mucositis present at baseline (one trial report:
Cheng 2006).
• Unclear if randomised (four trial reports: Apaydin 1996;
Howell 1983; Teshima 1986; Zanin 2010).
• No mucositis data - study stopped early because preset
stooping rule triggered (two trial reports: Antin 2002; Rades
2004).
• No clear mucositis data presented and unable to contact
authors (two trial reports: Niibe 1985; Rutkauskas 1993).
• Design flaw - confounded interventions (one trial report:
Papas 2003).
Of the 131 included trials 124 were designed as parallel group
studies and seven as cross-over studies (Anderson 1998; Chi 1995;
Dozono 1989; Jebb 1994; Loprinzi 1990; Mahood 1991; Pfeiffer
1990).None of the published reports of cross-over studies reported
the ’paired’ data in an appropriate form to be used in a meta-
analysis. All the authors were contacted and replies were received
supplying data for three studies (Anderson 1998; Loprinzi 1990;
Mahood 1991). Data from the other cross-over studies were ex-
tracted as outlined in the methods section.
Of the 131 included trials all included data on assessment of mu-
cositis. Ninety-two (70%) of the 131 included trials were con-
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ducted at a single site. Thirty-two of these trials were conducted
in Europe, 20 in the USA, seven in China, five in India, four
in Canada, three in Brazil and Japan, two in Iran, Israel, Thai-
land, Taiwan and Turkey, and one in each of the following coun-
tries: Argentina, Egypt, Hong Kong, Malaysia, Mexico, South
Africa, South Korea, and Uruguay. Thirty-six trials were multi-
centre studies. Ten of these were conducted in the USA (Blazar
2006; Crawford 1999; Dodd 1996; Freytes 2004; Giles 2004;
Hanson 1995; Mahood 1991; Meropol 2003; Scarantino 2006;
Spielberger 2004), three in the USA and Canada (Epstein 2001;
Foote 1994; Nemunaitis 1995), two in the USA and European
countries (Brizel 2000; Buentzel 2006), two in European coun-
tries alone (Castagna 2001; Vokurka 2005), one in the USA,
Canada and Europe (Trotti 2004), one in the USA and Australia
(Rosen 2006) and one in the USA, Australia and Canada (Brizel
2008). Two studies were conducted in Australia (Spencer 2005;
Veness 2006), Canada (Bjarnason 2009; El Sayed 2002), France
(Bensadoun 1999; Gandemer 2007), Iran (Abbasi-Nazari 2007;
Motallebnejad 2008) and Taiwan (Chi 1995; Lin 2006), and one
in each of the following countries: China (Tu 1998), Germany
(Dorr 2007), Italy (Gori 2007), South Korea (Wu 2009), Russia
(Peterson 2009) and Thailand (Veerasarn 2006). It was unclear
whether the remaining three studies were conducted at a single site
or were multisite studies (Bubley 1989; Lievens 1998; Qin 2007).
Eighty-one studies (62%) provided funding information. Thirty-
seven (28%) trials were funded by the pharmaceutical industry.
Twenty-three studies received government funding. Whilst an ad-
ditional nine trials were funded by a combination of funding
sources (Anderson 1998; Blazar 2006; Cerchietti 2006; Dodd
1996; Ferretti 1988; Foote 1994; Makkonen 1994; Sornsuvit
2008; van der Lelie 2001). Five studies were funded by chari-
ties (Bjarnason 2009; Dickson 2000; Franzen 1995; Lilleby 2006;
Lockhart 2005). Four trials reported that they received university
funding (Biswal 2003; Madan 2008; Motallebnejad 2008; Yuen
2001). Three studies were funded by other sources (Gori 2007;
Lin 2006; Oberbaum 2001). The remaining 50 (38%) studies
reported either none, or insufficient information about funding
sources. A dentist was involved in 26 (20%) of the trials.
Studies awaiting assessment
Due to changes in the inclusion criteria for studies in this review,
some previously excluded studies are being reconsidered for in-
clusion in the next update. Information about these studies is in
Characteristics of studies awaiting classification.
Characteristics of the participants
One hundred and fourteen (87%) of the included trials recruited
only adult patients, 13 included both adults and children (with
a difference in age as large as 1 to 70 years) and three trials were
conducted solely on paediatric patients (Cruz 2007; Gandemer
2007; Shenep 1988), the age group being unclear in one trial
(Mahood 1991). The type of cancer for which patients were being
treated was exclusively head and neck cancer in 69 trials (53%),
leukaemia in 13 trials, solid tumours in 22 trials and a combina-
tion of haematological and solid tumours in 21 trials, the cancer
type being unclear in six trials. The radiotherapy and/or chemo-
therapy regimen was described in most of the trials though the
chemotherapeutic agents were not always described in full detail.
Twenty-nine trials included patients who were undergoing a bone
marrow transplant. The chemotherapy regimen included 5-fluo-
rouracil (5-FU) in 25 trials. In 13 of these trials the patients had
solid tumours, in six trials patients had head and neck cancer, in
two trials patients had mixed cancers and in four trials the cancer
type was unclear. It was not always clear if the dose was in a bolus
or continuous form. Trials in which patients received radiother-
apy generally gave information about the total and daily or weekly
dose. Total radiotherapy for head and neck cancer was generally
60 to 74 Gy and the Karnofsky performance > 60.
Characteristics of the interventions
All of the 131 trials provided a clear description of the interven-
tions including the dose and method of administration for the test
and control groups. The dosage of the test agents varied for similar
products. Thirty-six trials compared an active intervention with
no treatment and 87 trials used a placebo control. In some trials
the placebo was matched in taste and appearance to the active
intervention and in others the following interventions were de-
scribed as placebo: water, albumin, glycine, sugar solution, poly-
cal, saline. Two trials included in the no treatment control group
tested different oral care protocols and in each case one group
received limited oral hygiene (usual care) (Borowski 1994; Shieh
1997). A further three trials included in the placebo control group
included both a placebo control and a direct comparison (Freytes
2004 - two different doses of keratinocyte growth factor, Madan
2008 - chlorhexidine versus povidone iodine versus salt & soda,
and Sorensen 2008 chlorhexidine mouthwash versus ice chips).
A further two trials (Huang 2003; Wang 2002) compared Chi-
nese medicine to a control described as Dobell’s solution, which
is “a solution of sodium borate, sodium bicarbonate, phenol, and
glycerol, used as a wash for mucous membranes” (Merck Index
2010). Two trials compared patients receiving radiotherapy in
the morning with patients receiving radiotherapy in the after-
noon (Bjarnason 2009; Goyal 2009). Another four trials com-
pared two active interventions: ice chips sucked for different time
periods (30 minutes versus 60 minutes) (Rocke 1993), granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) versus su-
cralfate (Saarilahti 2002), chlorhexidine versus laser (Arun Maiya
2006) and polaprezinc versus azulene (Watanabe 2010).
The interventions for the 131 studies assessing oralmucositis were:
• aciclovir (Bubley 1989)
• allopurinol mouthrinse (Abbasi-Nazari 2007; Dozono
1989; Loprinzi 1990; Panahi 2009)
• aloe vera (Puataweepong 2009; Su 2004;)
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• amifostine (Antonadou 2002; Bourhis 2000; Brizel 2000;
Buentzel 2006; Buntzel 1998; Haddad 2009; Hartmann 2001;
Koukourakis 2000; Spencer 2005; Vacha 2003; Veerasarn 2006)
• antibiotic pastille or paste (El Sayed 2002)
• antibiotic systemic (clarithromycin) (Yuen 2001)
• azulene (Watanabe 2010*)
• benzydamine (Epstein 1989; Epstein 2001; Kazemian
2009; Prada 1987)
• beta carotene (Mills 1988)
• chamomile (Fidler 1996)
• chewing gum (Gandemer 2007)
• Chinese herbs (details of herbs used are given in
Characteristics of included studies table) (Huang 2003*; Wang
2002*)
• chlorhexidine (Arun Maiya 2006*; Dodd 1996; Ferretti
1988; Foote 1994; Madan 2008*; McGaw 1985; Pitten 2003;
Sorensen 2008; Spijkervet 1989; Wahlin 1989)
• cryotherapy (Cascinu 1994; Gori 2007; Lilleby 2006;
Mahood 1991; Rocke 1993*; Svanberg 2007; Sorensen 2008*)
• dental stent (Qin 2007)
• epidermal growth factor (Wu 2009)
• glutamine (Anderson 1998; Cerchietti 2006; Choi 2007;
Dickson 2000; He 2008; Huang 2000; Jebb 1994; Li 2006;
Okuno 1999; Sornsuvit 2008)
• granulocyte colony-stimulating factor (G-CSF) (Crawford
1999; Katano 1995; Schneider 1999; Su 2006)
• granulocyte/macrophage colony-stimulating factor (GM-
CSF) (Cartee 1995; Chi 1995; Dazzi 2003; Ifrah 1999;
Makkonen 2000; McAleese 2006; Nemunaitis 1995; Saarilahti
2002*; van der Lelie 2001)
• histamine gel (Elad 2006)
• honey (Biswal 2003; Motallebnejad 2008; Rashad 2008)
• hydrolytic enzymes (details of enzymes used are given in
Characteristics of included studies table) (Dorr 2007; Gujral
2001; Kaul 1999)
• indigo wood root (You 2009)
• intestinal trefoil factor (Peterson 2009)
• iseganan (Giles 2004; Trotti 2004)
• keratinocyte growth factor (GF) (Blazar 2006; Brizel 2008;
Freytes 2004*; Meropol 2003; Rosen 2006; Spielberger 2004;
Vadhan-Raj 2010)
• laser (Antunes 2007; Arun Maiya 2006*; Bensadoun 1999;
Chor 2010; Cruz 2007; Schubert 2007)
• non-steroidal anti-inflammatory drug (Pillsbury 1986)
• oral care (Borowski 1994; Shieh 1997)
• pentoxifylline (Attal 1993)
• pilocarpine (Lockhart 2005; Scarantino 2006)
• PTA (polymixin/tobramycin/amphotericin) lozenges/paste
(Stokman 2003; Symonds 1996; Wijers 2001)
• polaprezinc (Watanabe 2010*)
• povidone iodine (Arun Maiya 2006; Madan 2008*; Rahn
1997; Vokurka 2005)
• prednisone (Leborgne 1997)
• propantheline anticholinergic (Ahmed 1993)
• prostaglandin (Duenas 1996; Hanson 1995; Labar 1993;
Pillsbury 1986; Veness 2006)
• radiation: morning versus evening (Bjarnason 2009*, Goyal
2009*)
• shenqi-fanghou (Hu 2005)
• superoxide dismutase (SOD) (Tu 1998)
• sucralfate (Carter 1999; Castagna 2001; Cengiz 1999;
Epstein 1994; Evensen 2001; Franzen 1995; Lievens 1998;
Makkonen 1994; Nottage 2003; Pfeiffer 1990; Saarilahti 2002*;
Scherlacher 1990; Shenep 1988)
• traumeel (Oberbaum 2001)
• yangygin-humo decoctalion (Dai 2009)
• zinc sulphate (Ertekin 2004; Lin 2006).
* studies with two or more different active treatments.
Characteristics of outcome measures
Mucositis
All trials used a graded scale to record the severity of mucositis.
Most described the index used or referred to published criteria,
mainly World Health Organization (WHO) or European Orga-
nization for Research and Treatment of Cancer (EORTC). Scales
were similar to the 5-point WHO scale ranging from 0 (normal)
to 4 (severe). The categories initially relate to visible changes in the
mucosa and gradually record pain and inability to eat solid foods.
The duration of the trials varied from a few days up to a year after
treatment. The interval during which mucositis was recorded var-
ied from 5 to 90 days or until the end of the radiotherapy, or the
leukocyte count was above 8000 mm³. Several studies presented
data at different time points, with the median time point being 28
days. The nearest assessment to 28 days was used for all studies.
Secondary outcomes
There was little consistency on the other outcome measures re-
ported.
• Oral hygiene measures (Biswal 2003; Cruz 2007; Dodd
1996; El Sayed 2002; Elad 2006; Ertekin 2004; Evensen 2001;
Ferretti 1988; Foote 1994; Gandemer 2007; Kazemian 2009;
Leborgne 1997; Lockhart 2005; Makkonen 1994; Makkonen
2000; McGaw 1985; Rahn 1997; Rashad 2008; Scherlacher
1990; Spijkervet 1989; Stokman 2003; Symonds 1996;
Vadhan-Raj 2010; Vokurka 2005; Wahlin 1989; Wijers 2001;
Wu 2009).
• Relief of pain/use of analgesia (morphine) (Antunes 2007;
Arun Maiya 2006; Attal 1993; Bensadoun 1999; Blazar 2006;
Brizel 2008; Carter 1999; Castagna 2001; Cengiz 1999;
Cerchietti 2006; Cruz 2007; Dazzi 2003; Dorr 2007; El Sayed
2002; Epstein 1989; Epstein 1994; Epstein 2001; Ertekin 2004;
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Ferretti 1988; Franzen 1995; Freytes 2004; Gandemer 2007;
Giles 2004; Hanson 1995; Lilleby 2006; Lockhart 2005;
Makkonen 2000; Meropol 2003; Nottage 2003; Oberbaum
2001; Peterson 2009; Pfeiffer 1990; Prada 1987; Puataweepong
2009; Rosen 2006; Saarilahti 2002; Schubert 2007; Shenep
1988; Shieh 1997; Spencer 2005; Spielberger 2004; Su 2004;
Svanberg 2007; Trotti 2004; Tu 1998; Vadhan-Raj 2010; van der
Lelie 2001; Veness 2006; Vokurka 2005; Watanabe 2010; Wijers
2001; Wu 2009).
• Duration or severity of dysphagia (Antonadou 2002;
Bensadoun 1999; Bjarnason 2009; Bourhis 2000; Brizel 2008;
Buntzel 1998; Castagna 2001; Cengiz 1999; Choi 2007; Dorr
2007; El Sayed 2002; Elad 2006; Epstein 1994; Fidler 1996;
Franzen 1995; Giles 2004; Goyal 2009; Gujral 2001; Haddad
2009; Hartmann 2001; Kaul 1999; Lievens 1998; Lilleby 2006;
Lockhart 2005; McAleese 2006; Oberbaum 2001; Prada 1987;
Rosen 2006; Scarantino 2006; Scherlacher 1990; Spielberger
2004; Su 2006; Symonds 1996; Trotti 2004; Vadhan-Raj 2010;
Veerasarn 2006; You 2009).
• Use of parenteral nutrition or feeding tube (Bjarnason
2009; Bourhis 2000; Brizel 2008; Carter 1999; Cerchietti 2006;
Cruz 2007; Dickson 2000; El Sayed 2002; Evensen 2001; Foote
1994; Franzen 1995; Gandemer 2007; Haddad 2009; Hanson
1995; Hartmann 2001; Leborgne 1997; Lilleby 2006; Lockhart
2005; Rashad 2008; Saarilahti 2002; Shenep 1988; Spencer
2005; Spielberger 2004; Stokman 2003; Su 2006; Symonds
1996; Trotti 2004; Vadhan-Raj 2010; van der Lelie 2001; Yuen
2001).
• Incidence of systemic infection or use of antibiotics
(Antunes 2007; Attal 1993; Blazar 2006; Borowski 1994; Brizel
2008; Bubley 1989; Buntzel 1998; Castagna 2001; Cerchietti
2006; Crawford 1999; Cruz 2007; Duenas 1996; El Sayed 2002;
Ertekin 2004; Ferretti 1988; Freytes 2004; Gandemer 2007;
Hanson 1995; Hartmann 2001; Ifrah 1999; Jebb 1994; Labar
1993; McGaw 1985; Pitten 2003; Puataweepong 2009; Shenep
1988; Sornsuvit 2008; Spencer 2005; Spielberger 2004; Su
2004; Symonds 1996; Trotti 2004; Tu 1998; Vadhan-Raj 2010;
van der Lelie 2001; Vokurka 2005; Wahlin 1989; Yuen 2001).
• Febrile episodes (Ahmed 1993; Anderson 1998; Attal 1993;
Borowski 1994; Brizel 2000; Chi 1995; Chor 2010; Crawford
1999; Duenas 1996; Ferretti 1988; Freytes 2004; Ifrah 1999;
Katano 1995; Labar 1993; McGaw 1985; Nemunaitis 1995;
Pitten 2003; Shenep 1988; Spencer 2005; Spielberger 2004; van
der Lelie 2001; Vokurka 2005; Wahlin 1989; Yuen 2001).
• Blood changes (Ahmed 1993; Antonadou 2002; Attal
1993; Blazar 2006; Brizel 2000; Buentzel 2006; Buntzel 1998;
Cartee 1995; Cascinu 1994; Cerchietti 2006; Chi 1995;
Crawford 1999; Dazzi 2003; Dickson 2000; Dorr 2007; Duenas
1996; Elad 2006; Epstein 2001; Ertekin 2004; Ferretti 1988;
Franzen 1995; Freytes 2004; Hartmann 2001; Huang 2003;
Ifrah 1999; Katano 1995; Labar 1993; Li 2006; Lilleby 2006;
Lin 2006; Mahood 1991; Makkonen 2000; Meropol 2003;
Nemunaitis 1995; Pitten 2003; Rocke 1993; Rosen 2006;
Saarilahti 2002; Schneider 1999; Shenep 1988; Sorensen 2008;
Sornsuvit 2008; Spencer 2005; Spielberger 2004; Svanberg
2007; van der Lelie 2001; Veerasarn 2006; Vokurka 2005;
Wahlin 1989; Wu 2009; You 2009).
• Treatment interruption (Antonadou 2002; Biswal 2003;
Bjarnason 2009; Bourhis 2000; Brizel 2000; Brizel 2008; Carter
1999; Dazzi 2003; El Sayed 2002; Foote 1994; Franzen 1995;
Haddad 2009; Huang 2003; Ifrah 1999; Koukourakis 2000;
Leborgne 1997; Makkonen 1994; Makkonen 2000; Pfeiffer
1990; Puataweepong 2009; Saarilahti 2002; Trotti 2004; van der
Lelie 2001; Vadhan-Raj 2010; Veness 2006; Wu 2009; You
2009).
• Days of stay in hospital (Antonadou 2002; Attal 1993;
Cerchietti 2006; Chor 2010; Dickson 2000; Duenas 1996; Ifrah
1999; Lilleby 2006; McGaw 1985; Saarilahti 2002; Sornsuvit
2008; van der Lelie 2001).
• Toxicity - nausea/vomiting/constipation/diarrhoea
(Antonadou 2002; Blazar 2006; Bourhis 2000; Brizel 2000;
Brizel 2008; Bubley 1989; Buentzel 2006; Cascinu 1994;
Castagna 2001; Cengiz 1999; Dickson 2000; Duenas 1996; El
Sayed 2002; Elad 2006; Epstein 1994; Epstein 2001; Ertekin
2004; Fidler 1996; Freytes 2004; Gandemer 2007; Giles 2004;
Gujral 2001; Haddad 2009; Hartmann 2001; He 2008;
Kazemian 2009; Labar 1993; Li 2006; Lievens 1998; Lockhart
2005; Mahood 1991; Meropol 2003; Nottage 2003; Oberbaum
2001; Okuno 1999; Peterson 2009; Pfeiffer 1990; Rocke 1993;
Rosen 2006; Scarantino 2006; Shenep 1988; Sornsuvit 2008;
Spencer 2005; Trotti 2004; Tu 1998; Vadhan-Raj 2010; Yuen
2001).
• Toxicity - skin changes (Antonadou 2002; Blazar 2006;
Bourhis 2000; Buntzel 1998; Choi 2007; Dickson 2000; Dorr
2007; El Sayed 2002; Evensen 2001; Giles 2004; Goyal 2009;
Gujral 2001; Haddad 2009; Kaul 1999; Lievens 1998; Lin 2006;
Meropol 2003; Rosen 2006; Scarantino 2006; Shenep 1988;
Spielberger 2004; Tu 1998; Vacha 2003; Yuen 2001).
• Toxicity - unspecific (Buentzel 2006; Cerchietti 2006; Chi
1995; Duenas 1996; El Sayed 2002; Epstein 1994; Fidler 1996;
Freytes 2004; Giles 2004; Gujral 2001; Mahood 1991;
Makkonen 1994; Makkonen 2000; Okuno 1999; Puataweepong
2009; Spielberger 2004; Su 2006; Tu 1998).
• Xerostomia (Antonadou 2002; Bourhis 2000; Brizel 2000;
Brizel 2008; Buentzel 2006; Buntzel 1998; Castagna 2001;
Cengiz 1999; Dazzi 2003; Elad 2006; Epstein 1994; Epstein
2001; Goyal 2009; Hartmann 2001; Koukourakis 2000;
Lockhart 2005; Makkonen 2000; McAleese 2006; Meropol
2003; Nottage 2003; Oberbaum 2001; Saarilahti 2002;
Scarantino 2006; Spencer 2005; Vacha 2003; Veerasarn 2006;
Watanabe 2010).
• Cost (Bourhis 2000; Brizel 2000; Buentzel 2006; Buntzel
1998; Choi 2007; Dodd 1996; Haddad 2009; Hartmann 2001;
Hu 2005; Huang 2000; Koukourakis 2000; Makkonen 2000;
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McAleese 2006; Nemunaitis 1995; Nottage 2003; Sornsuvit
2008; Su 2006; Yuen 2001).
• Patient quality of life (Bjarnason 2009; Brizel 2000;
McAleese 2006; Nottage 2003; Scarantino 2006; Spielberger
2004; Veness 2006).
• Death (Ahmed 1993; Attal 1993; Bjarnason 2009; Blazar
2006; Brizel 2008; Dickson 2000; Dodd 1996; Epstein 2001;
Ertekin 2004; Ferretti 1988; Giles 2004; Gujral 2001; Kazemian
2009; Leborgne 1997; Madan 2008; Mills 1988; Oberbaum
2001; Rahn 1997; Rosen 2006; Schubert 2007; Spielberger
2004).
• Weight loss/gain (Antonadou 2002; Biswal 2003;
Bjarnason 2009; Brizel 2000; Buentzel 2006; Buntzel 1998;
Carter 1999; Cengiz 1999; Cerchietti 2006; El Sayed 2002; Elad
2006; Ertekin 2004; Foote 1994; Freytes 2004; Haddad 2009;
Hanson 1995; He 2008; Hu 2005; Huang 2000; Koukourakis
2000; Leborgne 1997; Lievens 1998; Lilleby 2006; Lin 2006;
Makkonen 2000; Motallebnejad 2008; Nottage 2003; Pillsbury
1986; Puataweepong 2009; Qin 2007; Shenep 1988; Sornsuvit
2008; Stokman 2003; Su 2004; Su 2006; Symonds 1996; Trotti
2004; Vacha 2003; Veerasarn 2006; Veness 2006; Wu 2009; You
2009).
• Caloric intake by oral nutrition (Castagna 2001; Cruz
2007; Dickson 2000; Freytes 2004; Hartmann 2001; He 2008;
Lilleby 2006; Pfeiffer 1990; Shenep 1988; Spencer 2005;
Watanabe 2010).
• Eating/drinking difficulty (Anderson 1998; Carter 1999;
Cengiz 1999; Cerchietti 2006; Dickson 2000; El Sayed 2002;
Evensen 2001; Franzen 1995; Freytes 2004; Jebb 1994; Lilleby
2006; Lockhart 2005; Nottage 2003; Oberbaum 2001; Pfeiffer
1990; Prada 1987; Rashad 2008; Rosen 2006; Scarantino 2006;
Shenep 1988; Sornsuvit 2008; Spielberger 2004; Stokman 2003;
Symonds 1996; Vadhan-Raj 2010).
• Overall health (Antonadou 2002; Bourhis 2000; Brizel
2000; Buentzel 2006; Elad 2006; Ertekin 2004; Haddad 2009;
Ifrah 1999; Jebb 1994; Lilleby 2006; Makkonen 2000; McAleese
2006; Nemunaitis 1995; Rosen 2006; Shenep 1988; Su 2004; Su
2006; Wu 2009).
• Recurrence of cancer (Ahmed 1993; Attal 1993; Bjarnason
2009; Blazar 2006; Brizel 2000; Brizel 2008; Cerchietti 2006;
Chi 1995; Dickson 2000; Duenas 1996; Goyal 2009; Gujral
2001; Leborgne 1997; Li 2006; Makkonen 2000; Mills 1988;
Okuno 1999; Pillsbury 1986; Rosen 2006; Saarilahti 2002;
Schneider 1999; Spielberger 2004; Vadhan-Raj 2010; Watanabe
2010).
Risk of bias in included studies
Adequate sequence generation
Twenty-seven studies (21%) were deemed to have adequate se-
quence generation, and therefore were classified as being at low risk
of bias for this domain. Thirteen of these studies employed com-
puter-based sequence generation; while, four studies employed
minimization. Four studies did not provide enough information
about the randomisation process; however it was the opinion of
the assessors that the setting of these trials made adequate ran-
domisation likely. These studies were conducted at theDana Faber
cancer institute (Haddad 2009), the Memorial Sloan Kettering
Cancer Centre (Su 2004), the Duke Centre (Cartee 1995) and
the Finish cancer registry (Makkonen 2000). One study used bi-
ased coin randomisation (Su 2004). Of the remaining five studies,
three used a table of random numbers (Huang 2003; Koukourakis
2000; Pitten 2003), and two studies provided limited information
but made reference to appropriate literature concerning randomi-
sation (Brizel 2000; Shieh 1997). Those studies considered to use
an inappropriate method of randomisation were excluded; there-
fore no studies were given a decision of no for this category. The
remaining 104 studies (79%) were judged as ’unclear’. The ma-
jority of these unclear studies gave no more information than that
they were ’randomised’. Four studies stated that they employed
the “closed envelope” method of randomisation. However, no in-
formation was provided about whether these envelopes were shuf-
fled prior to the patient being randomised. They were therefore
classified as “unclear”.
Adequate allocation concealment
Nineteen studies (14%) employed adequate methods of alloca-
tion concealment and were therefore classified as being at low
risk of bias. Central randomisation was mentioned in 15 studies,
with eight studies employing pharmacy controlled randomisation,
six studies communicating by telephone, and one study by fax
(Gandemer 2007). Two studies employed sequentially numbered
drug containers which were identical in appearance (Foote 1994;
Madan 2008). Two studies (1.5%) used open number tables with-
out concealment and were therefore deemed to be at high risk of
bias (Huang 2003; Koukourakis 2000). The remaining 111 stud-
ies were classified as unclear.
Blinding
Blinding was assessed for three different groups: patients, carers
and outcome assessors.
Carer blinding: Nineteen studies (15%) described some method
of blinding and were therefore deemed to be at low risk of bias for
carer blinding. Forty-five studies (34%) were classified as being at
high risk of bias, as no blinding was employed. Sixty-seven (51%)
studies were classified as ’unclear’.
Patient blinding: Forty-five studies were classified as being at high
risk of bias for patient blinding. The majority of these were studies
which employed no blinding, however one study was described by
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its authors as double blind, but then went on to state that a pa-
tient withdrew from the study because they were not allocated the
intervention of interest (Wu 2009). The assessors were concerned
that this suggested a failure in the blinding of patients in this study,
and therefore decided to characterise the study at high risk of bias
for all three blinding categories. Seventy-five studies (58%) were
deemed to be at low risk of bias for patient blinding. Eleven studies
(8%) were classified as unclear. Of these studies, four were deemed
unclear as they employed the use of a placebo control, and there-
fore blinding could not be discounted, while three studies were
assessed for risk of bias from a data collection sheet provided by
a translator without any additional information. Of the remain-
ing four ’unclear’ studies, one study which compared povidone-
iodine to saline was described as ’blind’ to patients, however, this
was considered by the assessors to be an inappropriate control as
presumably the iodine solution would differ in colour from the
saline (Vokurka 2005). Another which investigated zinc in head
and neck patients receiving a mix of radiotherapy and chemora-
diotherapy (Ertekin 2004), was classified as unclear for two rea-
sons: firstly, because the study authors described the need for a
double blind study in the introduction, and then failed to provide
any information about blinding in the remainder of the text, and
secondly, because the authors used empty capsules as the control,
and the assessors were concerned that this would be noticeable to
the patients. The third study (Vadhan-Raj 2010) was deemed un-
clear because the authors stated that adverse events associated with
the intervention (keratinocyte growth factor) may have affected
the integrity of the blinding. The remaining trial (Ahmed 1993)
only stated that “trial drugs were administered blind”, without any
additional information.
Outcome assessor blinding: Seventy-seven studies (59%) were
deemed to describe any method of outcome assessor blinding ad-
equately and were considered to be at low risk of bias. Sixteen
studies (12%) were classified as unclear and 38 studies (29%) were
given a decision of ’no’ and were therefore considered to be at
high risk of bias in this category. In a subanalysis of those stud-
ies providing blinding information, only 19 studies gave specific
information regarding the blinding of an outcome assessor. The
remaining 58 studies were only described as “double blind” by the
authors.
Incomplete outcome data addressed
One hundred and six studies (82%) were considered to be at low
risk of bias for this category. Seventeen studies (13%) were given
a decision of unclear and eight were considered to be at high risk
of bias. These seven studies experienced a high rate of drop out.
Free of selective reporting
Forty-nine (37%) studies were deemed to be free of selective re-
porting for mucositis grade, which was determined prior to assess-
ment as the outcome of interest for this category. These studies
were therefore deemed to be at a low risk of bias. The remaining
82 studies were classified as unclear. These studies tended to only
provide subsets of data for severe mucositis (grade > 2) rather than
all the information of interest. No studies were given a decision
of ’no’, and consequently classified at high risk of bias, as studies
which did not provide mucositis information for at least one of
the dichotomies of interest could not be included in the review.
Free of other bias
Thirty-five studies (27%) were deemed to be at high risk of
bias in the final ’other’ category. A baseline imbalance was re-
ported by 11 studies. Three studies reported gender imbalances
(Abbasi-Nazari 2007; Makkonen 1994; Puataweepong 2009),
while three studies reported age imbalances (Bensadoun 1999;
Ifrah 1999; Makkonen 1994). Two or more baseline imbalances
were reported by four studies (Bensadoun 1999; Ifrah 1999;
Makkonen 1994; Puataweepong 2009). Puataweepong 2009 re-
ported baseline imbalances in both patient gender (P = 0.03) and
previous surgery (P = 0.04). Meanwhile, in the Ifrah 1999 study,
patients randomised to receive GM-CSF in the intervention arm
of the study, were older (P = 0.04) and more likely to have the
Philadelphia chromosomal re-arrangement (P = 0.026). Baseline
imbalances in age and gender were reported by Makkonen and
colleagues (Makkonen 1994). Bensadoun and colleagues reported
imbalances in the number of patients receiving supplementary ap-
plication of laser to the neck, which was hypothesised to exert a
distant beneficial effect. In this study patients in the intervention
group also tended to be older. However, no P values were pre-
sented by the authors for this imbalance (Bensadoun 1999). Risk
of bias was assessed for eight studies from a data collection form
completed by a translator. Loprinzi and colleagues initially aimed
to recruit 120 patients into their allopurinol study, however, the
power calculation was re-run after 77 patients and as the results
were found to favour the intervention, the study was terminated
and the data published (Loprinzi 1990). In the Duenas and col-
leagues study (Duenas 1996), an interim analysis conducted in the
16 patients recruited into the study showed a significant different
in favour of the placebo, and the authors therefore decided to cease
recruitment. Epstein and colleagues also report the results of an
interim analysis, in this case a trial of 33 patients which compared
sucralfate to placebo. This trial was terminated after an interim
analysis suggested that the impact of sucralfate on mucositis pre-
vention was minimal (Epstein 1994).
Overall risk of bias
Figure 1; Figure 2.
Eleven studies were assessed at low overall risk of bias (8%)
(Cartee 1995; Dazzi 2003; Foote 1994; Madan 2008; Oberbaum
2001; Pitten 2003; Saarilahti 2002; Schneider 1999; Shenep1988;
Stokman 2003; Su 2006), 82 (63%) were described as unclear
and the remaining 38 studies (29%) were defined as being at high
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overall risk of bias (Antonadou 2002; Antunes 2007; Biswal 2003;
Bjarnason 2009; Borowski 1994; Bourhis 2000; Brizel 2000;
Buntzel 1998; Cascinu 1994; Chi 1995; Choi 2007; Dai 2009;
Dozono 1989;Gandemer 2007;Gori 2007;Gujral 2001; Haddad
2009; Hartmann 2001; Huang 2000; Katano 1995; Kaul 1999;
Koukourakis 2000; Lilleby 2006; Makkonen 2000; Mills 1988;
Rahn 1997;Rashad 2008;Rocke 1993; Shieh1997; Spencer 2005;
Svanberg 2007; Vacha 2003; Vadhan-Raj 2010; Veerasarn 2006;
Wahlin 1989; Watanabe 2010; Wu 2009; Yuen 2001).
Figure 1. Risk of bias assessment graph: review authors’ judgements about each risk of bias domain
presented as percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias domain for each
included study.
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Effects of interventions
See: Summary of findings for the main comparison
Cryotherapy versus no treatment for preventing oral mucositis for
patients with cancer receiving treatment; Summary of findings
2 Amifostine versus placebo/no treatment for preventing oral
mucositis for patients with cancer receiving treatment; Summary
of findings 3 Keratinocyte GF versus placebo for preventing
oral mucositis for patients with cancer receiving treatment;
Summary of findings 4 Sucralfate versus placebo/usual care
for preventing oral mucositis for patients with cancer receiving
treatment; Summary of findings 5Chlorhexidine versus placebo/
no treatment for preventing oral mucositis for patients with cancer
receiving treatment
Interventions with more than one trial
Allopurinol versus placebo/no treatment (Analysis 1.1;
Analysis 1.2; Analysis 1.3)
There were four trials (Abbasi-Nazari 2007; Dozono 1989;
Loprinzi 1990; Panahi 2009), two designed as cross-over stud-
ies (Dozono 1989; Loprinzi 1990), which compared allopurinol
mouthrinse with placebo or no treatment. Three of these studies
were conducted in patients undergoing treatment with chemo-
therapy for solid tumours. One study was conducted in patients
receiving radiotherapy +/- chemotherapy for head and neck cancer
(Abbasi-Nazari 2007). Data were provided for all three outcome
categories.
All trials provided data for the outcome category of any mucositis,
and there was no statistically significant difference between allop-
urinol and control, risk ratio (RR) 0.77 (95% confidence interval
(CI) 0.50 to 1.19, P = 0.24, Analysis 1.1). Two trials, both assessed
as being at unclear risk of bias, provided data for themoderate plus
severe and severe outcome categories (Abbasi-Nazari 2007; Panahi
2009). There was substantial heterogeneity in both the moderate
plus severe meta-analysis (Chi2 = 8.24, degrees of freedom (df ) =
1, P = 0.004, I2 = 88%, Analysis 1.2) and the severe meta-anal-
ysis (Chi2 = 13.14, df = 1, P = 0.0003, I2 = 92%, Analysis 1.3),
probably due to differences with regard to the type of tumour and
cancer treatment in the trials. The effect estimates from these trials
are inconsistent; the risk of bias is unclear and there is substantial
heterogeneity.
Overall, there is weak inconsistent evidence which is insufficient
to indicate a benefit of allopurinol in the prevention of mucositis.
Aloe vera solution versus placebo (Analysis 2.1)
Two trials (Puataweepong 2009; Su 2004), comprising a total of
119 patients with head and neck cancer undergoing radiotherapy
or chemoradiotherapy compared aloe vera with placebo. Both tri-
als were found to be at unclear risk of bias. Both provided data
for the outcome category of prevention of moderate plus severe
mucositis and showed a statistically significant benefit in favour of
aloe vera, RR 0.74 (95% CI 0.58 to 0.96, P = 0.02, Analysis 2.1)
with moderate heterogeneity (Chi2 = 2.42, df = 1 (P = 0.12); I2 =
59%).
Su 2004 found a statistically significant reduction in severe mu-
cositis in the aloe vera group but Puataweepong 2009 found no
difference between the groups with regard to the prevention of
any mucositis (Additional Table 1).
Overall, there is weak unreliable evidence that aloe vera may be
beneficial in the prevention of moderate to severe mucositis.
Amifostine versus placebo/no treatment (Analysis 3.1;
Analysis 3.2; Analysis 3.3)
Eleven trials compared amifostine with no treatment (Antonadou
2002; Bourhis 2000; Brizel 2000; Buntzel 1998; Haddad 2009;
Hartmann 2001; Koukourakis 2000; Spencer 2005; Vacha 2003;
Veerasarn 2006) or a placebo (Buentzel 2006).Most of the trials re-
cruited adults with head and neck cancer being treated with radio-
therapy (Bourhis 2000; Brizel 2000; Veerasarn 2006) or chemo-
radiotherapy (Antonadou 2002; Buentzel 2006; Buntzel 1998;
Haddad 2009; Vacha 2003). Two trials (Hartmann 2001; Spencer
2005) included patients having bone marrow transplants, and one
trial (Koukourakis 2000) included adults with solid tumours re-
ceiving radiotherapy. Eight trials were found to be at high risk of
bias (Antonadou 2002; Bourhis 2000; Brizel 2000; Haddad 2009;
Koukourakis 2000; Spencer 2005; Vacha 2003; Veerasarn 2006)
and three trials were found to be at unclear risk of bias (Buentzel
2006; Buntzel 1998; Hartmann 2001).
Three trials provided data for the outcome of any mucositis. There
was a significant but small benefit for amifostine preventing mu-
cositis in this outcome category with RR = 0.95 (95% CI 0.91 to
0.99, P = 0.007, Analysis 3.1).
Six heterogeneous trials provided data for moderate plus severe
mucositis demonstrating a benefit for amifostine compared with
placebo or no treatment, RR = 0.75 (95% CI 0.58 to 0.96, P =
0.02, Analysis 3.2). However, this meta-analysis showed substan-
tial heterogeneity: Chi2 = 25.86, df = 5, P < 0.0001, I2 = 81%,
which is not explained by cancer treatment (radiotherapy or che-
motherapy) or dose of amifostine.
Nine trials provided data for severemucositis and the pooledmeta-
analysis showed weak evidence of a possible benefit for amifostine
in the prevention of severe mucositis, RR = 0.68 (95% CI 0.45 to
1.03, P = 0.07, Analysis 3.3).
A further trial (Vacha 2003) at high risk of bias provided a graph
of weekly mean mucositis scores and the text indicated that there
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was a statistically significant difference in favour of amifostine
compared to no treatment at 2 weeks, however no overall result
was given in this paper (Additional Table 2).
The results from these 11 studies indicate that there is weak un-
reliable evidence that amifostine may prevent oral mucositis in
adults.
Benzydamine versus placebo
Four studies compared benzydamine mouthwash (marketed as
Difflam®) with placebo, in a combined total of 332 patients.
Kazemian 2009 found a statistically significant reduction in severe
mucositis and Prada 1987 found a statistically significant reduc-
tion in the development of any mucositis associated with benzy-
damine (Additional Table 1). Both studies were assessed as being
at unclear risk of bias.
Two further studies (Epstein 1989; Epstein 2001), both assessed as
being at unclear risk of bias, compared benzydamine with placebo
and used other mucositis indices to evaluate the outcome. Both
trials reported statistically significant differences in favour of ben-
zydamine (Additional Table 2).
There is weak unreliable evidence that the use of benzydamine
may reduce the development of mucositis.
Chlorhexidine versus placebo/no treatment (Analysis 4.1;
Analysis 4.2; Analysis 4.3)
Nine trials, with a total of 692 participants, compared chlorhex-
idine mouthwash with either a placebo or no treatment con-
trol group. Four trials (Dodd 1996; Ferretti 1988; Foote 1994;
Sorensen 2008) provided data for the first outcome category (any
mucositis), three trials (Foote 1994; Pitten 2003; Sorensen 2008 )
provided data for the second outcome level, moderate plus severe
mucositis, and four trials (Foote 1994; Sorensen 2008; Spijkervet
1989; Wahlin 1989) provided data for severe mucositis (grade 3
or greater).
Madan 2008 compared three active treatments: chlorhexidine,
povidone iodine, and salt/soda mouthwashes with placebo, and
McGaw 1985 compared chlorhexidine mouthwash with placebo,
and both these studies presented data as mean mucositis scores for
each group (Additional Table 1).
Three studies were found to be at low risk of bias (Foote 1994;
Pitten 2003; Madan 2008), one study was found to be at high
risk of bias (Wahlin 1989). The remaining five studies were found
to be at unclear risk of bias (Dodd 1996; Ferretti 1988; McGaw
1985; Sorensen 2008; Spijkervet 1989).
There was substantial heterogeneity in the meta-analysis of any
mucositis (Chi2 = 30.49, df = 3, P < 0.00001, I2 = 90%, Analysis
4.1) and moderate plus severe (Chi2 = 10.84, df = 2, P = 0.004, I
2 = 82%, Analysis 4.2) mucositis levels which may be partly due
to clinical differences between the studies in terms of the can-
cer type and treatment. In one trial (Foote 1994) patients re-
ceived radiotherapy for head and neck cancer, in three trials (Dodd
1996; Pitten 2003; Sorensen 2008) patients received chemother-
apy for either solid tumours or mixed cancers and in the fifth study
(Ferretti 1988) patients were undergoing chemotherapy condi-
tioning prior to bone marrow transplant.
There was no evidence that chlorhexidine was more effective
than placebo or no treatment for any of the outcomes evaluated
(Analysis 4.1; Analysis 4.2; Analysis 4.3).
Two further trials (Madan 2008; McGaw 1985) at low and un-
clear risk of bias respectively, reported statistically significant dif-
ferences in mean mucositis scores in each group which favoured
chlorhexidine over placebo (Additional Table 2).
Overall, there is no evidence of a benefit for chlorhexidine com-
pared with placebo or no treatment, for the prevention of mucosi-
tis.
Cryotherapy (ice chips) versus no treatment (Analysis 5.1;
Analysis 5.2; Analysis 5.3)
Six trials (Cascinu 1994; Gori 2007; Lilleby 2006; Mahood 1991;
Sorensen 2008; Svanberg 2007) compared cryotherapy (ice chips)
with either no treatment or placebo (saline) control. Five trials
used a parallel group design and one (Mahood 1991) was a cross-
over trial. Three of these studies investigated the use of cryother-
apy in patients receiving chemotherapywith 5-FU (Cascinu 1994;
Mahood 1991; Sorensen 2008); participants in the trial by Gori
2007 received methotrexate, in Lilleby 2006 they were receiving
melphalan conditioning in preparation for stem cell transplanta-
tion, and in Svanberg 2007 patients received either chemother-
apy or total body irradiation prior to bone marrow or stem cell
transplantation. Four of these studies were found to be at high
risk of bias, and two studies was found to be at unclear risk of
bias (Mahood 1991; Sorensen 2008). Five trials presented data in
a format suitable for inclusion in meta-analysis.
There was evidence of a benefit associated with the use of ice chips
for each of the three outcome categories of mucositis, with RRs of
0.74 (95% CI 0.57 to 0.95, P = 0.02, Analysis 5.1), 0.53 (95%
CI 0.31 to 0.91, P = 0.02, Analysis 5.2) and 0.36 (95% CI 0.17
to 0.77, P = 0.008, Analysis 5.3) respectively. However, substan-
tial heterogeneity, likely to be related to the diversity of clinical
conditions and treatments, was also identified in each meta-anal-
ysis: Chi2 = 14.77, df = 4, P = 0.005, I2 = 73% for any mucositis
(Analysis 5.1), Chi2 = 19.02, df = 4, P = 0.0008, I2 = 79% for
moderate plus severe (Analysis 5.2), and Chi2 = 14.31, df = 4, P =
0.006, I2 = 72% for the severe outcome category (Analysis 5.3).
The trial by Svanberg 2007 also found that cryotherapy reduced
the development of mucositis and oral pain requiring treatment
with opioids (Additional Table 2).
Overall, these six heterogeneous trials provide some evidence, with
substantial risk of bias, that ice chips are effective in preventing
or reducing the severity of mucositis in patients receiving chemo-
therapy and/or radiotherapy.
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Glutamine versus placebo/usual care (Analysis 6.1; Analysis
6.2; Analysis 6.3)
Ten trials (Anderson 1998; Cerchietti 2006; Choi 2007; Dickson
2000; He 2008; Huang 2000; Jebb 1994; Li 2006; Okuno 1999;
Sornsuvit 2008) evaluating 433 patients compared the use of glu-
tamine with either a placebo (nine trials) or best supportive care
(Choi 2007). Two of these trials were designed as cross-over stud-
ies (Anderson 1998; Jebb 1994) and both had data from more
than 40% of randomised participants missing from the outcome
evaluation. The remaining eight trials used a parallel group design.
The smallest trial evaluated only 13 patients (Anderson 1998) and
the largest evaluated 124 patients (Okuno 1999). Three trials were
conducted in the USA (Anderson 1998; Dickson 2000; Okuno
1999), two in China (He 2008; Li 2006), and one each in Ar-
gentina (Cerchietti 2006), Korea (Choi 2007), Taiwan (Huang
2000), Thailand (Sornsuvit 2008), and the UK (Jebb 1994). Two
trials were conducted in head and neck cancers undergoing ra-
diation (Huang 2000) or chemoradiation (Cerchietti 2006). Five
studies were conducted in patients with solid cancers receiving
radiotherapy (Anderson 1998; Choi 2007; He 2008; Jebb 1994;
Li 2006). The remaining three studies were conducted in pa-
tients with cancers of the blood receiving chemotherapy (Sornsuvit
2008), a group of patients with mixed cancers receiving a mix of
radiotherapy and chemotherapy (Dickson 2000) and a group of
patients, with unclear cancer type, receiving chemotherapy.
Three trials used a glutamine suspension and instructed patients
to either swish it around the mouth and swallow, twice daily (
Anderson 1998; Okuno 1999) or swish and then expectorate (
Huang 2000). A further four trials compared oral supplementation
with 30 grams of glutamine daily (Choi 2007; Dickson 2000; Li
2006) or 15 grams per day (Jebb 1994).
For all three levels of mucositis prevention (any mucositis, moder-
ate to severe or severe), there was no evidence that oral glutamine
was different from placebo in the groups of five studies which re-
ported each level of mucositis (RR = 0.78, 95% CI 0.57 to 1.08,
P = 0.13, Analysis 6.1; RR = 0.88, 95% CI 0.69 to 1.12, P = 0.31,
Analysis 6.2; and RR = 0.69, 95% CI 0.37 to 1.29, P = 0.24,
Analysis 6.3 respectively. There was substantial heterogeneity be-
tween these studies, in part due to the lower dose in two studies
(Jebb 1994 15 g/day, Huang 2000 swish and expectorate) and the
lack of a placebo control in another study which was assessed as
being at high risk of bias (Choi 2007). The risk of bias was assessed
as high in Huang 2000 and unclear in the other five studies, but it
should be noted that both the cross-over studies (Anderson 1998;
Jebb 1994) had in excess of 40% loss to follow-up.
The remaining three studies compared intravenous (IV) glutamine
supplementation with placebo using approximately 30 grams/day
(Cerchietti 2006; Sornsuvit 2008) or 20 grams/day added to par-
enteral nutrition (He 2008). These trials were small (16 to 48
participants) and all are assessed as being at unclear risk of bias.
Only one trial reported the prevention of any grade of mucositis
or moderate to severe mucositis and found no difference between
glutamine and placebo (Sornsuvit 2008). All three trials (including
a total of 93 participants) reported the outcome of prevention of
severe mucositis, and found a statistically significant 75% decrease
in severe mucositis associated with IV glutamine supplementation
(RR = 0.25, 95% CI 0.10 to 0.62, P = 0.002, Analysis 6.3). This
result should be interpreted with caution as it is based on small
numbers of participants in studies at unclear risk of bias.
Overall, there is no evidence of a benefit for oral glutamine sup-
plementation in the prevention of mucositis but there is weak ev-
idence, from small trials at unclear risk of bias, that intravenous
glutamine supplementation may be beneficial for the prevention
of severe mucositis.
G-CSF (Analysis 7.1; Analysis 7.2)
Three trials, ranging in size from 14 to 195 patients, compared
granulocyte colony-stimulating factor (G-CSF) with placebo
(Crawford 1999; Schneider 1999; Su 2006) (total n = 249) and
one compared G-CSF with no treatment (Katano 1995) (n =
14), for the prevention of mucositis associated with chemotherapy
(Crawford 1999; Katano 1995) for solid tumours, or chemoradio-
therapy (Schneider 1999) or radiotherapy (Su 2006) for head and
neck cancers. Of the four studies in this group, Crawford 1999
has unclear risk of bias, Katano 1995 has high risk of bias, and
both Su 2006 and Schneider 1999 were found to be at low risk
of bias. However, the data presented in the Schneider 1999 paper
are from an interim analysis after the trial was stopped early for
reasons that are unclear. In Analysis 7.1 two trials show a benefit
associated with G-CSF in the prevention of any mucositis and two
do not. As well as substantial clinical heterogeneity with regard to
the primary tumours and cancer treatments, there is a very high
level of statistical heterogeneity (Chi2 = 20.48, df = 3, P = 0.0001,
I2 = 85%) among these four trials such that combining the results
bymeta-analysis is not appropriate. There was a statistically signif-
icant reduction in the incidence of severe mucositis in the G-CSF
groups compared to placebo (RR 0.36, 95% CI 0.15 to 0.86, P =
0.02, Analysis 7.2) in two homogenous trials (Schneider 1999; Su
2006). However, Su 2006 found no statistically significant differ-
ence between G-CSF and placebo in the prevention of moderate
plus severe mucositis.
Overall there is weak evidence that G-CSF may be beneficial in
the prevention of severe mucositis in patients with head and neck
cancer undergoing radiotherapy.
GM-CSF versus placebo/no treatment (Analysis 8.1; Analysis
8.2; Analysis 8.3)
Eight trials compared granulocyte/macrophage colony-stimulat-
ing factor (GM-CSF) with a placebo or no treatment control
group. Five trials were placebo controlled (Cartee 1995; Dazzi
2003; Ifrah 1999; Nemunaitis 1995; van der Lelie 2001) and three
trials had a no treatment control group (Chi 1995; Makkonen
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2000; McAleese 2006). Three studies were conducted in patients
receiving chemotherapy (Chi 1995) or radiotherapy for head and
neck cancer (Makkonen 2000; McAleese 2006). Two studies were
conducted in patients with solid cancers receiving chemotherapy
(Cartee 1995;Dazzi 2003). The remaining studieswere conducted
in patients with a mix of cancers receiving either radiotherapy (van
der Lelie 2001) or chemotherapy (Ifrah 1999), or a mix of differ-
ent therapies (Nemunaitis 1995).
Two trials were found to be at low risk of bias (Cartee 1995; Dazzi
2003), two trials were found to be at high risk of bias (Chi 1995;
Makkonen 2000) and the remaining four studies were assessed as
being at unclear risk of bias.
Two trials provided data for any mucositis, and moderate to severe
mucositis outcome categories, with six trials providing data for
the severe mucositis outcome category. There was no statistically
significant difference betweenGM-CSF and control for any of the
outcome categories (Analysis 8.1; Analysis 8.2; Analysis 8.3).
In the trial by Makkonen 2000 all patients in both groups de-
veloped mucositis and “there was no significant difference in the
frequency or degree of radiation-induced mucositis between GM-
CSF and the control groups”. Chi 1995 reported a cross-over study
of 20 patients, assessed as being at high risk of bias, which showed
some period effect from the first treatment period to the second.
The study reports a statistically significant benefit favouring GM-
CSF.
Based on these eight trials of 433 patients there is no evidence that
GM-CSF is different from either placebo or no treatment in the
prevention of mucositis.
Honey versus no treatment control (Analysis 9.1; Analysis
9.2; Analysis 9.3)
Three trials (Biswal 2003; Motallebnejad 2008; Rashad 2008),
each with 40 randomised patients, compared honey with a no
treatment control for the prevention of mucositis. In Biswal 2003,
20 patients in Malaysia with head and neck cancer, who were un-
dergoing radiotherapy, smeared honey on their mouth, and then
swallowed slowly to coat the mucosa, both prior to and after ra-
diotherapy. Patients in the control group received radiotherapy
only. This intervention was replicated some 4 years later in Iran
(Motallebnejad 2008) in another group of 40 patients undergoing
radiotherapy for head and neck cancer and also in Egypt (Rashad
2008) in a group of patients undergoing chemoradiotherapy for
head and neck cancer. In Motallebnejad 2008 outcome assessors
were blinded to treatment allocation and risk of bias in this study
was assessed as unclear, and in the other two studies there was no
blinding or allocation concealment and risk of bias is assessed as
high. None of these trials provided any information on compli-
ance with treatment and none recorded any drop outs or losses to
follow-up.
There is weak unreliable evidence from these three small trials that
honey is associated with a moderate benefit with regard to the
prevention of any mucositis (RR 0.70, 85% CI 0.56 to 0.88, P
= 0.002), moderate to severe mucositis (RR 0.48, 95% CI 0.31
to 0.74, P = 0.0009) and severe mucositis (RR 0.26, 95% CI
0.13 to 0.52, P = 0.0002). However, in view of the considerable
statistical heterogeneity and high risk of bias these results should
be interpreted with caution.
Hydrolytic enzymes versus no treatment (Analysis 10.1;
Analysis 10.2)
Three trials (Dorr 2007; Gujral 2001; Kaul 1999) compared hy-
drolytic enzymes with either a placebo (Dorr 2007) or radiother-
apy only control, in a total of 210 patients receiving radiotherapy
for head and neck cancers. Dorr 2007 was double blind, but over-
all risk of bias was unclear, and Gujral 2001 and Kaul 1999 were
assessed as being at high risk of bias overall.
Two trials reported the outcome category of any mucositis (Gujral
2001; Kaul 1999) with conflicting results (Analysis 10.1) and con-
siderable statistical heterogeneity, so these data were not pooled.
All three trials provideddata for the preventionofmoderate plus se-
vere mucositis. There was considerable heterogeneity identified so
these datawere not pooled. The placebo controlled study found no
difference between the groups (Dorr 2007) but the other two stud-
ies, both at high risk of bias, found a benefit favouring hydrolytic
enzymes with radiotherapy compared to radiotherapy alone which
was not statistically significant.
The three trials also had some differences with regard to the in-
gredients in the hydrolytic enzyme intervention. Dorr 2007 and
Gujral 2001 used a preparation containing papain 100mg, trypsin
40 mg and chymotrypsin 40 mg, and Kaul 1999 used a prepara-
tion containing papain, trypsin, chymotrypsin, pancreatin, rutin
and bromelain.
In summary, the evidence from these three trials is conflicting, and
all trials are at some risk of bias. There is insufficient evidence that
the use of hydrolytic enzymes to prevent mucositis associated with
radiotherapy for head and neck cancers is significantly different
from placebo or no treatment.
Iseganan versus placebo (Analysis 11.1; Analysis 11.2)
Two studies (Giles 2004; Trotti 2004), comprising a total of 1013
patients, both at unclear risk of bias, compared iseganan with
placebo for different outcome categories of mucositis. One study
was conducted in patients with a mix of cancers receiving a range
of different cancer treatments (Giles 2004). The other study was
conducted in patients with head and neck cancers receiving a mix
of cancer therapies (Trotti 2004). These studies provided data for
the moderate plus severe and severe outcome categories of mu-
cositis, and both meta-analyses showed no evidence of a difference
between iseganan and placebo (Analysis 11.1; Analysis 11.2).
Overall there is no evidence from these trials that iseganan is more
or less effective than placebo.
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Keratinocyte GF versus placebo (Analysis 12.1; Analysis
12.2; Analysis 12.3)
Seven trials compared keratinocyte growth factor (GF) (marketed
as either Palifermin® or Velafermin®) with placebo (Blazar 2006;
Brizel 2008; Freytes 2004;Meropol 2003;Rosen 2006; Spielberger
2004; Vadhan-Raj 2010). Six studies were judged to be at unclear
risk of bias. One study was judged to be at high risk of bias (
Vadhan-Raj 2010). Two provided data for any mucositis, seven
for moderate plus severe and six for severe. All three mucositis
outcome categories showed evidence of a benefit associated with
keratinocyte GF with RR 0.82 (95% CI 0.71 to 0.94, P = 0.005,
Analysis 12.1) for any mucositis, RR 0.74 (95% CI 0.62 to 0.89,
P = 0.002, Analysis 12.2) for moderate plus severe mucositis and
RR 0.72 (95% CI 0.58 to 0.90, P = 0.004, Analysis 12.3) for
severe mucositis.
However, there is substantial heterogeneity in the any mucositis
(Chi2 = 10.11, df = 1, P = 0.001, I2 = 90%, Analysis 12.1) and
moderate to severe mucositis outcome categories (Chi2 = 50.75,
df = 6, P < 0.00001, I2 = 88%, Analysis 12.2). From the table
below there is no evidence that this heterogeneity can be explained
by differences between the studies in terms of cancer type, cancer
treatment, dose or type of keratinocyte GF.
From these seven trials there is some evidence that keratinocyte
growth factor is effective in the prevention of mucositis.
Author Type of
keratinocyte
Dose of
keratinocyte
Schedule Num-
ber and gender
of patients
Cancer type Treatment
Blazar 2006 Palifermin 40 µg/kg or 60
µg/kg
Co-
hort 1: patients
randomised
toplaceboor pal-
ifermin at either
40 µg (8 pa-
tients, total dose
240 µg) or 60 µg
(10 patients, to-
tal dose 360 µg)
per day for 3
days before con-
ditioning (days -
11 to -9) and
for 3 days after
transplant (days
0, 1 and 2)
Cohort 2: 14
patients received
palifermin at 60
µg/day,
for 3 days be-
fore condition-
ing (day -11 to -
9) and then for 6
days after trans-
plant (days 0-2
and then days 7-
9) (9 doses total).
Total dose of pal-
ifermin received
was 540 µg
100 (58M/ 42F) Leukaemia, lym-
phoma,
myelodysplastic
syndrome
Allogeneic stem
cell transplant.
Cyclophos-
phamide 60 mg/
kg per day, TBI
total dose = 13.2
Gy (fractionated
as 165 Gy twice
daily for 4 days)
or
busulfan 1 mg/
kg per dose given
4 times daily for
4 days then cy-
clophos-
phamide 60 mg/
kg per day for 2
days
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Cohort 3: 37 pa-
tients
received palifer-
min at 60 µg/
day for 3 days be-
fore condition-
ing (day -11 to -
9) and then for 9
days after trans-
plant (days 0-2,
7-9 and 14-16)
(12 doses total).
Total dose of pal-
ifermin received
was 720 µg
Brizel 2008 Palifermin 60 µg (67 pa-
tients)
1 dose adminis-
tered weekly on
the Friday before
the first week of
chemother-
apy (then con-
tinued each Fri-
day for 7 consec-
utive weeks). 2
additional doses
given weeks 8
and 9
99 (82M/17F) Head and neck Chemotherapy
(cisplatin 20 mg/
m2/d IV bolus
and fluorouracil
1000 mg/m2/
d continuous in-
fusion) adminis-
tered for first 4
days of the first
and fifth weeks
of radiotherapy
Ra-
diotherapy (daily
fractions of 2 Gy
until 70 Gy)
or
hyper-
fractionated ra-
diotherapy (1.25
Gy twice daily
until 72 Gy)
Freytes 2004 Repifermin 25 µg/kg or 50
µg/kg
Cohort 1: 25 µg/
kg repifermin.
Cohort 2: 50 µg/
kg repifermin
42 (31M/11F) Hae-
matologic malig-
nancies or lym-
phoma
Autologous stem
cell transplant.
Cyclophos-
phamide, etopo-
side and carmus-
tine, or
melphalan
monotherapy, or
melphalan com-
bination, or cy-
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clophosphamide
+ TBI or
thiotepa
+ TBI or cyclo-
phosphamide +
busulfan
Meropol 2003 Palifermin 1 µg/kg/d or 10
µg/kg/d or 20
µg/kg/d or 40
µg/kg/d or 60
µg/kg/d or 80
µg/kg/d
All cohorts
received palifer-
min on days 1 to
3 of each cycle
Cohort 1: 1 µg/
kg/d palifermin
Cohort 2: 10 µg/
kg/d palifermin
Cohort 3: 20 µg/
kg/d palifermin
Cohort 4: 40 µg/
kg/d palifermin
Cohort 4: 60 µg/
kg/d palifermin
Cohort 5: 80 µg/
kg/d palifermin.
27
placebo patients
(randomised 1:1
in cohort 1 and
2:1 in all other
cohorts)
81(47M/34F) Metastatic
colorectal cancer
Leucov-
orin 20 mg/m2
by IV followed
immediately by
425 mg/m2 for 5
consecutive days
on days 4 to 8 of
each 28 day cycle
Rosen 2006 Palifermin 40 µg/kg per day
(28 patients)
3 consecutive
days before che-
motherapy
64 (42M/22F) Solid tumours
(colon and rec-
tum)
Chemotherapy
(5-FU 425 mg/
m2/day IV for
5 days, leucov-
orin 20 mg/m2/
day for 5 days)
Spielberger 2004 Palifermin 60 µg/kg per day 3 consec-
utive days (start-
ing 3 days before
TBI) and 3 con-
secutive doses af-
ter transplanta-
tion (day 0, day
1, day 2)
212 (131M/
81F)
Lymphoma,
leukaemia and
multiple
myeloma
Autologous stem
cell transplant.
TBI (total 1200
Gy)
chemotherapy
included etopo-
side (60 mg/kg)
and cyclophos-
phamide (100
mg/kg)
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Vadhan-Raj
2010
Palifermin 180 µg/kg 1 dose 3 days be-
fore chemother-
apy
48 (25M/23F) Sarcoma Chemotherapy
(doxorubicin 90
mg/m
2 over 72 hours,
ifosfamide 10m/
m2 3 hour infu-
sion for 4 days)
Laser versus placebo or sham control (Analysis 13.1;
Analysis 13.2; Analysis 13.3)
Five studies (Antunes 2007; Bensadoun 1999; Chor 2010; Cruz
2007; Schubert 2007), comprising a total of 234 patients, com-
pared laser with a sham laser placebo or no treatment control. Data
were provided for all three outcome categories of mucositis. Four
of these trials were found to be at unclear risk of bias (Bensadoun
1999; Chor 2010; Cruz 2007; Schubert 2007) and one was as-
sessed to be at high risk of bias (Antunes 2007). Two trials were
conducted in patients with a mix of cancers (Antunes 2007; Cruz
2007), one in patients with head and neck cancer undergoing
radiotherapy (Bensadoun 1999), one in patients with haemato-
logical malignancies undergoing a range of treatments (Schubert
2007) and in the remaining study, the type of cancer and cancer
treatment was unclear (Chor 2010).
There was no evidence of a difference in the incidence of any
mucositis (RR 0.91, 95% CI 0.71 to 1.17, P = 0.47, Analysis
13.1) ormoderate plus severemucositis (RR 0.64, 95%CI 0.38 to
1.08, P = 0.10, Analysis 13.2) between the laser and control, but
there was a statistically significant 80% reduction in the incidence
of severe mucositis in the laser group compared to sham or no
treatment control (RR 0.20, 95% CI 0.06 to 0.62, P = 0.006,
Analysis 13.3).
There was substantial heterogeneity in both the moderate plus
severe (Chi2 = 4.62, df = 1, P < 0.03, I2 = 78%, Analysis 13.2) and
severe outcome categories (Chi2 = 3.20, df = 1, P = 0.07, I2 = 69%,
Analysis 13.3), which may be partly explained by a variation in the
laser wavelengths used in the trials: one trial used a wavelength of
660 nm (Antunes 2007) while the other study used a wavelength
of 780nm (Cruz 2007). In addition,Cruz 2007 recruited children,
while Antunes 2007 recruited adults. Both studies were conducted
in patients undergoing stem cell transplantation.
The study by Bensadoun 1999 reported the outcome in terms of a
mean grade of mucositis in each group over the duration of radio-
therapy, and found a statistically significant difference favouring
laser (Additional Table 2). Schubert 2007 compared two different
lasers (650 nm and 780 nm) with a placebo arm in patients un-
dergoing myeloablative therapy prior to bone marrow transplan-
tation. Mean mucositis scores using the oral mucositis index were
reported every 3 days over the 21 day treatment period. “The peak
severity of mucositis that generally occurs during the second week
of transplant was reduced in the 650 nm laser group” (Additional
Table 2).
Overall there is weak evidence from two small studies at some
risk of bias that low energy laser application may be beneficial in
preventing severe mucositis.
Oral care protocol versus none (Additional Table 1)
Two studies (Borowski 1994; Shieh 1997) compared an intense
oral care protocol with none (usual care). Borowski 1994 included
166 patients both adults and children undergoing bone marrow
transplantation (study has unclear risk of bias) and Shieh 1997
included 30 adults undergoing radiotherapy for head and neck
cancers (study at high risk of bias).
Borowski 1994 found no evidence of a difference between the
groups with regard to the prevention of moderate plus severe or
severe mucositis, but Shieh 1997 found a statistically significant
difference favouring the oral care protocol in the prevention of
any mucositis (Additional Table 1).
Based on these two studies there is no evidence that specific oral
care protocols are any different from usual care with regard to the
prevention of mucositis.
Pilocarpine versus placebo (Analysis 14.1; Analysis 14.2;
Additional Table 1)
Two trials, both found to be at unclear risk of bias, compared
pilocarpine versus placebo in patients withmixed cancers receiving
a range of therapies (Lockhart 2005) and patients with head and
neck cancer receiving radiotherapy (Scarantino 2006). The two
trials showed inconsistent results and no evidence of benefit was
found with regard to the prevention of mucositis for any of the
outcome categories (Analysis 14.1; Analysis 14.2; Additional Table
1).
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Therefore there is no evidence from these two studies that pilo-
carpine is more or less effective than placebo in preventing mu-
cositis.
Povidone versus water (Analysis 15.1; Analysis 15.2; Analysis
15.3)
Two trials compared povidone with water or saline (Rahn 1997;
Vokurka 2005). One of these studies was found to be at unclear
(Vokurka 2005) risk of bias, and the other study was found to
be at high risk of bias (Rahn 1997). No statistically significant
differences were found for any of the outcome categories (Analysis
15.1; Analysis 15.2; Analysis 15.3).
There is no evidence from these two studies that povidone is more
or less effective than placebo in preventing mucositis.
Prostaglandin versus placebo (Analysis 16.1; Analysis 16.2)
Four trials, all found to be at unclear risk of bias, compared
prostaglandin with a placebo (Duenas 1996; Hanson 1995; Labar
1993; Veness 2006). Participants (total of 228) had a range of
cancers including head and neck (Hanson 1995; Veness 2006),
haematological (Labar 1993) and mixed locations (Duenas 1996),
treated by radiotherapy, radiotherapy and/or chemotherapy, and
chemotherapy respectively. There was no statistically significant
difference between prostaglandin and placebo for the prevention
of any mucositis (Analysis 16.1), or the prevention of severe mu-
cositis (Analysis 16.2). The trial by Hanson 1995 reported con-
flicting results for results for the two study centres (Additional
Table 1).
There is no evidence from these four trials that prostaglandin is
different from placebo in the prevention of mucositis.
PTA antibiotic pastille or paste versus placebo (Analysis
17.1; Analysis 17.2)
Two trials compared antibiotic + antifungal pastilles (containing
polymixin, tobramycin and amphotericin (PTA)) with a placebo
(Stokman 2003; Symonds 1996) and one trial compared PTA an-
tibiotic paste with a placebo (Wijers 2001). In total 356 patients,
all undergoing radiotherapy for head and neck cancers, were in-
cluded in the trials. Stokman 2003 was assessed as being at low
risk of bias and the other two trials at unclear risk of bias.
Two trials provided data for any mucositis (Symonds 1996;Wijers
2001) and the pooled estimate showed evidence of a benefit favour-
ing PTA for the prevention of any mucositis (RR 0.87, 95% CI
0.78 to 0.96, P = 0.008, Analysis 17.1).With regard to the preven-
tion of severe mucositis there was evidence of a difference between
PTA and placebo in the two studies that provided data for this
outcome (Stokman 2003; Wijers 2001; Analysis 17.2). Likewise
there was no statistically significant difference with regard tomod-
erate plus severe mucositis in the only study that provided data for
this outcome category (Wijers 2001; Additional Table 1).
In summary there is some weak evidence that the use of PTA
applied locallymay preventmucositis in adults with head and neck
cancer undergoing radiotherapy, but further high quality trials are
required to confirm this.
Radiation: morning versus afternoon (Analysis 18.1)
Two trials (Bjarnason 2009; Goyal 2009), with a total of 428 pa-
tients, compared radiotherapy delivered in the morning to admin-
istration of radiotherapy in the evening, in patients with head and
neck cancers. One of these studies was found to be at high risk of
bias (Bjarnason 2009) and the other study was assessed as being at
unclear risk of bias (Goyal 2009). No evidence of a difference was
found for the prevention of severe mucositis (Analysis 18.1) from
the two studies, nor for the prevention of moderate plus severe
mucositis in Goyal 2009 (Additional Table 3).
From these two studies there is no evidence that the time of day
that radiotherapy treatment is delivered makes a difference with
regard to the prevention of mucositis.
Sucralfate versus placebo/usual care (Analysis 19.1; Analysis
19.2; Analysis 19.3)
Twelve parallel group trials evaluated the use of sucralfate; 10 com-
pared sucralfate mouthwash with placebo (Carter 1999; Castagna
2001; Cengiz 1999; Epstein 1994; Franzen 1995; Lievens 1998;
Makkonen 1994;Nottage 2003; Pfeiffer 1990; Shenep 1988), and
one compared sucralfate mouthwash with usual care (Scherlacher
1990). The remaining trial in this group compared sucralfate
mouthwash with placebo, but also instructed all participants to
apply sucralfate gel to the skin on one side of the radiation area (re-
sulting in possible contamination of the placebo group) (Evensen
2001). Four trials were conducted in Scandinavia (Evensen 2001;
Franzen 1995; Makkonen 1994; Pfeiffer 1990), four in Europe
(Castagna 2001; Cengiz 1999; Lievens 1998; Scherlacher 1990),
two in the USA (Carter 1999; Shenep 1988), and two in Canada
(Epstein 1994;Nottage 2003).Only one of these studieswas found
to be at low risk of bias (Shenep 1988). All other studies were
assessed as being at unclear risk of bias.
Most of the trials recruited participants with head and neck cancer
undergoing radiotherapy (Cengiz 1999; Epstein 1994; Evensen
2001; Franzen 1995; Lievens 1998; Makkonen 1994; Scherlacher
1990;) and of the remainder two recruited participants with head
and neck cancer undergoing either chemotherapy or combined
treatments (Carter 1999; Pfeiffer 1990) and three recruited pa-
tients with both a range of cancers and treatment regimens. Pa-
tients were instructed to swish the solution in their mouths for 5
minutes, three or four times a day and either swallow the solution
or expectorate.
Because the intervention and comparison in Evensen 2001 are
unique in this sucralfate group, the results are reported in Addi-
tional Table 1. There was no evidence from this study, at unclear
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risk of bias, that sucralfate mouthwash plus sucralfate gel applied
to the skin is different from sucralfate gel alone in the prevention
of mucositis.
There was no evidence of a difference between the sucralfate group
and the placebo group in the proportion of patients who developed
any mucositis in the three trials, all at unclear risk of bias, that
reported this outcome (RR 1.00, 95% CI 0.91 to 1.10, P = 0.93,
Analysis 19.1).
However there was some evidence that sucralfate may be beneficial
in the prevention of moderate plus severe mucositis in the four
trials that reported this outcome (RR 0.75, 95% CI 0.54 to 1.04,
P = 0.08, Analysis 19.2). One of these trials was at low risk of bias
and the remaining three were assessed as unclear.
Seven trials, one at low and six at unclear risk of bias, provide
evidence that sucralfate was effective in the prevention of severe
mucositis, with a 33% reduction in severe mucositis in the sucral-
fate group compared to placebo (RR 0.67, 95% CI 0.48 to 0.92,
P = 0.01, Analysis 19.3).
A further two trials (Epstein 1994; Lievens 1998) reported out-
come data in a different format, but neither found a statistically
significant difference between sucralfate and placebo in the pre-
vention of mucositis (Additional Table 1).
From 9 trials including a total of 516 participants, which com-
pared sucralfate mouthwash with placebo, and provided data for
meta-analysis, there is some evidence that sucralfate may prevent
moderate plus severe mucositis and stronger evidence of a 33%
reduction in severe mucositis.
Zinc sulphate versus placebo
Two trials (Ertekin 2004; Lin 2006) including a total of 127 pa-
tients with head and neck cancer undergoing chemotherapy and/
or radiotherapy compared oral zinc supplementationwith placebo.
Both trials were assessed as being at unclear risk of bias.
Ertekin 2004 found no statistically significant difference between
zinc supplementation and placebo with regard to the prevention
of any mucositis, but a statistically significant difference favouring
zinc supplementation in the prevention of moderate plus severe
and severe mucositis (Additional Table 1). The other study evalu-
ating this comparison (Lin 2006) presented results in graphs and
stated that there was no statistically significant difference between
the groups (Additional Table 2).
There is conflicting evidence from these two studies and more
research is necessary to determine whether zinc supplementation
is better than placebo with regard to the prevention of mucositis.
Comparisons evaluated by a single study
Additional Table 1 presents the data from the comparisons for
which there was only one trial evaluating a comparison or only
one trial reporting data for one or more of the mucositis outcome
categories.
We have summarised the data from the single trials below, indi-
cating where a statistically significant difference is shown (detailed
data given in Additional Table 1).
• Aciclovir versus placebo - Bubley 1989: no statistically
significant difference for the prevention of any mucositis. Study
assessed as being at unclear risk of bias.
• BCoG (bacitracin, cotrimoxazole, gentamicin) antibiotic
pastilles - El Sayed 2002: no statistically significant difference
between antibiotic and placebo for any of the outcome
categories. Study assessed as being at unclear risk of bias.
• Beta carotene versus no treatment control - Mills 1988: no
statistically significant difference for severe mucositis. Study
assessed as being at high risk of bias.
• Camomile versus placebo - Fidler 1996: no statistically
significant difference for all levels of mucositis. Study assessed as
being at unclear risk of bias.
• Chewing gum versus no chewing gum - Gandemer 2007:
no statistically significant difference for any or severe mucositis.
Study assessed as being at high risk of bias.
• Clarithromycin (systemic antibiotic) versus no treatment -
Yuen 2001: no statistically significant difference for moderate
plus severe mucositis. Study assessed as being at high risk of bias.
• Dental stent versus no treatment control - Qin 2007: no
statistically significant difference for moderate plus severe or
severe mucositis. Study assessed as being at unclear risk of bias.
• Epidermal growth factor versus placebo - Wu 2009:
statistically significant benefit for prevention of moderate plus
severe mucositis. Study judged at high risk of bias.
• Histamine gel versus placebo - Elad 2006: no statistically
significant difference for any or severe mucositis. Study assessed
as being at unclear risk of bias.
• Indomethacin versus placebo - Pillsbury 1986: no
statistically significant difference for the prevention of moderate
plus severe mucositis. Study assessed as being at unclear risk of
bias.
• Indigo wood root versus saline - You 2009: no statistically
significant difference for moderate to severe mucositis.
Significant benefit for the prevention of severe mucositis. Study
assessed as being at unclear risk of bias.
• Intestinal trefoil factor versus placebo - Peterson 2009:
statistically significant benefit for prevention of any mucositis
and moderate plus severe mucositis, no statistically significant
difference for severe only mucositis. Study assessed as being at
unclear risk of bias.
• Pentoxifylline versus no treatment - Attal 1993: no
statistically significant difference for moderate to severe
mucositis. Study assessed as being at unclear risk of bias.
• Prednisone versus placebo - Leborgne 1997: no statistically
significant difference for all levels of mucositis. Study assessed as
being at unclear risk of bias.
• Propantheline versus placebo - Ahmed 1993: no statistically
significant difference for any mucositis. Study assessed as being at
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unclear risk of bias.
• Shenqi-fanghou versus no treatment - Hu 2005: statistically
significant benefit for the prevention of any, moderate plus severe
and severe mucositis. Study assessed as being at unclear risk of
bias.
• Superoxide dismutase (SOD) versus placebo - Tu 1998: no
statistically significant difference for the prevention of any
mucositis. Study assessed as being at unclear risk of bias.
• Traumeel versus placebo - Oberbaum 2001: no statistically
significant difference was found for any mucositis. Study assessed
as being at low risk of bias.
Comparisons of two active interventions for
preventing mucositis
Most of the studies compared an active intervention to either
placebo or no treatment. However, two trials (Freytes 2004;
Sorensen 2008) had three comparative treatment arms (two ac-
tive plus placebo) and the results of the direct comparisons are
included in Additional Table 3 and summarised below. A further
two of these trials (Bjarnason 2009; Goyal 2009) evaluated morn-
ing versus afternoon delivery of radiotherapy and the results are
described in the section ’Interventions with more than one trial’
because both studies used the same interventions. Further details
are in Analysis 18.1 and Additional Table 3.
A further seven trials directly compared two active interventions
only (Arun Maiya 2006; Dai 2009; Huang 2003; Rocke 1993;
Saarilahti 2002; Wang 2002; Watanabe 2010). The data reported
in these trials are recorded in Additional Table 3, and the outcomes
are summarised in the list below.
• Chinese herbs (mix of six types) versus Dobell’s solution
(Wang 2002: significant benefit for prevention of any and
moderate plus severe mucositis. Study judged at unclear risk of
bias).
• Chinese herbs (mix of 11 types) versus Dobell’s solution
(Huang 2003: significant benefit for the prevention of moderate
plus severe and severe mucositis. Study judged at unclear risk of
bias).
• Chlorhexidine verus cryotherapy (Sorensen 2008: no
statistically significant difference for all levels of mucositis).
• Cryotherapy 30 versus 60 minutes (Rocke 1993: no
statistically significant difference for all levels of mucositis).
• GM-CSF versus sucralfate (Saarilahti 2002: no statistically
significant difference for moderate plus severe and severe
mucositis).
• Keratinocyte growth factor 50 versus 25 mg (Freytes 2004:
no statistically significant difference for moderate plus severe and
severe only mucositis).
• Laser versus povidone (Arun Maiya 2006: statistically
significant for moderate plus severe, and severe only mucositis.
Study judged at unclear risk of bias).
• Polaprezinc versus azulene (Watanabe 2010: statistically
significant benefit for polaprezinc for moderate plus severe, and
severe only mucositis).
• Yangyin humo decoctalion versus ’traditional Western
medicine’ (Dai 2009: significant benefit for the prevention of
moderate plus severe mucositis. Study judged at high risk of bias).
Where there was no statistically significant difference between the
interventions compared, it is acknowledged that this could be
because the interventions were either equally effective or equally
ineffective.
This review proposed to conduct subgroup analyses for different
cancer types, cancer treatments and age groups. We were unable to
undertake this as there were insufficient numbers of studies in the
subgroups. However we did look at whether the heterogeneity was
explained by different cancer types or treatments for amifostine
and keratinocyte growth factor, by undertaking a sensitivity anal-
ysis and this is reported under these interventions in the section
above.
We prepared summary of findings tables for those interventions
where there was a substantial body of evidence comprising a com-
bined total of at least 550 participants in at least three trials. Se-
lection of interventions to be included in summary of findings
tables was not influenced by the results of the trials. Five interven-
tions with a substantial body of evidence were identified. For four
interventions there was a substantial body of evidence showing
some effectiveness: cryotherapy (Summary of findings for themain
comparison), amifostine (Summary of findings 2), keratinocyte
growth factor (Summary of findings 3) and sucralfate (Summary
of findings 4). The body of evidence concerning chlorhexidine
(Summary of findings 5) showed no evidence that chlorhexidine
was different from placebo or no treatment in the prevention of
mucositis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Amifostine versus placebo/no treatment for preventing oral mucositis for patients with cancer receiving treatment
Patient or population: preventing oral mucositis for patients with cancer receiving treatment
Settings:
Intervention: Amifostine versus placebo/no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Amifostine versus
placebo/no treatment
Mucositis (any)
0-4 scale
Follow-up: median 28
days
Low risk population1 RR 0.95
(0.91 to 0.99)
430
(3 studies)
⊕⊕⊕©
moderate2
600 per 1000 570 per 1000
(546 to 594)
High risk population1
950 per 1000 902 per 1000
(865 to 941)
Mucositis (severe)
0-4 scale
Follow-up: median 28
days
Low risk population3 RR 0.68
(0.45 to 1.03)
845
(9 studies)
⊕©©©
very low4,5,6
300 per 1000 204 per 1000
(135 to 309)
High risk population3
650 per 1000 442 per 1000
(292 to 669)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control
groups of the included studies.
2 Two trials at high risk of bias and one unclear.
3 Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the
control groups of included studies.
4 Six trials at high risk of bias and three unclear.
5 Substantial heterogeneity, Chi squared 40.39, df=8, P<0..0001, I squared =80% with inconsistency (one trial favouring control)
6 Wide confidence intervals, small studies and/or low event rates
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Keratinocyte GF versus placebo for preventing oral mucositis for patients with cancer receiving treatment
Patient or population: patients with preventing oral mucositis for patients with cancer receiving treatment
Settings:
Intervention: Keratinocyte GF versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Keratinocyte GF versus
placebo
Mucositis (any)
0-4 scale
Follow-up: median 28
days
Low risk population1 RR 0.82
(0.71 to 0.94)
160
(2 studies)
⊕⊕©©
low2,3
600 per 1000 492 per 1000
(426 to 564)
High risk population1
950 per 1000 779 per 1000
(674 to 893)
Mucositis (severe)
0-4 scale
Follow-up: median 28
days
Low risk population4 RR 0.72
(0.58 to 0.9)
559
(6 studies)
⊕⊕©©
low5,6
300 per 1000 216 per 1000
(174 to 270)
High risk population4
650 per 1000 468 per 1000
(377 to 585)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;30
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control
groups of the included studies.
2 Two studies at unclear risk of bias
3 Substantial heterogeneity Chi squared =10.11 df=1, P=0.001, I squared =90%.
4 Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the
control groups of the included studies.
5 One study at high risk of bias and five at unclear risk of bias.
6 Moderate heterogeneity Chi squared 10.37, df=5,P=0.07, I squared =52%
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Sucralfate versus placebo/usual care for preventing oral mucositis for patients with cancer receiving treatment
Patient or population: preventing oral mucositis for patients with cancer receiving treatment
Settings:
Intervention: Sucralfate versus placebo/usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Sucralfate versus
placebo/usual care
Mucositis (any)
0-4 scale
Follow-up: median 28
days
Low risk population1 RR 0.98
(0.88 to 1.1)
222
(3 studies)
⊕⊕⊕©
moderate2
600 per 1000 588 per 1000
(528 to 660)
High risk population1
950 per 1000 931 per 1000
(836 to 1000)
Mucositis (severe)
0-4 scale
Follow-up: median 28
days
Low risk population3 RR 0.67
(0.48 to 0.92)
428
(7 studies)
⊕⊕⊕©
moderate4
300 per 1000 201 per 1000
(144 to 276)
High risk population3
650 per 1000 435 per 1000
(312 to 598)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;32
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control
groups of the included studies.
2 All studies at unclear risk of bias
3 Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the
control groups of the included studies.
4 One study at low risk of bias and six at unclear risk of bias
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Chlorhexidine versus placebo/no treatment for preventing oral mucositis for patients with cancer receiving treatment
Patient or population: preventing oral mucositis for patients with cancer receiving treatment
Settings:
Intervention: Chlorhexidine versus placebo/no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Chlorhexidine versus
placebo/no treatment
Mucositis (any)
0-4 scale
Follow-up: median 28
days
Low risk population1 RR 0.76
(0.47 to 1.24)
454
(4 studies)
⊕⊕©©
low2,3
600 per 1000 456 per 1000
(282 to 744)
High risk population1
950 per 1000 722 per 1000
(446 to 1000)
Mucositis (severe)
0-4 scale
Follow-up: median 28
days
Low risk population4 RR 0.82
(0.54 to 1.23)
244
(4 studies)
⊕⊕©©
low5,6
300 per 1000 246 per 1000
(162 to 369)
High risk population4
650 per 1000 533 per 1000
(351 to 800)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control
groups of the included studies.
2 One study at low risk of bias and three unclear.
3 Substantial heterogeneity Chi squared 30.49, df=3, P<0.0001, I squared = 90%.
4 Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the
control groups of the included studies.
5 One high risk of bias, two unclear and one low
6 Moderate heterogeneity Chi squared 7.44,df=3, P=0.06, I squared = 60%, with some inconsistency (only one study, at unclear risk
of bias, showing benefit)
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D I S C U S S I O N
Summary of main results
This update has identified a further 42 included trials which have
been published in less than 3 years, bringing the total number
of included studies up to 131. The trials included in this review
have evaluated 43 different interventions and recruited a total of
10,514 patients.
There is some evidence of a benefit for cryotherapy (ice chips) and
keratinocyte growth factor based on a body of evidence comprising
at least 6 trials and at least 550 participants for each of these
interventions. However all these trials were assessed as being at
either high or unclear risk of bias.
• Cryotherapy was found to be beneficial in the prevention
of all the outcome categories of mucositis. Specifically the
prevention of any mucositis RR = 0.74 (95% CI 0.57 to 0.95, P
= 0.02), moderate plus severe mucositis RR = 0.53 (95% CI 0.31
to 0.91, P = 0.02), and severe mucositis RR = 0.36 (95% CI
0.17 to 0.77, P = 0.008).
• Keratinocyte Growth Factor was found to be beneficial for
the prevention of all the outcome categories of mucositis, with
RR = 0.82 (95% CI 0.71 to 0.94, P = 0.005) for any mucositis,
RR = 0.74 (95% CI 0.62 to 0.89, P = 0.002) for moderate plus
severe mucositis and RR = 0.72 (95% CI 0.58 to 0.90, P =
0.004) for severe mucositis.
There is weak unreliable evidence of a benefit for the following
eight interventions based on a smaller body of evidence (2 to 5
trials) involving 90 to 350 participants. Most of the trials in this
group are assessed as being at either high or unclear risk of bias.
• Aloe vera: weak unreliable evidence that solution was
beneficial for the prevention of moderate to severe mucositis: RR
= 0.74 (95% CI 0.58 to 0.96; P = 0.02).
• Amifostine **: weak unreliable evidence from 11 low
quality trials (8 trials high risk of bias and 3 unclear risk of bias)
that amifostine is beneficial for the prevention of any mucositis:
RR = 0.95 (95% CI 0.91 to 0.99, P = 0.007) and moderate to
severe mucositis: RR = 0.75 (95% CI 0.58 to 0.96, P = 0.02).
• Glutamine (intravenous): weak unreliable evidence that
glutamine administered intravenously is beneficial for the
prevention of severe mucositis (RR = 0.25, 95% CI 0.10 to
0.62).
• Granulocyte - Colony Stimulating Factor *: (G-CSF)
weak evidence that G-CSF is effective for the prevention of
severe mucositis (RR = 0.36, 95% CI 0.15 to 0.86, P = 0.02)
based on two small trials at low risk of bias
• Honey: weak unreliable evidence, with substantial
heterogeneity, that honey may be beneficial in the prevention of
any mucositis (RR = 0.70, 85% CI 0.56 to 0.88, P = 0.002),
moderate to severe mucositis (RR = 0.48, 95% CI 0.31 to 0.74,
P = 0.0009) and severe mucositis (RR = 0.26, 95% CI 0.13 to
0.52, P = 0.0002).
• Laser: weak unreliable evidence that laser is beneficial for
the prevention of severe mucositis: RR = 0.20 (95% CI 0.06 to
0.62, P = 0.006).
• Polymixin/Tobramycin/Amphotericin (PTA) lozenges/
paste *: weak unreliable evidence that PTA lozenges may be
beneficial for the prevention of any mucositis: RR = 0.87 (95%
CI 0.78 to 0.96, P = 0.008).
• Sucralfate: evidence that sucralfate is effective in the
prevention of severe mucositis, with a 33% reduction in severe
mucositis in the sucralfate group compared to placebo (RR =
0.67, 95% CI 0.48 to 0.92, P = 0.01)
* Conclusions based on at least one trial with a low risk of bias.
** Conclusions based on larger body of weak unreliable evidence.
The mechanisms by which these ten interventions act to either
prevent mucositis or reduce the severity of mucositis in cancer
patients receiving treatment, is not clearly established. There are
various explanations put forward in the literature, as to how the
’effective’ interventions listed above might mitigate the effects of
cancer treatment on the oral mucosa, but it is beyond the scope
of this systematic review to comment further.
Overall, three interventions (aloe vera, PTA antibiotics and honey)
were investigated almost exclusively in patients with head and
neck cancer undergoing radiotherapy. Cryotherapy was investi-
gated solely in patients with haematological malignancies under-
going chemotherapy or stem cell transplantation. Sucralfate was
investigated mostly in patients with head and neck cancer under-
going radiotherapy, with a minority of trials including participants
with other cancer types.The remainder (amifostine, granulocyte-
colony stimulating factor, intravenous glutamine, keratinocyte
growth factor, and laser treatment) were tested in combinations
of patients with head and neck cancer, other solid tumours and
haematological malignancies undergoing radiotherapy, stem cell
transplantation, non-myeloablative chemotherapy or a combina-
tion.
Of the chemotherapeutic agents used to treat cancer, 5-fluouracil
was the most frequently reported. However, a wide variety of dif-
ferent agents and schedules were examined, precluding analysis
specific to a particular chemotherapy regimen.
It is important to note that a substantial body of evidence con-
cerning chlorhexidine, has clearly shown no evidence of a benefit
compared to either placebo or no treatment.
• Chlorhexidine - no evidence of a benefit for chlorhexidine
based on 9 trials including a total of more than 650 participants.
Risk of bias was assessed as low in 3 trials, high in one trial, and
unclear in the remaining five trials.
In conclusion, there is some evidence of the effectiveness of
cryotherapy and keratinocyte growth factor, and weaker evidence
of a benefit associated with aloe vera, amifostine, glutamine (intra-
venous), granulocyte-colony stimulating factor, honey, laser, PTA
antibiotic pastille/paste and sucralfate. There is no evidence of a
benefit associated with the use of chlorhexidine.
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Overall completeness and applicability of
evidence
The number and range of interventions studied and reported in
this review indicate the importance of this condition to clinicians
and patients and the lack of a well-defined and effective means
of prevention of oral mucositis in cancer patients. The presumed
modes of action of the different interventions are very varied and
include free radical scavenging (amifostine), local vasoconstriction
(cryotherapy), reductions in concurrent mucosal infection (antibi-
otic pastilles) and enhancement of wound healing (honey, ker-
atinocyte growth factor). Nine of the 43 interventions examined
were found to have some evidence of a benefit, albeit sometimes
weak, in preventing or reducing the severity of mucositis.
Despite the large number of trials included in the review few inter-
ventions were studied by several independent groups. This has led
to limitations in the strength and generalisability of the evidence
and several groups have highlighted the need for a co-ordinated
research agenda (Wright 2003). The eligible trials varied in their
setting, design, country of conduct, financial support and quality.
The majority (79%) were conducted primarily by medical teams
who did not report the involvement of dental practitioners. It was
unfortunate that many studies presented data in a format unsuit-
able for meta-analysis in this review. The use of structured ab-
stracts and adherence to the Consolidated Standards of Reporting
Trials (CONSORT) guidelines would greatly improve the con-
duct and reporting of randomised controlled trials (RCTs), allow-
ing a greater number to be included in future meta-analyses (Begg
1996; Moher 2001).
With respect to publication bias, several negative studies for mu-
cositis have been reported and we congratulate the authors and
editors for doing so. It was not possible to detect any existing pub-
lication bias, as there were insufficient studies in each meta-anal-
ysis investigating the same interventions. This review has focused
heavily on the prevention of mucositis in adults due to a lack of
true RCTs conducted in paediatric populations, highlighting the
difficulties of conducting research in this patient population.
Quality of the evidence
All studies included in this update of the review were assessed for
risk of bias in six categories: adequate sequence generation, ad-
equate allocation concealment, blinding (of patients, carers and
outcome assessors), incomplete outcome data addressed, free of
selective reporting and free of other bias. Overall risk of bias was
described for each included study. Studies were deemed to be at
low risk of overall bias if they were assessed as being at low risk for
both allocation concealment and outcome assessor blinding. Only
10 studies (7.6%) met both criteria. Eighty-three studies (63.4%)
were described as being at unclear overall risk of bias. The remain-
ing 38 studies (29%) were found to be at high overall risk of bias.
In general, methods of allocation concealment were not reported
in publications, or poorly described by authors, which prevented
the study being described as at low risk of bias for this category.
The use of adequate allocation concealment, together with the
publication of full descriptions of any methods used, needs to be
incorporated into future trials. Of the 77 studies described as dou-
ble blind, only 19 studies specifically stated that the outcome as-
sessor was blinded. Adequate outcome assessor blinding is crucial
to obtain unbiased assessments, even with the most objective of
assessment instruments. It is both possible and highly desirable
that future trials employ adequate outcome assessor blinding, even
where blinding of patients or support staff to the intervention is
impossible.
Although there was general consistency among the included stud-
ies in the number of categories of mucositis severity, scoring sys-
tems were not always clearly defined. The most frequently used
assessment instrument in this review was theWorld Health Orga-
nization (WHO) score, followed by the Radiation Therapy On-
cology Group (RTOG) instrument. Since our last review update, a
systematic review has been published (Gibson 2010) which iden-
tified 54 oral assessment instruments in the literature. In order
for the results of future studies to be synthesised with others, it is
recommended that authors should employ a ’simple’ assessment,
in addition to any multicomponent instrument, to allow for data
to be dichotomised.
The appearances of mucositis and oral candidiasis can be similar,
and moreover, the two frequently co-exist. Consequently, if the
assessors were lacking experience in the differential diagnosis of
these oral lesions, the validity of mucositis scores may have been
compromised. Candidiasis was not routinely screened for or re-
ported in the trials included in this review, and the addition of
candidiasis screening may assist in the differential diagnosis and
treatment of the two conditions.
The reporting of secondary outcomes other thanmucositis severity
was variable and these outcomes were mentioned more frequently
in trials published within the last 5 years. The types of outcome
reported have changed to reflect characteristics of greater clinical
relevance to clinicians and patients (Bellm 2002; Chang 2003;
Sonis 2004; Wright 2003). In addition to reporting mucositis-
related outcomes some groups reported known side effects of the
interventions. For some trials these side effects were reported only
in the intervention group and it was not clear if there were any
events in the control group. In future trials these side effects should
be measured and reported on all patients in both groups in a
consistent manner. This adverse event data should be presented
per patient and not per episode.
Potential biases in the review process
The meta-analyses in this review include only studies where mu-
cositis outcomes were graded on a 0-4 scale. The most recent up-
date of the review has also included a further 13 studies where
the outcomes are recorded in Additional Table 2, and the results
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are incorporated into the text of the review. However, 16 trial re-
ports were excluded from this systematic review because the au-
thors collected outcome data using an instrument which individ-
ually graded components of oral health, to produce a composite
score (Eilers 1988). As such instruments include in the total score
categories such as teeth and voice, the scores are not comparable
with scales that measure only mucositis.
A further 16 trials are awaiting classification pending further in-
formation being made available by the authors of the papers and
it is hoped that these trials may be included in future updates of
this review.
Agreements and disagreements with other
studies or reviews
This updated systematic review has identified nine interventions
for the prevention of mucositis for which there is evidence of
effectiveness. Four of these interventions: amifostine, locally ap-
plied antibiotic (PTA), cryotherapy and keratinocyte growth fac-
tor, have also been identified as having some evidence of effec-
tiveness by practice guidelines and other systematic reviews (Keefe
2007; McDonnell 2007; Sasse 2006; Stokman 2006). We have
also found weak evidence to support the effectiveness of the use
of aloe vera, granulocyte-colony stimulating factor and honey for
the prevention of oral mucositis, but we are not aware of other
systematic reviews which support the use of these interventions.
Regarding the use of laser for the prevention of mucositis there
is evidence based on two studies that laser reduces the incidence
of severe mucositis, a finding which is supported by a Cochrane
review on the treatment of oral mucositis which found that laser
treatment was effective in reducing the severity of established mu-
cositis (Clarkson 2010).
Our systematic review includes a small study by Oberbaum 2001
(n = 32) which is also included in another systematic review by
Kassab 2009 which evaluated homeopathic interventions for the
adverse effects of cancer treatments. In their review, Kassab et al
reported the mucositis outcome as mean area under the curve for
each group, and found a statistically significant difference favour-
ing traumeel, the homeopathic intervention. In our systematic re-
view we used a different outcome category: prevention of any mu-
cositis, and found no statistically significant difference between
traumeel and placebo. Both reviews assessed this study as being at
low risk of bias. We agree with Kassab et al that further research
is required to confirm any benefit of this intervention.
Our updated systematic review has found some weak evidence
for the effectiveness of intravenous glutamine in the prevention
of severe oral mucositis, based on three trials that have been pub-
lished since 2006, but this intervention is not recommended by the
current Multinational Association of Supportive Care in Cancer
(MASCC) guidelines, based on a single study from 2002 (Keefe
2007). There are plans to update these guidelines in the near fu-
ture.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Cryotherapy (ice chips) and Keratinocyte Growth Factor (Palif-
ermin®) have shown some evidence of benefit in the prevention
of mucositis. There is weaker less reliable evidence of a benefit
associated with aloe vera, amifostine, intravenous glutamine sup-
plementation, granulocyte-colony stimulating factor, honey, laser,
polymixin/tobramycin/amphotericin (PTA) lozenges and sucral-
fate.
There is no evidence that chlorhexidine is more effective that
placebo and this intervention should not be used in the prevention
of mucositis.
The patient groups studied were diverse, the associated treatment
modalities were varied and the strength of the evidence of effective-
ness was variable. As some interventions were studied exclusively
in certain patient groups receiving specific treatment modalities
generalisation of the results to other tumour types and treatment
modalities must be done with caution as some benefits may be
specific to certain cancer types and treatments.
Implications for research
There is a need for well designed and conducted trials of inter-
ventions to prevent mucositis induced by chemotherapy, radio-
therapy or targeted therapies. Such trials should be reported ac-
cording to the Consolidated Standards of Reporting Trials (CON-
SORT) guidelines with sufficient numbers of participants to per-
form subgroup analyses by type of disease and chemotherapeu-
tic agent. This review has highlighted several interventions (aloe
vera, amifostine, G-CSF, PTA antibiotic pastille/paste, cryother-
apy, intravenous glutamine, honey, keratinocyte growth factor and
laser therapy) with evidence of effectiveness from more than one
trial included in a meta-analysis. Further research into the benefits
and harms of these interventions and whether these results can be
generalized to other forms of cancer and its treatment should be
conducted. In addition, as several agents were reported to show
efficacy in a single trial, further well designed, adequately pow-
ered randomised controlled trials of these and other novel agents
for mucositis prevention should be undertaken. The concurrent
use of two or more interventions, with different modes of action,
may be worth evaluating in well conducted, adequately powered
randomised controlled trials.
We recognise the importance of multicomponent indices for oral
health. However, to facilitate comparison between interventions
for preventing mucositis it would be helpful if researchers used a
simple mucositis index with a 0-4 scale (e.g. World Health Orga-
nization (WHO), Radiation Therapy Oncology Group (RTOG),
National Cancer Institute - Common Toxicity Criteria (NCI-
CTC)) as part of their outcome evaluation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abbasi-Nazari 2007
Methods Randomised, parallel group multicentre study conducted in Iran. Unclear if dentist
involved in the study. Drop outs: unclear. Duration: 42 days
Participants Adults with cancers of the oral cavity, nasopharynx or hypopharynx treated with radio-
therapy or chemoradiotherapy (Cisplatine). Data presented for 24 patients. No dates for
start and finish of recruitment
Interventions 2 groups: placebo versus allopurinol mouthrinse. 10 mL of solution rinsed three times a
day for three minutes. Solution then discarded
Outcomes Authors state that mucositis was graded weekly using the WHO instrument. However,
the instrument reproduced in the publication is not the WHO instrument. Other re-
ported outcomes: None
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “A dynamic randomization pro-
cedure was utilized to divide patients to
receive allopurinol mouthwash (treatment
group) or placebo mouthwashes (control
group)”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear Quote: “Patients who experienced hyper-
sensitivity reaction or serious side effects
were excluded from the study. Also pa-
tients who complained about pain or other
62Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abbasi-Nazari 2007 (Continued)
signs attributed to severemucositis were ex-
cluded from the study.”
Comment: 24patients included in analysis.
However, it is unclear how many patients
were recruited
Free of selective reporting? Unclear Data presented for 24 patients for grade of
mucositis by grade of mucositis by week
for each arm of the study (figures 1 and 2)
. However, it is unclear how many patients
were initially recruited
Free of other bias? No Significant gender imbalance between the
arms of the study (P = 0.028)
Authors state that they used to WHO in-
strument. However, this is not the instru-
ment presented in table 1
Ahmed 1993
Methods Randomised, parallel group study conducted in USA. Unclear whether dentist was in-
volved in study
Participants Adults with haematological malignancies prior to BMT after conditioning with etopo-
side. 12 enrolled and completed
Interventions 2 groups, placebo versus propantheline (30 mg every 6 hours during infusion and 12
hours after, for total of 6 doses)
Outcomes Mucositis graded with reference to previous publication. Data presented as number of
patients developing mucositis in both groups. Assessment used: day 3. Other reported
outcomes: blood counts febrile episodes, survival, tumour response
Notes All patients received conditioning regimen of etoposide, cyclophosphamide and carmus-
tine, together with acyclovir, and nystatin or clotrimazole.
Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were randomly assigned”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
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Ahmed 1993 (Continued)
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Unclear Quote: “Trial drugs were administered
blind”.
Comment: unclear who was blind.
Blinding?
Outcome assessors
Unclear Quote: “Assessment of mucositis severity
was performed by two independent ob-
servers”
Comment: unclear if they were blinded to
allocation.
Incomplete outcome data addressed?
All outcomes
Unclear 12 patients randomised. Authors do not
give information about drop outs. Unclear
how many patients in each arm. Unclear
how many patients included in results
Free of selective reporting? Unclear Brief mucositis data presented in text
(enough for use in mucositis absent versus
present dichotomy)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Anderson 1998
Methods Randomised, cross-over study conducted in USA. Unclear if dentist was involved in
study. Duration 14 days. Recruitment May 1993 to April 1996
Participants Children and adults with solid cancer (sarcoma/blastoma) who have previously had
chemotherapy and experiencedmucositis. 24patients eligible and enrolled, 13 completed
Interventions 2 groups, glycine control (described as placebo) versus glutamine (4 ml/M² twice daily
swish and swallow) for 14 days
Outcomes Mucositis (patient’s description on 0-4 scale). Grade >= 2 painful mucositis which altered
food intake. Assessment used: day 14. Other reported outcomes: none
Notes Funding source: charity/university.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were assigned randomly
to two courses of glutamine and two
courses of glycine”
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Anderson 1998 (Continued)
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Yes Quote: “In addition to the patients, the
nurses and oncologists involved in the care
of these patients also were blinded”
Comment: probably done.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
No 24 patients randomised. Paired outcome
data available for 13 patients. Authors give
full reasons for attrition/exclusion. Poten-
tial for overall estimate to be reversed if ex-
cluded patients were included
Free of selective reporting? Unclear Data presented for total days of mucositis
compared to patient age and days of mu-
cositis > grade 2 by chemotherapy regime
Free of other bias? Yes Study appears to be free of other sources of
bias.
Antonadou 2002
Methods Randomised, parallel group study conducted in Greece. Clear information on with-
drawals: 3/26 control, 2/24 intervention. Dentist not involved in study. Drop outs: 10%.
Duration 3 months
Participants Adults with head and neck cancer. Radiotherapy total 60-74 Gy 2 Gy fractions 5 days
weekly. Chemotherapy carboplatin (90 mg/m2 once per week (no surgery before radio-
therapy)). 50 patients enrolled between January 1997 and January 1998. 45 completed
Interventions 2 groups, no treatment control versus amifostine 300 mg/m2 15-30 min before radio-
therapy for 6-7 weeks
Outcomes Mucositis assessed weekly EORTC criteria. Assessment used: day 28. Other reported
outcomes: dysphagia, xerostomia, treatment interruptions, haematological changes, side
effects (nausea, transient hypotention)
Notes Funding source: unclear.
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Antonadou 2002 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Eligible patients were random-
ized (1:1) to receive radiochemotherapy
plus amifostine (study group) or ra-
diochemotherapy”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Comment: amifostine versus no interven-
tion. No apparent blinding
Blinding?
Patients
No Comment: amifostine versus no interven-
tion. No apparent blinding
Blinding?
Outcome assessors
No Comment: amifostine versus no interven-
tion. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 50 patients randomised. Assessable data
from 45 patients. 2/24 in the amifostine
group and 3/26 in the control group. Au-
thors give full reasons for attrition and ex-
clusion
Free of selective reporting? Yes Data presented for 45 patients bymucositis
grade (table 4).
Free of other bias? Yes Study appears to be free from other sources
of bias.
Antunes 2007
Methods Randomised, parallel group study conducted inBrazil. Study conducted between January
4th 2004 and May 20th 2005. Dentist involved in study
Participants Adults with leukaemia, lymphoma or myelodysplastic syndrome undergoing HSCT. 38
patients recruited and completed
Interventions 2 groups, lazer (50 mW InGaAlP diode laser, emitting continuous light at 660 nm, with
a real power output of 46.7 mW and energy density (ED) of 4 J/cm2, measured at the
fiberoptic end with 0.196 cm2 of section area) versus sham laser control
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Antunes 2007 (Continued)
Outcomes Mucositis incidence (OMAS,WHO), correlation betweenOMAS andWHO,mucositis
free survival, ulcerative area extension, evaluator agreement, pain, clinical outcomes
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised on the
day of admission for the transplantation,
between receiving laser therapy, or not re-
ceiving laser therapy”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Yes Quote: “the dentists were the only mem-
bers of the team who knew which group
the patient was randomized to”
Comment: probably done.
Blinding?
Patients
Yes Quote: “the dentists were the only mem-
bers of the team who knew which group
the patient was randomized to”
Comment: probably done.
Blinding?
Outcome assessors
No Quote: “one dentist and 3 nurses (blinded
for the study) performed daily oral evalua-
tion of the patients”
Comment: one outcome assessor was not
blind.
Incomplete outcome data addressed?
All outcomes
Yes 38 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented for all patients by mucositis
grade (fig 1).
Free of other bias? Yes Study appears to be free from other sources
of bias.
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Arun Maiya 2006
Methods Randomised, parallel group study conducted in India. Clear information about with-
drawals: 0. Unclear if dentist involved in study. Duration: until the completion of ra-
diotherapy. Recruitment took place between January 2003 and January 2004
Participants Adults with carcinoma off the oral cavity receiving radiotherapy (66 Gy in 33 fractions)
Interventions 2 groups, analgesics, anaesthetics, 0.9% saline and chlorhexidine versus laser (632.8 nm,
10 mW) for 3 minutes, 5 days per week
Outcomes Mucositis assessed weekly using the WHO score. Other reported outcome measures:
pain
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “the patients were divided based
on computer generated randomization into
laser (study group) and control group with
25 patients in each group.”
Comment: computer generated randomi-
sation.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Neon laser versus oral analgesics, local ap-
plication of anaesthetics, 0.9% saline and
povidine wash. No apparent blinding
Blinding?
Patients
No Neon laser versus oral analgesics, local ap-
plication of anaesthetics, 0.9% saline and
povidine wash. No apparent blinding
Blinding?
Outcome assessors
Yes Quote: “Physician blinded to the type of
treatment using WHO scale for mucositis
and visual analogue scale for pain evalua-
tion recorded the objective assessment of
the degree of mucositis weekly”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 50 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented for all patients by arm and
grade of mucositis in text (page 401)
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Arun Maiya 2006 (Continued)
Free of other bias? Unclear No information given on characteristics of
patients in each group at baseline. Amount
of analgesics used in each group not re-
ported
Attal 1993
Methods Randomised, parallel group study conducted in France. Clear information on with-
drawals: 6/70 control, 6/70 test. Unclear if dentist involved in study. Drop outs: 0%.
Duration: day -8 to day +100
Participants Adults with mixed blood cancers admitted to BMT unit. 140 patients enrolled 6 died
in each group, but all were evaluated. Recruited December 1990 to September 1992
Interventions 2 groups, no treatment control versus pentoxifylline (oral PTX 1600 mg 1 per day in 4
doses)
Outcomes Number requiring MSO4 for grade II or higher mucositis (by published criteria). As-
sessment used: day 100. Other reported outcomes: duration of stay in hospital, renal
insufficiency, days morphine, fever, septicaemia, 100 day survival
Notes All patients received one of 4 possible standard regimens either; Cyclophosphamide
+TBI, or cyclophosphamide + bisulfan, or melphalan + TBI or cyclophosphamide +
etoposide + carmustine, prior to autologous or allogenic BMT.
Funding source: not stated.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “patients were randomised to re-
ceive or not PTX. The treatment allocation
for each patients was assigned by telephone
by the biostatistics department, which had
prepared before initiation of the trial a com-
puter-generated sequence unknown to the
physicians participating in the trial.”
Comment: computer generated randomi-
sation.
Allocation concealment? Yes Quote: “The treatment allocation for each
patient was assigned by telephone by the
biostatistics department.”
Comment: central method of allocation.
Blinding?
Carers
No PTX versus no treatment. No apparent
blinding.
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Attal 1993 (Continued)
Blinding?
Patients
No PTX versus no treatment. No apparent
blinding.
Blinding?
Outcome assessors
Unclear The authors state that the physicians par-
ticipating in the trial were unaware of the
randomisation sequence. However, it is un-
clear who was doing the outcome assess-
ment
Incomplete outcome data addressed?
All outcomes
Yes 140 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented in the text for the number
of patients with mucositis grade 2 or higher
in each study arm
Free of other bias? Yes Study appears to be free of other sources of
bias.
Bensadoun 1999
Methods Randomised, parallel multisite study conducted in France. Clear information about
withdrawals: 0. Dentist involved in study. 30 patients recruited between September
1994 and March 1998. Duration: 5 consecutive days each week during the 7 weeks of
radiotherapy
Participants Adults with head and neck cancers receiving radiotherapy (at least 65 Gy in total)
Interventions 2 groups, sham laser versus laser (wavelength: 632.8 nm; power: 60 mW in Nice and
Mareilles, 25 mW in Reims)
Outcomes Mucositis assessed weekly using the WHO scale. Other outcome measures: pain, ability
to swallow, incidence and duration of treatment gaps
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “patients were assigned to either
laser treatment or sham-treatment by com-
puter blocked randomisation, 15 in each
arm”
Comment: computer generated randomi-
sation.
70Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bensadoun 1999 (Continued)
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Yes Quote: ”this operator was the only person
to know whether or not the patients was
being sham treated, and did not participate
in the evaluation and scoring of mucositis“
Comment: unlikely that nursing staff
would know of allocation
Blinding?
Patients
Yes Quote: ”double blind“.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”Objective assessment of degree of
mucositis was recorded weekly by a physi-
cian blinded to the type of treatment the
patient received“
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 30 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented formean grade ofmucositis
by arm by week of treatment (table 3/ fig
3) and distribution of mucositis grades, in
number of weeks, for both treatment weeks
Free of other bias? Unclear Possible imbalance of groups at baseline
laser group older (mean 62.7 vs 58.1). Also
12/15 of laser group vs. 6/15 of placebo
group received laser treatment to skin of
neck (”possible distant laser effect”). Dif-
ferent power of laser used at one study site
(Relms)
Biswal 2003
Methods Randomised, parallel group study conducted in Malaysia. Clear information on with-
drawals. Unclear if dentist was involved in study. Drop outs: 0%. Duration: 49 days
Participants Adults with head and neck cancer. 40 patients recruited and evaluated. RecruitedNovem-
ber 2000 to October 2001
Interventions 2 groups, rinse then swallow 20 ml natural honey before radiotherapy, 20 ml after and
20 ml 6 hours after that versus no treatment control
Outcomes Mucositis RTOG grading. Other reported outcomes: weight gain
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Biswal 2003 (Continued)
Notes Funding source: university. All patients received radiotherapy 60-70 Gy over 6-7 weeks
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “twenty patients were allocated
equally to one study arm and another 20
to the control arm by computer generated
random numbers”
Comment: computer generated random
numbers.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Honey versus no intervention.No apparent
blinding.
Blinding?
Patients
No Honey versus no intervention.No apparent
blinding.
Blinding?
Outcome assessors
No Honey versus no intervention.No apparent
blinding.
Incomplete outcome data addressed?
All outcomes
Yes 40 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented for number of patients with
mucositis, number of patients with grade
3/4mucositis, mean grade, mean onset and
mean total duration (all table 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Bjarnason 2009
Methods Randomised parallel group multisite study conducted in Canada. Clear information
aboutwithdrawals.Dentist involved in study. Recruitment of patients tookplace between
August 1999 and November 2004
Participants Adults with head and neck cancers receiving radiotherapy (50-70 Gy)
Interventions 2 groups, radiotherapy in themorning (8am to 10am) versus radiotherapy in the evening
(4pm to 6pm)
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Bjarnason 2009 (Continued)
Outcomes Mucositis assessed weekly using the OMAS instrument. Other reported outcomes: dis-
ease reoccurrence, quality of life, compliance with treatment, death, smoking status,
weight loss
Notes Funding source: National Cancer Institute of Canada.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “A minimization procedure was
used to randomize patients”
Quote: “patients were stratified by treat-
ment centre, pretreatment smoking be-
haviour...tobacco use questionnaire, and
planned total radiation dose”
Comment: minimization.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Morning versus evening radiation. No ap-
parent blinding.
Blinding?
Patients
No Morning versus evening radiation. No ap-
parent blinding.
Blinding?
Outcome assessors
No Quote: “the oncologists performing the
evaluations were aware of the treatment
arm for each patient”
Incomplete outcome data addressed?
All outcomes
Yes 216 patients recruited. 7 patients deemed
ineligible (4/108 arm A, 3/108 arm B), 3
patients in arm A did not receive radiother-
apy (3/108 arm A), 1 patient in arm B did
not havemucositis assessment. 205patients
included in final analysis
Free of selective reporting? Unclear Data presented for number of patients with
grade 3 or greater mucositis, median inter-
val to mucositis and median grade of mu-
cositis (all RTOG). Data collected using
OMAS instrument also presented (table 3)
Free of other bias? Yes Study appears to be free from other sources
of bias.
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Blazar 2006
Methods Randomised, parallel group, multisite study conducted in the USA. Clear information
about withdrawals: 20 (17 patients withdrew and were replaced). Unclear if dentist
involved in study
Participants Adults and children with haematological malignancies (acute lymphoblastic leukaemia,
acute myelogenous leukaemia, chronic myelogenous leukaemia, myelodysplastic syn-
drome, non-Hodgkin leukaemia, Hodgkin’s disease, other) aged between 3 and 65 years
old, receiving allogeneic hematopoietic stem cell transplantation. Conditioning regimes:
cyclophosphamide and total body irradiation or busulfan and cyclophosphamide
Interventions 3 cohorts, cohort 1 received either palifermin (60 µg/kg in 6 doses), palifermin (40 µg/
kg in 6 doses) or placebo. Cohort 2 received palifermin (60 µg/kg in 9 doses) or placebo.
Cohort 3 received palifermin (60 µg/kg in 12 doses)
Outcomes Mucositis assessed weekly using the world health organisation and common toxicities
criteria scales. Other reported outcomemeasures: adverse events, GVHD, hematopoietic
recovery, methotrexate dosing, survival and relapse
Notes Funding source: National Institute of Health grants and Amgen (pharmaceutical)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Randomisation was structured to
achieve balance between the placebo and
palifermin groups within each study site in
each cohort”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 100 patients randomised. 17 patients dis-
continued and replaced (1/31 placebo
group). 3 patients suffered SAE and were
not replaced (1/31placebo group). Full rea-
sons given for attrition/exclusion
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Blazar 2006 (Continued)
Free of selective reporting? Yes Data presented for all patients by mucositis
grade. Palifermin doses combined (table 4)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Borowski 1994
Methods Randomised, parallel group study conducted in France. Clear information on with-
drawals: 7/82 control, 9/84 test. Dentist involved in study. Duration: 30 days
Participants Children and adults withmixed cancer and candidates for BMT. 166 eligible and enrolled
between February 1986 and November 1989 with 150 completing
Interventions 2 groups, limited oral hygiene versus intense oral hygiene (brushing 3 times per day after
meals as instructed by dentist)
Outcomes Moderate or severe mucositis with detailed description of each category. Assessment
used: day 30. Other outcomes: plaque, fever, septicaemia
Notes Chlorhexidine mouthrinse used at least 5 times daily by both groups.
Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients fulfilling the enrolment
criteria were randomly allocated by tele-
phone”
Quote: “randomisation was balanced every
4 subjects and stratified on IOS.”
Comment: random component not de-
scribed.
Allocation concealment? Yes Quote: “Patients fulfilling the enrolment
criteria were randomly allocated by tele-
phone”
Comment: central allocation.
Blinding?
Carers
No Intensive oral hygiene versus limited oral
hygiene. No apparent blinding
Blinding?
Patients
No Intensive oral hygiene versus limited oral
hygiene. No apparent blinding
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Borowski 1994 (Continued)
Blinding?
Outcome assessors
No Quote: “these evaluations could not be per-
formed blindly because of dental plaque.”
Incomplete outcome data addressed?
All outcomes
Yes 166 patients randomised. 16 patients ex-
cluded from analysis: 9/ 84 intensive oral
hygiene group, 7/82 limited oral hygiene
group. Authors give complete reasons for
exclusion/attrition
Free of selective reporting? Unclear Data presented in the text for proportions
of patients with moderate/severe mucositis
according to treatment allocation. Percent-
age of patients withmoderate or severe mu-
cositis presented over time for both arms
of the study (fig 2) and patients receiving
TBI/no TBI (fig 1)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Bourhis 2000
Methods Randomised, parallel group study conducted in France. Unclear information on with-
drawals: 1 died and 1 refused, unclear which group. Unclear if dentist involved in study.
Drop outs: 8%. Duration: unclear
Participants Adults with head and neck cancer, stage IV not amenable to conventional radiosurgical
treatment. Karnofsky performance > 60. Radiotherapy 64 Gy in 22-23 days. 26 patients
enrolled and randomised between May 1996 and February 1998. 24 were evaluated
Interventions 2 groups, no treatment control versus amifostine (subcutaneous infusion 150 mg/m²
amifostine administered IV twice daily 15-30 minutes prior to each radiotherapy session)
Outcomes MaxWHOgrade (I to IV). Assessment used: day 23. Other reported outcomes: duration
of feeding tube, vomiting, liver function, erythema (tolerance of amifostine). Duration
of feeding tube
Notes RTOG index also given with mean duration of at least grade 3 mucositis.
Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomized to re-
ceive or not 150mg/m2 amifostine 15-30
min prior to each radiation session.”
Comment: random component not de-
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Bourhis 2000 (Continued)
scribed.
Allocation concealment? Yes Quote: “The randomisation procedure was
done by telephone”.
Comment: central allocation. Probably
done.
Blinding?
Carers
No Comment: amifostine versus no interven-
tion. No apparent blinding
Blinding?
Patients
No Comment: amifostine versus no interven-
tion. No apparent blinding
Blinding?
Outcome assessors
No Comment: amifostine versus no interven-
tion. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 26 patients randomised. 2 patients not in-
cluded in mucositis assessment. Full rea-
sons for drop outs
Free of selective reporting? Unclear Data presented WHO grades 2 to 4 and
meandurationof > grade 3mucositis (days)
(table 1)
Free of other bias? No Study stopped early due to problems with
the tolerance of amifostine
Brizel 2000
Methods Randomised, parallel group multisite study conducted in USA, Germany and France.
Clear information about withdrawals: none. Unclear if dentist involved in study. Drop
outs: 0%. Duration: 1 year
Participants Adults with head and neck cancer. Newly diagnosed squamous cell radiation more than
or equal to 70% both parotid glands more than or equal to 40 Gy - daily 2 Gy. 315
enrolled and randomised between October 1995 to October 1997. 12 patients never
received any treatment or follow-up. The results are presented for the remaining 303
Interventions 2 groups, no treatment control versus amifostine 200 mg/m2 daily 15-20 minutes prior
to radiation
Outcomes Mucositis assessed weekly by physician. Radiation Therapy Oncology Group Scoring
systems. Assessment used: day 90. Other reported outcomes: nausea, vomiting, xerosto-
mia, saliva production, survival, local disease control
Notes Funding source: pharmaceutical.
Risk of bias
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Brizel 2000 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “three hundredfifteenpatientswere
enrolled and randomised from October
1995 to October 1997”
Quote: “Patients were randomized using a
dynamic allocation process.”
Comment: random component not de-
scribed, however, authors make reference
to two articles on randomisation. Probably
done
Allocation concealment? Yes Quote: “treatment assignment was deter-
mined by a phone call from the enrolling
institution to the protocol sponsor”
Comment: central allocation. Probably
done.
Blinding?
Carers
No Quote: “open label”.
Blinding?
Patients
No Quote: “open label”.
Blinding?
Outcome assessors
No Quote: “open label”.
Incomplete outcome data addressed?
All outcomes
Yes 315 patients randomised. 12 patients never
received intervention. 22 patients discon-
tinued but included in efficacy analysis. 2/
150 patients in amifostine group missing
from mucositis analysis. Observed event
risk not sufficient to have clinically relevant
impact
Free of selective reporting? Yes Data presented for 301 patients by grade of
mucositis.
Free of other bias? Yes Study appears to be free of other sources of
bias.
Brizel 2008
Methods Randomised, parallel groupmultisite study conducted in theUSA,Canada andAustralia.
Withdrawals unclear (see ROB). Unclear if dentist involved in study
Participants Adults with stage III/IV or IV squamous carcinoma of the oral cavity, oropharynx,
hypopharynx and larynxundergoing concurrent chemoradiotherapy. Radiotherapy given
in 2 Gy fractions to 70 Gy, hyperfractionated radiotherapy given in 1.25 Gy fractions
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Brizel 2008 (Continued)
twice daily. Chemotherapy: cisplatin 20 mg/m2 for 4 days and fluorouracil 1000 mg/m
2/d for 4 days (weeks 1 and 5 of radiotherapy).
Interventions 2 groups: placebo versus palifermin 60 µg once weekly during radiotherapy for 9 con-
secutive weeks
Outcomes Mucositis assessed weekly using CTCAE (version 2). Other reported outcomes: dyspha-
gia, xerostomia, radiotherapy breaks, supplemental nutrition, safety
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “A multicentre, double blind, ran-
domised, placebo controlled studywas con-
ducted at 22 centres”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear Quote: “Ninety-nine of 100 patients who
were randomly assigned (67 palifermin, 32
placebo received at least 1 dose of study
treatment and were evaluated”
Comment: 101 patients stated as ran-
domised in figure 1. Table 1 gives baseline
data for 99 patients
Comment: 21 patients discontinued. 17/
67 in palifermin group, 4/32 in placebo
group. Authors give incomplete reasons for
attrition/exclusion
Free of selective reporting? Unclear Data only presented for mucositis scores >
2 and > 3 (fig 2)
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Brizel 2008 (Continued)
Free of other bias? No Authors used NCI CTC tool to assess pa-
tients for first 12weeks and then theRTOG
late onset tool at weeks 14/16/18/20. This
prevented direct comparisons between the
groups
Bubley 1989
Methods Randomised, parallel group study conducted in USA. Clear information about with-
drawals: 0. Unclear if dentist involved in study
Participants Adults with head and neck cancer. Prior positive titre to Herpes Simplex. Results pre-
sented for 57 patients
Interventions 2 groups, placebo versus acyclovir 200 mg tablets 12 hourly.
Outcomes Mucositis assessed by nurse. Assessment used: unclear. Other reported outcomes: herpes
simplex virus
Notes Data presented separately for patients receiving chemo and radiotherapy.
Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomization occurred on the
basis of computer-generated random codes
supplied by the sponsor of the study”
Comment: computer generated randomi-
sation sequence.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 57 patients recruited. All patients included
analysis.
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Bubley 1989 (Continued)
Free of selective reporting? Unclear Data presented for absent versus present
dichtomy.
Free of other bias? Yes Study appears to be free of other sources of
bias.
Buentzel 2006
Methods Randomised, parallel group, multicentre study conducted in USA/Europe. Clear infor-
mation on withdrawals: none. Unclear if dentist involved in study. Drop outs: 22%.
Duration: up to 90 days
Participants Adults with head and neck cancer. 132 enrolled and randomised between October 1996
to October 1998. 102 completed but ITT analysis presented
Interventions 2 groups, placebo versus intravenous amifostine (300 mg/m2 before carboplatin 70 mg/
m2 and radiotherapy on days 1 to 5 and 21 to 25, and intravenous amifostine 200 mg/
m2 or placebo before radiotherapy on 6 to 20 and 26 to 30/35 days)
Outcomes Mucositis graded with reference to RTOG criteria on a 0-4 scale. Assessment used up to
90 days. Other reported outcomes: xerostomia, 1 yr locoregional failure, progression-free
survival, overall survival, treatment related adverse events: vomiting, nausea, asthenia,
allergic reaction, anaemia, phlebitis, leukopenia, hypotension, allergic reaction
Notes Funding source: industry.
Pharmacological company provided drug and organised randomisation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”Patients were randomly assigned
in a ratio of 1:1”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine “yes”
or “no”.
Blinding?
Carers
Unclear Insufficient information to determine “yes”
or “no”.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
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Buentzel 2006 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 132 patients randomised. 20/67 missing
from treatment group, 9/65 missing from
placebo group. 1 patient from each group
not treated. Authors give full reasons for
exclusions and withdrawals. ITT analysis.
Mucositis data presented for 129 patients
Free of selective reporting? Yes Data presented for 129 patients by mucosi-
tis grade (table 2)
Free of other bias? Yes Study appears to be free from other sources
of bias.
Buntzel 1998
Methods Randomised, parallel group study conducted in Germany. Clear information on with-
drawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 6 weeks
Participants Adults with head and neck cancer, hospitalised with stage III-IV tumour, no evidence of
systemic infection, liver or renal impairment, tumour resected or excised before adjuvant
radiotherapy. 28 patients enrolled, 28 were evaluated
Interventions 2 groups, radiotherapy with or without amifostine (15 min infusion 500 mg preceded
by antiemetic regimen of 12 mg dexamethasone and 8 mg ondansetron)
Outcomes WHOmucositis grades 3/4. Assessment used: day 42. Other reported outcomes: xeros-
tomia, dysphagia, loss of taste, dermatitis, haematological side effects
Notes More data presented but included extra 11 patients in amifostine group who were not
entered into study.
Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “eligible patients were randomised
to receive RCT±amifostine”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Amifostine versus no intervention. No ap-
parent blinding.
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Buntzel 1998 (Continued)
Blinding?
Patients
No Amifostine versus no intervention. No ap-
parent blinding.
Blinding?
Outcome assessors
No Amifostine versus no intervention. No ap-
parent blinding.
Incomplete outcome data addressed?
All outcomes
Yes 28 patients initially randomised. After pos-
itive results suggested an additional 11 pa-
tients were recruited to the amifostine arm.
No missing outcome data
Free of selective reporting? Yes Data presented for all patients by mucositis
grade (see table 2)
Free of other bias? No Quote: “In view of these positive results, an
additional 11 patients were subsequently
accrued to the amifostine arm.”
Cartee 1995
Methods Randomised, parallel group study conducted in USA. Unclear information on with-
drawals: 5 withdrew, unclear from which groups. Dentist involved in study. Drop outs:
10%. Duration: 21 days
Participants Adults with breast cancer stage IV, with combination of chemotherapy including 5-FU,
adriamycin & methotrexate. First cycle of chemotherapy. 50 patients were enrolled and
45 were evaluated
Interventions 5 groups, 0.1% albumin (described as placebo, dose 0), GM-CSF (molgramostim, range
of doses, 0.01, 0.10, 1.00, 10.00 mcg/ml. Mouthwash solutions administered 4 times
daily starting 24 hours after chemotherapy initiation). Continuing until end of cycle
Outcomes Mucositis (CALGB GRADE >= 3). Assessment used: day 15. Other reported outcomes:
WBC, plasma GM-CSF
Notes Doses 0.01, 0.10, 1.00, 10.00 were combined and compared with dose 0 (control).
Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “patients were randomised by the
Duke Centre Protocol office according to a
block randomisation scheme and assigned a
unique identifier number which designated
the GM-CSF dose level to be received”
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Cartee 1995 (Continued)
Comment: random component not ex-
plicit. However, setting makes adequate
randomisation likely
Allocation concealment? Yes Quote: “The patient supply of mouthwash
was labelled to correspond with the as-
signed identifier number and dispensed by
pharmacy. The patient assignment infor-
mation was maintained by the pharmacy to
perverse the study double blind”
Comment: pharmacy controlled randomi-
sation.
Blinding?
Carers
Yes Adequate allocation concealment. Unlikely
that carers would know of allocation
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 50 patients randomised. 5 patients with-
drew. Authors give full reasons for with-
drawals and exclusions, but do not state
which arm patients were randomised to
Free of selective reporting? Unclear Data presented for grade 3 mucositis by
dose (table 1).
Free of other bias? Yes Study appears to be free of other sources of
bias.
Carter 1999
Methods Randomised, parallel group study conducted inUSA.Clear information on withdrawals:
none. Dentist Involvement unclear. Drop outs: 0%. Duration: up to 4 months post
radiotherapy
Participants Adults with head and neck cancer receiving curative intent radiotherapy, Karnofsky
performance > 60. 102 patients enrolled and 102 completed
Interventions 2 groups, placebo versus sucralfate (added as suspension of 1 gm sucralfate/15 ml solu-
tion) swish 2 minutes and swallow 4 times per day
Outcomes RTOG graded mucositis. Assessment used: maximum during treatment at 60 Gy. Other
reported outcomes: pain, need for placement of feeding tube, use of narcotics, need for
intravenous fluids, diet, need for treatment break. All assessed weekly
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Carter 1999 (Continued)
Notes Funding source: not stated.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomly assigned
to receive either sucralfate or placebo”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Quote: “Both radiation oncology staff and
patients were blinded to assigned treat-
ment”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Quote: “Both radiation oncology staff and
patients were blinded to assigned treat-
ment”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 102 patients randomised. 16 patients with-
drew. 7/50 placebo, 9/52 sucralfate. Au-
thors give reasons for attrition/exclusion
Free of selective reporting? Unclear Data presented for grade 3 mucositis (table
3), time to healing of mucositis (figure 3)
and cumulative fraction of patients with >
grade 3 mucositis during treatment
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Cascinu 1994
Methods Randomised, parallel group study conducted in Italy. Clear information on withdrawals:
none. Unclear if dentist involved in study. Drop outs: 0%. Duration: unclear
Participants Adults with solid cancer (GI & prostate). Chemotherapy: 5-FU. First course of chemo-
therapy. 84 patients eligible, enrolled and completed
Interventions 2 groups, control (no treatment) versus ice chips (cryotherapy, 5 mins before 5-FU for
30 mins after). Checked every week and judgement on mucositis performed on day of
next chemotherapy course
Outcomes Mucositis (global assessment of physician’s and patient’s description on 0-4 scale). As-
sessment used: unclear
Notes Statistical handling of data incorrect as all cycles included but used data from first cycle.
Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised to a control arm or to
receive chemotherapy”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Ice chips versus no intervention. Blinding
impossible.
Blinding?
Patients
No Ice chips versus no intervention. Blinding
impossible.
Blinding?
Outcome assessors
No Ice chips versus no intervention. No appar-
ent blinding.
Incomplete outcome data addressed?
All outcomes
Yes 84 patients randomised. No patients dis-
continued over first cycle (data used in
meta-analysis)
Free of selective reporting? Yes Data presented for all patients by mucositis
grade for first cycle (see table 3)
Free of other bias? Yes Study appears to be free from other sources
of bias.
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Castagna 2001
Methods Randomised, parallel group multicentre study conducted in France, Italy and Switzer-
land. Clear information about withdrawals: 2/53 sucralfate, 1/52 placebo. Unclear if
dentist involved in study. Drop outs: 2.8%
Participants Adults with mixed cancer (hospitalised for allogenic or autologous BMT). 105 enrolled,
102 completed
Interventions 2 groups, placebo (n = 51) versus 2 g sucralfate (n = 51) every 3 hours daily, swish and
swallow, for a maximum of 7 mouthwashes
Outcomes Mucositis grade 3-4. Other reported outcomes: duration, diarrhoea, caloric intake by
oral nutrition
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients fulfilling the enrolment
criteria ... were randomly allocated to the
sucralfate or the placebo group. Randomi-
sation was stratified on TBI”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 105 patients randomised. 3 patients with-
drawn due to disease recurrence (2/53 Su-
cralfate, 1/52 placebo)
Free of selective reporting? Unclear Data presented in percentages for grades 3
and 4 mucositis, but stated that 51 patients
in each group were evaluated (text)
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Cengiz 1999
Methods Randomised, parallel group study conducted in Turkey. Clear information on with-
drawals: none. Dentist involved in study. Drop outs: 0%. Duration from beginning to
end of radiotherapy
Participants Adults with head and neck cancer. 28 patients enrolled and completed
Interventions 2 groups, placebo versus sucralfate (6 g sucralfate suspension mouthwash 4 doses orally
before meals and bedtime)
Outcomes RTOG mucositis (0-IV). Topical and systemic analgesic use, weight loss, dry mouth.
Assessment used: day 42. Other reported outcomes: pain, difficulty eating, constipation,
analgesics, dry mouth
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were randomised”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes Data presented for 28 patients (18 sucral-
fate, 10 placebo). All randomised patients
included in analysis
Free of selective reporting? Yes Data presented for 28patients by treatment
allocation and grades of mucositis
Free of other bias? Yes Study appears to be free from other sources
of bias.
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Cerchietti 2006
Methods Randomised, parallel group study conducted in Argentina. Clear information on with-
drawals: none. Dentist involvement unclear. Drop outs: 0%. Duration: 60 days
Participants Adults with head and neck cancer. Chemoradiotherapy - radiotherapy 2 Gy /day up
to total 70 Gy, plus cisplatin and 5-FU daily on days 1-5 repeated every 3 weeks. 32
enrolled 29 randomised and completed
Interventions 2 groups, placebo versus glutamine. (patients intravenous L-alanyl-L-glutamine 0.4 g/
kg weight/day on each day of chemo through a separate IV line)
Outcomes Mucositis assessed by mean of 3 highest scores by Objective Mucositis Score (OMS) and
theWHO grading system on a 0-4 scale. Mucositis graded once/week during chemo and
every other day during CRT. Assessment used up to 60 days. Other reported outcomes:
pain, feeding tubes, mucositis related hospitalisation, adverse drug effects, body weight
change, incidence of local infections, tumour response
Notes Funding source: industry and foundation. Pharmacological company provided drug and
organised randomisation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomly assigned
(in a 1:1 ratio in blocks of 6) to receive, in
a double blind methodology, either intra-
venous L-alanyl-L-glutamine or placebo”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 29 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for intensity of objec-
tive mucositis developed (mean 3 highest
OMS), patients with severe objective mu-
cositis, and patients with mucositis WHO
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Cerchietti 2006 (Continued)
grade 4 (table 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Chi 1995
Methods Randomised cross-over multisite study conducted in Taiwan. Clear information on with-
drawals: 0. Unclear if dentist involved in study. Duration: 10 days (day 5 to day 14)
Participants Adults with head and neck cancer undergoing chemotherapy (two cycles of cisplatin 20
mg/m2/day, fluorouracil 800 mg/m2/day and leucovorin 90 mg/m2/day).
Interventions 2 groups, no therapy versus GM-CSF (4 µg/kg/day subcutaneously) crossed over for
2nd cycle
Outcomes Mucositis assessed daily for 17 days (0-4 scale). Other outcome measures: tumour re-
sponse rate, neutrophil and leukocyte counts, adverse events
Notes Funding information: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficent information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficent information to determine ’yes’
or ’no’.
Blinding?
Patients
No GM-CSF versus no intervention. No ap-
parent blinding.
Blinding?
Outcome assessors
No GM-CSF versus no intervention. No ap-
parent blinding.
Incomplete outcome data addressed?
All outcomes
Yes 20 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data provided in text for percentage reduc-
tion in incidence of severe mucositis, the
mean duration of severe mucositis
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Chi 1995 (Continued)
Free of other bias? Yes Study appears to be free from other sources
of bias.
Choi 2007
Methods Randomised, parallel group study conducted in Korea. Clear information about with-
drawals: 0. Unclear if dentist involved in study. Drop outs: 0%. Recruitment September
2003 to August 2005
Participants Adults with solid tumours receiving 5FU chemotherapy. 51 enrolled and randomised,
all completed
Interventions 2 groups, glutamine 30 g/day as supplement administered enterally for 15 days, versus
best supportive care. Patients in both groups received cryotherapy
Outcomes Mucositis severity evaluated using 0-4 scale, CTCAE criteria, any mucositis, ≥ grade 2
mucositis, ≥ grade 3 mucositis, cost and adverse events
Notes Funding source: not stated.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “patients were randomised by the
clinical trials office, using stage of therapy
as the stratifying variable”
Comment: computer generated randomi-
sation.
Allocation concealment? Unclear Quote: ”Packages containing anonymous
treatment supplies for each patient were
provided by the clinical trials office”
Comment: unclear if packages were se-
quentially numbered.
Blinding?
Carers
No Quote: “open label trial”.
Blinding?
Patients
No Quote: “open label trial”.
Blinding?
Outcome assessors
No Quote: “open label trial”.
Incomplete outcome data addressed?
All outcomes
Yes 51 patients recruited. Nomissing outcome
data.
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Choi 2007 (Continued)
Free of selective reporting? Yes Data presented for 51 patients by grade of
mucositis and treatment arm
Free of other bias? Yes Study appears to be free of other sources of
bias.
Chor 2010
Methods Randomised parallel group study conducted in Brazil. Clear information about with-
drawals: 0. Dentist involved in study. Duration: 7 days (day -7 to day 0)
Participants 34 adults undergoing autologous transplantation. No disease or treatment information
Interventions 2 groups, sham laser (led) versus laser (diode laser of 50 mW AsGaA1 applied emitting
continuous light at 660 nm)
Outcomes Mucositis assessed daily from day-2 until discharge using the Tardieu scale. Other out-
come measures: febrile episodes, cumulative probability of developing mucositis, length
of hospital stay
Notes Funding Source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 34 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented in the text for the number
of patients experiencing mucositis in each
arm
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Chor 2010 (Continued)
Free of other bias? Yes Study appears to be free of bias.
Crawford 1999
Methods Randomised, parallel group multicentre study conducted in USA. Unclear information
on withdrawals (previously described): 6/110 placebo, 6/101 test. Dentist involvement
unclear. Drop outs: 9%. Duration: from day 4 to day 17 of cycle
Participants Adults with small cell lung cancer. 211 patients enrolled, 199 evaluated, 195 evaluated
on first cycle
Interventions 2 groups: placebo (not described) versus filgrastim (230 ug/m²)
Outcomes WHO mucositis grades 0-4. Assessment used: day 21. Other reported outcomes: neu-
tropenia, infections complications
Notes Used first cycle data.
Funding source: not stated.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised within each study
centre to receive chemotherapy with ei-
ther filgrastim or the equivalent volume of
placebo”
comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “patients remained on blinded
study drug until the primary endpoint of
the study, FN, was reached.”
Blinding?
Outcome assessors
Yes Quote: “A blinded chart review confirmed
the exclusion of dental and oral problems
related to mucositis”
Comment: outcome assessors presumed to
be blind.
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Crawford 1999 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 211 patients randomised. 12 patients ex-
cluded (6/110 placebo, 6/101 interven-
tion). 199 patients received at least one cy-
cle of chemotherapy and were included in
the efficacy analysis. Authors provide rea-
sons for exclusions in linked paper
Free of selective reporting? Unclear Data presented for incidence of mucosi-
tis in percentages (present versus absent)
for both treatment arms and time to first
episode of mucositis.
Free of other bias? Yes Study appears to be free of other sources of
bias.
Cruz 2007
Methods Randomised parallel group study conducted in Brazil. Unclear information about with-
drawals. Dentist involved in study. Duration: 5 consecutive days from initiation of che-
motherapy. Recruitment ran from May 2003 to February 2005
Participants Children aged between 3 and 18 years old. 62 patients recruited. 56 patients evaluated
on second visit, 59 patients evaluated at the 3rd evaluation. 35 patients had leukaemia
or lymphoma, 25 patients had solid tumours. All patients received chemotherapy, 24
patients also received a stem cell transplant
Interventions 2 groups, no treatment control versus laser (continuous 780 nm wavelength, 60 mW
power, fluence 4 J/cm2.
Outcomes Oral assessments performed 3 times (days 1, 8 and 15) using the Common Toxicity
Criteria National Cancer Institute toxicity scale (0-4 scale). Other reported outcomes:
use of drugs to treat infection, food intake (kcal), nutritional status (BMI), buccal health
(number of decayed,missing and filled teeth), white cell count, number of teeth brushing
sessions
Notes Funding information: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “patients were randomized to re-
ceive or not laser treatment according to
group allocation”
Comment: author contacted and replied
that sequence was computer generated
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Cruz 2007 (Continued)
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Laser versus no intervention. No apparent
blinding.
Blinding?
Patients
No Laser versus no intervention. No apparent
blinding.
Blinding?
Outcome assessors
Yes Quote: “oral mucositis was scored by the
same investigator...who was blind to the
randomisation allocation using the CTC
NCI.”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 62 patients randomised. 2 patients ex-
cluded. Authors do not provide allocation
information. 56 patients evaluated at 2nd
assessment. 59 patients evaluated at assess-
ment 3. Authors give no reasons for omis-
sions
Free of selective reporting? Unclear Data presented for 59 patients in text and
fig 1.
Free of other bias? Yes Study appears to be free of other sources of
bias.
Dai 2009
Methods Randomised, parallel group study conducted in China. Clear information about with-
drawals: 0. Unclear if dentist involved in study. Drop outs: 0%
Participants Adults with head and neck cancer receiving radiotherapy. 42 enrolled and randomised
between January 2008 to December 2008, all completed
Interventions 2 groups, YHD Humo Decoction (honeysuckle flower 15 g, forsythia fruit 9 g, scullcap
root 15 g, glehnia root 15 g, lilyturf root 15 g, crude rehmannia root 15 g, figwort root
15 g, red peony root 10 g, red sage 10 g, milkvetch root 10 g, asiabell root 10 g, balloon
flower root 10 g, arctium fruit 10 g, and liquorice 6 g). It was decocted in water, boiling
down to 150 mL of decoction, one dose daily, administered in six times by keeping it
in the mouth for 2 min and then swallowed. No treatment control. All patients gargled
with 2% lidocaine before meals and at night
Outcomes Mucositis severity evaluated daily using RTOG 0-4 scale and the highest grade reported.
Unclear how often this was measured but results reported by grade of mucositis and as
days to reach each RTOG grade
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Dai 2009 (Continued)
Notes Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”They were randomised equally
into the test group and control group”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Yangyin Humo Decoction (YHD) versus
no treatment. No apparent blinding
Blinding?
Patients
No Yangyin Humo Decoction (YHD) versus
no treatment. No apparent blinding
Blinding?
Outcome assessors
No Yangyin Humo Decoction (YHD) versus
no treatment. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 42 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented for 42 patients by arm and
grade of mucositis
Free of other bias? No Patients in the intervention group received
a higher dose of radiation than those in the
control group (P < 0.05)
All Chinesemedicine RCTs are now a cause
for concern in light of the findings of Taix-
iang et al, 2007
Dazzi 2003
Methods Randomised, parallel group study conducted in Italy. Clear information about with-
drawals: 0. Unclear if dentist involved in study. Drop outs: 0%
Participants Adults with solid cancer. 90 enrolled and randomised between July 1997 and February
2002, 90 completed
Interventions 2 groups, placebo versus GM-CSF mouthwash (150 ug/day) in 100 cl 4 times per day.
Rinse 1 minute. All patients 0.2% chlorhexidine and amphotericin B
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Dazzi 2003 (Continued)
Outcomes Mucositis severity evaluated daily using NCI CTC. Other reported outcomes: oral pain
evaluated daily using visual scale and pain requiring opioids
Notes Funding source: none (c).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “were randomly allocated to the
GM-CSF or the placebo group”
Comment: random component not de-
scribed.
Allocation concealment? Yes Quote: “Study suspensions were prepared
by the pharmacy unit and provided to the
bone marrow transplant patients.”
Comment: pharmacy controlled randomi-
sation.
Blinding?
Carers
Yes Comment: intervention and control were
dispatched from pharmacy, unlikely that
carers would have knowledge of allocation
Blinding?
Patients
Yes Quote: “double blind“.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 90 patients randomised. ITT analysis used.
No missing outcome data.
Free of selective reporting? Unclear Data presented for incidence of stomatitis,
incidence and duration of severe stomatitis,
and patients judged maximum mucositis
score (table 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Dickson 2000
Methods Randomised, parallel group study conducted inUSA.Clear information on withdrawals:
none. Dentist not involved in study. Drop outs: 0%. Duration: first day of treatment
until discharge or max 28 days after transplant. Recruitment June 1995 to August 1997
Participants Adults receiving bone marrow transplant (BMT) or peripheral blood progenitor cell
transplant (PBPCT). 58 enrolled and evaluated with leukaemia or lymphoma
Interventions 2 groups, powdered sugar added to food or drink (placebo) versus glutamine (10 g doses
mixed with food or liquid chosen by patient) 3 times daily (30 g/day)
Outcomes Stamford University Hospital BMT toxicity scale for mucositis scale 0-4. Reported as
grade 2+. Parenteral nutrition with TPN. Assessment used: day 28. Other reported
outcomes: length of hospital stay. Days in total, parenteral nutrition, diarrhoea, toxicity
Notes Funding source: pharmaceutical supply product/small grants programme of Stanford
University Hospital’s Nursing Management Department
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “the BMT or PBPCT patients were
registered with the data managers and ran-
domly assigned to receive glutamine”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 58 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for median mucositis du-
ration (days), median mucositis grade and
mucositis grades 2-4 (in percentages)
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Dodd 1996
Methods Randomised, parallel group, multicentre study conducted in USA. Dentist involved in
study. Duration: up to 3 months
Participants Adults with solid cancer receiving chemotherapy. Followed for 3 cycles of chemotherapy.
303 eligible, 227 enrolled and evaluated
Interventions 2 groups: water control (described as placebo) versus chlorhexidine mouthrinse (0.12%,
20 ml, twice per day)
Outcomes Oral assessment guide (OAG) 0-24, scores over 10 were considered to be oral mucositis.
Maximum of 3 months. Assessment used: day 90. Other reported outcomes: survival,
cost, time to onset of mucositis, severity of mucositis
Notes Severity of mucositis at onset measured. ITT analysis.
Funding source: government and pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Researchers used a randomised,
double-blind, placebo controlled trial de-
sign”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Yes Quote:“physicians and intervention nurses
performed blinded assessments”
Comment: probably done.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote:“physicians and intervention nurses
performed blinded assessments.”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 227 patients randomised. 5 patients were
ineligible. Final sample of 222 patients. 89
patients (40%) did not finish 3 cycles of
chemotherapy. ITT analysis conducted
Free of selective reporting? Unclear Data presented for 222 patients for mu-
cositis incidence, time to onset of mucositis
and severity of mucositis (table 3)
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Dodd 1996 (Continued)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Dorr 2007
Methods Randomised, parallel group multisite study conducted in Germany. Clear information
about withdrawals: 8 (4/36 wobe mugos; 4/33 placebo). Unclear if dentist involved
in study. Duration: treatment continued until 5 days after radiotherapy. Recruitment
conducted between June 1996 and May 2000
Participants Adults with head and neck cancers undergoing radiotherapy (all patients received dose
> 40 Gy)
Interventions 2 groups, placebo versus wobe mugos (papain 100 mg, trypsin 40 mg and chymotrypsin
40 mg), 3 x 4 tablets per day
Outcomes Mucositis assessed weekly using the RTOG/ EORTC classification. Other reported out-
comes: side effects, pain on swallowing, dysphagia, skin erythema, skin desquamation
Notes Funding source: unclear. Figure 1 data used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “randomisation was performed
with the software ’Rancode plus’ in ran-
domly permuted blocks at a ratio of 1:1”
Comment: computer generated random
numbers.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Quote: “triple blind”.
Comment: unclear who the third blind
party was. Nurse or statistician?
Blinding?
Patients
Yes Quote: “triple blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “triple blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 69 patients randomised. 8 patients with-
drew/excluded (4/36 wobe mugos; 4/33
placebo)
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Dorr 2007 (Continued)
Free of selective reporting? Unclear Data presented for frequency distribution
of oral mucositis by grade (fig 1, percent-
ages, not clear if all participants included)
, mean values of maximum scores (fig 2),
and average mucositis score (fig 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Dozono 1989
Methods Randomised, cross-over study conducted in Japan. Clear information on withdrawals:
none. Unclear if dentist was involved. Drop outs: 0%. Duration: unclear
Participants Adults with solid cancer receiving chemotherapy. 15 patients enrolled and completed
both periods
Interventions 2 groups: no treatment control versus allopurinol mouthwash (carboxymethylcellulose
(CMC-Na) 5 g and allopurinol 500 mg, water to 500 ml solution)
Outcomes Japan Society for Cancer Therapy criteria for stomatitis 0-4 scale
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “the subject was randomised into
allopurinol administration and control one
by the envelope method”
Comment: unclear if envelopes were se-
quentially numbered or suffled. Random
component not described
Allocation concealment? Unclear Envelope method of randomisation. Un-
clear if envelopes were opaque and sequen-
tially numbered
Blinding?
Carers
No Allopurinol mouthwash versus no inter-
vention. No apparent blinding
Blinding?
Patients
No Allopurinol mouthwash versus no inter-
vention. No apparent blinding
Blinding?
Outcome assessors
No Allopurinol mouthwash versus no inter-
vention. No apparent blinding
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Dozono 1989 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 15 patients randomised into cross-over
study. No missing outcome data
Free of selective reporting? Yes Data presented for grade of stomatitis for
control and treatment arms by treatment
regimen
Free of other bias? No Risk of bias assessed from translation.
Duenas 1996
Methods Randomised, parallel group study conducted in Mexico. Clear information on with-
drawals: none. Unclear if dentist was involved in study. Drop outs: 0%. Duration: -4 to
day 16
Participants Adults with mixed cancer undergoing peripheral stem cell transplant, receiving high dose
(ifosfamide, carboplatin, etoposide). 15 patients enrolled (16 course of chemotherapy)
and completed
Interventions 2 groups, placebo versus misoprostol (racemic prostaglandin E1 analogue) 250 µg 3
times per day
Outcomes WHO mucositis grades 0-4, candidiasis, days in hospital with range. Assessment used:
day 16.
Other reported outcomes: diarrohea, fever, days in hospital, duration of antibiotics
Notes All patients received fluconazole prophylaxis. Also received ranitidine, ketoconazole &
ciprofloxacin. Severity of mucositis also given but no SD. Study stopped prematurely
due to a significant finding at an interim analysis, favouring the placebo.
Funding source: government, pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “...randomly assigned to receive
misoprostol 250 mg three times a day by
mouth, or identical tablets of placebo in the
same schedule”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
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Duenas 1996 (Continued)
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 15 patients randomised to receive 16
courses of chemotherapy. No missing out-
come data
Free of selective reporting? Unclear Data presented for severity of mucositis in
a graph (figure 1)
Free of other bias? No 15 patients received 16 courses of radio-
therapy. Data presented for 16 patients
Study ended prematurely: interim analy-
sis demonstrated a significant difference
favouring placebo in the incidence and
severity of mucositis
El Sayed 2002
Methods Randomised, parallel group, multicentre study conducted in Canada. Clear information
on withdrawals. Dentist not involved in study. Drop outs: 0%. Duration: over radio-
therapy
Participants Adults with head and neck cancer treated with radiotherapy to the oral cavity, pharynx
or larynx. 137 enrolled randomised and completed
Interventions 2 groups, placebo versus antimicrobial lozenge (bacitracin, clotrimazole and gentamicin
(BCoG) 1 lozenge qid, day 1 to end of radiotherapy)
Outcomes Mucositis graded according to the OMAS scale extent of severe mucositis score, worst-
ever grade of ulceration/pseudomembrane. Assessment used: time to development of
severe mucositis. Other reported outcomes: number of treatment days lost, changes in
body weight, worst-ever grade of oral toxicity measured in patient diary, general non-
mucosal toxicity assessed by the investigator.
Mucositis measured twice weekly using the NCI CTC v2 scoring scale and the OMAS
scale. Assessment used up to 28 days. Other reported outcomes: oral pain and ability to
swallow using 10 cm VAS, salivary flow rate, adverse events nausea and vomiting
Notes Funding source: National Cancer Institute.
Risk of bias
Item Authors’ judgement Description
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El Sayed 2002 (Continued)
Adequate sequence generation? Unclear Quote: “enrolled patients were random-
ized”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 138 patients randomised. 1 patient (1/68
placebo) deemed ineligible. 4 patients re-
moved from primary analysis due to miss-
ing data (1/69 BCoG, 3/68 placebo). 137
patients included in extent of severe mu-
cositis analysis
Free of selective reporting? Yes Data presented for severity of mucositis by
grade of mucositis for all randomised pa-
tients (table 4)
Free of other bias? No Variation in radiation protocols and stan-
dard care between sites
Elad 2006
Methods Randomised, parallel group study conducted in Israel, fromAugust 2002 toMarch 2003.
Unclear information on withdrawals. Dentist involvement unclear. Drop outs: 13%.
Duration: 28 days
Participants Adults with mixed cancer. BMT, total body irradiation, chemotherapy, chemoradiother-
apy. 45 enrolled and randomised 39 completed
Interventions 2 groups, placebo versus topical histamine gel (a semi viscous solution containing 0.12%
w/wHDC (histamine dihydrochloride) in a carbomer-based vehicle). Patients instructed
to use 5 ml (1 teaspoon) 4 times a day
Outcomes Mucositis measured twice weekly using the NCI CTC v2 scoring scale and the OMAS
scale. Assessment used up to 28 days. Other reported outcomes: oral pain and ability to
swallow using 10 cm VAS, salivary flow rate, adverse events nausea and vomiting
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Elad 2006 (Continued)
Notes Funding source: early part of study funded by industry, rest of funding unclear. All
received standard oral care: chlorhexidine mouthrinse 2/day amphotericin B lozenges 4/
day. Pharmacological company provided drug and organised randomisation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were allocated at random
to one of two treatment arms in a blocked
randomisation schedule.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Yes Quote: “Patient, investigator and staff were
blinded to the treatment assignment.”
Comment: probably done.
Blinding?
Patients
Yes Quote: “Patient, investigator and staff were
blinded to the treatment assignment.”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “Patient, investigator and staff were
blinded to the treatment assignment.”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear 45 patients randomised. 39 patients
matched inclusion criteria for efficacy anal-
ysis. No information given about 6 with-
drawals
Free of selective reporting? Unclear Data presented for maximum intensity, av-
erage intensity, and duration of mucositis.
Incidence of mucositis > grade 2 (table 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Epstein 1989
Methods Randomised, parallel group single site study conducted in Canada. Clear information on
withdrawals: 6/24 placebo. Dentist involved in study. Drop outs: 12%. No information
given about dates of recruitment. Duration: unclear
Participants Adults with head and neck cancer receiving radiotherapy (25 patients received 4500 cGy
in 15 daily fractions over 3 weeks, 18 patients received 6000 cGy in 25 daily fractions
over 5 weeks). 49 patients enrolled, 43 patients completed
Interventions 2 groups, placebo (10% alcohol) base versus benzydamine (1.5 mg/ml benzydamine
hydrochloride in a 10% alcohol base). Both groups asked to rinse 15 ml for 30 seconds,
4 times daily, and then expectorate
Outcomes Multivariable scale (area of involvement, severity of inflammation, severity of ulceration
and maximum size of ulceration each graded using a 0-3 scale. Scores then combined)
. Other outcomes measures: pain (at rest and on eating), burning, anesthetic effect of
benzydamine, salivary flow rate
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”the patients were selected ran-
domly to receive drug (Bzd) or placebo
rinse (carrier base only)”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Quote: “Drugs were dispensed in a double
blind manner”.
Comment: insufficient information to de-
termine ’yes’ or ’no’
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 49 patients recruited. 43 included in anal-
ysis. 6 patients (all placebo) withdrawn due
to non-compliance
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Epstein 1989 (Continued)
Free of selective reporting? Unclear Data presented for maximum size of ulcer-
ations, total area of ulcerations, average ul-
ceration size and area of reaction x severity
of inflammation/surfaces involved
Free of other bias? Yes Study appears to be free of other sources of
bias.
Epstein 1994
Methods Randomised parallel group study conducted in Canada. Clear information about with-
drawals: 0. Dentist involved in study. Duration: 5-7 weeks
Participants Adults with head and neck cancer receiving radiotherapy (either 5000 cGy in 16 fractions
or 6000 cGy in 25 fractions). 33 patients randomised and completed study
Interventions 2 groups, placebo versus sucralfate (1 g/5 ml). Drug or placebo rinsed and swallowed for
1 or 2 minutes, 4 times daily
Outcomes Mucositis assessed weekly using a cumulative mucositis score (Epstein). Other reported
outcome measures: compliance, pain, adverse events, dysphagia, xerostomia
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”following consent and randomisa-
tion”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 33 patients randomised. No missing out-
come data.
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Epstein 1994 (Continued)
Free of selective reporting? Unclear Data presented for totalmucositis score and
total ulceration by arm
Free of other bias? Yes Study appears to be free from other sources
of bias.
Epstein 2001
Methods Randomised parallel group multisite study conducted in the USA and Canada. Clear
information about withdrawals. Unclear if dentist involved in study. Duration: until 2
weeks after completion of radiotherapy
Participants Adults with head and neck cancers receiving radiotherapy (total planned dose of 5000
Gy) or concomitant radiotherapy and chemotherapy (cisplatin, or 5-fluorouracil)
Interventions 2 groups, placebo versus benzydamine (0.15%, 1.5 mg/ml). Patients asked to rinse with
15 ml of mouthwash for 2 minutes, 4-8 times daily 173 patients randomised
Outcomes Mucositis assessed at every clinic visit using amultivariable scale (Epstein).Other reported
outcome measures: use of analgesics, mouth and throat pain, compliance, number of
patients diluting rinses, adverse events, risk of mucositis, weight loss, number of patients
needing nasogastric or percutaneous endoscopic gastrostomy tube feeds
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”randomised”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Unclear Placebo controlled study, however no
blinding information is given
Blinding?
Outcome assessors
Unclear Placebo controlled study, however no
blinding information is given
Incomplete outcome data addressed?
All outcomes
Yes 173 patients randomised. 172 patients
treated. 165 patients (who had received at
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Epstein 2001 (Continued)
least 1 on-radiation evaluation) included in
ITT analysis
Free of selective reporting? Unclear Data presented for mean AUCs by radio-
therapy interval.
Free of other bias? Yes Study appears to be free from other sources
of bias.
Ertekin 2004
Methods Randomised, parallel group study conducted in Turkey, between May 2001 and May
2002. Clear information about withdrawals, 3 in placebo. Dentist not involved in study.
Drop outs: 10%
Participants Adults with head and neck cancer. 30 enrolled, 27 completed.
Interventions 2 groups, zinc sulphate 50mg zinc capsules 3 times per day starting first day of radiother-
apy until 6 weeks after versus placebo. All patients access to local anaesthetic solutions
and analgesic agents
Outcomes Mucositis RTOG grading. Other reported outcomes: non-steroidal analgesics
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: randomly assigned to receive either
zinc sulphate or placebo during RT”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Quote: “the placebos were empty capsules
bought from the same medical firm to be
identical to the zinc sulphate capsules”
Blinding?
Carers
Unclear Zinc versus placebo.
Reference made to the need for a “well-de-
signed double-blind randomized study to
evaluate the reliability and effectiveness” of
zinc. However, no information on blinding
provided
Blinding?
Patients
Unclear Reference made to the need for a “well-de-
signed double-blind randomized study to
evaluate the reliability and effectiveness” of
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Ertekin 2004 (Continued)
zinc. However, no information on blinding
provided
Blinding?
Outcome assessors
Unclear Reference made to the need for a “well-de-
signed double-blind randomized study to
evaluate the reliability and effectiveness” of
zinc. However, no information on blinding
provided
Incomplete outcome data addressed?
All outcomes
Yes 30 patients randomised. 3 patients with-
drew (3/15 placebo). Authors give no infor-
mation about which arm patients were ran-
domised to. 27 patients included in analy-
sis
Free of selective reporting? Yes Data presented in the text for grade of mu-
cositis by treatment arm. Data also pre-
sented for start ofmucositis (week), severity
of mucositis, dose of radiotherapy at which
mucositis developed (table 2), and mucosi-
tis levels 6 weeks after radiotherapy (table
3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Evensen 2001
Methods Randomised, parallel group study conducted in Norway. All randomised patients in-
cluded in evaluation. Dentist involvement unclear. Recruitment September 1995-June
1998
Participants Adults with hand and neck cancer undergoing radiotherapy. 60 enrolled, 60 completed
Interventions 2 groups, patients randomised to sucralfate mouthrinse or placebo, swish and spit, 5
times daily and same patients also received sucralfate gel to skin on one side of radiation
field and placebo gel to other side of the radiation field (i.e. all patients received some
sucralfate gel)
Outcomes Mucositis & skin reaction, RTOG grading. Other reported outcomes: food intake
Notes Funding source: not stated.
Risk of bias
Item Authors’ judgement Description
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Evensen 2001 (Continued)
Adequate sequence generation? Unclear Quote: “The same patients were randomly
allocated to receive either Na-SOS or
placebo for the oral rinsing procedure”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 60 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented for 60patients by treatment
allocation and grade of mucositis
Free of other bias? Unclear Difference between groups at baseline
regarding tumour stage (23% sucralfate
group T3/4, 53% placebo group). No P
value presented
Ferretti 1988
Methods Randomised, parallel group study conducted in USA. Unclear information on with-
drawals: 1/28 control, 4/28 test. Dentist involved in study. Drop outs: 10%. Recruit-
ment period April 1983 to March 1985. Duration: up to 90 days
Participants Children and adults (1-51 years) with mixed blood haematological and solid cancers
receiving BMT. Pretransplant chemoradiotherapy and TBI. 56 patients enrolled and 51
completed, but variable numbers of patients evaluated at each time point (24-50)
Interventions 2 groups, placebo versus chlorhexidine gluconate mouthrinse (15 cc 0.12%, 3 times per
day for 30s)
Outcomes Mucositis (clinical scale 0-3, but then dichotomised and measured at 7, 14, 25, 33, 60
& 90 days). Assessment used: day 33. Other reported outcomes: gross candida (clinical
appearance + swab culture or KOH preparation), oral streptococus, yeast, gram -ve
bacilli, death, morphine use, febrile episodes, use of antibiotic, blood changes
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Ferretti 1988 (Continued)
Notes Candidemia (persistant candidiasis) also recorded, with 3 deaths due to candida in the
control group. Mean mucositis scores given graphically with bars for SE. Given oral
nystatin suspension 15 ml 4 times daily or clotrimazole troches. Supplemental nystatin
soaks or popsicles were used liberally.
Funding source: pharmaceutical and government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “By prospective randomisation, pa-
tients were assigned in a double-blind
fashion a mouthrinse containing 0.12%
chlorhexidine digluconate or a control
mouthrinse identical in composition but
minus chlorhexidine”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Quote: “Mouthrinse use was supervised by
transplant unit nursing staff for the dura-
tion of hospitalization”
Comment: insufficient information to de-
termine ‘yes’ or ‘no’
Blinding?
Patients
Yes Quote: “double blind”.
Quote: “mouthrinse identical in composi-
tion but without chlorhexidine”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double Blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear 56 patients randomised. 5 patients ex-
cluded. Authors give reasons for attrition/
exclusion but variable numbers are eval-
uated at each time point and reasons for
missing data are not provided
Free of selective reporting? Unclear Data presented for percentage of patients
withmucositis andmeanmucositis score in
the form of graphs (figure 1 and figure 2).
Different numbers of patients re-evaluated
at each time point
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Ferretti 1988 (Continued)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Fidler 1996
Methods Randomised, parallel group study conducted in USA. Unclear information on with-
drawals: 1/165 total. Unlcear if dentist involved in study. Drop outs: 1%. Duration: 14
days
Participants Adults, cancer type not given. Chemotherapy: first course 5-FU based. 165 enrolled,
164 clinical evaluation, 135 patient evaluation
Interventions 2 groups, placebo versus camomile (30 drops in 100 ml water, 3 times per day)
Outcomes Mucositis (physician and patient scales 0-4). Score judged historically 4-5 weeks after
chemotherapy cycle initiation. Additionally patient form filled out on daily basis for
first 3 weeks after first day of chemotherapy. Assessment used: day 21. Other reported
outcomes: toxicity
Notes Mean daily mucositis scores shown graphically but no SD. All patients used ice chips 5
mins before chemotherapy and for 30 minutes in total.
Patient’s mucositis scores used.
Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Randomised in a double-blind
manner to receive a chamomilemouthwash
or an identical-appearing placebo.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double-blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double-blind”.
Comment: probably done.
113Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fidler 1996 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 165 patients randomised. 1 patient re-
moved due to a major protocol viola-
tion. 164 patients had evaluable physician
judged mucositis scores. Patient judged
mucositis scores evaluable in 135 patients
Free of selective reporting? Yes Data presented for maximum severity of
mucositis by grade for physician and pa-
tients judged mucositis scores (table 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Foote 1994
Methods Randomised, parallel group, multicentre study conducted in USA and Canada. Clear
information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%.
Duration: 14 days
Participants Adults with head and neck cancer. 52 patients were eligible, enrolled and evaluated
Interventions 2 groups, placebo versus chlorhexidine (15 ml 4 times per day for 130 s)
Outcomes Mucositis scale 0-4 by patient and clinician at weekly intervals. Assessment used: day
unclear
Notes Funding source: pharmaceutical and government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Following randomisation, they
were randomized in a double-blind man-
ner to receive a chlorhexidine mouthwash
or a placebo mouthwash.”
Comment: random component not de-
scribed.
Allocation concealment? Yes Quote: “only a coded bottle was commu-
nicated to the treatment centre”
Comment: central allocation. Probably
done.
Blinding?
Carers
Yes Adequate allocation concealment. Unlikely
that carers would know allocations
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Foote 1994 (Continued)
Blinding?
Patients
Yes Quote: “double Blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double Blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 52 patients randomised. No incomplete
outcome data.
Free of selective reporting? Yes Data presented for 52 patients for maxi-
mum mucositis severity score by grade of
mucositis and intervention
Free of other bias? No Quote: “Due to the significantly higher
toxicity rates and the lack of evidence of
efficacy associated with chlorhexidine, the
double-blinded portion of the trial was per-
manently closed”
Franzen 1995
Methods Randomised, parallel group study conducted in Sweden. Unclear information on with-
drawals: 2/50 total. Unclear if dentist involved in study. Drop outs: 4%. Duration of
treatment: 6 weeks (starting 2 weeks after start of radiotherapy)
Participants Adults with head and neck cancer. 50 patients were randomised and 48 evaluated
Interventions 2 groups, placebo versus sucralfate (granules of sucralfate an alkaline aluminimum hy-
droxide of suphated sucrose, swish with 1 dose package 1 g dissolved in water 6 times/
day)
Outcomes Patient based assessment of mucositis on 0-3 scale, number with grades 2 or 3 reported.
Assessement used: day 28. Other reported outcomes: mucosal reaction, pain, functional
impairment. Mucositis evaluations from -2 to 14 weeks
Notes Funding source: charity.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “granules of sucralfate or placebo
similar in taste, colour, and consistency
were dispensed randomly”
Comment: random component not de-
scribed.
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Franzen 1995 (Continued)
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear 50 patients randomised. 2 patients ex-
cluded from analysis. Authors give full rea-
sons for attrition/exclusion. Numbers of
patients reported in outcome assessments
not reported information only given in per-
centages
Free of selective reporting? Unclear Data presented in a graph for mucosal re-
action over time (figure 1). Figures given in
percentages
Free of other bias? Yes Study appears to be free of other sources of
bias.
Freytes 2004
Methods Randomised, parallel group, multicentre study conducted in USA. Clear information
on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: 28 days
after last dose of intervention
Participants Adults with mixed cancer. BMT. 42 enrolled, randomised and evaluated
Interventions 3 groups, placebo versus repifermin 25 mug/kg and repifermin 50 mug/kg (patients re-
ceived intravenous repifermin or placebo for 3 days before their autologous haematopoi-
etic stem cell transplantation (auto-HSCT) conditioning regimen and for up to 10 days
after auto-HSCT)
Outcomes Mucositis measured 3/week until mucositis resolved using the NCI CTC mucositis
toxicity scale for bone marrow transplant studies (on a scale of 0-4). Mucositis was also
assessed by the OMAS scale. Assessment used: up to day 28. Other reported outcomes:
severity and duration of ambient oral and oropharyngeal pain and pain on swallowing, an
ability to eat score, narcotic pain medication use, adverse events incuded the frequency,
severity and duration of diarrhoea
Notes Funding source: unclear.
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Freytes 2004 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “This study was a multicentre
randomised, double-blinded, placebo con-
trolled, phase I/II study.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 42 patients recruited. Nomissing outcome
data.
Free of selective reporting? Unclear Data only presented in percentages for mu-
cositis grades between 2 and 4 (figure 1)
Free of other bias? No Authors highlight possible bias because of
the multiplicity of conditioning regimens
used.
Gandemer 2007
Methods Randomised, parallel multicentre study conducted in France. Clear information about
withdrawals: 3/73 intervention, 2/72 control. Duration: from first day of chemotherapy
to 3 days after the end of chemotherapy. Recruitment conducted between March 1999
and December 2002
Participants Children aged between 5 and 18 years old undergoing chemotherapy. Mix of diseases
(osteosarcoma, Hodgkin lymphoma, acute lymphoblastic leukaemia, acute myeloblastic
leukaemia, rhabdomysarcoma, lymphoma, Ewing sarcoma). all chemotherapy regimens
were associated with at least a 30% rate of grade 3/4 mucositis
Interventions 2 groups, no treatment control versus chewing gum. Patients in the chewing gum arm
were asked to chew 5-6 pieces of gum per day. All patients received standard oral care
(brushing with a soft toothbrush and rinsing with sodium bicarbonate)
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Gandemer 2007 (Continued)
Outcomes Mucositis assessed daily using theWHO score and a detailed instrument designed by the
authors. Other reported outcome measures: pain, abdominal disorders, use of parenteral
nutrition, adverse events, infection, factors associated with severe mucositis (multivariate
analysis)
Notes Funding source: publicly funded research grant and a national clinical research grant
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Eligible patients were randomised
by the study randomisation centre...”
Quote: “A minimization procedure was
used...”
Comment: minimization.
Allocation concealment? Yes Quote: “the study centres and the randomi-
sation centres communicated by fax”
Blinding?
Carers
No Chewing gum versus no intervention.
Blinding impossible.
Blinding?
Patients
No Chewing gum versus no intervention.
Blinding impossible.
Blinding?
Outcome assessors
No Chewing gum versus no intervention.
Incomplete outcome data addressed?
All outcomes
Yes 145 patients randomised. Primary end
point (WHO score) was evaluable in 140
patients. Excluded patients equally dis-
tributed (3/73 intervention, 2/72 control)
. Authors do not give reasons for with-
drawals/exclusions
Free of selective reporting? Unclear Data presented in percentages for 140 pa-
tients for mucositis grades 1 and 2 com-
bined and mucositis grades 3 and 4 com-
bined (fig 2A)
Free of other bias? Yes Study appears to be free of other sources
of bias.
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Giles 2004
Methods Randomised, parallel group, multicentre study conducted in USA between November
2001 and June 2002. Clear information on withdrawals: none. Dentist not involved in
study. Drop outs: 0%. Duration: 21 days
Participants Adults and children with mixed cancer. BMT. 502 randomised and completed
Interventions 2 groups, placebo versus iseganan (patients received an oral rinse, consisting of iseganan
9 mg or placebo, to be swished/swallowed 6 times daily, for up to 21 days)
Outcomes Mucositis assessed 3/weekly by the proportion of patients who did not develop a peak
NCI CTC stomatitis grade 2 or above. Assessment used up to 21 days. Other reported
outcomes: mouth pain, difficulty swallowing, incidence of ulcerative oral mucositis
(UOM), opioid use, adverse events included fatigue, anxiety, sore throat, dermatitis,
insomnia and erythema
Notes Funding source: unclear. Pharmacological company provided drug and organised ran-
domisation.
Correspondence with Dr D Peterson: clinical trials with iseganan were discontinued
approximately 6 years ago. Approval of the drug for oral mucositis was not obtained in
the United States
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “A randomised, double blind,
placebo controlled study”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Quote: “all study drugs were packaged in
identical white opaque plastic bottles, each
containing a 5 day supply.”
Comment: authors do not state whether
drugs were sequentially numbered. Insuffi-
cient information to determine ‘yes’
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Quote: “Patients, study personnel, and the
sponsor were blinded to whether an indi-
vidual patient received isegananor placebo”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Quote: “Patients, study personnel, and the
sponsor were blinded to whether an indi-
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Giles 2004 (Continued)
vidual patient received isegananor placebo”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear 502 patients randomised. 56% of Iseganan
group and 66% of placebo group com-
pleted study. Authors give incomplete rea-
sons for exclusion/attrition
Free of selective reporting? Unclear Data presented for percentage without mu-
cositis, peakmucositis grade,meanmucosi-
tis grade, and incidence (percentage) of ul-
cerative mucositis
Free of other bias? Yes Study appears to be free of other sources of
bias.
Gori 2007
Methods Randomised, parallel multisite study conducted in Italy between October 2004 and
January 2006. Clear information on withdrawals. Unclear if dentist involved in study
Participants Adults and children with haematological malignancies undergoing allogeneic stem cell
transplantation. All patients received methotrexate (20 mg/m2 on day +1, 5 mg/m2
on days +3, +6 and +11). 130 patients were randomised. 8 patients were excluded. 50
patients received folinic acid rescue
Interventions 2 groups, no treatment control versus cryotherapy (1 hour, ice chips or popsicles)
Outcomes Mucositis assessed daily using theWHO score. Other reported outcome measures: mul-
tivariate analysis of factors affecting mucositis development (lack of folinic acid rescue
and use of TBI)
Notes Funding source: Italian HSCT Nurses Group.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “After giving their informed con-
sent, patients were included in a preformed
randomization list that was updated by the
co-ordinating centre. Randomization was
performed at the ratio of 1 patient per arm
with no further stratification.”
Comment: random component not de-
scribed.
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Gori 2007 (Continued)
Allocation concealment? Unclear Co-ordinating centre described in text,
however, unclear who held the schedules.
Therefore, there is insufficient information
to determine ‘yes’ or ‘no’
Blinding?
Carers
No Ice chips versus no intervention. Blinding
impossible.
Blinding?
Patients
No Ice chips versus no intervention. Blinding
impossible.
Blinding?
Outcome assessors
No Ice chips versus no intervention.
Incomplete outcome data addressed?
All outcomes
Yes 130 patients were randomised. 8 patients
were excluded. Authors give complete rea-
sons for exclusions/withdrawals but do not
state which arm patients were randomised
to.
Free of selective reporting? Yes Data presented for 122 patients by mucosi-
tis grade and arm.
Free of other bias? Yes Study appears to be free of other sources of
bias.
Goyal 2009
Methods Randomised, parallel group study conducted in India. All patients underwent oro-dental
prophylaxis prior to randomisation. Recruitment conducted from July 2006 until July
2007
Participants Adults with head and neck cancer (non-metastatic carcinoma of the oral cavity, pharynx
or larynx) receiving radiotherapy. 212 patients randomised. 35 patients excluded
Interventions Morning radiotherapy (8am-11am) versus evening radiotherapy (3pm-6pm)
Outcomes Oral mucositis assessed weekly using RTOG instrument (0-4) for 7 weeks. Week 4
data used (table 3). Other reported outcomes: highest grade of mucositis, response to
radiation, dysgeusia, dysphagia, xerostomia, skin reaction
Notes Funding source unclear.
Risk of bias
Item Authors’ judgement Description
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Goyal 2009 (Continued)
Adequate sequence generation? Unclear Quote: “All patients were hospitalised dur-
ing the course of treatment and were ran-
domised to arm 1, receiving radiation in
themorning and arm 2, receiving radiation
in the evening.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Morning versus evening radiation. Blind-
ing impossible.
Blinding?
Patients
No Morning versus evening radiation. Blind-
ing impossible.
Blinding?
Outcome assessors
Yes Quote: “Radiation reactions were assessed
weekly by a blinded observer according by
RTOG criteria”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
No 212 patients randomised. 35 patients ex-
cluded. Authors give incomplete reasons
for drop outs/exclusions and no informa-
tion about which arms these patients were
allocated
Free of selective reporting? Yes Data presented for grade of mucositis by
arm and week of treatment (table 3). Data
also presented for grades I and II and grades
III and IV in percentages (table 2)
Free of other bias? Yes Study appears to be free from other sources
of bias.
Gujral 2001
Methods Randomised, parallel group study conducted in India. Unclear information about with-
drawals. Dentist no involved in study. Drop outs: 1%. Duration: 6 months
Participants Adults with head and neck cancer. T3 and T4 squamous cell cancer, 100 enrolled, 99
evaluated
Interventions 2 groups, no treatment versus hydrolytic enzymes, papain 100 mg, trypsin 40 mg and
chymotrypsin 40 mg. 3 tablets 3 times a day - 3 until + 5
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Gujral 2001 (Continued)
Outcomes RTOG/EORTC scoring. Assessment used: day 54. Other reported outcomes: dysphagia,
dermatitis
Notes No oral care except toothbrushing. Funding source: pharmaceutical
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”patient randomisation was carried
out by the sealed envelope method.“
Quote: ”The patients were enrolled in
chronological order. They were assigned
consecutive patient numbers, and received
either radiation therapy, or radiation ther-
apy together with enzyme therapy”
Comment: unclear if envelopes were shuf-
fled. Random component not described
Allocation concealment? Unclear Quote: “sealed envelope method.”
Comment: unclear whether envelopes were
sequentially numbered and opaque
Blinding?
Carers
No Quote: “randomised, open trial”.
Blinding?
Patients
No Quote: “randomised, open trial”.
Blinding?
Outcome assessors
No Quote: “randomised, open trial”.
Incomplete outcome data addressed?
All outcomes
Yes 100 patients randomised. Outcome data
given for 99 patients. 53: intervention, 46:
control. 2 patients died during study 2/53
intervention. Missing patient from control
group. No information given. Observed
event risk not sufficient to have clinically
relevant impact on result
Free of selective reporting? Yes Data presented for 99 patients bymucositis
grade (table 3). AUC data presented for 93
patients with complete data (table 4). Min-
imum and maximum, mean (SD) grades
given for 99 patients (table 2). Data pre-
sented for time to mucositis grade 2 (table
5)
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Gujral 2001 (Continued)
Free of other bias? Yes Study appears to be free from other sources
of bias.
Haddad 2009
Methods Randomised, parallel group, 1 site study conducted in USA. Clear information on with-
drawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: up to 43
days
Participants Adults with head and neck cancer. 58 patients enrolled and randomised between May
2003 and April 2006, all completed
Interventions 2 groups, no amifostine versus intravenous amifostine (500 mg/m² concomitant with 4
weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m²) and
boost radiation 72 Gy in 42 fractions)
Outcomes Mucositis secondary outcome as determined by Common Terminology Criteria for
Adverse Events, version 3.0), assessment every 4 weeks and the worst grade recorded.
Only percent of patients with grades 3 and 4 reported
Other reported outcomes: xerostomia, locoregional failure, progression-free survival,
overall survival (all up to 60 months), treatment related adverse events: cytokine level,
feeding tubes, swallowing function, breaks in treatment, allergic reaction
Notes Funding source: industry.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “the randomisation process was
centralised and managed through the
Dana-Farber Cancer Institute protocol of-
fice”
Comment: random component not ex-
plicit. However, setting makes adequate
randomisation likely
Allocation concealment? Unclear Quote: “central method of allocation”.
Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Radiotherapy with or without subcuta-
neous amifostine. No apparent blinding
Blinding?
Patients
No Radiotherapy with or without subcuta-
neous amifostine. No apparent blinding
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Haddad 2009 (Continued)
Blinding?
Outcome assessors
No Radiotherapy with or without subcuta-
neous amifostine. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 58 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented in percentages for number
of patients experiencing grade 3 and 4 mu-
cositis
Free of other bias? No The study was stopped before the comple-
tion of planned accrual because IMRT was
becoming the de facto standard technique
in treating head and neck cancer
Hanson 1995
Methods Randomised, parallel group multisite study conducted in the USA. Clear information
about withdrawals: 0. Unclear if dentist involved in study. Duration: 5-7 weeks
Participants Adults with head and neck cancer undergoing radiotherapy (daily fractions of 2 Gy/day,
total dose: 50-70 Gy over 5-7 weeks)
Interventions 2 groups, placebo tablets or misoprostol tablets (200 µg) dissolved in 15 ml tap water.
Patient asked to swish and gargle without swallowing
Outcomes Mucositis assessed weekly using a 0-4 scale. Other reported outcome measures: plasma
values of misoprostol in healthy volunteers, ability of physician to guess randomisation
after blinded chart review, number of patients receiving antifungals, nasogastric tubes
and parotid sparing
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomized”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Quote: 35 tablets containing200µg each of
MPof 35 placebo tablets containing the ve-
hicle alone were supplied by Searle in coded
bottles”
Comment: unclear if bottles were sequen-
tially numbered.
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Hanson 1995 (Continued)
Blinding?
Carers
Yes Quote: ”each patient was assigned a bottle
of tablets without knowledge of the con-
tent (MPor placebo), nor did the attending
physician, nursing or administrative staff
knew the content or coding”
Comment: probably done.
Blinding?
Patients
Yes Quote: “each patient was assigned a bottle
of tablets without knowledge of the con-
tent (MPor placebo), nor did the attending
physician, nursing or administrative staff
knew the content or coding”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”each patient was assigned a bottle
of tablets without knowledge of the con-
tent (MPor placebo), nor did the attending
physician, nursing or administrative staff
knew the content or coding”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 69 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for mean mucositis score
over time for both hospital sites
Free of other bias? No Significant difference seen between the 2
investigative sites in this study (1 showed
an effect , the other did not). Authors have
no definitive explanation but there is a sug-
gestion that there may have been differ-
ences in the compliance with study proto-
col and/or the time between administration
of prostagladin and the start of RT
Hartmann 2001
Methods Randomised, parallel group study conducted in Germany. Clear information about
withdrawals: 0. Unclear if dentist involved in study. Drop outs: 0%
Participants Adults with solid cancer. 40 enrolled between August 1997 and January 1999, 40 com-
pleted
Interventions 2 groups, amifostine 910 mg/m², 15 minute IV infusion before carboplatin and ifos-
famide for 3 consecutive days versus no amifostine control
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Outcomes Mucositis WHO percentage patients grade 3-4. Other reported outcomes nausea/vom-
iting, costs of total care, diarrhoea
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients had given informed con-
sent for the treatment with HD-VIC and
for the randomization to pre-treatment
with or without amifostine.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Amifostine versus no intervention. No ap-
parent blinding.
Blinding?
Patients
No Amifostine versus no intervention. No ap-
parent blinding.
Blinding?
Outcome assessors
No Amifostine versus no intervention. No ap-
parent blinding.
Incomplete outcome data addressed?
All outcomes
Yes 40 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for median WHO grade
and for percentage of patients with mucosi-
tis grades > 3 and 4
Free of other bias? Yes Study appears to be free of other sources of
bias.
He 2008
Methods Randomised, parallel group study conducted in China. Clear information about with-
drawals: 0. Unclear if dentist involved in study. Drop outs: 0%. Recruitment period:
unclear
Participants Adults with oesophageal and cardiac cancer receiving chemotherapy. 48 enrolled and
randomised, all completed
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He 2008 (Continued)
Interventions 2 groups, 20 g glutamine daily versus a placebo (compound amino acid) given by ’in-
jection’ possibly into parenteral nutrition solution
Outcomes Mucositis severity evaluated using 0-4 scale NCI CTCAE criteria, grade 0, 1, 2 versus
grade 3, 4, nausea/vomiting, diarrhoea, leucopenia, weight loss
Notes Funding source: government. All above information obtained from Chinese translation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote “randomization table”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Quote “randomization table”.
Comment: method of concealment un-
clear.
Blinding?
Carers
Unclear Parenteral amino acid solution with or
without glutamine. No apparent blinding
Blinding?
Patients
Unclear Parenteral amino acid solution with or
without glutamine. No apparent blinding
Blinding?
Outcome assessors
Unclear Parenteral amino acid solution with or
without glutamine. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 48 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for number of patients with
grades 0-2 mucositis and grades 3-4 mu-
cositis for both arms
Free of other bias? No ROB assessed from a translation.
Hu 2005
Methods Randomised, parallel group study conducted in China. Clear information about with-
drawals: 0. Unclear if dentist involved in study. Drop outs: 0%
Participants Adults with head and neck cancer receiving radiotherapy. 140 enrolled and randomised,
all completed
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Hu 2005 (Continued)
Interventions 2 groups, Shenqi Fanghou recipe (author named) Chinese herb decoction containing 22
specifically selected herbs such as codonopsis pilosula 30 g, raidx astragali 30 g, Indian
buead 30 g, etc. altogether 406 g as a dosage for a day. All the herbs were put into water
for boiling then removing the herbs and 400 ml of solution obtained. The patients were
asked to intake the solution orally, 200 ml a time and twice a day. No treatment control.
All patients gargled with 2% lidocaine before meals and at night
Outcomes Mucositis severity evaluated using 0-4 scale and the highest grade throughout radiother-
apy course reported. Unclear how often this was measured but results reported by grade
of mucositis
Notes Funding source: unclear. All above information obtained from Chinese translation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised”.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Shenqi Fanghou recipe versus no treat-
ment. No apparent blinding
Blinding?
Patients
No Shenqi Fanghou recipe versus no treat-
ment. No apparent blinding
Blinding?
Outcome assessors
No Shenqi Fanghou recipe versus no treat-
ment. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 140 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented for 140 patients by grade
and treatment arm.
Free of other bias? No Risk of bias assessed from translation.
Huang 2000
Methods Randomised, parallel group study conducted in Taiwan. Clear information about with-
drawals: none. Dentist not involved in study. Drop outs: 0%. Duration: beginning of
radiation treatment until 25 factions (5 weeks). Recruitment July 1997 to June 1998
Participants Adults with head and neck cancer. 17 patients were enrolled and evaluated
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Huang 2000 (Continued)
Interventions 2 groups, placebo (30 ml saline) versus glutamine (2 g in 30 ml saline, swish 30 ml 3
mins then expectorate)
Outcomes Clinicians assessed subjective mucositis on 0-4 scale and objective RTOG/EORTC 0-4
scale. WHO step of analgesic drugs. Assessment used: day unclear
Notes Subjective mucositis scale used. Funding source: not stated.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were sequentially ran-
domised to two treatment arms”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “single blind randomised study”.
Comment: probably done.
Blinding?
Outcome assessors
No Quote: “due to manpower problems, not
all physicians who evaluated patients were
blind to test solutions”
Comment: assessors not blind.
Incomplete outcome data addressed?
All outcomes
Yes 17 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Maximum grade of mucositis by grade and
treatment arm (table 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Huang 2003
Methods Randomised, parallel group study conducted in China. Clear information on with-
drawals. Unclear whether dentist involved in study. Drop outs: 0%. Duration: average
radiotherapy 50 days
Participants Adults with head and neck cancer treated with chemotherapy cisplatin (DDP 30 mg/
m²) with concomitant radiotherapy. 101 patients recruited and evaluated
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Huang 2003 (Continued)
Interventions 2 groups, Dobell’s solution (unclear what this is) gargled 5-8 times daily versus Chinese
medicine (sucked and swallowed) 6 times fromfirst to sixthweek of radiotherapy. Patients
received either Chinese medicine or Dobell’s solution 5-8 times daily.
The decoction is made as solution by cooking the 11 herbs together with water. Doses
of the herbs for 1 day are: coastal glehnia 30 g, dwarf lilyturf tuber root 30 g, rehmannia
dried root 30 g, figwort rood 15 g, spreading hedyotis herb 30 g, belamcauda rhizome
15 g, platycodon root 15 g, shinyleaf pricklyoash root 15 g, honeysuckle flower 15 g,
licorice root 3 g, lalanggrass rhizome 20 g.
The authors follow theoretical principles of Chinese medicine: treatment should be
modified in adapting the changes of the diagnosis. So, if the patients with symptoms
of rhinorrhagia or blood clot in the sputum, adding hairy vein agrimony herb 20 g,
hyacinth bletilla tuber 15 g; with nausea and vomiting adding red ochre 15 g, magnolis
bark of Sichuan 15 g, bamboo shaving 15 g; with obstruction of the nose, adding sibirian
cocklebur fruit 15 g, magnolia flower 15 g; with malaise and poor appetite, adding
pseudostellaria root 30 g, bighead atractylodes rhizome 15 g, malt 30 g, millet sprout 30
g; with the tongue in dark pink colour, adding root of red rooted salvia 15 g, powder of
notoginsen 3 g
Outcomes Mucositis assessed according to acute oropharyngeal mucositis grade on a 0-4 scale
Notes Pharmacological company provided drug and organised randomisation. This informa-
tion was provided by Chinese translation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Randomisation were randomly as-
signed by random numbers generated from
random number table”
Allocation concealment? Unclear Comment: random number table.
Blinding?
Carers
No Difference between intervention and con-
trol in the mode of application (gargle ver-
sus suck and swallow). Blinding impossi-
ble.
Blinding?
Patients
No Difference between intervention and con-
trol in the mode of application (gargle ver-
sus suck and swallow). Blinding impossi-
ble.
Blinding?
Outcome assessors
Unclear Insufficient information to determine ’yes’
or ’no’.
Incomplete outcome data addressed?
All outcomes
Yes 101 patients randomised. No withdrawals/
exclusions.
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Huang 2003 (Continued)
Free of selective reporting? Yes Data presented for 101patients formucosi-
tis incidence by grade and treatment
Free of other bias? No Risk of bias assessed from a translation.
Ifrah 1999
Methods Randomised, parallel group study conducted in France. Unclear information about drop
outs. Unclear if dentist involved in study
Participants Adults with blood cancer. 67 enrolled and randomised between November 1990 and
April 1992, results given on 64
Interventions 2 groups, rGM-CSF 5 ug/kg as a 6 hour IV infusion versus placebo
Outcomes WHO mucositis score (> 3).
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”At admission, patients were ran-
domised to receive either rGM-CSF or a
placebo 24 hours after induction treatment
was completed.“
Quote: ”the randomisation sequences were
generated by the co-ordinating centre and
were balanced with each centre“
Allocation concealment? Unclear Quote: ”the randomisation sequences were
generated by the co-ordinating centre and
were balanced with each centre“
Comment: unclear if allocation remained
with the co-ordinating centre. Insufficient
information to determine ‘yes’ or ‘no’
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
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Ifrah 1999 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 67 patients randomised. 3 patients with-
drew (1 patient was ineligible, 2 patients
withdrawn due to major dose errors). Au-
thors give full reasons for attrition/exclu-
sion but do not state which arms patients
were randomised too
Free of selective reporting? Unclear Data presented for mucositis grade > 3
(WHOscore) (table 2) anddurationofmu-
cositis grade > 2 (median values in days)
(table 4) for patients receiving autologous
transplantation
Free of other bias? No Patients randomised to the rGM-CSF arm
were older (median age 36 years versus 28
years, P = 0.04)
More patients randomised to the rGM-
CSF arm had Philadelphia chromosome, P
= 0.026
Jebb 1994
Methods Randomised, cross-over study conducted in UK. Unclear information about with-
drawals: 11/28 in total. Dentist not involved in study. recruitment period: not stated.
Drop outs: 39%. Duration: (1st part) 8 days.
Participants Adults with gastrointestinal cancer undergoing 5-FU & folic acid daily for 5 days and
repeated 4 weeks from start. 28 patients enrolled and 17 completed 2 cycles
Interventions 2 groups, glucose polymer (Polycal) (described as placebo) versus glutamine (16 mg daily
divided into 4 equal doses and dissolved in 150 ml water before consumption), swish
and swallow
Outcomes WHO mucositis score, mouth comfort, ease of eating. Assessment used: day 8
Notes Funding source: not stated.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised to re-
ceive either glutamine or placebo with the
first cycle of treatment and the alternative
supplement with cycle 2, such that each pa-
tient could act as his or her control”
Comment: random component not de-
scribed.
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Jebb 1994 (Continued)
Allocation concealment? Unclear Quote: “Patients and investigator were un-
aware of the randomisation order for each
subject”
Comment: insufficient information to de-
termine ‘yes’ or ‘no’
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
No 28 patients randomised. Paired outcome
data available for 17 patients who com-
pleted 2 courses of treatment. Authors give
full reasons for attrition/exclusion. How-
ever, there is the potential for the overall
estimate to be reversed if excluded patients
included
Free of selective reporting? Yes Data presented for maximum WHO mu-
cositis grade for 17 patients (34 scores) (fig-
ure 1a and figure 1b)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Katano 1995
Methods Randomised, parallel group study conducted in Japan. Clear information about with-
drawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: adminis-
tration ceased when leukocyte exceeded 8000/mm³
Participants Adultswith solid (breast cancer). 14patients enrolled and evaluated. Recruitment January
1992 to December 1996
Interventions 2 groups, no treatment versus G-CSF (by injection 125 ug).
Outcomes WHO mucositis score (0-4) by clinician. Other reported outcomes: alopecia, fever.
Assessment used: day 8
Notes Funding source: pharmaceutical supply product.
Risk of bias
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Katano 1995 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “they were randomised into two
groups of 7 patients each”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No G-CSF versus no intervention. No appar-
ent blinding.
Blinding?
Patients
No G-CSF versus no intervention. No appar-
ent blinding.
Blinding?
Outcome assessors
No G-CSF versus no intervention. No appar-
ent blinding.
Incomplete outcome data addressed?
All outcomes
Yes 14 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for incidence and duration
(days) of mucositis
Free of other bias? Yes Study appears to be free of other sources of
bias.
Kaul 1999
Methods Randomised, parallel group study conducted in India. Unclear information about with-
drawals. Dentist not involved in study. Drop outs unclear. Duration unclear
Participants Adults with head and neck cancer radiotherapy 50-60Gy/5-6 weeks. 50 patients enrolled
Interventions 2 groups, no treatment control versus wobe-mugos enzyme preparation 3 tablets/day 3
days prior to RT until 1 week after
Outcomes Mucositis. Assessment used: day 28. Other reported outcomes: xerostomia, skin changes,
dysphagia, hospitalisation
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
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Kaul 1999 (Continued)
Adequate sequence generation? Unclear Quote: “A prospective randomised phase
III clinical trial”.
Quote: “A randomisation of 50 patients
fulfilling inclusion criteria”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No No intervention versus 9 tablets. No appar-
ent blinding.
Blinding?
Patients
No No intervention versus 9 tablets. No appar-
ent blinding.
Blinding?
Outcome assessors
No No intervention versus 9 tablets. No appar-
ent blinding.
Incomplete outcome data addressed?
All outcomes
No 50 patients randomised. 1 patient died dur-
ing study. 69.4% of patients completed
the study without a treatment gap. How-
ever, authors presented data for 25 patients
(50%) at week 11 of the study. Authors do
not give full reasons for attrition/exclusion
Free of selective reporting? Unclear Data presented for oral mucositis by grade
for radiotherapy and radiotherapy plus
wobe-mugos for 11 weeks of treatment.
Data only presented for 50% of sample at
week 11
Free of other bias? Yes Study appears to be free of other sources of
bias.
Kazemian 2009
Methods Randomised, parallel group study conducted in Iran between 2004 and 2005. Full
information given on withdrawals. Dentist involved in study. Drop outs: 19%
Participants Adults and children with head and neck cancer receiving radiotherapy. 100 enrolled in
study, 81 were evaluated, 39 in the benzydamine group and 42 in the placebo group
Interventions 2 groups, placebo versus benzydamine (0.15 benzydamine oral rinse). Participants rinsed
with 15 ml for 2 minutes, 4 times per day from the first day of radiotherapy treatment
to the end
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Kazemian 2009 (Continued)
Outcomes Assessment on the RTOG grading system for oral mucositis, assessment carried out
weekly. Other reported outcomes: effects of smoking, effects of chemoradiotherapy
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “one hundred patients were ran-
domised into this study”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 100 patients randomised. 81 patients
included in the analysis. 19 cases ex-
cluded. Exclusions equally distributed. 17/
19 stopped due to side effects. Authors pro-
vide full reasons for withdrawals/drop outs
Free of selective reporting? Unclear Data presented for grade > 3 mucositis (in
text).
Free of other bias? Yes Study appears to be free of other sources of
bias.
Koukourakis 2000
Methods Randomised, parallel group study conducted in Greece. Unclear information on with-
drawals 0/20 control, 1/20 test. Unclear if dentist involved in study. Drop outs: 3%.
Duration 6-7 weeks
Participants Adults with 3 cancer types: thoracic, pelvic, RT postoperative or inoperable dose 64-70
Gy. 140 patients enrolled between July 1997 and May 1999, 130 completed
Interventions 2 groups, no treatment control versus amifostine 500 mg daily before RT
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Koukourakis 2000 (Continued)
Outcomes Mucositis 0-4 scale combined categories. Assessment used: unclear. Other reported out-
comes RT delay, side effects
Notes Patients selected from other types of cancer because mucositis data available. Funding
source: government & pharmaceutical
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “patientswere randomly assigned to
undergo radiotherapy or radiotherapy sup-
ported with subcutaneous administration
of Amifostine, according to a table of ran-
dom numbers (0 V 1).”
Comment: authors used random number
table.
Allocation concealment? No Comment: open random table.
Blinding?
Carers
No Amifostine versus no intervention. No ap-
parent blinding.
Blinding?
Patients
No Amifostine versus no intervention. No ap-
parent blinding.
Blinding?
Outcome assessors
No Amifostine versus no intervention. No ap-
parent blinding.
Incomplete outcome data addressed?
All outcomes
Unclear 140 patients randomised. Interruption of
treatment in 10 patients. 10/70 amifostine.
Mucositis data presented for 130 patients
Free of selective reporting? Unclear Data presented for 130 patients for grades
0/1, grade 2, and grade 3/4 (table 4)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Labar 1993
Methods Randomised, parallel group study conducted in Croatia. Clear information about with-
drawals: none. Dentist not involved in study. Drop outs: 0%. Duration: +7 to day +21
Participants Children and adults (5-43 years) with blood cancers, undergoing BMT. 60 patients
eligible, enrolled and evaluated
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Labar 1993 (Continued)
Interventions 2 groups, placebo versus prostaglandin E2 (0.5 mg 3 times per day)
Outcomes Clinical and culture fungal measurement. Mucositis (WHO scale for 0-II vs III+, and
0 vs 1+). Severity over -7 to +35 days. Severity of mucositis also measured but no SD
given. Assessment used: day 35. Other reported outcomes: HSV infection, microbiology,
vomiting, diarrhoea, fever, death, GVHD (c)
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “the patientswere randomised to re-
ceive either prophylactic regimenA or B ac-
cording to the Pocock and Simon method”
Comment: minimization.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear 60 patients randomised. Authors give out-
come data in percentages making it diffi-
cult to assess the possibility of incomplete
outcome data
Free of selective reporting? Unclear Data presented in percentages in a piechart
for grades I and II vs grades III and IV (fig-
ure 1) and severity of OM over time (figure
2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Leborgne 1997
Methods Randomised, parallel group study conducted in Uruguay. Unclear information about
withdrawals. Unclear whether dentist involved in study. Drop outs: 4%. Duration 90
days
Participants Adults with head and neck cancer radical RT. 69 enrolled, 66 completed
Interventions 2 groups, placebo versus prednisone 40 mg once daily through day 28 reduced dose to
day 43
Outcomes Mucositis WHO. Assessment used: unclear. Other reported outcomes: duration of treat-
ment, treatment interruptions, parenteral nutrition, hospital stay, weight loss, locore-
gional control, survival
Notes Funding source: not stated. Mucositis data for all grades of severity obtained after writing
to authors
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “69 patients were randomized”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Quote: “The codes were broken after the
mucosal reactions in the last patient were
scored.”
Comment: insufficient information to de-
termine ‘yes’ or ‘no’
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 69 patients randomised. 3 patients were ex-
cluded due to major protocol violations.
Authors give full reasons for exclusions but
do not state which arms patients were ran-
domised to
Free of selective reporting? Yes Mucositis data for all grades of severity ob-
tained after writing to authors
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Leborgne 1997 (Continued)
Free of other bias? No Baseline differences: significantly more pa-
tients in the treatment arm had stage 3 dis-
ease compared to placebo (P = 0.02)
Li 2006
Methods Randomised, parallel group study conducted in China. Clear information about with-
drawals: 1 from glutamine group. Unclear if dentist involved in study. Drop outs: 2%.
Recruitment March 2001 to December 2002
Participants Adults with breast cancer receiving 5-FU chemotherapy. 60 enrolled and randomised,
59 completed
Interventions 2 groups, 30 received 30 g oral glutamine per day for 12 days prior to chemotherapy, 29
received placebo
Outcomes Mucositis severity evaluated using 0-4 scale (NCI CTCAE) (grade 3-4). Other reported
outcomes: intestinal permeability, intestinal toxicity, plasma glutamine levels
Notes Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Eligible study patients were ran-
domly assigned to a placebo (n = 30) or a
glutamine group (n = 30).”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Unclear Glutamine versus placebo (glycerine).
Blinding?
Outcome assessors
Unclear Glutamine versus placebo (glycerine).
Incomplete outcome data addressed?
All outcomes
Yes 60 patients randomised. 1 patient (1/30
glutamine) excluded from analysis due to
lack of toxicity data
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Li 2006 (Continued)
Free of selective reporting? Unclear Data presented in a graph for grade of stom-
atitis (grade 0, grade 1-2, grade 3-4) by arm
in percentages
Free of other bias? Yes Study appears to be free of other sources of
bias.
Lievens 1998
Methods Randomised, parallel group study conducted in Belgium. Clear information about with-
drawals: 19 (12 sucralfate and 7 placebo). Unclear if dentist involved in study. Duration:
25-33 days (entire duration of therapy)
Participants 102 adults with head and neck cancers receiving radiotherapy (5 fractions per week,
doses ranged from 55 Gy in 25 daily fractions of 2.2 Gy to 66 Gy in 33 daily fractions
of 2 Gy)
Interventions 2 groups, placebo versus sucralfate (1 g 6 times daily).
Outcomes Mucositis scored once weekly using 0-6 scale. Other reported outcome measures: sub-
jective intolerance to radiotherapy treatment, dysphagia, nausea, dermatitis, weight loss,
side effects
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”Randomised”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear 102 patients randomised. 19 patients with-
drew (12 sucralfate, 7 placebo)
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Lievens 1998 (Continued)
Free of selective reporting? Unclear Data presented for mean peak mucositis.
Free of other bias? Yes Study appears to be free from other sources
of bias.
Lilleby 2006
Methods Randomised, parallel group study conducted inUSA.Clear information on withdrawals:
1 in saline group withdrew consent because wanted ice chips. Dentist not involved in
study. Drop outs: 2%. Duration: -2 to 28 days post-transplant
Participants Adults with blood cancer - multiple myeloma scheduled to receive melphalan 200 mg/
m² followed by BMT- autologous stem cell transplantation (ASCT). 41 enrolled and
randomised, 40 completed
Interventions 2 groups, room temperature normal saline rinse versus ice chips (oral cryotherapy) 30
minutes before and 6 hours after high-dose therapy
Outcomes Mucositis was assessed as part of routine care using theNCI CTC grades 0-4. Assessment
used: -2 to 28 days. Other reported outcomes: days of total parenteral nutrition (TNP)
, narcotic use, hospitalisation, weight loss and resumption of oral caloric intake for 28
days after transplant
Notes Funding source: charity.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised to re-
ceive either ice-chips or room temperature
normal saline rinses.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Ice chips versus saline. Blinding impossible.
Blinding?
Patients
No Ice chips versus saline. Blinding impossible.
Blinding?
Outcome assessors
No Ice chips versus saline. No apparent blind-
ing.
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Lilleby 2006 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 41 patients randomised. 1 patient with-
drew: 1/20 saline group. Authors give rea-
sons for attrition/ exclusion
Free of selective reporting? Yes Data presented for all patients by arm and
mucositis grade (table 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Lin 2006
Methods Randomised, parallel, multisite study conducted in Taiwan. Clear information on with-
drawals: 3 (2 placebo, 1 intervention). Unclear if dentist involved in study. Recruitment
conducted from January 2003 until August 2004. Duration: during radiotherapy treat-
ment (approximately 2 months)
Participants Adults with head and neck cancers receiving radiotherapy (180 cGy to 200 cGy in 5
weekly fractions) with or without concurrent chemotherapy (no extra information). 100
randomised, 97 completed
Interventions 2 groups, soya bean oil placebo versus oral zinc (25 mg Pro-Z) (3 capsules a day)
Outcomes Mucositis assessed weekly using the RTOG criteria for acute morbidity. Other reported
outcome measures: dermatitis, weight loss, interruption of radiotherapy, adverse events
Notes Funding source: Chi-Mei Foundation Medical Centre.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ”Blocked randomisation was used
for all subjects to achieve balanced assign-
ment. We adapted the RV.Uniform (0,1)
function in SPSS for windows to generate
randomnumbers and to assign distinct ran-
dom permuted blocks to subjects”
Comment: computer generated randomi-
sation.
Allocation concealment? Unclear Quote: “The drug contents were not re-
vealed, even to the principal investigator
until the end of the experiment”
Comment: insufficient information to de-
termine ’yes’ or ’no’
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Lin 2006 (Continued)
Blinding?
Carers
Unclear Comment: authors state that serum zinc
levels were checked biweekly, staff who
checked these levels would presumably
have knowledge of allocation
Blinding?
Patients
Yes Quote: ”double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Unclear Comment: authors state that serum zinc
levels were checked biweekly, staff who
checked these levels would presumably
have knowledge of allocation
Incomplete outcome data addressed?
All outcomes
Yes 100 patients randomised. 3 patients
dropped out (1/50 intervention, 2/50
placebo group). Authors give reasons for
withdrawals/drop outs
Free of selective reporting? Unclear Data presented for time to grade 2 and 3
mucositis in text.Mean scores formucositis
plotted over time by treatment arm in fig 3
Free of other bias? Yes Study appears to be free from other sources
of bias.
Lockhart 2005
Methods Randomised, parallel group study conducted inUSA.Clear information on withdrawals:
none. Unclear whether dentist involved in study. Drop outs: 0%. Duration: unclear
Participants Adults with mixed cancer. BMT - autologous blood stem cell transplant (ABSCT). 36
enrolled, randomised and completed
Interventions 2 groups, placebo versus pilocarpine (patients were randomised to receive a 5 mg tablet
of pilocarpine, or a placebo, during and following chemotherapy)
Outcomes Mucositis assessed every other day using theWHOmucositis score and the authors’ own
developed data entry forms to capture subjective and objective data, including toxicity
criteria. This new tool is a highly modified version of the Southwest Oncology Group
(SWOG) toxicity scale. We used the highest score mucositis score recorded, supplied
by author. Assessment used: up to day 10. Other reported outcomes: problems with
nutrition, oral infection, use of narcotics for mucosal pain, problems with oral hygiene,
gingival bleeding, eating, speaking and sleeping (ordinal variables), pain at rest or with
swallowing, mouth dryness (VAS scale)
Notes Funding source: charity/foundation.
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Lockhart 2005 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Subjects were stratified accord-
ing to initial diagnosis and randomized by
computer generated numbering scheme to
receive either pilocarpine or an identical-
appearing placebo”
Comment: computer generated randomi-
sation.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 36 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for incidence and duration
of oral mucositis, gingival mucositis and
oropharyngeal mucositis (days) (Table 3)
; highest grade of mucositis by treatment
arms, average mucositis score between days
4 and 8 by treatment arm and average mu-
cositis score between days 6 and 8 (sepa-
rated into oral, gingival andoropharyngeal)
(fig 1).
Free of other bias? Yes Study appears to be free of other sources of
bias.
Loprinzi 1990
Methods Randomised cross-over trial conducted inUSA.Clear information onwithdrawals: none.
Dentist was not involved. Drop outs: 0%. Duration: 5 days
Participants Adults with colorectal cancer receiving first 5 day course of 5-FU. 77 patients enrolled,
and completed 1st period, only 20 completed 2nd period
146Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Loprinzi 1990 (Continued)
Interventions 2 groups, placebo versus allupurinol mouthrinse 1 mg/ml made from 450 mg + 150 ml
cologel (450 mg/5 mg methylcellulose with 5% alcohol) +450 ml flavouring agent. 20
ml used for 30s immediately after treatment then at 1, 2, 3 hours)
Outcomes Mucositis (physician and patient scales 0-4). Assessed used: day 30
Notes Data cross-tabulated in a form suitable for meta-analysis provided by authors.
Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “a dynamic randomization proce-
dure was utilized for assigning patients to
initially receive either the allopurinol or the
placebo mouthwash.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 77patients recruited.Data fromall patients
included in analysis
Free of selective reporting? Yes Data presented for 77patients for physician
judged mucositis (table 2) and 71 patients
for patient judged mucositis grade (table 3)
Free of other bias? No Study aimed to recruit 120 patients but was
terminated early after 77 patients were re-
cruited after the power calculation was re-
run and the results found to favour the in-
tervention
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Madan 2008
Methods Randomised, parallel study conducted in India. Clear information on withdrawals: 4.
Unclear if dentist involved in study. Duration: 6 weeks
Participants Adults with head and neck cancer receiving radiotherapy (2 Gy daily dose, total dose 60
Gy)
Interventions 4 groups, 0.12% chlorhexidine versus 1% povidone-iodine versus salt/sodium bicarbon-
ate versus plain water. All mouthwashes given in doses of 10 ml twice a day for 6 weeks
Outcomes Mucositis assessed weekly using WHO scale. Other reported outcome measures: none
Notes Funding source: Manipal University, India.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomly assigned”.
Comment: random component not de-
scribed.
Allocation concealment? Yes Quote: ”the mouthwashes were numbered
randomly from 1 to 80 by the mouthwash
manufacturer. The coding was done by the
manufacturer and was known only to him.
It was revealed to the investigator only at
the end of the study. Mouthwashes were
dispensed in identical 500 ml coded glass
bottles”
Comment: sequentially numbered drugs
containers of identical appearance
Blinding?
Carers
Yes Double blind study with adequate allo-
cation concealment. Unlikely that carers
would have knowledge of allocations
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 80patients randomised. 4 patients dropped
out (1/20 chlorhexidine group, 1/20 povi-
done, 2/20 salt and bicarbonate). Authors
give reasons for withdrawals
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Madan 2008 (Continued)
Free of selective reporting? Unclear Data presented for mean mucositis scores
by armbyweek of treatment (fig2 and table
2)
Free of other bias? Yes Study appears to be free from other sources
of bias.
Mahood 1991
Methods Randomised, cross-over study conducted in USA. Unclear information on withdrawals:
2/45 control, 0/50 treatment in first cycle. Dentists not involved in study. Drop outs
2%. Duration from 5 mins before 5-FU and for 30 mins after
Participants Adults mostly over 40 years with cancer of the colon (solid cancer). Chemotherapy first
5 day course of 5-FU. 95 patients eligible and enrolled and 93 completed first cycle,
however, only 82 patients assessed mucositis
Interventions 2 groups, no treatment control versus ice chips (cryotherapy) placed in the mouth 5
mins before each dose of 5-FU and replenished over 30 mins
Outcomes Mucositis (physician & patients scales 0-4) and historical 1 month after treatment.
Assessment used: day 28
Notes Data cross-tabulated in a form suitable for meta-analysis provided by authors.
Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “prior to therapy, patients were
stratified by age and whether or not they
had denture. They were then randomised
to a control arm or to receive cryotherapy”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Ice chips versus saline. Blinding impossible.
Blinding?
Patients
No Ice chips versus saline. Blinding impossible.
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Mahood 1991 (Continued)
Blinding?
Outcome assessors
Unclear Quote: “the attending physician who
judged the mucositis grade was frequently
not aware of whether the patient had re-
ceived cryotherapy or not”
Comment: insufficient information to de-
termine ‘yes’ or ‘no’
Incomplete outcome data addressed?
All outcomes
Unclear 95 patients randomised. 2 patients not in-
cluded in final analysis due to lack of data.
Authors do not state which arms missing
were randomised. Patient judged mucositis
scores collected from 85 patients. Authors
do not state to which arms missing were
randomised
Free of selective reporting? Yes Physician judgedmucositis scales presented
for 93 patients (table 2). Patient judged
mucositis scales presented for 82 patients
(table 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Makkonen 1994
Methods Randomised, parallel group study conducted in Finland. Clear information about with-
drawals: none mentioned. Dentist involved in study. Drop outs: 0%. Duration: during
therapy (9 weeks). Recruitment November 1989 to December 1991
Participants Adults with head and neck cancer. 40 patients eligible, enrolled and evaluated
Interventions 2 groups, placebo versus sucralfate (suspension 1 g 6 times per day orally, patients
mix granules with 100 ml water rinse for 1 min then swallow). Rinsed throughout
radiotherapy, dose 45-73 Gy
Outcomes Mucositis on scale 0-2 (0 = nomucositis, 1 =moderate, 2 = severe), at 9 weekly evaluation
visits. Assessment used: day 28. Other reported outcomes: salivary lactoferrin, salivary
albumin, amount of anaesthetic mouthwash, radiotherapy interrupted, toxicity
Notes Visit at week 4 taken. Antifungal agents given to 29 patients during study.
Funding source: government.
Risk of bias
Item Authors’ judgement Description
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Makkonen 1994 (Continued)
Adequate sequence generation? Unclear Quote: “The sealed envelope method was
used in randomization, and the envelopes
were opened only after all clinical informa-
tion for each patient had been collected.”
Comment: unclear if envelopes were shuf-
fled. Random component not described.
Allocation concealment? Unclear Quote: “All drugs prepared by the manu-
facturer, 1 g sucralfate or identically look-
ing placebo granules were sealed in coded
paper bags”
Sealed envelope method of randomisation.
However, authors do not state whether en-
velopes or bagswere sequentially numbered
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 40 patients recruited. Authors give mucosi-
tis data for 40patients after 3weeks of treat-
ment
Free of selective reporting? Yes Data presented for grade of mucositis at
week 3 for all patients (text), and for per-
centage of patients with radiation mucosi-
tis in each group at each evaluation visit (fig
1).
Free of other bias? No Significant differences between the group
for sex (P = 0.05) and age (P = 0.04) of
patients at randomisation. Both have been
suggested as independent variables for mu-
cositis severity
3 patients had a buccal mucosa resection
as part of their treatment. Authors provide
no information about allocation of these
patients.
Dentate patients (10 sucralfate & 6
placebo) also receivedweekly fluoride treat-
ments
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Makkonen 2000
Methods Randomised, parallel group study conducted in Finland. Clear information about with-
drawals: none. Dentist involved in study. Drop outs: 0%. Duration: during therapy (9
weeks)
Participants Adults with head and neck cancer. 40 patients eligible, enrolled betweenNovember 1994
and August 1996, all were evaluated
Interventions 2 groups, no treatment control versus GM-CSF (150 to 300 ug given subcutaneously
daily until last day of irradiation. Dose depends on body weight)
Outcomes Mucositis on scale 0-2 (0 = no mucositis, 1 = moderate, 2 = severe). Assessment used:
day 28. Other reported outcomes: oral pain on scale 1-4, and patient VAS scale for pain.
Evaluated weekly during treatment then 1 and 6 months after therapy, use of analgesic,
weight loss, toxicity, survival
Notes All patients used sucralfate suspension 1 g 6 times daily.
Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “after obtaining an oral informed
consent, assignment to the treatment
groups were carried out via a phone call
to the randomisation centre at the Finnish
Cancer registry, Helsinki.”
Comment: random component not ex-
plicit. However, setting makes adequate
randomisation likely
Allocation concealment? Yes Quote: “after obtaining an oral informed
consent, assignment to the treatment
groups were carried out via a phone call
to the randomisation centre at the Finnish
Cancer registry, Helsinki.”
Comment: central method of allocation.
Blinding?
Carers
No Quote: “open, prospective, randomised
study”.
Comment: no blinding.
Blinding?
Patients
No Quote: “open, prospective, randomised
study”.
Comment: no blinding.
Blinding?
Outcome assessors
No Quote: “open, prospective, randomised
study”.
Comment: no blinding.
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Makkonen 2000 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 40 patients recruited. Nomissing outcome
data.
Free of selective reporting? Unclear Data presented in graphs showing percent-
ages of patients with mucositis (fig 1) and
mucosal pain (fig 2). Figures given in the
text for percentage of patients with mucosi-
tis at weeks 1 and 3
Free of other bias? Yes Study appears to be free of other sources of
bias.
McAleese 2006
Methods Randomised, parallel group study single centre study conducted in the UK. Clear infor-
mation about withdrawals: 2/29. Unclear if dentist involved in study. Drop outs: 7%.
Duration: 10 weeks
Participants Adults with head and neck cancer to be treated with radiotherapy. 29 patients eligible,
enrolled between September 1997 and October 2000. 27 patients evaluated
Interventions 2 groups, GM-CSF at dose of 150 ug subcutaneous injection once daily for 14 days
beginning at the end of second week of radiotherapy. Compared to no treatment
Outcomes RTOG rating for mucositis on 0-4 scale.
Notes Maximum value of mucositis taken. Funding unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “29 patients agreed to enter and
were randomly assigned to the active or
control arms.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
No Quote: “A placebo injection was not used
because it was not considered ethically jus-
tifiable”
Comment: GM-CSF versus no interven-
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tion.
Blinding?
Outcome assessors
Yes Quote: “At each visit one of two indepen-
dent observers, blinded to group allocation,
scored mucositis by the RTOG system?”
Incomplete outcome data addressed?
All outcomes
Yes 29 patients recruited. 2 patients withdrew
(2/15 intervention group). Authors give
full reasons for exclusions and withdrawals.
ITT analysis performed. Mucositis data
given for 29 patients
Free of selective reporting? Yes Maximum mucositis grades given for 29
patients by arm in text. Data also presented
for the proportion of patients with each
grade by arm in graphs (fig 1 and fig 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
McGaw 1985
Methods Randomised, parallel group single site study conducted in Canada. Dentist involved in
study. Drop outs: 0%. Duration: 28 days. No enrolment dates
Participants 16 patients with acute myeloblative leukaemia aged between 17 and 54 years old. All
patients received conditioning with cytosine-arabinoside (200 mg/m2 daily for 5 days)
, adriamycin (40 mg/m2 on day 1 and 2) and amsacrine (100 mg/m2 daily for 5 days)
chemotherapy.
Interventions 2 groups, intervention group received 10 ml of 0.1% aqueous solution of chlorhexidine
gluconate (corsodyl), placebo group received a identically coloured and flavoured solu-
tion. Both groups rinsed twice daily for 2 minutes
Outcomes Hickey instrument used (0-3 scale). Other outcome measures: dental plaque scores, gin-
givitis scores, numbers of patients developing candidiasis, number of patients requiring
antibiotics, average number of febrile days, level of tooth staining and discolouration
Notes Funding source: not stated.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”patients randomised into two ex-
perimental groups”.
Comment: random component not de-
scribed.
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Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 16 patients randomised. No incomplete
outcome data.
Free of selective reporting? Unclear Data presented formeanmucositis score by
week for both study arms
Free of other bias? Yes Study appears to be free from other sources
of bias.
Meropol 2003
Methods Randomised, parallel group, multicentre study conducted in USA. Clear information
about withdrawals: 0. Dentist not involved in study. Drop outs: 0% Duration: 28 days
Participants Adults with solid cancer treated with 5-FU. Patients enrolled, 81 completed
Interventions 2 groups, KGF IV injection patient cohorts treated with escalating doses of KGF 1,10,
20, 40, 60 and 80 micrograms/kg per day versus placebo control
Outcomes Mucositis WHO grading evaluated by examination on day 1, 4, 8, 15 and 28. Other
reported outcomes: nausea, vomiting, blood changes
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “This study was a multicentre, ran-
domized, double blinded, placebo con-
trolled, phase I study”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
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Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 81 patients recruited. Nomissing outcome
data.
Free of selective reporting? Unclear Data only presented in graphical form for
incidence of grade 2 to 4 mucositis (as per-
centage), duration of mucositis (days) and
patient reports of mucositis. Full data not
presented
Free of other bias? Yes Study appears to be free of other sources of
bias.
Mills 1988
Methods Randomised, parallel group study conducted in South Africa. Clear information about
withdrawals: 0. Dentist not involved in study. Drop outs: 0%. Duration: unclear
Participants Adults with head and neck cancer. 10 enrolled, 10 completed.
Interventions 2 groups, beta carotene (250 mg/day for 21 days, 75 mg daily after this) versus no
treatment control
Outcomes Mucositis.
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “...randomised to receive stan-
dard diet with supplemental beta carotene
(study patients) or standard diet only with
no placebo (control patients).”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
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Blinding?
Carers
No Beta-carotene versus no intervention. No
apparent blinding.
Blinding?
Patients
No Beta-carotene versus no intervention. No
apparent blinding.
Blinding?
Outcome assessors
No Beta-carotene versus no intervention. No
apparent blinding.
Incomplete outcome data addressed?
All outcomes
Yes 20 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented bymucositis grade byweeks
of treatment (table 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Motallebnejad 2008
Methods Randomised, parallel group study conducted in Iran. Clear information about with-
drawals. Unclear if dentist involved in study. Duration unclear (5-6 weeks?)
Participants Adults with head and neck cancer receiving radiotherapy (1.8 Gy to 2 Gy per day, total
dose 50-60 Gy)
Interventions 2 groups, saline (20 ml saline 0.09% before and after radiotherapy) versus honey (20
ml pure honey, 15 minutes before and 15 minutes after radiotherapy, and 6 hours after
radiotherapy)
Outcomes Mucositis assessed using theOMAS instrumentweekly.Other reported outcomes: weight
loss
Notes Funding source: university.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
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Blinding?
Patients
No Honey versus saline. Single blind study.
Blinding?
Outcome assessors
Yes Quote: ”evaluator was blinded to the group
assignments of the patients”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 40 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for mean rank of OMAS
(table 1), end of week OMAS score (fig 1)
and change in OMAS score (fig 2) for both
arms of the study
Free of other bias? Yes Study appears to be free from other sources
of bias.
Nemunaitis 1995
Methods Randomised, parallel group, multicentre study conducted in USA and Canada. Clear
information about withdrawals: none. Unclear if dentist involved in study. Drop outs:
0%. Duration: 1 year
Participants Adults with mixed cancer receiving BMT, chemotherapy cyclosporine & prednisolone.
109 patients enrolled between November 1990 and July 1993. 109 completed
Interventions 2 groups, placebo versus RhGM-CSF (human granulocyte macrophage colony-stimu-
lating factor) 250 ug/m²/day IV day 0-20
Outcomes Mucositis scored by nurse 3 grades (categorised according to WHO criteria for analysis)
. Assessment used: day 28. Other reported outcomes: infection, anorexia, diarrhoea,
hypertension, stomatitis. Mucositis reported on all 109 patients
Notes Funding source: pharmaceutical.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Assignment to treatmentwasmade
via a randomisation schema prepared by
Almedica Corporation (Waldwick, NJ)”
Comment: random component not de-
scribed.
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Allocation concealment? Unclear Quote: “Blinded numbered vials contain-
ing placebo or rhGM-CSF were provided
to each participating centre”
Comment: unclearwhether these vialswere
sequentially numbered
Blinding?
Carers
Yes Quote: “The pharmacists, principal inves-
tigators, patients, support care personnel
and sponsoring company were blinded to
the study medication for the entire course
of the study”
Blinding?
Patients
Yes Quote: “The pharmacists, principal inves-
tigators, patients, support care personnel
and sponsoring company were blinded to
the study medication for the entire course
of the study”
Blinding?
Outcome assessors
Yes Quote: “The pharmacists, principal inves-
tigators, patients, support care personnel
and sponsoring company were blinded to
the study medication for the entire course
of the study”
Incomplete outcome data addressed?
All outcomes
Yes 109 patients recruited. 21 patients with-
drew (13/53 intervention, 8/56 placebo).
Authors provide full reasons for drop outs/
withdrawals. All patients included in effi-
cacy and toxicity analyses
Free of selective reporting? Unclear Data given in the text for percentage of pa-
tients with > grade 2 mucositis and grade
3/4 mucositis
Free of other bias? No 5 patients in placebo arm also received cy-
tokines off study during the first 42 days
post-transplant
Nottage 2003
Methods Randomised, parallel group study conducted in Canada. Clear information about with-
drawals, 1 placebo. Dentists not involved in study. Drop outs: 1.2%
Participants Adults with solid cancer treated with 5-FU. 81 enrolled 80 completed
Interventions 2 groups, placebo versus sucralfate mouthwash (10 ml mouthwash for 2 minutes then
swallow 4 times per day)
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Outcomes Mucositis severity (patient daily diary scores). Other reported outcomes: pain eating/
drinking difficulty, quality of life score, weight loss, nausea and vomiting
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “permuted block randomisation
was used to allocate patients to the treat-
ment with sucralfate suspension or placebo
with identical appearance”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Quote: “the study nurse, in accordance
with usual clinical practice estimated the
severity of mucositis retrospectively. This
personwas blinded to treatment allocation”
Comment: no information given about
other support staff.
Blinding?
Patients
Yes Quote: “Investigators, treating physicians,
and study subjects were all blinded to study
allocation”
Comment: probably done.
Blinding?
Outcome assessors
Unclear Quote: ”Investigators, treating physicians,
and study subjects were all blinded to study
allocation”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 81 patients randomised. 1 patient was ex-
cluded from the placebo group 1/40. Re-
maining randomised patients included in
outcome assessment. 89 missing data days
(14%) in sucralfate group and 63 (11%)
in placebo. Method of assigning values for
missing data to give conservative outcome
estimate clearly described
Free of selective reporting? Unclear 81 patients randomised. 1 patient was ex-
cluded from the placebo group 1/40. Re-
maining randomised patients included in
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outcome assessment. 89 missing data days
(14%) in sucralfate group and 63 (11%)
in placebo. Method of assigning values for
missing data to give conservative outcome
estimate clearly described
Free of other bias? Unclear Authors suggest underreporting of mucosi-
tis by study staff due to the retrospective
method of assessment
Oberbaum 2001
Methods Randomised, parallel group study conducted in Israel. Clear information about with-
drawals: 1/16 control, 1/16 test. Unclear if dentist involved in study. Drop outs: 6%.
Duration: unclear
Participants Children and adultswithmixed cancer receiving aBMT. 32 consecutive patients enrolled,
30 completed
Interventions 2 groups, placebo versus traumeel (homeopathic) rinse vigorously 30 sec before swal-
lowing 5/day for a minimum 14 days
Outcomes Mucositis WHO scale evaluated every 2 days. Assessment used: day 7. Other reported
outcomes: subjective symptom score for dry mouth, oral pain and difficulty in eating
Notes All patients twice daily chlorhexidine, oral amphotericin B, gentle toothbrushing.
Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “The randomisation code was pre-
pared by the manufacturer (HEEL) and
was revealed only on completion of the
study.”
Comment: random component not de-
scribed.
Allocation concealment? Yes Quote: “packages of Traumeel S and
placebo were prepared by the HEEL com-
pany and were identified by serial number
only”
Comment: adequate.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
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Blinding?
Patients
Yes Quote: ”double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “all evaluations were performed
blind by the same observer (the study
nurse)”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 32 patients randomised. 2 patients (1/15
placebo and 1/15 traumeel S), received a
single dose of study drug and then refused
further treatment. Patients not included in
analysis.
Free of selective reporting? Unclear Data presented for individual AUC scores
(table 3), and mean AUC scores for each
group
Free of other bias? Yes No other sources of bias identified.
Okuno 1999
Methods Randomised, parallel group study conducted in USA. Clear information about with-
drawals: none. Dentist not involved in study. Drop outs: 0%. Duration: up to 5 weeks
after initial chemotherapy. Dentist involvement unclear
Participants Adults with cancer (type unclear) receiving chemotherapy with 5-FU, 134 eligible, en-
rolled and 134 evaluated by physician, but patient assessment only completed by 124
patients
Interventions 2 groups, placebo versus glutamine (4 g twice a day, swish for 10 seconds, then swallow)
Outcomes Maximum severity of mucositis over 14 days using 0-4 scale, both physician and patient
assessment. Other reported outcomes: toxicity (no detail). Assessment used: day 14
Notes All patients used ice chips 5 minutes before 5-FU for 30 minutes.
Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were subsequently ran-
domised to receive 4 g of glutamine or an
identical appearing placebo twice daily for
14 days”
Comment: random component not de-
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scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 134 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Physician judgedmucositis scales presented
for 134 patients by grade (table 3). Patient
judged scores presented for 124 patients
(table 4)
Free of other bias? No Statistically significant age difference be-
tween placebo and intervention group (P =
0.01)
Panahi 2009
Methods Randomised, parallel group study conducted in Iran. Clear information on withdrawals.
Unclear if dentist involved in study. Duration: 3 days
Participants Adults with solid tumours (colon, breast, stomach, pancreas, rectum, esophagus and
other) receiving chemotherapy
Interventions 2 groups, placebo versus allopurinol (1 mg/ml), patients asked to swish 20 ml of mouth-
wash for 30 seconds at 1 hr, 2 hrs and 3 hrs after chemotherapy
Outcomes Mucositis assessed 3 times (day 1, day 3 and day 7) using theWHO scale. Other reported
outcome measures: use of dentures and education (multiple logistic regression)
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”patients were divided randomly
into two groups and received allopurinol
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mouthwash (1mg/ml) or placebo in a dou-
ble blind fashion”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Quote: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Quote: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 33 patients recruited. 3 patients excluded
due to inappropriate use of themouthwash.
Authors do not state which arm excluded
patients were randomised to
Free of selective reporting? Yes Data presented in the text (and in figure 1)
for the distribution of mucositis grades by
arm
Free of other bias? Yes Study appears to be free of other sources of
bias.
Peterson 2009
Methods Parallel group study. Duration 14 days treatment from the beginning of cycle 2 of
chemotherapy, final follow-up at day 21+/-2. Dentist involvement - unclear
Participants Inclusion criteria: aged > 18 years with colorectal cancer, undergoing chemotherapy &
having experienced grade 2 or greater OM in cycle 1. Patients had to have WHO grade
0 OM at study entry and ECOG performance status </= 2
Exclusion: pregnancy, lactation, administration of other investigational drugs within 14
days of start of study or plans to use topical or systemic treatments for OM during study,
radiotherapy to head & neck, alcohol or drug abuse, active fungal or herpetic infection
Number randomised 99; number completed 98.
Interventions 3 groups: low dose (n = 33) 10 mg/ml recombinant human intestinal trefoil factor
(rhITF) in aqueous solution dispensed as 3.5 ml spray vial. Patients (all outpatients)
administered 3 puffs (approx 100 ul each) to oral mucosa 8 times daily for 14 days. High
dose (n = 33) 80 mg/ml rhITF, administered as above. Placebo (n = 33) water packaged
and administered as above
Outcomes Incidence of grade 2 or greater OM, duration of grade 2 or greater OM
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Notes Funding source: the GI company (private pharma).
All patients received analgesia as required but dose was low and comparable between
groups
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “eligible patients who had devel-
opedWHO grade > 2 OM in the first cycle
of chemotherapywere randomised in a 1:1:
1 ratio to receive one of two doses of rhITF
or a matched placebo oral spray during the
second cycle of chemotherapy”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Yes Quote: “The placebo oral sprays wereman-
ufactured by the GI company.”
Intervention was manufactured in the US
and conducted in Russia. Therefore, carers
likely to be blinded
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 99 patients randomised. 1 patient (1/33
low dose rhITF) lost to follow-up on day
21. Patient included in overall incidence of
OM incidence data
Free of selective reporting? Yes Data presented for all patients by grade and
treatment arm (fig 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Methods Randomised, cross-over study conducted in Denmark. Unclear information about with-
drawals. Dentist not involved in study. Drop outs: 43%. Duration: 14 days
Participants Adults with head and neck cancer. 40 patients enrolled, 23 evaluable
Interventions 2 groups, placebo versus sulcralfate (1 g 15 ml suspension, swish for 2 min then spit out
or swallow)
Outcomes Ulceration or not.
Assessment used: day 14. Other reported outcomes: pain, problems eating
Notes Funding source: pharmaceutical support for product.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “The patients were randomly as-
signed to receive either sucralfate-placebo
or placebo-sucralfate”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
No 40 patients randomised. Only 23 patients
(58%) included in the outcome assessment.
5 due to change to chemotherapy regimen,
2 died, 10 not evaluable due to ’swishing’
(7 had increased nausea and 3 excluded due
to poor compliance). Authors give no in-
formation about which arms excluded pa-
tients were allocated
Free of selective reporting? Unclear Data presented for numbers of patients in
each treatment arm experiencing erythema,
edema, erosion and ulceration (table 2)
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Free of other bias? No Mode of application changed after 18 pa-
tients (next 22 patients were asked to swish
and expectorate the solution rather than
swallowing)
Pillsbury 1986
Methods Randomised, parallel study conducted in USA. Clear information about withdrawals,
2/10 control, 0/10 test. Dentist involved in study. Drop outs: 10%.
Duration: until treatment was completed.
Participants Adults with head and neck cancer. 20 enrolled, 18 completed.
Interventions 2 groups, placebo versus prostaglandin inhibitor (25 mg of indomethacin 4 times per
day)
Outcomes Mucositis grade at day 1, 2 and 3.
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Ten patients
received indomethacin, 25 mg four times
a day, whereas the others received placebo
during the entire course of treatment in a
double-blind fashion”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 20 patients recruited. 1 patient withdrew
from control group. Authors give complete
reasons for withdrawal. In addition, 1 pa-
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tient in control groupwas excluded because
they had not yet completed treatment.Mu-
cositis data presented for 18 patients.
Free of selective reporting? Unclear Data presented for mucositis grade at days
1-3 for 18 patients (table 1).
Free of other bias? Yes Study appears to be free of other sources of
bias.
Pitten 2003
Methods Randomised, parallel group study conducted in Germany. Clear information about
withdrawals: none. Dentist involved in study. Drop outs: 0%
Participants Adults with mixed cancer treated with chemotherapy, 47 enrolled, 47 completed
Interventions 2 groups, placebo versus chlorhexidine 100 ml 0.3% chlorhexidine, 10.4 g ethanol, 1.
67 g hydrogen peroxide versus stannous fluoride
Outcomes Mucositis WHO grading. Other reported outcomes: systemic infection, febrile episodes,
blood changes, microbial counts
Notes Funding source: external.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “the patients were assigned to one
of the two treatment groups by stratified
block randomisation; the blocks were se-
lected using a set of random sampling num-
bers”
Comment: probably done.
Allocation concealment? Yes Quote: “the rinses were filled into brown
glass bottles by the pharmacy of the Uni-
versity of Greifswald, which was responsi-
ble for randomisation”
Blinding?
Carers
Yes Quote: ”Neither the patient, nor the den-
tist knew whether the patient received the
chlorhexidine based product or the con-
trol medication. In addition, none of the
nurses, physicians, or oncologists knew the
specific drug used for oral rinsing”
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Blinding?
Patients
Yes Quote: “Neither the patient, nor the den-
tist knew whether the patient received the
chlorhexidine based product or the con-
trol medication. In addition, none of the
nurses, physicians, or oncologists knew the
specific drug used for oral rinsing”
Blinding?
Outcome assessors
Yes Quote: ”Neither the patient, nor the den-
tist knew whether the patient received the
chlorhexidine based product or the con-
trol medication. In addition, none of the
nurses, physicians, or oncologists knew the
specific drug used for oral rinsing”
Incomplete outcome data addressed?
All outcomes
Yes 47 patients randomised. No incomplete
outcome data.
Free of selective reporting? Unclear Data presented for 47 patients bymucositis
grades 0-1 and 2-4 (table 4)
Free of other bias? No Data from unplanned interim analysis.
Prada 1987
Methods Randomised, parallel group study conducted in Italy. Unclear information about with-
drawals. Dentist not involved in study. Drop outs: 10%. Duration: 10 days
Participants Adults with head and neck cancer. 40 patients eligible and enrolled, 36 evaluated
Interventions 2 groups, placebo versus benzydamine (120 ml solution of 0.15% benzydamine, 15 ml
mouthwash for 5 mins every 3 hours up to max of 6 times daily)
Outcomes Physician evaluation of mucositis on 0 (absent) to 3 (intense or remarkable) scale every
day for 10 days. Assessment used: day 10. Other reported outcomes: global clinical
symptomatology, burning, chewing pain, dysphasia and odynophasia assessed
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote:.“...according to the randomization
code”.
Comment: random component not de-
scribed.
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Allocation concealment? Unclear Quote: “8 anonymous and indistinguish-
able bottles... ”
Comment: unclear if bottles were sequen-
tially numbered.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear 40 patients randomised. 4 patients with-
drew (1/20 benzydamine, 3/20 control).
Authors give no reasons for withdrawal
Free of selective reporting? Unclear Data presented for onset of mucositis
(probability analysis) (fig 1) and the num-
ber of patients with mucositis in each arm
(text).
Free of other bias? No Not all patients had an oral mucositis score
of 0 when entering the study. Double blind
study. However, placebo patients also re-
ceived paracetamol for pain control
Puataweepong 2009
Methods Parallel group study. Duration 8 weeks (throughout 3-4 weeks of radiotherapy and until
8 week follow-up. Dentist involvement - unclear
Participants Inclusion criteria: stage 2-4 histologically confirmed head and neck cancer planning to
undergo adjuvant or definitive radiotherapy. Karnofsky performance status > 70%
Exclusions: prior RT, history of allergy to aloe vera, underlying diabetes mellitus, HIV
positive
Number randomised 61; completed 60; evaluated 61.
Interventions 2 groups: A (n = 30) 15 ml aloe vera solution 3 times daily beginning on day 1 of RT.
B (n = 31) 15 ml of placebo (identical in taste and appearance) 3 times daily beginning
on day 1 of RT
Outcomes Onset & incidence of severe mucositis, weight loss, number of patients & duration of
radiotherapy interruption, adverse events, requirement for analgesics, antibiotics, anti-
fungals
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Puataweepong 2009 (Continued)
Notes Funding source: The Thailand Research Fund.
All patients received daily supportive care including rinsing mouth with water, saline or
viscous lidocaine. Analgesic drugs and antibiotics were allowed and feeding tubes were
used as required
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”double blind randomised placebo
controlled trial”.
Quote: “Stratified block randomisation”.
Comment: insufficient information to de-
termine ’yes’ or ’no’
Allocation concealment? Unclear Quote: ”The allocation was concealed”.
Comment: insufficient information to de-
termine ’yes’ or ’no’
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “The allocation was concealed and
blinded to physician, patients and person-
nel involved in the study”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”The allocation was concealed and
blinded to physician, patients and person-
nel involved in the study”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 61 patients recruited. 1 patient (1/31
placebo group) discontinued but was in-
cluded in mucositis data
Free of selective reporting? Yes Data presented in percentages for mucosi-
tis incidence by grade and arm. Data also
presented for the incidence of severe mu-
cositis by arm
Free of other bias? No Significant baseline imbalances between
the study arms: gender (P = 0.03), previous
smoking (P = 0.056), previous surgery (P
= 0.04)
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Qin 2007
Methods Randomised, parallel group study conducted inChina.Withdrawals: 0.Unclear if dentist
involved in study, duration: duration of therapy
Participants Adults and children aged 16 to 70 with nasogastric carcinoma receiving radiotherapy
(total dose 50-78 Gy)
Interventions 2 groups, no treatment control versus dental stent (worn by patients during radiotherapy)
Outcomes Mucositis assessed using a 0-4 scale. Other reported outcome measures: weight loss, taste
disruption
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Outcome assessors
Unclear Insufficient information to determine ’yes’
or ’no’.
Incomplete outcome data addressed?
All outcomes
Yes 43 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented for all patients by grade of
mucositis and arm
Free of other bias? No ROB assessed from translation.
Baseline imbalance: control group experi-
enced more taste dysfunction at baseline
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Rahn 1997
Methods Randomised, parallel group study conducted in Germany. Clear information about
withdrawals: none. Dentist involvement unclear. Drop outs: 0%. Duration: until 1 week
after end of radiotherapy
Participants Adults with head and neck cancer. 40 patients eligible, enrolled. 2 died but all 40 were
evaluated
Interventions 2 groups, control (sterile water) versus povidone iodine rinse (rinsing for 3 mins with
100 ml solution 4 times daily)
Outcomes WHO assessment of mucositis on 0-4 scale. During therapy and at 2, 6 weeks after
therapy. Assessment used: day 28
Notes All patients received nystatin, dexpanthenol, ratoside and immunoglobin.
Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “40 patients were enrolled in the
study and randomly assigned to a treatment
or control group”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Quote: “Open, placebo controlled and ran-
domised clinical trial”
Blinding?
Patients
No Quote: “Open, placebo controlled and ran-
domised clinical trial”
Blinding?
Outcome assessors
No Quote: “Open, placebo controlled and ran-
domised clinical trial”
Incomplete outcome data addressed?
All outcomes
Yes 40 patients recruited. 37 patients com-
pleted the study. Authors give incomplete
reasons for attrition/exclusion. Mucositis
data presented for 40 patients
Free of selective reporting? Yes Data presented for grades of mucositis for
40 patients (figure 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Rashad 2008
Methods Randomised parallel group trial conducted in Egypt. Duration of follow-up 7 week.s
Participants Adults with histologically confirmed SCCHN T1-4, N0-3, m0, KPS ≥ 50%. 40 ran-
domised and evaluated. Recruited April 2005 to July 2006
Interventions Honey (fromTrifolium Alexandrenum) versus no treatment. 15min before, 15min after
and 6 hours after radiotherapy patients smeared mouth with honey, and then swallowed
slowly to smear honey on mucosa
Outcomes WHO mucositis grade, weekly during therapy (7 weeks) 4-week data used
Notes All patients received chemoradiotherapy (60-66 Gy plus cisplatin 20 mg/m2 weekly) for
6-7 weeks.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “enrolled patients were randomised
to either the treatment group, to receive
concomitant chemotherapy and radiother-
apy plus topical application of pure natural
honey, or the control group, to receive con-
comitant chemotherapy and radiotherapy
without honey”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Honey versus no intervention. Blinding
impossible.
Blinding?
Patients
No Honey versus no intervention. Blinding
impossible.
Blinding?
Outcome assessors
No Honey versus no intervention.No apparent
blinding.
Incomplete outcome data addressed?
All outcomes
Yes 40 patients randomised. No missing out-
come data.
Free of selective reporting? Yes Data presented for grade of mucositis by
arm for 40 patients
Free of other bias? Unclear Insufficient information to determine ’yes’
or ’no’.
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Rocke 1993
Methods Randomised parallel group study conducted in USA. Clear explanation of withdrawals:
1 in 30 min arm. Drop outs: < 1%. Duration: 5 days
Participants Adults receiving first course of 5-FU, cancer type unclear. 179 eligible, and randomised,
178 evaluated
Interventions 2 groups, 30 versus 60 minute cryotherapy. Ice chips placed in mouth 5 min before 5-
FU and then swished round during treatment and replenished as ice melted
Outcomes Physician and patient assessment of mucositis on 0-4 scale.
Notes Some cross-over data were included in paper. We have not included this as only patients
with mild mucositis crossed-over
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised to re-
ceive cryotherapy for either 30 or 60 min-
utes”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No 30 minutes versus 60 minutes of cryother-
apy. Blinding impossible
Blinding?
Patients
No 30 minutes versus 60 minutes of cryother-
apy. Blinding impossible
Blinding?
Outcome assessors
No 30 minutes versus 60 minutes of cryother-
apy. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 179 patients recruited. 1 patient with-
drawn. 1/90 30-minute cryotherapy. Au-
thors give reason for attrition
Free of selective reporting? Yes Physician judged mucositis scores pre-
sented for 178 patients (table 2). Patient
judged scores presented for 163 patients
(table 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Rosen 2006
Methods Randomised, parallel group multisite study conducted in the USA and Australia. Clear
information on withdrawals. Unclear if dentist involved in study
Participants Adults with tumours of the colon and rectum receiving chemotherapy or chemoradio-
therapy. All patients received leucovorin 20 mg/m2/day and fluorouracil 425 mg/m2/
day for 5 consecutive days.
Interventions 2 groups, placebo versus palifermin (40 µg/kg) for 3 days before chemotherapy admin-
istration
Outcomes Mucositis assessed on days 1, 4, 8, 12, and 15 and day 28 using the WHO score.
Patients completed the oral mucositis daily questionnaire daily between days 1 and 27.
Other reported outcomes: diarrhoea, patient reported mouth and throat soreness, safety,
laboratory assessments, disease outcomes, antibody assessments
Notes Funding source: pharmaceutical (Amgen).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were randomly assigned
(by centre and prior chemotherapy) in a 1:
1 ratio to receive palifermin or placebo”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 65 patients recruited. 64 patients received
study drugs. No patients discontinued dur-
ing 1st cycle (data used in meta-analysis).
10 patients withdrew during 2nd cycle of
chemotherapy. 8/28 palifermin and 2/36
placebo.
Free of selective reporting? Yes Data presented in percentages for all pa-
tients by mucositis grade (figure 2a)
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Rosen 2006 (Continued)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Saarilahti 2002
Methods Randomised, parallel group study conducted in Finland. Clear information about with-
drawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 10 weeks
Participants Adults with head and neck cancer. 40 patients eligible, enrolled between October
1999 and April 2001, and evaluated.
Interventions 2 groups, GM-CSF mouthwash made by dissolving 150 mg of dried powder in 100 ml
sterile water versus mouthwash of 4 g sucralfate with 100 ml sterile water. 4 doses x 25
ml per day after meals
Outcomes RTOG rating for mucositis on 0-4 scale. Author provided data in right form for the
review
Notes Maximum value of mucositis taken.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomisation was done using
computer generated digits”
Allocation concealment? Yes Quote: “After patients provided written
consent, they were assigned to a treatment
group by way of a telephone call to the ran-
domisation office”
Quote: “The drug vials were marked with
a study code that prevented identification
of the allocation group”
Comment: central method of randomisa-
tion.
Blinding?
Carers
Yes Comment: double blind study with ade-
quate allocation concealment, drugs pre-
pared by pharmacy
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
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Saarilahti 2002 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 40 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for mean mucositis score
over time (fig 1) and mean mucosal pain
scores (fig 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Scarantino 2006
Methods Randomised, parallel group study conducted inUSA.Clear information on withdrawals:
1 in pilocarpine and 2 in placebo group refused protocol treatment. Dentist not involved
in study. Drop outs: 1%. Duration: 13 weeks
Participants Adults with head and neck cancer. Planned radiotherapy to include have 50% of the
volume of the major salivary glands receive 50 Gy. 249 enrolled, 4 ineligible, 245 ran-
domised, 242 completed
Interventions 2 groups, placebo versus pilocarpine 5 mg 4 times per day.
Outcomes Mucositis graded 3 times per week according to the RTOG acute mucositis toxicity
scale (0-4). Assessment used: unclear. We used the highest RTOG score recoded. Other
reported outcomes: sialometry of unstimulated and stimulated whole saliva, eating, taste
swallowing, pain, adverse events included nausea and vomiting
Notes Funding source: government. Pharmacological company provided drug and organised
randomisation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “249 patients were randomised:
124 to receive 5 mg of pilocarpine four
times daily and 125 to receive a placebo on
the same schedule”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
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Scarantino 2006 (Continued)
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 249 patients randomised. 4 patients were
later deemed ineligible. A further 3 pa-
tients withdrew (1/121 pilocarpine, 2/124
placebo). Authors give full reasons for ex-
clusions/withdrawals
Free of selective reporting? Unclear Data presented for 242 patients by grade of
mucositis for grades 0, 1 and 2+
Free of other bias? Unclear Baseline imbalance: more patients with a
KPS of 90-100 were in the pilocarpine
group (P+0.03). However, it is unclear how
this would affect mucositis development
Scherlacher 1990
Methods Randomised, parallel group study conducted in Germany. Clear description of with-
drawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration 6-7 weeks
Participants Adults with head and neck cancer. 45 eligible.
Interventions 2 groups: usual care control versus sucralfate suspension (1 g orally 4 times per day for
5 mins)
Outcomes Mucositis scored on 1-5 scale and number with mucositis 3-5 given
Notes Both groups received standard oral hygiene, frequent tooth cleaning and disinfection of
oral and pharyngeal mucosa.
Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”random allocation to test and con-
trol group”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
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Scherlacher 1990 (Continued)
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Outcome assessors
Unclear Insufficient information to determine ’yes’
or ’no’.
Incomplete outcome data addressed?
All outcomes
Unclear 45 patients recruited. Outcomes given in
percentages.
Free of selective reporting? Unclear Data presented for number of patients with
mucositis grades 3-5
Free of other bias? No Risk of bias assessed from translation.
Schneider 1999
Methods Randomised, parallel group study conducted in USA. Clear information about with-
drawals: none. Dentist involved in study. Drop outs: 0%
Participants Adults with head and neck cancer. 14 patients enrolled and evaluated. Recruitment
January 1995 to April 1996
Interventions 2 groups, placebo versus filgrastim (subcutaneous injections daily throughout treatment
titrated to keep neutrophil count between 10x 109/l and 30x 109/l).
Outcomes WHO mucositis 0-4 scale, and Hickey mucositis scores. Proportion of patients greater
than WHO mucositis grade 3 presented. Assessment used: week 10
Notes All patients had oral hygiene instruction. Funding source: pharmaceutical
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “The patients were randomised
equally between the two treatment groups
to receive either subcutaneous injections of
filgrastim or placebo starting concurrently
with the first day of radiation and contin-
uing daily”
Comment: random component not de-
scribed.
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Schneider 1999 (Continued)
Allocation concealment? Yes Quote: “Amgen Inc. prepared and pack-
aged all drug and placebo in identical con-
tainers, with the only designator being the
randomisation number. The study mate-
rial and randomisation list were held by the
UCLA pharmacy for the duration of the
study”
Comment: pharmacy controlled randomi-
sation.
Blinding?
Carers
Yes Pharmacy controlled randomisation. Un-
likely that carers would know allocations
Blinding?
Patients
Yes Quote: “double Blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double Blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 14 patients randomised. 1 patient with-
drew, however, results were included in
analysis. No missing outcome data
Free of selective reporting? Unclear Data presented formeanworst Hickeymu-
cositis score by week (fig 1) and mean
worst WHOmucositis by week (fig 2) and
the proportion of patients whose scores re-
mained below 3 by week (fig 3 and fig 4)
Free of other bias? No Studywas stopped after an interim analysis.
Authors state that “owing to administrative
obstacles completion of the trial is not pos-
sible”. Authors do not meet either of their
previously stated early stopping rules
Schubert 2007
Methods Randomised, parallel group study conducted in the USA. Clear information about with-
drawals. Duration: 7-13 days
Participants Adults (children over 12 could be recruited, however, youngest participant appears to have
been 18) undergoing transplantation (both allogeneic and autologous). Conditioning:
busulfan and cytoxan, TBI and cytoxan, fludarabine and busulfan, and other
Interventions 3 groups, sham laser versus laser (650 nm, (40 mW)) laser, versus laser (780 nm (60
mW)). Laser therapy started on the first day of conditioning and continued for 3 days
post-transplant
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Schubert 2007 (Continued)
Outcomes Mucositis assessed using the oral mucositis index on days 0, 4, 7, 11, 14, 18, and 21.
Other reported outcomes: oral pain, adverse events (death)
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”subjects who consented were ran-
domised into one of two laser treatment
arms or a placebo therapy group”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Quote: “by having subjects wear both laser
safety goggles and a soft cloth blindfold, it
was physically impossible for them to see
the tip of the laser emitting device or the
control panel of the unit, thus ensuring that
subjects were blinded as to whether they
were receiving actual laser”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Quote: “mucositis examinations were car-
ried out by trained and calibrated oral
medicine personnel who were blind to the
subjects treatment arm assignment”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 70 patients randomised. 2 patients died
during study. 67% had scores for all time
points and a similar number in each group
had missing data. Self assessment of pain
was only completed by 17/70 patients
Free of selective reporting? Unclear Data presented for mean mucositis scores
over time (fig 1) and mean mucositis scores
by arm (table 2)
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Schubert 2007 (Continued)
Free of other bias? No Patients in the 650 nm laser arm were sig-
nificantly more likely to have received a
conditioning regimen which included TBI
Shenep 1988
Methods Randomised, parallel group study conducted in USA. Clear information about with-
drawals: none. Dentist not involved in study. Drop outs: 0%. Duration: 50 days
Participants Children with leukaemia. Chemotherapy- remission induction multiagent ANLL-83.
48 patients enrolled and evaluated
Interventions 2 groups, placebo versus sucralfate (0.75 mg/kg daily, suspension swished every 6 hours)
Outcomes Mucositis (clinical and patients scales given, 0-4), gram-ve, gram+ve, fungal, all organ-
isms. Assessment used: day 50. Other reported outcomes: gastroenteritis, gingival bleed-
ing, nutrition, fever, infection, rash
Notes Clinician’s mucositis score used.
Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomisationof treatment for pa-
tients was performed by the hospital phar-
macist according to a scheme obtained
from Biostatics Division.”
Comment: random component not de-
scribed.
Allocation concealment? Yes Pharmacy controlled randomisation.
Blinding?
Carers
Yes Double blind study with adequate alloca-
tion concealment.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 48 patients recruited. Nomissing outcome
data.
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Shenep 1988 (Continued)
Free of selective reporting? Unclear Data presented for observed mucositis and
patient reports of mucositis at grades 0, 1
and > 2 (table 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Shieh 1997
Methods Randomised, parallel group study conducted in China. Clear information about with-
drawals: none. Dentist involved in study. Drop outs: 0%. Duration: 5 weeks
Participants Adults with head and neck cancer. 30 patients were enrolled between June 1994 and
May 1995 and all evaluated
Interventions 3 groups (oral care protocols), control given no instructions, E1 given protocol to follow
1 day before radiotherapy, E2 given protocol to follow 1 week before radiotherapy.
Oral care protocol included instructions on how to brush teeth. Data from E1 and E2
combined as oral care intervention
Outcomes Stomatitis free survival (graph). Also means and standard deviations of oral assessment
guide (OAG) index, which includes multiple factors including voice and teeth. Assess-
ment used: day 28
Notes Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “to achieve an equal number of
study subjects in each group, every 3 con-
secutive entries of eligible patients over
time were treated as a block wherein a sim-
ple randomisation was performed”
Comment: random component not de-
scribed. However, reference made to ran-
domisation article
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No 2 different methods of oral care (E1/ E2)
versus control. Blinding impossible
Blinding?
Patients
No 2 different methods of oral care (E1/ E2)
versus control. Blinding impossible
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Shieh 1997 (Continued)
Blinding?
Outcome assessors
No 2 different methods of oral care (E1/ E2)
versus control. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 30 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented in the text for the per-
centage of patients with mucositis at week
2. Data also presented for onset time of
stomatitis (figure 1), percentage incidence
of stomatitis by treatment day (figure 2)
, mean OAG scores compared to days of
treatment (figure 3), and increases in mean
OAG score by treatment day (figure 4)
Free of other bias? No Baseline OAG score was 1.5 point higher
for the E1 group due to random allocation
of 3 patients with history of betel nut chew-
ing to this group. Authors state that conclu-
sions regarding the mean onset of mucosi-
tis did not change after these patients were
excluded from the analysis. However, mean
OAG scores are not provided for compari-
son.
Sorensen 2008
Methods Randomised, parallel group study conducted in Denmark. Clear information about
withdrawals. Unclear if dentis involved in study. Drop outs: 8%
Participants Adults with gastric or colorectal cancer treated with 5-FU containing chemotherapy, 225
enrolled, 206 completed
Interventions 3 groups, placebo (saline mouthrinse 3 times/day) versus chlorhexidine mouthrinse (3
times/day) versus crushed ice
Outcomes CTCv2grading ofmucositis. Assessment used: day 28.Other reported outcomes: patient
reporting of severity and duration of mucositis, compliance
Notes Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised after informed con-
sent to 1 of 3 prophylactic regimens”
Comment: random component not de-
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Sorensen 2008 (Continued)
scribed.
Allocation concealment? Unclear Quote: “identical 500 mL bottles labelled
x and y”.
Comment: unclear if bottles were sequen-
tially numbered.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 150 patients randomised to double blind
arms. 11patientswithdrew (2/75 chlorhex-
idine, 9/75 placebo). 139 patients included
in final analysis
75 patients randomised to cryotherapy
arm. 8 patients did not return question-
naire on side effects and compliance and
were removed from final analysis. 67 pa-
tients included in final analysis
Free of selective reporting? Yes Data presented for mucositis by grade and
treatment arm.
Free of other bias? Yes Study appears to be free of other sources of
bias.
Sornsuvit 2008
Methods Randomised, parallel group study conducted in Thailand. No withdrawals, losses to
follow-up described. Unclear if dentist involved in study. Duration: 5 days concurrently
with each chemotherapy cycle. Recruitment period: not stated
Participants Adults with acute myeloid leukaemia. 16 patients eligible, and evaluated
Interventions 2 groups, glutamine 30 g/day IV or and equivalent quantity of standard amino acid
mixture (control) each day on days 1-5 of each chemotherapy cycle
Outcomes Grades for mucositis on 0-4 scale, blood changes, infection, weight loss, adverse effects
Notes Any mucositis, ≥ grade 2 mucositis, ≥ grade 3 mucositis.
Risk of bias
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Sornsuvit 2008 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised to receive intravenous
supplementation with either 30 g/day Gln
or an equivalent quantity of a standard
amino acid mixture”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Unclear Glutamine versus standard amino acids.
Blinding?
Outcome assessors
Unclear Glutamine versus standard amino acids.
Incomplete outcome data addressed?
All outcomes
Yes 16 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for mean severity grade,
number of patients with mucositis > 2 and
number of patients with mucositis > 3 (ta-
ble 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Spencer 2005
Methods Randomised, parallel group,multicentre study conducted inAustralia. Clear information
on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration:
up to 46 months
Participants Adults blood cancer - multiple myeloma undergoing BMT high dose melphalan condi-
tioned autologous stem cell transplantation (ASCT). BetweenMay 1999 and November
2000, 90 patients were randomised, with 82 evaluable at end of trial
Interventions 2 groups, no treatment control versus amifostine (patients undergoing ASCT were ran-
domised to receive or not receive amifostine 910 mg/m² prior to melphalan 200 mg/
m²)
Outcomes Mucositis graded according to the adapted WHO toxicity scale. Assessment used: time
unclear. Other reported outcomes: parenteral nutrition, analgesic use, complete remis-
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Spencer 2005 (Continued)
sion, adverse events included: toxicity, nausea (grade 1), vomiting and hypotention
Notes Funding source: industry and charity. All participants received antibacterial prophylaxis
and fluconazole. Pharmacological company provided drug and organised randomisation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were randomised to re-
ceive Mel200 with or without amifostine
910mg/m2 pretreatment 15-30 mins prior
to melphalan infusion.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Quote: “open label”.
Blinding?
Patients
No Quote: “open label”.
Blinding?
Outcome assessors
No Quote: “open label”.
Incomplete outcome data addressed?
All outcomes
Yes 90 patients randomised. 82 patients were
evaluable at the end of the trial. Authors do
not denote which group withdrawals were
from. ITT analysis performed
Free of selective reporting? Unclear Data presented for percentage of patients
with grade 0, grades 1/2 and 3/4 mucosi-
tis (figure 1), median mucositis grade, me-
dian duration (table 5) and percentage of
patients with no mucositis
Free of other bias? Yes Study appears to be free of other sources of
bias.
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Spielberger 2004
Methods Randomised, parallel group, multicentre study conducted in USA. Clear information
on withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: 28 days
Participants Adults with mixed cancer. BMT. Treated with fractionated total-body irradiation plus
high-dose chemotherapy and auto-HSCT. 212 enrolled, randomised and completed
Interventions 2 groups, placebo versus palifermin (recombinant human keratinocyte growth factor) 60
micrograms per kilogram of body weight per day iv for 3 consecutive days immediately
before the initiation of conditioning therapy
Outcomes Mucositis assessed daily using 3 scales: theWHO oral-toxicity scale (0-4) (primary scale)
, RTOG (0-4) acute radiation morbidity scoring criteria for mucous membranes, and the
4-grade Western Consortium for Cancer Nursing Research (WCCNR) revised staging
system for oral mucositis. Assessment used: -8 up to day 28. Other reported outcomes:
soreness of the mouth and throat, swallowing limitations, opioid use, incidence of febrile
neutropenia, incidence of infections, incidence of the use of total parenteral nutrition.
Adverse events: included rash, purities, erythema, taste alteration
Notes Funding source: industry. Pharmacological company provided drug and organised ran-
domisation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised in a 1:1
(stratified according to centre and type of
hematologic cancer) to receive Palifermin
or placebo”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 214 patients randomised. 212 patients re-
ceived at least 1 dose of palifermin. 7 pa-
tients did not complete the study: 2/106
palifermin, 4/106 placebo. Authors give
no reasons for non-completion. Mucositis
189Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Spielberger 2004 (Continued)
data given for 212 patients
Free of selective reporting? Yes Data presented in percentages for 212 pa-
tients by mucositis grade (figure 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Spijkervet 1989
Methods Randomised, parallel group study conducted in The Netherlands. Clear information
about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: 5 weeks
Participants Adults with head and neck cancer treated with radiotherapy. 30 patients eligible, enrolled
and evaluated
Interventions 2 groups, placebo versus chlorhexidine spray/rinse (0.1% chlorhexidine 100 ml per day
(spray 50 ml) rinsing 3 times with 15 ml)
Outcomes Semiquantitative scoring of mucositis in “described elsewhere”. Assessed thrice weekly
until end of treatment (at least 50 Gy). Assessment used: day 35. Other reported out-
comes: microflora
Notes Used data from text: 24 patients showed the most severe stage of pseudomembrane
formation (12 in placebo and 12 in test). During radiotherapy daily cleaning of teeth by
hygienist.
Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “This study was a prospective, dou-
ble-blind, randomised placebo controlled
program.”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
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Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 30 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for number of patients with
severe mucositis (pseudomembrane forma-
tion) in text.
Free of other bias? Yes Study appears to be free of other sources of
bias.
Stokman 2003
Methods Randomised, parallel group study conducted in The Netherlands. Clear information on
withdrawals: 2/32 placebo, 5/33 test. Unclear whether dentist involved in study. Drop
outs: 10.7%
Participants Adults with head and neck cancer. 65 enrolled, 58 completed.
Interventions 2 groups, placebo versus active lozenges (containing polymyxin E 2 mg, tobramycin 1.
8 mg and amphotericin B 10 mg (PTA))
Outcomes Percentage developing mucositis (WHO 3-4). Other reported outcomes: weight loss
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomisation was performed
by the hospital pharmacist according to
a computer-generated, randomised alloca-
tion schedule”
Comment: computer generated randomi-
sation.
Allocation concealment? Yes Pharmacy controlled randomisation.
Blinding?
Carers
Yes Adequate allocation concealment. Unlikely
that carers would know of allocations
Blinding?
Patients
Yes Quote: “Patients, clinicians, dental hygien-
ists and microbiologists were blind for who
was taking antibiotics”
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Blinding?
Outcome assessors
Yes Quote: “Patients, clinicians, dental hygien-
ists and microbiologists were blind for who
was taking antibiotics”
Incomplete outcome data addressed?
All outcomes
Yes 65 patients randomised. 7 patients with-
drew (5/33 PTA, 2/32 placebo). ITT anal-
ysis performed
Free of selective reporting? Unclear Data presented formeanmucositis score by
weeks of radiation in a graph (fig 1) and a
table (table 2). Percentages of patients with
grades 3 and 4 mucositis presented in the
text
Free of other bias? Yes Study appears to be free of other sources of
bias.
Su 2004
Methods Randomised, parallel group study conducted in USA. Clear information about with-
drawals: 0. Unclear if dentist involved in study. Drop outs: 0%
Participants Adults with head and neck cancer. 58 enrolled, 58 completed.
Interventions 2 groups, placebo versus aloe vera solution (AV). 20 cc aloe vera a day during radiotherapy
Outcomes Mucositis RTOG grade 3-4. Other reported outcomes: mean overall health, mean sore-
ness score
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “the assignment procedure was
termed ”biased coin“ randomization and
ensures that the number of subjects as-
signed to aloe vera would be roughly equal
to those receiving chemotherapy and those
with the same primary care site.”
Comment: biased coin randomisation.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
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Blinding?
Patients
Yes Quote: “double blind”.
Quote: “To minimize biases, both study
physicians andpatientswere unaware of the
results of randomisation”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Quote: “To minimize biases, both study
physicians andpatientswere unaware of the
results of randomisation”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Unclear 58 patients recruited. All patients included
in analysis. Mucositis data (table 2) pre-
sented in percentages
Free of selective reporting? Unclear Data presented for grade 2-3 mucositis in
percentages (table 2) and maximum toxic-
ity grade (table 3)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Su 2006
Methods Randomised double blind placebo controlled parallel group study conducted in USA.
Dentist involvement unclear
Participants Adults with stage 2-4 M0 SCCHN recruited January 92 to December 96. 19 in G-CSF
and 22 in placebo, all but 1 patient in placebo group completed treatment and were
evaluable
Interventions G-CSF 3 µg/kg daily SC, 7 times/week. Placebo equal volume 5% dextrose in water.
Treatment started 3 days prior to radiotherapy and continued throughout. Planned dose
reductions if white blood cell count exceeded set limits, assessed by investigator who
communicated directly with pharmacist to maintain blinding
Outcomes Primary: incidence of percutaneous endoscopic gastrostomy placement. Also mucositis
grade, level of mucositis treatment required, overall survival, progression free survival,
locoregional control
Notes Funding source: NCI grant. Median duration of follow-up 7.25 years
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Yes Quote: “Patients were randomised to either
G-CSF or placebo by randomly permuted
blocks, after stratification by primary dis-
ease site”
Comment: random component not ex-
plicit. However, setting makes adequate
randomisation likely
Allocation concealment? Yes Quote: “a randomization list was prepared
by the Memorial Sloan-Kettering Cancer
centre biostatics service and held by the
pharmacy. Investigators did not have access
to this list”
Comment: pharmacy controlled randomi-
sation.
Blinding?
Carers
Yes Adequate allocation concealment. Unlikely
that carers would know of allocation
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 41 patients recruited. 1 patient (1/22
placebo)withdrew.Authors donot give rea-
son for withdrawal.
Free of selective reporting? Yes Data presented for 40 patients by grade of
mucositis and arm
Free of other bias? Yes Study appears to be free of other sources of
bias.
Svanberg 2007
Methods Randomised, parallel group study conducted in Sweden. Clear information about with-
drawals: 0. Dentist involved in study. Duration: during chemotherapy administration.
Recruitment between January 2002 and August 2004
Participants Adults with a mix of testicular cancer and haematological malignancies undergoing
myeloablative therapy prior to bone marrow or stem cell transplantation
Interventions 2 groups, no treatment versus cryotherapy.
Outcomes Mucositis assessed daily using theOMAS instrument.Other reported outcomemeasures:
blood counts, c-reactive protein, compliance, adverse events. Days of intravenous opioids
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Notes 45 staff members assessed mucositis using the OMAS instrument. Unclear if inter-rater
reliability had been conducted before starting data collection. Probably not due to the
number of staff involved
Funding: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”The study was a randomised con-
trolled trial with a random assignment
to experimental (EXP) or control (CTR)
group”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Cryotherapy versus standard treatment.
Blinding impossible.
Blinding?
Patients
No Cryotherapy versus standard treatment.
Blinding impossible.
Blinding?
Outcome assessors
No Cryotherapy versus standard treatment.No
apparent blinding.
Incomplete outcome data addressed?
All outcomes
Yes 78 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented in the text for mucositis
scores on day 10 (autologous patients), day
16 (allogeneic patients), days of mucositis
Free of other bias? Yes Study appears to be free from other sources
of bias.
Symonds 1996
Methods Randomised, parallel group study conducted in Scotland. Clear information about with-
drawals: 30/139 control, 24/136 test. Unclear if dentist involved in study. Drop outs:
20%. Duration: until radiation reaction settled, 8 weeks
Participants Adults with head and neck cancer. 275 patients enrolled and 221 evaluated
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Interventions 2 groups, placebo versus antibiotic pastille (polymyxin E 2 mg, tobramycin 1.8 mg and
amphotericin B 10 mg, 4 times daily from start of radiotherapy)
Outcomes Physician assessment of mucositis (none, patchy confluent). Assessment used: day 56.
Other reported outcomes: patients asked about pain on swallowing anddysphagia, weight
loss and compliance
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised to re-
ceive either a placebo or active pastilles con-
taining polymyxin E 2 mg, tobramycin 1.
8 mg and amphotericin B 10 mg”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Yes Quote: “The active and placebo pastilles
were identical and neither the patients,
clinicians, nurses nor microbiologists were
aware who were taking antibiotics”
Quote: “double blind”.
Comment: probably done.
Blinding?
Patients
Yes Quote: “The active and placebo pastilles
were identical and neither the patients,
clinicians, nurses nor microbiologists were
aware who were taking antibiotics”
Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “The active and placebo pastilles
were identical and neither the patients,
clinicians, nurses nor microbiologists were
aware who were taking antibiotics”
Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
No 275 patients randomised. 54 patients were
unevaluable (24 pastilles, 30 placebo). Au-
thors do not give full reasons for with-
drawal/drop out
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Free of selective reporting? Unclear Data presented for erythema of mucosa
for 220 patients (nil/slight/moderate/se-
vere), mucositis distribution for 221 pa-
tients (none/patchy/confluent) and mu-
cositis area (median/IQ range/range)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Trotti 2004
Methods Randomised, parallel group, multicentre study conducted in USA, Canada, Germany,
France and UK between July 2000 and December 2001. Clear information about with-
drawals: 0. Dentist involvement unclear. Drop outs: 0%
Participants Adults with head and neck cancer receiving chemoradiotherapy. 545 enrolled, 511 results
reported
Interventions 3 groups, placebo plus SOC, iseganan (9 mg as 0.3% aqueous solution) plus SOC, SOC
alone
Outcomes Percentage mucositis NCI CTC grade 2-4. Other reported outcomes: completion of
radiotherapy and chemotherapy up to 28 days after radiotherapy
Notes Funding source: pharmaceutical.
Correspondence with Dr D Peterson: clinical trials with iseganan were discontinued
approximately 6 years ago. Approval of the drug for oral mucositis was not obtained in
the United States
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised double blind”.
Quote: “patients were randomised to re-
ceive 9 mg doses of iseganan formulated as
a 0.3% aqueous vehicle solution plus insti-
tute specific standard-of-care (SOC) man-
agement of oral hygiene, or placebo (vehi-
cle solution) plus SOC, or SOC alone in a
3:2:1 distribution”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Quote: “all study drugs were packaged in
identical multidose, white, opaque plastic
bottles”
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Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Quote: “Patients, study personnel, and the
sponsor were blinded as to whether an in-
dividual received iseganan or placebo”
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Quote: “Patients, study personnel, and the
sponsor were blinded as to whether an in-
dividual received iseganan or placebo”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 545 patients randomised. 27 patients were
potentially affected by randomisation er-
ror and were subsequently excluded from
the efficacy analysis. 7 patients additionally
excluded because they did not receive the
study drug/baseline assessment. Authors do
not state which arms patients were ran-
domised to
Free of selective reporting? Unclear Data presented for mucositis grades 0/1, 2
and 3/4 in percentages, mean peak severity
of OM, and average OM
Free of other bias? Yes Study appears to be free of other sources of
bias.
Tu 1998
Methods Randomised, parallel group multisite study conducted in China. Unclear if dentist in-
volved in study. Drop outs: 0%. Duration: 4 to 6 weeks
Participants Data presented for 159 patients with mixed cancers receiving radiotherapy
Interventions 2 groups, placebo group (intramuscular injection of lactose liquid) versus copper zinc
super oxide dismutase (SOD) (40000 units by intramuscular injection). Both groups
received 1 injection a day, 5 days per week
Outcomes Oral mucositis graded as slight, moderate and severe. Other outcome measures: skin
pelvic visceral and systemic adverse events
Notes Funding source: unclear.
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Unclear Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: ”double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 159 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for mild and moderate to
severe mucositis.
Free of other bias? No ROB assessed from translation.
Vacha 2003
Methods Randomised, parallel group study conducted in Germany. Clear information on with-
drawals. Unclear if dentist involved in study. Duration: during radiotherapy
Participants Adults with cancers of the larynx, oropharynx and hypopharynx receiving radiotherapy
(60 Gy /70 Gy) and chemotherapy (70 mg/m2).
Interventions 2 groups, no treatment versus amifostine (250 mg). Amifostine given over short infusion
(10-15 minutes)
Outcomes Mucositis assessed weekly using the CTC criteria. Other reported outcome measures:
xerostomia, skin toxicity, body weight, performance status
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”randomised”.
Comment: random component not de-
scribed.
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Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Chemotherapy and radiotherapy with or
without amifostine. No apparent blinding
Blinding?
Patients
No Chemotherapy and radiotherapy with or
without amifostine. No apparent blinding
Blinding?
Outcome assessors
No Chemotherapy and radiotherapy with or
without amifostine. No apparent blinding
Incomplete outcome data addressed?
All outcomes
Yes 56 patients randomised. 6 patients ex-
cluded. Authors do not state which arm
these patients were randomised to but do
give full reasons for exclusion
Free of selective reporting? Unclear Data presented for mean mucositis scores
by week of treatment for both arms of the
study
Free of other bias? Yes Study appears to be free from other sources
of bias.
Vadhan-Raj 2010
Methods Parallel group study, but 2 very different randomisation schedules used within this study.
Duration: planned to be 6 cycles of chemotherapy but results reported based on 2
“blinded cycles” only. Dentist involvement: unclear
Participants Inclusion criteria: patients with sarcoma who were planned to undergo multicycle che-
motherapy aged 15-65 years with Karnofsky performance status >/= 80% & adequate
bone marrow, hepatic and renal function
Exclusion criteria: patients with history of pelvic radiation or clinically significant cardiac
disease or those who had undergone surgery in previous 2 weeks were excluded
Number randomised 48. Number completed (6 cycles) 25.
Interventions 2 groups: (n = 32) 180 Ug/kg palifermin IV 3 days prior to the start of each cycle of
chemotherapy. (n = 16) placebo single dose IV 3 days prior to chemotherapy
Outcomes Moderate to severe, severe mucositis according to WHO grades, adverse effects
Notes Funding source: Amgenprovided the palifermin andplacebo, provided a grant to partially
fund the study, and the principal investigator is a member of the Amgen board
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Two distinct computer-generated
randomization lists were prepared by the
Dept of Biostatistics, University of Texas
MD Anderson Cancer Centre, one for the
20 patients who consented to pharmacoki-
netic sampling and the other for the 28 pa-
tients who did not. For the pharmacoki-
netics cohort the treatment allocation ra-
tio was 4:1 palifermin:placebo in 4 blocks
of 5; for the other cohort the ratio was 4:3
palifermin to placebo in 2 blocks of 14.”
Comment: the clinical research teamwould
have known that 4/5 of the pharmacoki-
netic group were receiving active treatment
Comment: random component not de-
scribed.
Allocation concealment? Yes Both randomisation lists were held by the
pharmacy who assigned the patient to the
next sequential slot and treatment on the
basis of whether or not there was consent
for pharmacokinetic sampling
Blinding?
Carers
No Quote: “the patient and the clinical re-
search team (who assessed outcomes) were
blinded to the study treatment”
Comment: however paper states that
“blinding might not have been maintained
due to the adverse effects of palifermin
(pronounced leukoedema of buccal mu-
cosa & gingival)”, and describes cycles 1&
2 as ’blinded cycles’. Pre- and post-admin-
istration biopsies in ’8 consenting patients’
would have also revealed who was allocated
to active treatment. Those patients con-
senting to the pharmacokinetic study had
a 4/5 chance of receiving active treatment.
Comment: we consider it likely that none
of the treatment cycles were truly blinded
Blinding?
Patients
Unclear Quote: “the patient and the clinical re-
search team (who assessed outcomes) were
blinded to the study treatment”
Comment: however paper states that
“blinding might not have been maintained
due to the adverse effects of palifermin
(pronounced leukoedema of buccal mu-
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Vadhan-Raj 2010 (Continued)
cosa & gingival)”, and describes cycles 1&
2 as ’blinded cycles’. Pre- and post-admin-
istration biopsies in ’8 consenting patients’
would have also revealed who was allocated
to active treatment. Those patients con-
senting to the pharmacokinetic study had
a 4/5 chance of receiving active treatment.
Comment: we consider it likely that none
of the treatment cycles were truly blinded
Blinding?
Outcome assessors
No Quote: “the patient and the clinical re-
search team (who assessed outcomes) were
blinded to the study treatment”
Comment: however paper states that
“blinding might not have been maintained
due to the adverse effects of palifermin
(pronounced leukoedema of buccal mu-
cosa & gingival)”, and describes cycles 1&
2 as ’blinded cycles’. Pre- and post-admin-
istration biopsies in ’8 consenting patients’
would have also revealed who was allocated
to active treatment. Those patients con-
senting to the pharmacokinetic study had
a 4/5 chance of receiving active treatment.
Comment: we consider it likely that none
of the treatment cycles were truly blinded
Incomplete outcome data addressed?
All outcomes
Unclear 12/32 (38%) and 12/16 (75%) patients in
the palifermin and placebo groups respec-
tively discontinued treatment. Some rea-
sons are given. The reported rates of dis-
ease progression, chemotoxicity & surgery
are similar in each group, but the rate of
switching to open label treatment is much
higher in placebo group and there is some
mismatch between information in figures
1 & 3.
Outcomes are reported as percentages only,
and for the ’blinded cycles’ 1 & 2 the num-
bers evaluated in each group are unclear
Free of selective reporting? Unclear Reported outcomes of moderate/severe &
severemucositis. However all reported out-
comes are expressed as percentages together
with a statement that “all patients were
evaluable for toxicity and response to pal-
ifermin”
Planned outcomes also included duration
of oral mucositis, patient reported out-
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comes, use of narcotic analgesics, weight
loss & dose reductions/delays in chemo-
therapy. These outcomes are not reported
in the paper
Free of other bias? Unclear Use of granulocyte macrophage colony-
stimulating factor is listed as not permitted,
but patients received Pegfilgrastim which
is a pegylated form of human granulocyte
colony-stimulating factor
van der Lelie 2001
Methods Randomised, parallel group study conducted in The Netherlands. Clear information
about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: until
neutrophil recovery
Participants Adults with mixed cancer receiving BMT or cell stem. 39 patients eligible, 36 enrolled
between May 1997 and August 1999, all evaluated
Interventions 2 groups, placebo versus GM-CSF (300 ug of GM-CSF daily dose in 2% methylocellu-
lose gel, 5 ml gel twice daily, keep in oral cavity as long as possible then swallow)
Outcomes WHO mucositis scale 0-4. Assessment used: day 14. Other reported outcomes: VAS
mucositis pain, OAS mucositis, required morphine or not, fever, infection treated with
antibiotics, duration of netropenia, days in hospital
Notes All rinsed with 0.9% saline and in case of inflamation 0.12% chlorhexidine 6 times daily.
Funding source: university, pharmaceutical for intervention
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “After giving their informed con-
sent, the patients were randomised to re-
ceive GM-CSF or placebo”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
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Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 36 patients randomised. 8 patients with-
drew. 4/18 GM-CSF, 4/18 placebo. Au-
thors give full reasons for attrition/ exclu-
sion
Free of selective reporting? Unclear Data presented for average WHO score,
OAS and pains scores by days for both in-
tervention and placebo group. Number of
patients with grade 3 and grade 4mucositis
presented in text.
Free of other bias? Yes Study appears to be free of other sources of
bias.
Veerasarn 2006
Methods Randomised, parallel group, multicentre study conducted in Thailand. Clear informa-
tion on withdrawals: none. Unclear if dentist involved in study. Drop outs: 7%. Dura-
tion: up to 90 days
Participants Adults with head and neck cancer. 67 enrolled and randomised between February 1999
and September 2001. 62 completed
Interventions 2 groups, no amifostine control versus intravenous amifostine with radiotherapy (200
mg/m² 50 ml infusion daily 30 minutes prior to radiation treatment) (radiotherapy: 66-
70 Gy or postoperative 50-60 Gy both in 2 Gy fractions)
Outcomes Mucositis graded with reference to RTOG criteria on a 0-4 scale. Assessed at 1-6 weeks
during treatment, 4 week data used for mucositis > 2.
Other reported outcomes: xerostomia, dysphasia; treatment related adverse events: vom-
iting, nausea, allergic reaction, haematologic, hypotension, hot flushes, somnolence,
sneezing, hiccup
Notes Funding source: pharmaceutical company.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “...were randomised to receive ra-
diotherapy or radiotherapy plus amifos-
tine”
Comment: random component not de-
scribed.
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Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Quote: “open label”.
Blinding?
Patients
No Quote: “open label”.
Blinding?
Outcome assessors
No Quote: “open label”.
Incomplete outcome data addressed?
All outcomes
Unclear 67 patients randomised. 5 patients (5/35
patients control group) excluded because
they were missing baseline data
Free of selective reporting? Unclear Data presented in percentages for number
of patients with mucositis (> grade 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Veness 2006
Methods Randomised, parallel group study conducted in Australia. Clear information on with-
drawals: 10 (4/42 misoprostol, 6/41 placebo). Dentist involved in study. Duration: until
grade 1 or less mucositis was recorded
Participants Adults with head and neck cancer radiotherapy (n = 52) or concomitant chemotherapy
and radiotherapy (n = 31). All patients had > 50% of the oral /oropharyngeal mucosa in
the radiation field and received > 50 Gy
Interventions 2 groups, placebo tablets versus misoprostol tablets (200 µg) dissolved in 15 ml of water.
Patients asked to swish liquid around the oral cavity for 2 minutes and gargled before
being swallowed
Outcomes Mucositis assessed weekly using a 0-4 scale. Other reported outcomes: quality of life,
weight loss, hospital admission, pain,
Notes Data used from table 3 (incidence of mucositis). Data treated as provided the wrong way
round, as the text suggests that 42 patients were received into the misoprostol group and
41 into the placebo group, while the table provides data for 42 placebo patients and 41
misoprostol patients
Funding source: government.
Risk of bias
Item Authors’ judgement Description
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Veness 2006 (Continued)
Adequate sequence generation? Unclear Quote: “randomisation was carried out us-
ing stratified minimization”
Comment: minimization. Authors give in-
formation about which factors used for
stratification
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “the patient’s mucositis grade was
scored by an experienced head and neck
clinic nurse on a weekly basis. She had no
prior knowledge of patient randomisation”
Comment: probably done.
Incomplete outcome data addressed?
All outcomes
Yes 83 patients randomised. 10 patients with-
drew (4/42 misoprostol, 6/41 placebo).
Mucositis data presented for 83 patients
Free of selective reporting? Yes Data presented for incidence of mucositis
by grade and arm (table 3) for 83 patients
Free of other bias? Yes Study appears to be free from other sources
of bias.
Vokurka 2005
Methods Randomised, parallel group, multicentre study conducted in Czech/Slovak Republics
between January 2002 and June 2004. Unclear whether assessors blind. Unclear infor-
mation on withdrawals: 3 refused after start, 2 lost. Unclear if dentist involved in study.
Drop outs: 4%. Duration: 28 days, total in-patient stay
Participants Adults. Disease unclear. BMT. High dose chemotherapy followed by autologous periph-
eral stem cell transplantation. 137 enrolled and randomised, 132 completed
Interventions 2 groups, placebo (saline) versus povidone iodine (betadine 1ml and 100ml water freshly
made every morning) (1:100 mouthwashes after high-dose chemotherapy comprising
BEAM or HD-L-PAM), patients gargled 4 times a day
Outcomes Mucositis assessed once daily using the WHO grading on a scale of 0-4. Assessment
used: up to 28 days. Other reported outcomes: oral pain, tolerability of mouthwashes,
occurrence of infections, fever and oral microbiology in patients with clinical suspicion
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Vokurka 2005 (Continued)
of local infection
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “prospective, randomised, multi-
centre study”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
No Only patients were blinded to the treat-
ment allocation. Authors give no informa-
tion on who made up the solutions each
morning
Blinding?
Patients
Unclear Quote: “their composition was blinded to
the patients.”
Comment: normal saline versus povidone-
iodine. Likely that patientswould be able to
tell the difference between the treatments.
Presumably iodine solution would be or-
ange
Blinding?
Outcome assessors
Unclear Insufficient information to determine ’yes’
or ’no’.
Incomplete outcome data addressed?
All outcomes
Yes 132 patients recruited. 5 patients excluded.
Authors give reasons for attrition/ exclu-
sion, but do not state which arms patients
were allocated to
Free of selective reporting? Yes Data presented in percentages for grades of
mucositis for both arms of the study (fig 1)
, and for incidence of maximum mucositis
severity (fig 2/3)
Free of other bias? No Patients in the povidone group received sig-
nificantly more cycles of chemotherapy in
the year prior to ASCT than the normal
saline group (P = 0.01)
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Wahlin 1989
Methods Randomised, parallel group study conducted in Sweden. Clear information about with-
drawals: 4/14 control, 3/14 test. Dentist involved in study. Drop outs: 0%. Duration:
21 days
Participants Children and adults with acute leukaemia at start of chemotherapy. 28 patients enrolled,
14 patients completed (although mucositis data presented on 28)
Interventions 2 groups: no treatment versus chlorhexidine (0.2% 10 ml twice daily)
Outcomes Mucositis scored at the level of ulceration. Assessment used: day 28. Other reported
outcomes: candidiasis verified by detecting pseudohypae in smears, days fever, plaque,
gingival bleeding, burning sensation
Notes Funding source: government.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “28patientswere randomly divided
into 2 groups”.
Quote: “randomisation was performed by
means of the closed envelope method in
blocks of 6”
Comment: unclear if envelopes were shuf-
fled. Random component not described
Allocation concealment? Unclear Quote: “Closed envelope method”.
Comment: unclear if envelopes were se-
quentially numbered.
Blinding?
Carers
No Chlorhexidine versus no intervention. No
apparent blinding.
Blinding?
Patients
No Chlorhexidine versus no intervention. No
apparent blinding.
Blinding?
Outcome assessors
No Chlorhexidine versus no intervention. No
apparent blinding.
Incomplete outcome data addressed?
All outcomes
Unclear 28 patients randomised. Data from 7 pa-
tients excluded. 3/14 chlorhexidine, 4/14
control group. Authors give reasons for
withdrawals and exclusions
Free of selective reporting? Unclear Ulceration data presented for 17 patients
(table 4).
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Wahlin 1989 (Continued)
Free of other bias? No Blocked randomisation in an unblinded
study.
Wang 2002
Methods Randomised, parallel group study conducted in China. Unclear information about with-
drawals, although there appeared to be none. Dentist not involved in study. Drop outs:
0%. Duration: 1 week after course of chemotherapy
Participants Adults with solid cancer (breast, lung and lymphoma). CHOP for malignant lymphoma,
CMF for breast cancer and CAP for lung cancer. 147 eligible and enrolled, and with
data
Interventions 2 groups, Dobell’s solution as control (30 ml for 3 min, gargling 5 times per day). Con-
coction of Chinese medicine including 5 herbs (corktree bark, Chinese gaul, European
vebena herb, catechu, forsythia fruit) and borneol (sucked and gargled 5 times per day)
Outcomes Mucositis scored on 4-point scale. Time of healing ulcers.
Notes Funding source: none. All information is from translation from Chinese
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Intervention and control were different in
terms of colour, smell, and style of packag-
ing
Blinding?
Patients
No Intervention and control were different in
terms of colour, smell, and style of packag-
ing
Blinding?
Outcome assessors
Unclear Insufficient information to determine ’yes’
or ’no’.
Incomplete outcome data addressed?
All outcomes
Yes 147 patients randomised. No missing out-
come data.
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Wang 2002 (Continued)
Free of selective reporting? Unclear Data presented for 147 patients by grade
and arm. However, it is unclear over what
time interval
Free of other bias? No Risk of bias assessed from translation.
Watanabe 2010
Methods Randomised parallel group study conducted in Japan. Open study. No blinding. Clear
information about withdrawals: none
Participants 31 adults with head and neck cancer. Recruitment ran from January 2009 until October
2009. 21 patients received chemoradiotherapy. Remaining 9 patients received radiother-
apy only. Difference between arms non-significant
Interventions 2 groups. Polaprezinc (zinc-L-carnosine) granules (0.5 g dissolved in 20ml of 5% sodium
alginate solution) compared to azulene oral rinse (7 drops of 4% liquid in 100 ml water).
Patients rinsed with solution for 3 minutes 4 times daily. Polaprezinc solution swallowed
Outcomes Mucositis assessed weekly using Common Terminology Criteria for Adverse Events (CT-
CAE). Other reported outcomes: pain, xerostomia, taste disturbances, reduction in the
use of analgesics, number of patients experiencing inability to intake orally, reduction in
daily meals
Notes Funding source: no information (e-publication ahead of print)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ”randomly assigned“.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Quote: ”open trial”.
Comment: polaprezinc compared to azu-
lene control.
Blinding?
Patients
No Quote: “open trial”.
Comment: polaprezinc compared to azu-
lene control.
Blinding?
Outcome assessors
No Quote: ”open trial”.
Comment: polaprezinc compared to azu-
lene control.
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Watanabe 2010 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 31 patients recruited. Nomissing outcome
data.
Free of selective reporting? Yes Data presented for 31patients by treatment
arm and grade of mucositis
Free of other bias? No Baseline imbalance: mean serum creatinine
values lower in the control arm compared
to the polaprezinc arm (P = 0.006).
Wijers 2001
Methods Randomised, parallel group study conducted in The Netherlands. Unclear information
about withdrawals. Dentist involvement unclear. Drop outs: 32%. Duration: 3 weeks
after radiation
Participants Adults with head and neck cancer. 114 patients enrolled, 37 refused to continue, 77
completed
Interventions 2 groups, placebo versus PTA paste containing antibiotics, polymyxin E, tobramycin,
amphotericin
Outcomes Mucositis scored weekly, 5 point scale, Van der Schneren system. Assessment used: day
28 min. Other reported outcomes: pain, microflora
Notes Funding source: unclear.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised to PTA
or placebo paste”.
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Carers
Unclear Insufficient information to determine ‘yes’
or ‘no’.
Blinding?
Patients
Yes Quote: “double blind”.
Comment: probably done.
Blinding?
Outcome assessors
Yes Quote: “double blind”.
Comment: probably done.
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Wijers 2001 (Continued)
Incomplete outcome data addressed?
All outcomes
Unclear 114 patients randomised. 37 patients with-
drewduring the first 4weeks of the trial (32.
5%). Authors give incomplete randomisa-
tion and withdrawal information. 77 pa-
tients included in efficacy analysis
Free of selective reporting? Yes Data presented for mucositis grade at week
4 (77 patients) by grade for both groups
(table 2). Authors also present data for max
mucositis grade and moment of max mu-
cositis grade (table 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
Wu 2009
Methods Randomised, parallel group study conducted in Korea between January 2007 and August
2007. Unclear if dentist involved in study. Withdrawal information included
Participants Adults with head and neck cancer receiving radiotherapy. 116 patients were screened. 3
refused to participate, 113were randomised. 13 patients dropped out before the 5thweek
of radiotherapy so the endpoint evaluation was only done on 100 patients, 6 because of
interruption of radiotherapy formore than 2 consecutive days, 3 for receiving prohibitive
drug treatments, 2 for refusal to participate, 1 because of adverse effects of radiotherapy,
1 for not being treated with the test drug
Interventions Patients were randomised to 1 of 4 arms: placebo, epidermal growth factor 10 µg/mL,
50 µg/mL or 100 µg/mL. Epidermal growth factor and placebo both administered as
a spray over the entire oral mucosa, twice daily with patients swallowing the residual.
Treatment from day 1 to day 5 of radiotherapy
Outcomes Mucositis scored weekly using RTOG scoring criteria. Assessment used: day 28. Other
reported outcomes:WHOoral toxicity grade, patient weight, pain score, opioid analgesia
use and time to develop mucositis
Notes Funding source: grant from the National R&D Program for Cancer Central, Ministry
of Health, Welfare and Family Affairs, Republic of Korea
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “We randomised patients to insti-
tution and concurrent use of chemother-
apy”
Comment: random component not de-
scribed.
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Wu 2009 (Continued)
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Quote: “double blind”.
Comment: possible patient knowledge of
allocation. Therefore all blinding deemed
inadequate
Blinding?
Patients
No Quote: “double blind”.
Comment: authors state that 1 patient
dropped out because they were not ran-
domised to the test drug. Patient knowl-
edge of allocation. Therefore blinding
judged to be inadequate
Blinding?
Outcome assessors
No Quote: “double blind”.
Comment: possible patient knowledge of
allocation. Therefore all blinding deemed
inadequate
Incomplete outcome data addressed?
All outcomes
Yes 70 patients randomised (1/28 control
group, 3/29 10 µg/mL arm, 3/29 50 µg/
mL arm, 5/27 100 µg/mL arm). No miss-
ing outcome data
Free of selective reporting? Unclear Data presented in text for percentage of pa-
tients with oral mucositis > RTOG grade
3. Data also presented for average grade of
mucositis by week for patient treated with
50 mg/mL compared with placebo (fig 4)
Free of other bias? Yes Study appears to be free of other sources of
bias.
You 2009
Methods Randomised, parallel group study conducted in Taiwan. Clear information about with-
drawals. Unclear if dentist involved in study. Drop outs: 9%. Duration: 1 week after
course of chemotherapy
Participants Adults with head and neck cancer receiving radiotherapy. 22 patients randomised to 2
groups enrolled between October 2005 and May 2006. 2 patients in control withdrew
due to refusal to give blood sample
Interventions 2 groups, saline and indigo wood root (IR) (Isatis indigotica called Ban-Lan-Gen in
Chinese is a medicinal plant belonging to the Brassicacaee family). Patients gargled with
30-mL solution of either saline or IR for 3 minutes and then swallowed before meals
daily
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You 2009 (Continued)
Outcomes Mucositis scored on 4-point scale. Time of healing ulcers. Also reported difficulty swal-
lowing, anorexia, rest from treatment, blood changes
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were sequentially ran-
domised into two treatment arms: (I) in-
digowood root group: 0.5g IR powder in
30mL double distilled water; (II) Control
group: placebo with 30mL normal saline”
Comment: random component not de-
scribed.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Patients
Unclear Indigo wood root or placebo. No apparent
blinding.
Blinding?
Outcome assessors
Unclear Indigo wood root or placebo. No apparent
blinding.
Incomplete outcome data addressed?
All outcomes
Yes 22 patients were randomised. 2 patients
withdrew from the placebo group. 20 pa-
tients included in analysis.
Free of selective reporting? Yes Data presented for 20 patients for mucosi-
tis incidence by arm and treatment
Free of other bias? No All Chinesemedicine RCTs are now a cause
for concern in light of the findings of Taix-
iang et al 2007
Yuen 2001
Methods Randomised, parallel group study conducted in Hong Kong. Clear information on
withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 60
days after BMT
Participants Adults withmixed cancer receivingBMT, 70 enrolled betweenOctober 1996 to February
1998. 70 evaluated
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Yuen 2001 (Continued)
Interventions 2 groups no treatment versus clarithromycin oral 500 mg twice daily or IV 500 mg 12
hourly. Start day -7
Outcomes Mucositis scoring system not clear. Grade 2 data used. Assessment used: unclear. Other
reported outcomes: toxicity (rash, diarrhoea, liver function), infection, duration of fever,
neutropenic fever, use of antibiotics, parenteral nutrition, growth factors
Notes Funding source: none.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “The 70 patients were randomly di-
vided into 2 subgroups by computer”
Comment: computer generated randomi-
sation.
Allocation concealment? Unclear Insufficient information to determine ’yes’
or ’no’.
Blinding?
Carers
No Quote: “open-label”.
Comment: no blinding.
Blinding?
Patients
No Quote: “open-label”.
Comment: no blinding.
Blinding?
Outcome assessors
No Quote: “open-label”.
Comment: no blinding.
Incomplete outcome data addressed?
All outcomes
Yes 70 patients randomised. No missing out-
come data.
Free of selective reporting? Unclear Data presented for grade 0-1 and grade 2
mucositis (table 2)
Free of other bias? Yes Study appears to be free of other sources of
bias.
ASTC = autologous stem cell transplantation
BMT = bone marrow transplant
EORTC = European Organization for Research and Treatment of Oral Cancer
GI = glycaemic index
GM-CSF = granulocyte/macrophage colony-stimulating factor
GVHD = graft-versus-host disease
HSCT = haematopoietic stem cell transplant
HSV = herpes simplex virus
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ITT = intention-to-treat analysis
IV = intravenous
KGF = keratinocyte growth factor
NCI CTC = National Cancer Institute Common Toxicity Criteria
OAG = oral assessment guide
OM = oral mucositis
OMAS = oral mucosa assessment scale
OMS = objective mucositis score
ROB = risk of bias
RT = radiotherapy
RTOG = Radiation Therapy Oncology Group
SD = standard deviation
SOC = standard oral care
TBI = total body irradiation
TPN = total parenteral nutrition
UOM = ulcerative oral mucositis
VAS = visual analogue scale
WBC - white blood count
WHO = World Health Organization
5-FU = 5-fluorouracil
(c) indicates from correspondence with authors.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abramoff 2008 Patients considered new case and re-randomised for each CT cycle (laser versus no treatment)
Aisa 2005 Not RCT (cryotherapy).
Altmann 1999 Not RCT (amifostine).
Andersen 1987 Cancer treatments comparing toxic effects.
Anderson 1998b Mucositis at baseline in some patients (glutamine versus placebo)
Antin 2002 Study stopped early due to adverse event triggering preset stopping rule - data only for 10 patients in
rhIL group and 3 placebo (rhIL-11 versus placebo)
Antonadou 1998 Abstract, insufficient information (radiotherapy with or without GM-CSF)
Apaydin 1996 Unclear whether allocation is randomised.
Aquino 2005 Composite score for mucositis including teeth with plaque (Walsh). Unable to use mucositis outcome
outcomes (oral glutamine)
Ardizzoni 2002 Cancer treatments comparing toxic effects and confounded by cancer (G-CSF)
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(Continued)
Arora 2008 Not RCT (laser).
Awada 2002 Cancer treatment comparing toxic effects.
Awada 2004 Not RCT (temozolomide plus liposomal doxorubicin).
Awidi 2001 Episodes not patients. Type of cross-over study but some patients were included in more than 2 ’courses’
(pilocarpine versus placebo)
Awwad 2002 Cancer treatments comparing toxic effects (conventional fractionation versus accelerated hyperfraction-
ation radiotherapy)
Barasch 1995 As patients had already received some chemotherapy before intervention started, some patients, but not
all, have some mucositis. The trial is therefore a combination of prevention and treatment (He-Ne laser
versus no treatment)
Baydar 2005 Not RCT (cryotherapy).
Bensadoun 2006 Comparison of different cancer treatment regimens, not primary outcome
Bentzen 2001 Comparing different chemotherapy regimens.
Bleehen 1996 Different chemotherapy regimens.
Bourhis 2006 Comparing 2 radiotherapy regimens but looking at toxicity.
Braaksma 2002 Email sent to author requesting further information; no reply received by March 2011
Buentzel 1999 Abstract - insufficient information (amifostine).
Calais 2000 Trial of cancer treatments.
Calais 2004 Not RCT (chemotherapy).
Cassidy 2002 Cancer treatments comparing toxic effects.
Castro 2009 Abstract.
Cella 2003 Emailed authors Nov 17 2010 requesting data to include this study in review. Authors replied stating
that data held by pharma company and no longer available
Cheng 2001 Not RCT (oral care protocol).
Cheng 2002 Not RCT (oral care protocol).
Cheng 2006 Grade 2 mucositis was an exclusion criteria. However, unclear how many patients had grade 1 mucositis
at baseline. Email sent to authors. No reply
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(Continued)
Clarke 2001 Abstract, insufficient information (rHuKGF).
Colella 2010 Open non-randomised trial.
Collova 2004 Abstract - insufficient information.
Colombat 1995 Abstract - insufficient information (fluconazole versus amphotericin B)
Costa 1999 Abstract, not RCT (chlorhexidine versus no treatment).
Costa 2003 Not RCT (chlorhexidine versus control).
Cowen 1997 Daily mucositis index used and summed across all categories (including voice, saliva). A cumulative oral
mucositis score generated for both nursing and patient assessments was used and categorised into a 0-3
mucositis scale. Daily mucositis index ranging from 0-48 used, with means (SD) presented but excluded
as composite scale (He-Ne laser versus no treatment)
Cunningham 1995 Investigating new cancer treatment, tomudex, with oral mucositis as one of the minor side effects
Damon 2004 Trial investigating 2 different methods of administering etoposide
De Boer 2002 Cancer treatments comparing toxic effects (conventional versus accelerated infusional chemotherapy)
Denham 1999 Cancer treatments comparing toxic effects (conventional versus accelerated fractionation)
Djuric 2006 Some mucositis present at baseline.
Dobrowsky 1998 Added to speed up radiotherapy, not radio-protection-toxic (mitomycin)
Doroshow 1987 Cancer treatments comparing toxic effects.
Dreicer 1997 Not RCT(edatrexate).
Dudjak 1987 Uses Beck’s OAG mucositis score (includes ability to swallow, saliva, diet and patient ability to self care)
(2 oral care protocols)
Edelman 1998 Not RCT (cryotherapy).
Eisen 2003 Not RCT (valacyclovir versus acyclovir).
El-Sayed 2002a Not RCT (antimicrobial lozenge).
Epstein 1992 Sum of composite self-reported scale including mouth pain and its effect on oral intake, and the absence
or presence of stomatitis. Unable to use in review (3 groups: chlorhexidine rinse, nystatin suspension
and saline solution)
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(Continued)
Erkisi 1996 Patients randomised to different cancer treatments and where given G-CSF when clinically indicated,
not randomly allocated (G-CSF versus no treatment)
Erlichman 1988 Comparing different chemotherapy regimens.
Etiz 2000 Multicomponent scale of mucositis including pain, dysphasia and use of systemic analgesics (sucralfate
versus placebo)
Ezzat 2005 Comparing 3 different radiotherapy regimens, survival not mucositis is primary outcome
Fahlke 1999 Not RCT (amifostine).
Falcone 2001 Comparing different radiotherapy regimens.
Fay 1994 Not RCT (GM-CSF).
Feber 1995 Oral assessment guide not just mucositis but includes plaque and voice changes (hydrogen peroxide
versus sodium chloride rinses)
Feber 1996 Oral assessment guide not just mucositis but includes plaque and voice changes (2 oral care protocols)
Ferreira 2004 Email sent to authors Nov 2010 requesting sufficient information to include study in this review. No
reply received March 2011
Ferretti 1990 Patients had mucositis at baseline.
Foncuberta 2001 Patients assigned sequentially not RCT (GF-B3).
Gabison 1995 Abstract - insufficient information (zinc picolinate).
Gandara 1997 Not RCT (edatrexate).
Genot-Klastersky 2008 Some patients had grade 1 mucositis in prevention trial (laser versus placebo)
Ghoreishi 2007 Email sent to authors Nov 2010 requesting further information to enable this study to be included. No
reply received by March 2011
Giles 2003a Comparing chemotherapy regimens not mucositis interventions.
Giles 2003b Cancer treatment toxicity (troxacitabine).
Gladkov 2007 Comparing different radio-chemo regimes for oral cancer.
Goldberg 2003 Abstract - insufficient information (en3247).
Gordon 1993 Abstract, insufficient information (GM-CSF).
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(Continued)
Grotz 2001 Index not in suitable form. Total RTOG scores including salivary glands, mucosa, skin (comarin/trox-
erutine versus placebo)
Gutierrez 1996 Not RCT (fluconazole).
Harris 1995 Abstract, insufficient information (folinic acid mouthwash versus placebo)
He 2004 Abstract - insufficient information (amifostine).
Hickey 1982 Problems with data. 21 patients in total, unclear how many patients per group, but data presented as 67
courses of chemotherapy (oral hygiene protocols)
Horsley 2007 Not RCT (keratinocyte).
Howell 1983 Unclear if randomised. Cross-over study provided 59 paired course of treatment in 23 patients (allop-
urinol)
Hu 2003 Not RCT (amifostine).
Hunter 2007 Not RCT. This study combines patients who were in cohorts with increasing doses of mouthrinse to
assess safety, with an RCT (ATL-104 mouthwash versus placebo)
Hwang 2004 Email sent to authors Nov 2010 requesting further details concerning this study. No reply was received
by March 2011
Inagaki 2006 Not RCT (cryotherapy).
Ito 2002 Not RCT (allopurinol spray).
Jebb 1995 Index of mucositis had multiple components other than mucositis (glutamine versus placebo)
Jham 2007 Study for prevention of xerostomia (bethanechol versus saliva supplement)
Johnson 2002 Not RCT (prostaglandin e1).
Ju 2009 Quasi-randomised study. Patients alternatively allocated to intervention and placebo
Kante 1995 Abstract - insufficient information (oral care regimens).
Karacetin 2004 Patients were ’randomised’ to intervention or control according to file number (amifostine versus no
treatment)
Karthaus 1998 Problems with the data. 8 patients, 32 chemo cycles and results presented assuming independent (G-
CSF versus placebo)
Kenny 1990 Oral assessment guide not only mucositis but includes plaque and voice changes (2 oral care protocols)
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(Continued)
Khouri 2009 Quasi-randomised study. Patients allocated to intervention and placebo alternatively based on date of
hospitalisation
Klocke 2006 Abstract - insufficient information.
Kuhn 2009 Children had mucositis grades 2+ on entry into trial.
Kuriakose 2002 Not RCT (edatrexate).
Labbate 2003 Not RCT.
Lanzos 2010 7 patients had mucositis at baseline (including 2 patients with grade 4 mucositis)
Lavendag 1998 Abstract, insufficient information (polyenes versus placebo)
Le 2008 Abstract (keratinocyte growth factor).
Lee 1989 Intervention given as part of cancer treatment, not to prevent mucositis
Leong 1995 Abstract, insufficient information (thymidine versus no treatment)
Levi 1997 Comparison of 2 cancer treatments where the primary outcome was maximum tumour response to
therapy
Loo 2010 130 of the 139 patients recruited into the study had mucositis at baseline
Lopez 1994 Data presented as number of days patients suffered for each grade of mucositis. Cannot be used in meta-
analysis unless we obtain further information from authors. Unable to contact authors
Lopez-Campo 2004 Abstract only. Insufficient information to include in review. No subsequent publication identified (March
2011)
Lorusso 2003 Episodes not patients considered in analysis (amifostine).
Lozada 1998 Abstract with insufficent information given (pilocarpine).
Luglié 2002 Not RCT.
Maddocks-Jennings 2009 Not RCT (alternate allocation and if patient could not gargle they were re-allocated to other groups)
(essential oils)
Madero 1999 No response to query whether patients were randomised to groups (rhGM-CFS)
Mahmoud 1996 Comparison of 2 cancer treatments where the primary outcome was survival (folinic acid)
Malaker 1991 Not RCT (B-Carotene retinoic acid).
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(Continued)
Mantovani 2003 Not randomised.
Marcial 1994 Abstract, insufficient information. It states it is an RCT but mentions historical control group (low
energy laser versus no treatment)
Martin 2006 Not RCT (G-CSF).
Masucci 2005 Treatment of mucositis not prevention.
Matejka 1990 Not RCT (prostaglandin E2).
McIlroy 1996 Scoring system incorporated visible signs of mucositis with pain dysphasia and weight loss. Qualitative
assessment with no data given (polyenes versus placebo)
Merte 1999 Abstract (German).
Mills 1995 Not RCT.
Mori 2006 Not RCT (cryotherapy).
Nicolatou-Galitis 2006 Not an RCT. Patients who received the intervention were compared to a control cohort
Niibe 1985 Report in Japanese. Translator describes outcome as oral mucous symptoms, time of assessment unclear
(based on radiation dose delivered) and reported as percentages per group with no denominators or
estimate of precision. Insufficient information to include and study to old to be able to contact authors
(amifostine versus placebo)
Nikoletti 2005 Cross-over study, some doubt as to whether patients had any mucositis at baseline and outcomes used
OAG assessment scale which is an exclusion criterion for this review
Okuno 1997 Major change to protocol half way through study (antibiotic lozenge versus placebo). Data from blinded
and unblinded patients combined. Chlorhexidine for first part included as study by Foote 1994. Data
from first part comparing antibiotic lozenge with placebo mouthrinse have not been included as we feel
this is an inappropriate control
Okutomi 2000 Not RCT (Z-100 injections).
Papadeas 2007 CCT (cryotherapy).
Papas 1984 Abstract (patient management system).
Papas 2003 The interventions were calcium phosphate rinses plus fluoride tray applications versus fluoride rinses +
placebo tray applications. The individual interventions were confounded
Penpattanagul 2007 Not RCT. “Patients were assigned to their treatment groups at the discretion of the investigator with an
attempt to achieve equal distribution of patient demographics.”
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Peters 1993 CCT. Paper states “Randomisation procedure was done according to day of birth.”
Phillips 2002 Not RCT (amifostine).
Piccirillo 2003 Excluded as mucositis index inappropriate for review. Mucositis index included pain and difficulty in
swallowing (response from authors)
Pouli 1999 Abstract, insufficient information (GM-CSF versus sodium bicarbonate mouthwash)
Prada 1985 Mucositis present at baseline (benzydamine versus placebo mouthwash)
Putwatana 2009 Quasi-randomised trial. Patients allocated to the intervention (glycerin payayor) or control (benzy-
damine) by alternative allocation
Pyrhonen 1995 Mucositis not primary outcome. Only presents data for test arm as adverse event (chemotherapy agents)
Pytlik 2002 Inappropriate mucositis index includes voice quality and teeth (glutamine versus placebo)
Rabinovitch 2006 Trial of radiotherapy for head and neck cancer looking at cancer treatment
Rades 2004 Study halted when preset stopping rules were triggered due to adverse effects of amifostine. Nomucositis
outcomes reported (amifostine)
Radmard 2002 Abstract - insufficient information (rhGM-CSF).
Raether 1989 Average mucosal rating presented without standard deviation. Cannot be used in meta-analysis unless
we obtain further information from authors. Unable to contact authors
Robustelli 1999 Abstract - insufficient information (galenic preparation).
Rocci 2005 Not eligible since it is not dealing with prevention or treatment of mucositis, but uses mucositis to
measure side effect of 2 different ways to deliver an antitumoural drug for the treatment of gastrointestinal
tumours
Rojas 2001 Episodes not patients.
Rothwell 1990 Mucositis scores presented as means. Oral screening tool includes moniliasis (candidiasis)
Rutkauskas 1993 No data for mucositis presented by randomised group, just line graph of all patients with no P values
(chlorhexidine versus placebo)
Ryu 2007 6% of patients had oral mucositis at baseline.
Samaranayake 1988 Average mucosal rating presented without standard deviation. Cannot be used in meta-analysis unless
we obtain further information from authors. Unable to contact authors
Sato 1997 Unsure if RCT and author has not responded to letter requesting further information
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(Continued)
Sato 2006 Not RCT (cryotherapy).
Schuster 2008 Not RCT (velafermin).
Schwerkoske 1999 Abstract, insufficient information (rhIL11).
Shabanloei 2009 Quasi-randomised study. “Patients selected based on their ID code and by choosing from the box and
were divided into three groups.”
Sharma 2009 Abstract.
Shea 2007 Abstracts only, insufficient information (palifermin).
Shidfar 2008 Abstract.
Simoes 2009 Not RCT (laser).
Spadaro 1991 Abstract, insufficient information (vitamin E + vitamin A + fluconazole versus no treatment)
Spielberger 2001 Abstract, insufficient information (keratinocyte).
Stokman 2004 Not RCT. This was a cross-over study but not randomised. All patients had control cycle first
Teshima 1986 Japanese paper. Unclear information as to whether this was randomised. Written to authors but no reply
Thieblemont 2002 Not RCT.
Throuvalas 1995 Abstract, probably not RCT described as comparative study (GM-CSF)
Tiemann 2006 Not RCT (herbs).
Toubai 2003 Probably not RCT, only 12 patients in total? (itraconazole).
Uchiyama 2005 Not RCT.
Valcarcel 2002 Participants had mucositis at baseline.
Valcárcel 1997 Abstract - insufficient information (thymostimulin).
van Zaanen 1994 Patients randomised per treatment cycle, 15 patients and 20 treatments cycles. Patients randomised up
to 3 times, data treated as independent but not reported per patient (glutamine + TPN versus standard
TPN)
Verdi 1995 Mucositis measured by OAG which includes teeth. Only in 10 patients (pentoxifylline versus placebo)
Vesole 1999 Abstract insufficient information (IB-367).
Villar 2009 Abstract.
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(Continued)
Vitello 2000 Abstract, insufficient information (lidocaine versus dyclone mouthrinses)
Wagner 2002 Abstract for treatment of mucositis review (GM-CSF).
Wang 2002a Not RCT.
Ward 2007 CCT (glutamine).
Warde 2002 Maximal toxicity during treatment presented as percentages. Cannot be used in meta-analysis unless we
obtain further information from authors. Email sent 17 Nov 2010, no reply received by March 2011
Weisdorf 1989 Outcome data presented as graph with standard deviations. Cannot be used in meta-analysis unless we
obtain further information from authors. Unable to contact authors
Weiss 1990 Not randomised. Cross-over trial and data in wrong form for review (allopurinol)
Whelan 2002 Not RCT.
Whelan 2004 Not RCT (from author).
Wollina 2002 Not RCT (dexpanthenol).
Wymenga 1999 Not RCT (TGF-B3 mouthrinse versus no treatment).
Yokomizo 2004 Not RCT.
Zanin 2010 Mucositis data presented as mean values. Unclear if randomised. Authors contacted - no reply
CCT = controlled clinical trial; CT = chemotherapy; RCT = randomised controlled trial; SD = standard deviation.
Characteristics of studies awaiting assessment [ordered by study ID]
Cheng 2003
Methods Randomised cross-over comparison of chlorhexidine versus benzydamine oral care protocols
Participants Children aged 6-17 undergoing chemotherapy recruited between April 2000 and April 2001
Interventions 2 groups, oral care protocol based on chlorhexidine mouthrinse twice daily during chemotherapy compared to an
oral care protocol based on benzydamine twice daily
Outcomes WHO mucositis scores, oral symptoms (eating, chewing, swallowing, speaking, mouth dryness on VAS scale), pain,
use of analgesics, concomitant medications
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Cheng 2003 (Continued)
Notes 3 publications relating to the same study. Unclear whether any patients had oral mucositis at baseline. Email sent to
authors requesting clarification
de Koning 2007
Methods Randomised, cross-over study conducted in The Netherlands.
Participants Children with haematological malignancies receiving chemotherapy
Interventions 2 groups, placebo feeds versus TGF-2 enriched feeds (dose dependant on patient weight)
Outcomes Mucositis assessed daily using the WHO scale. Other reported outcomes: diarrhoea, pain, use of analgesics, admin-
istration of antibiotics, frequency of blood cultures
Notes Discrepancy between data presented in tables 2 & 3 in the paper. Awaiting clarification of data from authors
Grzegorczyk 2006
Methods Randomised, parallel group study conducted in Poland.
Participants Adults undergoing stem cell transplantation.
Interventions 2 groups, placebo (methylcellulose) versus G-CSF (300 µg in 2% methylcellulose)
Outcomes Mucositis assessed using the WHO score. Other reported outcomes: granulocytes, patient report of pain
Notes Translation provided insufficient information. Discrepancy between graph legends and descriptions. Awaiting more
information from translators
Jellema 2006
Methods Randomised, parallel group study conducted in The Netherlands. Clear information about withdrawals: 0. Unclear
if dentist involved in study. Recruitment took place between August 1999 and August 2003
Participants Adults with head and neck cancer undergoing radiotherapy.
Interventions 3 groups, no treatment control versus amifostine (200 mg/m2) 5 times weekly versus amifostine (200 mg/m2) 3
times weekly. Amifostine administered 15-30 minutes before irradiation
Outcomes Unclear how mucositis was assessed. Other reported outcomes: xerostomia, patient quality of life, sticky saliva,
locoregional control and survival
Notes Discrepancy between legend for Figure 2 and the text in this paper. Email sent. Awaiting clarification from authors
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Peterson 2007
Methods Randomised, multicentre cross-over study conducted in Russia. Dentist involved in study. Duration: randomised to
glutamine versus placebo in cycle 1 and then crossed over to alternative treatment in cycle 2
Participants Adults with breast cancer receiving chemotherapy.
Interventions Glutamine versus placebo.
Outcomes Mucositis on OMAS scale. Mean score calculated as mean ulceration score across all sites. Mean erythema score
similarly calculated. Also WHO score assessed. Other outcomes: nausea, vomiting, dry mouth
Notes Eligible if experienced WHO mucositis > 2 during screening cycle. Percentage of patients with WHO scores > 2
presented 1 to 21 days in graph for each group during cycle 1. Significant carry-over effect from cycle 1 to cycle 2.
Need to obtain further information from authors
Wu 2010
Methods Randomised, parallel group study conducted in China. Recruited between February 2006 and May 2007
Participants Patients with nasopharyngeal carcinoma undergoing chemoradiotherapy
Interventions 3 groups; actovegin from start of chemo, actovegin from time of grade 2 mucositis, versus no treatment
Outcomes NCI-CTC mucositis scale, pain, weight loss, adverse events.
Notes Full text paper published October 2010. To be included in next update
BMT = bone marrow transplant; G-CSF = granulocyte colony-stimulating factor; NCI-CTC = National Cancer Institute - Common
Toxicity Criteria; OMAS = oral mucosa assessment scale; RT = radiotherapy; RTOG = Radiation Therapy Oncology Group; VAS
= visual analogue scale; WHO = World Health Organization.
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D A T A A N D A N A L Y S E S
Comparison 1. Allopurinol versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 4 Risk Ratio (Random, 95% CI) 0.77 [0.50, 1.19]
2 Mucositis (moderate plus severe) 2 54 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.50, 0.86]
3 Mucositis (severe) 2 54 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.63, 1.04]
Comparison 2. Aloe vera versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (moderate plus severe) 2 119 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.58, 0.96]
Comparison 3. Amifostine versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 3 430 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.91, 0.99]
2 Mucositis (moderate plus severe) 6 757 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.58, 0.96]
3 Mucositis (severe) 9 845 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.45, 1.03]
Comparison 4. Chlorhexidine versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 4 454 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.47, 1.24]
2 Mucositis (moderate plus severe) 3 233 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.72, 1.21]
3 Mucositis (severe) 4 244 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.54, 1.23]
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Comparison 5. Cryotherapy versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 5 Risk Ratio (Random, 95% CI) 0.74 [0.57, 0.95]
2 Mucositis (moderate plus severe) 5 Risk Ratio (Random, 95% CI) 0.53 [0.31, 0.91]
3 Mucositis (severe) 5 Risk Ratio (Random, 95% CI) 0.36 [0.17, 0.77]
Comparison 6. Glutamine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 6 Risk Ratio (Random, 95% CI) Subtotals only
1.1 Oral
suspension/supplementation
5 Risk Ratio (Random, 95% CI) 0.78 [0.57, 1.08]
1.2 IV supplementation 1 Risk Ratio (Random, 95% CI) 0.33 [0.04, 2.63]
2 Mucositis (moderate plus severe) 6 Risk Ratio (Random, 95% CI) Subtotals only
2.1 Oral
suspension/supplementation
5 Risk Ratio (Random, 95% CI) 0.88 [0.69, 1.12]
2.2 IV supplementation 1 Risk Ratio (Random, 95% CI) 0.33 [0.04, 2.63]
3 Mucositis (severe) 8 Risk Ratio (Random, 95% CI) Subtotals only
3.1 Oral
suspension/supplementation
5 Risk Ratio (Random, 95% CI) 0.69 [0.37, 1.29]
3.2 IV supplementation 3 Risk Ratio (Random, 95% CI) 0.25 [0.10, 0.62]
Comparison 7. G-CSF versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 4 263 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.48, 1.23]
2 Mucositis (severe) 2 54 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.15, 0.86]
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Comparison 8. GM-CSF versus no treatment/placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 2 119 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.84, 1.04]
2 Mucositis (moderate plus severe) 2 138 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.76, 1.05]
3 Mucositis (severe) 6 373 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.39, 1.40]
Comparison 9. Honey versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 3 120 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.56, 0.88]
2 Mucositis (moderate plus severe) 2 80 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.31, 0.74]
3 Mucositis (severe) 2 80 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.13, 0.52]
Comparison 10. Hydrolytic enzymes versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Mucositis (moderate plus severe) 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 11. Iseganan versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (moderate plus severe) 2 926 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.89, 1.03]
2 Mucositis (severe) 2 926 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.89, 1.10]
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Comparison 12. Keratinocyte GF versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 2 160 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.71, 0.94]
2 Mucositis (moderate plus severe) 7 640 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.62, 0.89]
3 Mucositis (severe) 6 559 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.58, 0.90]
Comparison 13. Laser versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 3 131 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.71, 1.17]
2 Mucositis (moderate plus severe) 2 97 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.38, 1.08]
3 Mucositis (severe) 2 97 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.06, 0.62]
Comparison 14. Pilocarpine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 2 276 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [1.00, 1.10]
2 Mucositis (moderate plus severe) 2 276 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.94, 1.16]
Comparison 15. Povidone versus water
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 2 172 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.76, 1.08]
2 Mucositis (moderate plus severe) 2 172 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.62, 1.10]
3 Mucositis (severe) 2 172 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.40, 1.06]
231Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 16. Prostaglandin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 3 159 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.94, 1.12]
2 Mucositis (severe) 2 143 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.72, 1.43]
Comparison 17. PTA antibiotic pastille or paste versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 2 298 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.78, 0.96]
2 Mucositis (severe) 2 135 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.66, 1.09]
Comparison 18. Radiotherapy: am versus pm
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (severe) 2 382 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.85, 1.36]
Comparison 19. Sucralfate versus placebo/usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mucositis (any) 3 222 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.88, 1.10]
2 Mucositis (moderate plus severe) 4 164 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.54, 1.04]
3 Mucositis (severe) 7 Risk Ratio (Random, 95% CI) 0.67 [0.48, 0.92]
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Analysis 1.1. Comparison 1 Allopurinol versus placebo/no treatment, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 1 Allopurinol versus placebo/no treatment
Outcome: 1 Mucositis (any)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Dozono 1989 -1.2518 (0.463) 15.1 % 0.29 [ 0.12, 0.71 ]
Loprinzi 1990 0.167 (0.205) 31.6 % 1.18 [ 0.79, 1.77 ]
Abbasi-Nazari 2007 -0.14 (0.13) 37.7 % 0.87 [ 0.67, 1.12 ]
Panahi 2009 -0.46 (0.45) 15.6 % 0.63 [ 0.26, 1.52 ]
Total (95% CI) 100.0 % 0.77 [ 0.50, 1.19 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 8.51, df = 3 (P = 0.04); I2 =65%
Test for overall effect: Z = 1.17 (P = 0.24)
0.1 0.2 0.5 1 2 5 10
Favours allopurinol Favours control
Analysis 1.2. Comparison 1 Allopurinol versus placebo/no treatment, Outcome 2 Mucositis (moderate plus
severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 1 Allopurinol versus placebo/no treatment
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Allopurinol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abbasi-Nazari 2007 5/14 10/10 43.9 % 0.38 [ 0.20, 0.76 ]
Panahi 2009 13/15 15/15 56.1 % 0.87 [ 0.69, 1.09 ]
Total (95% CI) 29 25 100.0 % 0.66 [ 0.50, 0.86 ]
Total events: 18 (Allopurinol), 25 (Control)
Heterogeneity: Chi2 = 8.24, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 3.03 (P = 0.0024)
0.01 0.1 1 10 100
Favours allopurinol Favours control
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Analysis 1.3. Comparison 1 Allopurinol versus placebo/no treatment, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 1 Allopurinol versus placebo/no treatment
Outcome: 3 Mucositis (severe)
Study or subgroup Allopurinol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abbasi-Nazari 2007 1/14 4/10 23.1 % 0.18 [ 0.02, 1.37 ]
Panahi 2009 15/15 15/15 76.9 % 1.00 [ 0.88, 1.13 ]
Total (95% CI) 29 25 100.0 % 0.81 [ 0.63, 1.04 ]
Total events: 16 (Allopurinol), 19 (Control)
Heterogeneity: Chi2 = 13.14, df = 1 (P = 0.00029); I2 =92%
Test for overall effect: Z = 1.68 (P = 0.092)
0.01 0.1 1 10 100
Favours allopurinol Favours control
Analysis 2.1. Comparison 2 Aloe vera versus placebo, Outcome 1 Mucositis (moderate plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 2 Aloe vera versus placebo
Outcome: 1 Mucositis (moderate plus severe)
Study or subgroup Aloe vera Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Su 2004 18/28 21/30 43.3 % 0.92 [ 0.64, 1.32 ]
Puataweepong 2009 16/30 27/31 56.7 % 0.61 [ 0.43, 0.88 ]
Total (95% CI) 58 61 100.0 % 0.74 [ 0.58, 0.96 ]
Total events: 34 (Aloe vera), 48 (Control)
Heterogeneity: Chi2 = 2.42, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 2.27 (P = 0.023)
0.1 0.2 0.5 1 2 5 10
Favours aloe vera Favours control
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Analysis 3.1. Comparison 3 Amifostine versus placebo/no treatment, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 3 Amifostine versus placebo/no treatment
Outcome: 1 Mucositis (any)
Study or subgroup Amifostine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Buntzel 1998 23/25 14/14 6.0 % 0.94 [ 0.80, 1.09 ]
Brizel 2000 140/148 152/153 89.6 % 0.95 [ 0.91, 0.99 ]
Spencer 2005 34/43 42/47 4.4 % 0.88 [ 0.74, 1.06 ]
Total (95% CI) 216 214 100.0 % 0.95 [ 0.91, 0.99 ]
Total events: 197 (Amifostine), 208 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.72 (P = 0.0065)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours amifostine Favours control
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Analysis 3.2. Comparison 3 Amifostine versus placebo/no treatment, Outcome 2 Mucositis (moderate plus
severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 3 Amifostine versus placebo/no treatment
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Amifostine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Koukourakis 2000 12/60 38/70 11.2 % 0.37 [ 0.21, 0.64 ]
Brizel 2000 116/148 130/153 24.4 % 0.92 [ 0.83, 1.03 ]
Antonadou 2002 19/22 23/23 22.5 % 0.87 [ 0.72, 1.04 ]
Spencer 2005 19/43 32/47 15.6 % 0.65 [ 0.44, 0.96 ]
Veerasarn 2006 4/32 14/30 4.9 % 0.27 [ 0.10, 0.72 ]
Buentzel 2006 47/65 45/64 21.3 % 1.03 [ 0.83, 1.28 ]
Total (95% CI) 370 387 100.0 % 0.75 [ 0.58, 0.96 ]
Total events: 217 (Amifostine), 282 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 25.86, df = 5 (P = 0.00010); I2 =81%
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours amifostine Favours control
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Analysis 3.3. Comparison 3 Amifostine versus placebo/no treatment, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 3 Amifostine versus placebo/no treatment
Outcome: 3 Mucositis (severe)
Study or subgroup Amifostine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Buntzel 1998 0/14 12/14 2.0 % 0.04 [ 0.00, 0.62 ]
Bourhis 2000 11/12 11/12 17.2 % 1.00 [ 0.79, 1.27 ]
Koukourakis 2000 1/60 15/70 3.5 % 0.08 [ 0.01, 0.57 ]
Brizel 2000 52/148 60/153 16.7 % 0.90 [ 0.67, 1.20 ]
Hartmann 2001 5/20 10/20 10.0 % 0.50 [ 0.21, 1.20 ]
Antonadou 2002 5/22 18/23 10.8 % 0.29 [ 0.13, 0.65 ]
Spencer 2005 5/43 15/47 9.6 % 0.36 [ 0.14, 0.92 ]
Buentzel 2006 25/65 14/64 13.7 % 1.76 [ 1.01, 3.07 ]
Haddad 2009 22/29 20/29 16.5 % 1.10 [ 0.80, 1.51 ]
Total (95% CI) 413 432 100.0 % 0.68 [ 0.45, 1.03 ]
Total events: 126 (Amifostine), 175 (Control)
Heterogeneity: Tau2 = 0.24; Chi2 = 40.39, df = 8 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours amifostine Favours control
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Analysis 4.1. Comparison 4 Chlorhexidine versus placebo/no treatment, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 4 Chlorhexidine versus placebo/no treatment
Outcome: 1 Mucositis (any)
Study or subgroup Chlorhexidine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ferretti 1988 4/23 13/23 14.2 % 0.31 [ 0.12, 0.80 ]
Foote 1994 25/25 26/27 31.5 % 1.04 [ 0.93, 1.15 ]
Dodd 1996 26/112 28/110 24.8 % 0.91 [ 0.57, 1.45 ]
Sorensen 2008 39/70 49/64 29.5 % 0.73 [ 0.57, 0.93 ]
Total (95% CI) 230 224 100.0 % 0.76 [ 0.47, 1.24 ]
Total events: 94 (Chlorhexidine), 116 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 30.49, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chlorhexidine Favours control
Analysis 4.2. Comparison 4 Chlorhexidine versus placebo/no treatment, Outcome 2 Mucositis (moderate
plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 4 Chlorhexidine versus placebo/no treatment
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Chlorhexidine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Foote 1994 22/25 21/27 37.0 % 1.13 [ 0.88, 1.45 ]
Pitten 2003 9/24 2/23 3.7 % 4.31 [ 1.04, 17.87 ]
Sorensen 2008 20/70 31/64 59.3 % 0.59 [ 0.38, 0.92 ]
Total (95% CI) 119 114 100.0 % 0.93 [ 0.72, 1.21 ]
Total events: 51 (Chlorhexidine), 54 (Control)
Heterogeneity: Chi2 = 10.84, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 0.55 (P = 0.58)
0.01 0.1 1 10 100
Favours chlorhexidine Favours control
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Analysis 4.3. Comparison 4 Chlorhexidine versus placebo/no treatment, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 4 Chlorhexidine versus placebo/no treatment
Outcome: 3 Mucositis (severe)
Study or subgroup Chlorhexidine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wahlin 1989 8/14 9/14 22.3 % 0.89 [ 0.49, 1.62 ]
Spijkervet 1989 12/15 12/15 32.2 % 1.00 [ 0.70, 1.43 ]
Foote 1994 14/25 15/27 26.7 % 1.01 [ 0.62, 1.64 ]
Sorensen 2008 9/70 21/64 18.8 % 0.39 [ 0.19, 0.79 ]
Total (95% CI) 124 120 100.0 % 0.82 [ 0.54, 1.23 ]
Total events: 43 (Chlorhexidine), 57 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 7.44, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 0.96 (P = 0.33)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours chlorhexidine Favours control
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Analysis 5.1. Comparison 5 Cryotherapy versus no treatment, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 5 Cryotherapy versus no treatment
Outcome: 1 Mucositis (any)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Mahood 1991 -0.462 (0.26) 13.8 % 0.63 [ 0.38, 1.05 ]
Cascinu 1994 -0.4526 (0.271) 13.1 % 0.64 [ 0.37, 1.08 ]
Lilleby 2006 -0.4479 (0.174) 19.9 % 0.64 [ 0.45, 0.90 ]
Gori 2007 -0.02 (0.04) 30.3 % 0.98 [ 0.91, 1.06 ]
Sorensen 2008 -0.36 (0.14) 22.8 % 0.70 [ 0.53, 0.92 ]
Total (95% CI) 100.0 % 0.74 [ 0.57, 0.95 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 14.77, df = 4 (P = 0.01); I2 =73%
Test for overall effect: Z = 2.33 (P = 0.020)
0.1 0.2 0.5 1 2 5 10
Favours cryotherapy Favours control
Analysis 5.2. Comparison 5 Cryotherapy versus no treatment, Outcome 2 Mucositis (moderate plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 5 Cryotherapy versus no treatment
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Mahood 1991 -1.2 (0.57) 13.0 % 0.30 [ 0.10, 0.92 ]
Cascinu 1994 -0.673 (0.38) 18.6 % 0.51 [ 0.24, 1.07 ]
Lilleby 2006 -1.197 (0.408) 17.7 % 0.30 [ 0.14, 0.67 ]
Gori 2007 0.01 (0.09) 27.6 % 1.01 [ 0.85, 1.20 ]
Sorensen 2008 -0.65 (0.25) 23.1 % 0.52 [ 0.32, 0.85 ]
Total (95% CI) 100.0 % 0.53 [ 0.31, 0.91 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 19.02, df = 4 (P = 0.00078); I2 =79%
Test for overall effect: Z = 2.30 (P = 0.022)
0.01 0.1 1 10 100
Favours cryotherapy Favours control
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Analysis 5.3. Comparison 5 Cryotherapy versus no treatment, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 5 Cryotherapy versus no treatment
Outcome: 3 Mucositis (severe)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Mahood 1991 -2.04 (0.9) 11.3 % 0.13 [ 0.02, 0.76 ]
Cascinu 1994 -1.022 (0.55) 18.7 % 0.36 [ 0.12, 1.06 ]
Lilleby 2006 -1.6399 (0.552) 18.6 % 0.19 [ 0.07, 0.57 ]
Gori 2007 -0.13 (0.18) 28.8 % 0.88 [ 0.62, 1.25 ]
Sorensen 2008 -1.08 (0.41) 22.6 % 0.34 [ 0.15, 0.76 ]
Total (95% CI) 100.0 % 0.36 [ 0.17, 0.77 ]
Heterogeneity: Tau2 = 0.47; Chi2 = 14.31, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.66 (P = 0.0079)
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Analysis 6.1. Comparison 6 Glutamine versus placebo, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 6 Glutamine versus placebo
Outcome: 1 Mucositis (any)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Oral suspension/supplementation
Jebb 1994 (1) -0.201 (0.38) 12.0 % 0.82 [ 0.39, 1.72 ]
Anderson 1998 -0.478 (0.22) 20.9 % 0.62 [ 0.40, 0.95 ]
Okuno 1999 0.077 (0.12) 28.3 % 1.08 [ 0.85, 1.37 ]
Li 2006 -0.05 (0.14) 26.9 % 0.95 [ 0.72, 1.25 ]
Choi 2007 (2) -1.11 (0.38) 12.0 % 0.33 [ 0.16, 0.69 ]
Subtotal (95% CI) 100.0 % 0.78 [ 0.57, 1.08 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 12.39, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 1.51 (P = 0.13)
2 IV supplementation
Sornsuvit 2008 -1.11 (1.06) 100.0 % 0.33 [ 0.04, 2.63 ]
Subtotal (95% CI) 100.0 % 0.33 [ 0.04, 2.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.30)
0.01 0.1 1 10 100
Favours glutamine Favours placebo
(1) 15g/day
(2) control = ’best supportive care’
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Analysis 6.2. Comparison 6 Glutamine versus placebo, Outcome 2 Mucositis (moderate plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 6 Glutamine versus placebo
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Oral suspension/supplementation
Jebb 1994 (1) -0.3567 (0.2) 25.5 % 0.70 [ 0.47, 1.04 ]
Okuno 1999 -0.0202 (0.27) 16.5 % 0.98 [ 0.58, 1.66 ]
Dickson 2000 0.058 (0.2) 25.5 % 1.06 [ 0.72, 1.57 ]
Huang 2000 (2) -0.02 (0.18) 29.1 % 0.98 [ 0.69, 1.39 ]
Choi 2007 (3) -1.24 (0.66) 3.4 % 0.29 [ 0.08, 1.06 ]
Subtotal (95% CI) 100.0 % 0.88 [ 0.69, 1.12 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.52, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 1.02 (P = 0.31)
2 IV supplementation
Sornsuvit 2008 -1.11 (1.06) 100.0 % 0.33 [ 0.04, 2.63 ]
Subtotal (95% CI) 100.0 % 0.33 [ 0.04, 2.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.30)
0.01 0.1 1 10 100
Favours glutamine Favours placebo
(1) 15g/day
(2) swish % expectorate oral suspension
(3) control = ’best supportive care’
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Analysis 6.3. Comparison 6 Glutamine versus placebo, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 6 Glutamine versus placebo
Outcome: 3 Mucositis (severe)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Oral suspension/supplementation
Jebb 1994 (1) 0.2231 (0.23) 33.0 % 1.25 [ 0.80, 1.96 ]
Anderson 1998 -1.109 (0.46) 21.9 % 0.33 [ 0.13, 0.81 ]
Okuno 1999 -0.198 (0.65) 15.1 % 0.82 [ 0.23, 2.93 ]
Huang 2000 -2.12 (1.35) 5.0 % 0.12 [ 0.01, 1.69 ]
Li 2006 -0.29 (0.39) 25.0 % 0.75 [ 0.35, 1.61 ]
Subtotal (95% CI) 100.0 % 0.69 [ 0.37, 1.29 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 9.24, df = 4 (P = 0.06); I2 =57%
Test for overall effect: Z = 1.17 (P = 0.24)
2 IV supplementation
Cerchietti 2006 -1.542 (0.68) 44.7 % 0.21 [ 0.06, 0.81 ]
He 2008 -1.17 (0.67) 46.1 % 0.31 [ 0.08, 1.15 ]
Sornsuvit 2008 -1.61 (1.5) 9.2 % 0.20 [ 0.01, 3.78 ]
Subtotal (95% CI) 100.0 % 0.25 [ 0.10, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
0.01 0.1 1 10 100
Favours glutamine Favours placebo
(1) 15g/day crossover design
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Analysis 7.1. Comparison 7 G-CSF versus placebo or no treatment, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 7 G-CSF versus placebo or no treatment
Outcome: 1 Mucositis (any)
Study or subgroup G-CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Katano 1995 2/7 7/7 12.6 % 0.33 [ 0.12, 0.95 ]
Schneider 1999 8/8 6/6 30.0 % 1.00 [ 0.77, 1.30 ]
Crawford 1999 26/93 48/102 27.0 % 0.59 [ 0.40, 0.87 ]
Su 2006 17/19 18/21 30.5 % 1.04 [ 0.83, 1.32 ]
Total (95% CI) 127 136 100.0 % 0.77 [ 0.48, 1.23 ]
Total events: 53 (G-CSF), 79 (Control)
Heterogeneity: Tau2 = 0.17; Chi2 = 20.48, df = 3 (P = 0.00013); I2 =85%
Test for overall effect: Z = 1.11 (P = 0.27)
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Analysis 7.2. Comparison 7 G-CSF versus placebo or no treatment, Outcome 2 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 7 G-CSF versus placebo or no treatment
Outcome: 2 Mucositis (severe)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schneider 1999 1/8 3/6 24.7 % 0.25 [ 0.03, 1.85 ]
Su 2006 4/19 11/21 75.3 % 0.40 [ 0.15, 1.05 ]
Total (95% CI) 27 27 100.0 % 0.36 [ 0.15, 0.86 ]
Total events: 5 (Experimental), 14 (Control)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
0.01 0.1 1 10 100
Favours G-CSF Favours control
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Analysis 8.1. Comparison 8 GM-CSF versus no treatment/placebo, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 8 GM-CSF versus no treatment/placebo
Outcome: 1 Mucositis (any)
Study or subgroup GM-CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dazzi 2003 40/46 42/44 76.1 % 0.91 [ 0.80, 1.04 ]
McAleese 2006 14/15 13/14 23.9 % 1.01 [ 0.82, 1.23 ]
Total (95% CI) 61 58 100.0 % 0.93 [ 0.84, 1.04 ]
Total events: 54 (GM-CSF), 55 (Control)
Heterogeneity: Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
0.2 0.5 1 2 5
Favours GM-CSF Favours control
Analysis 8.2. Comparison 8 GM-CSF versus no treatment/placebo, Outcome 2 Mucositis (moderate plus
severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 8 GM-CSF versus no treatment/placebo
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup GM-CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nemunaitis 1995 42/53 47/56 77.3 % 0.94 [ 0.79, 1.13 ]
McAleese 2006 10/15 13/14 22.7 % 0.72 [ 0.49, 1.06 ]
Total (95% CI) 68 70 100.0 % 0.89 [ 0.76, 1.05 ]
Total events: 52 (GM-CSF), 60 (Control)
Heterogeneity: Chi2 = 1.60, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.37 (P = 0.17)
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Analysis 8.3. Comparison 8 GM-CSF versus no treatment/placebo, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 8 GM-CSF versus no treatment/placebo
Outcome: 3 Mucositis (severe)
Study or subgroup GM-CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cartee 1995 15/36 2/9 14.4 % 1.88 [ 0.52, 6.76 ]
Nemunaitis 1995 4/53 16/56 18.1 % 0.26 [ 0.09, 0.74 ]
Ifrah 1999 2/35 6/29 11.7 % 0.28 [ 0.06, 1.27 ]
van der Lelie 2001 11/18 8/18 25.3 % 1.38 [ 0.73, 2.59 ]
Dazzi 2003 15/46 17/44 26.8 % 0.84 [ 0.48, 1.47 ]
McAleese 2006 0/15 1/14 3.8 % 0.31 [ 0.01, 7.09 ]
Total (95% CI) 203 170 100.0 % 0.73 [ 0.39, 1.40 ]
Total events: 47 (GM-CSF), 50 (Control)
Heterogeneity: Tau2 = 0.32; Chi2 = 11.78, df = 5 (P = 0.04); I2 =58%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Honey versus control, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 9 Honey versus control
Outcome: 1 Mucositis (any)
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Biswal 2003 13/20 13/20 24.1 % 1.00 [ 0.63, 1.58 ]
Motallebnejad 2008 7/20 20/20 38.0 % 0.37 [ 0.21, 0.65 ]
Rashad 2008 17/20 20/20 38.0 % 0.85 [ 0.70, 1.05 ]
Total (95% CI) 60 60 100.0 % 0.70 [ 0.56, 0.88 ]
Total events: 37 (Honey), 53 (Control)
Heterogeneity: Chi2 = 10.71, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 3.10 (P = 0.0019)
0.1 0.2 0.5 1 2 5 10
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Analysis 9.2. Comparison 9 Honey versus control, Outcome 2 Mucositis (moderate plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 9 Honey versus control
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Biswal 2003 4/20 15/20 48.4 % 0.27 [ 0.11, 0.66 ]
Rashad 2008 11/20 16/20 51.6 % 0.69 [ 0.44, 1.08 ]
Total (95% CI) 40 40 100.0 % 0.48 [ 0.31, 0.74 ]
Total events: 15 (Honey), 31 (Control)
Heterogeneity: Chi2 = 3.95, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 3.31 (P = 0.00094)
0.1 0.2 0.5 1 2 5 10
Favours honey Favours control
248Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.3. Comparison 9 Honey versus control, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 9 Honey versus control
Outcome: 3 Mucositis (severe)
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Biswal 2003 4/20 15/20 55.6 % 0.27 [ 0.11, 0.66 ]
Rashad 2008 3/20 12/20 44.4 % 0.25 [ 0.08, 0.75 ]
Total (95% CI) 40 40 100.0 % 0.26 [ 0.13, 0.52 ]
Total events: 7 (Honey), 27 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.76 (P = 0.00017)
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Analysis 10.1. Comparison 10 Hydrolytic enzymes versus no treatment, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 10 Hydrolytic enzymes versus no treatment
Outcome: 1 Mucositis (any)
Study or subgroup Hydrolytic enz Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaul 1999 11/25 25/25 0.45 [ 0.29, 0.70 ]
Gujral 2001 51/53 46/46 0.96 [ 0.90, 1.03 ]
0.1 0.2 0.5 1 2 5 10
Favours hydrolytic enzyme Favours control
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Analysis 10.2. Comparison 10 Hydrolytic enzymes versus no treatment, Outcome 2 Mucositis (moderate
plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 10 Hydrolytic enzymes versus no treatment
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Hydrolytic enz Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaul 1999 2/25 8/25 0.25 [ 0.06, 1.06 ]
Gujral 2001 16/53 42/46 0.33 [ 0.22, 0.50 ]
Dorr 2007 31/31 29/30 1.03 [ 0.94, 1.13 ]
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Analysis 11.1. Comparison 11 Iseganan versus placebo, Outcome 1 Mucositis (moderate plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 11 Iseganan versus placebo
Outcome: 1 Mucositis (moderate plus severe)
Study or subgroup Iseganan Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Trotti 2004 230/253 156/171 54.1 % 1.00 [ 0.94, 1.06 ]
Giles 2004 143/251 158/251 45.9 % 0.91 [ 0.78, 1.04 ]
Total (95% CI) 504 422 100.0 % 0.95 [ 0.89, 1.03 ]
Total events: 373 (Iseganan), 314 (Control)
Heterogeneity: Chi2 = 2.46, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.26 (P = 0.21)
0.5 0.7 1 1.5 2
Favours iseganan Favours control
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Analysis 11.2. Comparison 11 Iseganan versus placebo, Outcome 2 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 11 Iseganan versus placebo
Outcome: 2 Mucositis (severe)
Study or subgroup Iseganan Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giles 2004 138/251 153/251 55.5 % 0.90 [ 0.78, 1.05 ]
Trotti 2004 167/253 103/171 44.5 % 1.10 [ 0.94, 1.27 ]
Total (95% CI) 504 422 100.0 % 0.99 [ 0.89, 1.10 ]
Total events: 305 (Iseganan), 256 (Control)
Heterogeneity: Chi2 = 3.25, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.22 (P = 0.83)
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Analysis 12.1. Comparison 12 Keratinocyte GF versus placebo, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 12 Keratinocyte GF versus placebo
Outcome: 1 Mucositis (any)
Study or subgroup KGF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blazar 2006 60/65 31/31 61.8 % 0.93 [ 0.86, 1.01 ]
Rosen 2006 15/28 30/36 38.2 % 0.64 [ 0.44, 0.93 ]
Total (95% CI) 93 67 100.0 % 0.82 [ 0.71, 0.94 ]
Total events: 75 (KGF), 61 (Control)
Heterogeneity: Chi2 = 10.11, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 2.79 (P = 0.0052)
0.2 0.5 1 2 5
Favours keratinocyte GF Favours control
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Analysis 12.2. Comparison 12 Keratinocyte GF versus placebo, Outcome 2 Mucositis (moderate plus
severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 12 Keratinocyte GF versus placebo
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup KGF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Meropol 2003 23/54 18/27 10.5 % 0.64 [ 0.42, 0.96 ]
Freytes 2004 16/28 14/14 12.8 % 0.59 [ 0.42, 0.82 ]
Spielberger 2004 98/106 106/106 21.3 % 0.92 [ 0.87, 0.98 ]
Blazar 2006 53/65 31/31 19.7 % 0.82 [ 0.73, 0.93 ]
Rosen 2006 8/28 22/36 6.0 % 0.47 [ 0.25, 0.89 ]
Brizel 2008 60/65 31/32 20.6 % 0.95 [ 0.87, 1.05 ]
Vadhan-Raj 2010 13/32 14/16 9.2 % 0.46 [ 0.29, 0.73 ]
Total (95% CI) 378 262 100.0 % 0.74 [ 0.62, 0.89 ]
Total events: 271 (KGF), 236 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 50.75, df = 6 (P<0.00001); I2 =88%
Test for overall effect: Z = 3.15 (P = 0.0016)
0.2 0.5 1 2 5
Favours keratinocyte GF Favours control
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Analysis 12.3. Comparison 12 Keratinocyte GF versus placebo, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 12 Keratinocyte GF versus placebo
Outcome: 3 Mucositis (severe)
Study or subgroup KGF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Freytes 2004 4/28 1/14 1.1 % 2.00 [ 0.25, 16.26 ]
Spielberger 2004 67/106 104/106 36.8 % 0.64 [ 0.56, 0.75 ]
Blazar 2006 43/65 24/31 27.7 % 0.85 [ 0.66, 1.11 ]
Rosen 2006 1/28 4/36 1.1 % 0.32 [ 0.04, 2.72 ]
Brizel 2008 43/65 26/32 29.1 % 0.81 [ 0.64, 1.04 ]
Vadhan-Raj 2010 4/32 8/16 4.2 % 0.25 [ 0.09, 0.71 ]
Total (95% CI) 324 235 100.0 % 0.72 [ 0.58, 0.90 ]
Total events: 162 (KGF), 167 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.37, df = 5 (P = 0.07); I2 =52%
Test for overall effect: Z = 2.86 (P = 0.0042)
0.02 0.1 1 10 50
Favours keratinocyte GF Favours control
Analysis 13.1. Comparison 13 Laser versus no treatment, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 13 Laser versus no treatment
Outcome: 1 Mucositis (any)
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cruz 2007 13/28 11/31 24.9 % 1.31 [ 0.70, 2.43 ]
Antunes 2007 16/19 19/19 46.5 % 0.85 [ 0.68, 1.05 ]
Chor 2010 8/17 12/17 28.6 % 0.67 [ 0.37, 1.20 ]
Total (95% CI) 64 67 100.0 % 0.91 [ 0.71, 1.17 ]
Total events: 37 (Laser), 42 (Control)
Heterogeneity: Chi2 = 2.83, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.73 (P = 0.47)
0.1 0.2 0.5 1 2 5 10
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Analysis 13.2. Comparison 13 Laser versus no treatment, Outcome 2 Mucositis (moderate plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 13 Laser versus no treatment
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Antunes 2007 7/19 17/19 81.7 % 0.41 [ 0.22, 0.76 ]
Cruz 2007 6/28 4/31 18.3 % 1.66 [ 0.52, 5.28 ]
Total (95% CI) 47 50 100.0 % 0.64 [ 0.38, 1.08 ]
Total events: 13 (Laser), 21 (Control)
Heterogeneity: Chi2 = 4.62, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.67 (P = 0.095)
0.01 0.1 1 10 100
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Analysis 13.3. Comparison 13 Laser versus no treatment, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 13 Laser versus no treatment
Outcome: 3 Mucositis (severe)
Study or subgroup Laser Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cruz 2007 2/28 3/31 18.0 % 0.74 [ 0.13, 4.10 ]
Antunes 2007 1/19 13/19 82.0 % 0.08 [ 0.01, 0.53 ]
Total (95% CI) 47 50 100.0 % 0.20 [ 0.06, 0.62 ]
Total events: 3 (Laser), 16 (Control)
Heterogeneity: Chi2 = 3.20, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 2.76 (P = 0.0058)
0.01 0.1 1 10 100
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Analysis 14.1. Comparison 14 Pilocarpine versus placebo, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 14 Pilocarpine versus placebo
Outcome: 1 Mucositis (any)
Study or subgroup Pilocarpine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lockhart 2005 17/18 16/16 13.3 % 0.95 [ 0.81, 1.11 ]
Scarantino 2006 119/120 114/122 86.7 % 1.06 [ 1.01, 1.12 ]
Total (95% CI) 138 138 100.0 % 1.05 [ 1.00, 1.10 ]
Total events: 136 (Pilocarpine), 130 (Control)
Heterogeneity: Chi2 = 1.83, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 1.86 (P = 0.063)
0.5 0.7 1 1.5 2
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Analysis 14.2. Comparison 14 Pilocarpine versus placebo, Outcome 2 Mucositis (moderate plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 14 Pilocarpine versus placebo
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Pilocarpine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lockhart 2005 13/18 14/16 13.1 % 0.83 [ 0.59, 1.16 ]
Scarantino 2006 105/120 99/122 86.9 % 1.08 [ 0.97, 1.20 ]
Total (95% CI) 138 138 100.0 % 1.05 [ 0.94, 1.16 ]
Total events: 118 (Pilocarpine), 113 (Control)
Heterogeneity: Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.83 (P = 0.41)
0.5 0.7 1 1.5 2
Favours pilocarpine Favours control
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Analysis 15.1. Comparison 15 Povidone versus water, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 15 Povidone versus water
Outcome: 1 Mucositis (any)
Study or subgroup Povidone Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rahn 1997 14/20 20/20 30.5 % 0.71 [ 0.53, 0.95 ]
Vokurka 2005 47/67 46/65 69.5 % 0.99 [ 0.79, 1.24 ]
Total (95% CI) 87 85 100.0 % 0.90 [ 0.76, 1.08 ]
Total events: 61 (Povidone), 66 (Control)
Heterogeneity: Chi2 = 3.35, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 1.10 (P = 0.27)
0.2 0.5 1 2 5
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Analysis 15.2. Comparison 15 Povidone versus water, Outcome 2 Mucositis (moderate plus severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 15 Povidone versus water
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Povidone Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rahn 1997 9/20 20/20 41.0 % 0.46 [ 0.29, 0.75 ]
Vokurka 2005 32/67 29/65 59.0 % 1.07 [ 0.74, 1.55 ]
Total (95% CI) 87 85 100.0 % 0.82 [ 0.62, 1.10 ]
Total events: 41 (Povidone), 49 (Control)
Heterogeneity: Chi2 = 7.55, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 15.3. Comparison 15 Povidone versus water, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 15 Povidone versus water
Outcome: 3 Mucositis (severe)
Study or subgroup Povidone Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rahn 1997 4/20 13/20 43.0 % 0.31 [ 0.12, 0.78 ]
Vokurka 2005 16/67 17/65 57.0 % 0.91 [ 0.51, 1.65 ]
Total (95% CI) 87 85 100.0 % 0.65 [ 0.40, 1.06 ]
Total events: 20 (Povidone), 30 (Control)
Heterogeneity: Chi2 = 3.73, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 1.72 (P = 0.085)
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Analysis 16.1. Comparison 16 Prostaglandin versus placebo, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 16 Prostaglandin versus placebo
Outcome: 1 Mucositis (any)
Study or subgroup Prostaglandin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Labar 1993 29/31 29/29 40.8 % 0.94 [ 0.84, 1.05 ]
Duenas 1996 8/9 2/7 3.0 % 3.11 [ 0.94, 10.27 ]
Veness 2006 41/42 41/41 56.2 % 0.98 [ 0.91, 1.04 ]
Total (95% CI) 82 77 100.0 % 1.03 [ 0.94, 1.12 ]
Total events: 78 (Prostaglandin), 72 (Control)
Heterogeneity: Chi2 = 7.87, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.58 (P = 0.57)
0.1 0.2 0.5 1 2 5 10
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Analysis 16.2. Comparison 16 Prostaglandin versus placebo, Outcome 2 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 16 Prostaglandin versus placebo
Outcome: 2 Mucositis (severe)
Study or subgroup Prostaglandin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Labar 1993 17/31 15/29 46.0 % 1.06 [ 0.66, 1.70 ]
Veness 2006 18/42 18/41 54.0 % 0.98 [ 0.60, 1.60 ]
Total (95% CI) 73 70 100.0 % 1.01 [ 0.72, 1.43 ]
Total events: 35 (Prostaglandin), 33 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
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Analysis 17.1. Comparison 17 PTA antibiotic pastille or paste versus placebo/no treatment, Outcome 1
Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 17 PTA antibiotic pastille or paste versus placebo/no treatment
Outcome: 1 Mucositis (any)
Study or subgroup PTA antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Symonds 1996 85/112 97/109 74.1 % 0.85 [ 0.75, 0.96 ]
Wijers 2001 32/39 34/38 25.9 % 0.92 [ 0.76, 1.10 ]
Total (95% CI) 151 147 100.0 % 0.87 [ 0.78, 0.96 ]
Total events: 117 (PTA antibiotic), 131 (Control)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.67 (P = 0.0077)
0.5 0.7 1 1.5 2
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Analysis 17.2. Comparison 17 PTA antibiotic pastille or paste versus placebo/no treatment, Outcome 2
Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 17 PTA antibiotic pastille or paste versus placebo/no treatment
Outcome: 2 Mucositis (severe)
Study or subgroup PTA antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wijers 2001 15/39 18/38 41.2 % 0.81 [ 0.48, 1.37 ]
Stokman 2003 22/28 27/30 58.8 % 0.87 [ 0.70, 1.10 ]
Total (95% CI) 67 68 100.0 % 0.85 [ 0.66, 1.09 ]
Total events: 37 (PTA antibiotic), 45 (Control)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
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Analysis 18.1. Comparison 18 Radiotherapy: am versus pm, Outcome 1 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 18 Radiotherapy: am versus pm
Outcome: 1 Mucositis (severe)
Study or subgroup AM PM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bjarnason 2009 63/101 55/104 82.0 % 1.18 [ 0.93, 1.49 ]
Goyal 2009 7/88 12/89 18.0 % 0.59 [ 0.24, 1.43 ]
Total (95% CI) 189 193 100.0 % 1.07 [ 0.85, 1.36 ]
Total events: 70 (AM), 67 (PM)
Heterogeneity: Chi2 = 2.37, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.59 (P = 0.56)
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Analysis 19.1. Comparison 19 Sucralfate versus placebo/usual care, Outcome 1 Mucositis (any).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 19 Sucralfate versus placebo/usual care
Outcome: 1 Mucositis (any)
Study or subgroup Sucralfate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Makkonen 1994 20/20 19/20 20.3 % 1.05 [ 0.92, 1.20 ]
Castagna 2001 43/51 45/51 46.7 % 0.96 [ 0.82, 1.12 ]
Nottage 2003 32/41 31/39 33.0 % 0.98 [ 0.78, 1.23 ]
Total (95% CI) 112 110 100.0 % 0.98 [ 0.88, 1.10 ]
Total events: 95 (Sucralfate), 95 (Control)
Heterogeneity: Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
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Analysis 19.2. Comparison 19 Sucralfate versus placebo/usual care, Outcome 2 Mucositis (moderate plus
severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 19 Sucralfate versus placebo/usual care
Outcome: 2 Mucositis (moderate plus severe)
Study or subgroup Sucralfate Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Shenep 1988 17/24 18/24 32.1 % 0.94 [ 0.67, 1.33 ]
Makkonen 1994 14/20 15/20 29.7 % 0.93 [ 0.64, 1.37 ]
Franzen 1995 7/24 15/24 15.3 % 0.47 [ 0.23, 0.94 ]
Cengiz 1999 9/18 9/10 22.8 % 0.56 [ 0.33, 0.92 ]
Total (95% CI) 86 78 100.0 % 0.75 [ 0.54, 1.04 ]
Total events: 47 (Sucralfate), 57 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.16, df = 3 (P = 0.10); I2 =51%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Not applicable
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Analysis 19.3. Comparison 19 Sucralfate versus placebo/usual care, Outcome 3 Mucositis (severe).
Review: Interventions for preventing oral mucositis for patients with cancer receiving treatment
Comparison: 19 Sucralfate versus placebo/usual care
Outcome: 3 Mucositis (severe)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Shenep 1988 -1.11 (0.6) 6.4 % 0.33 [ 0.10, 1.07 ]
Scherlacher 1990 -1.5187 (0.572) 6.9 % 0.22 [ 0.07, 0.67 ]
Pfeiffer 1990 -0.1748 (0.2) 27.3 % 0.84 [ 0.57, 1.24 ]
Cengiz 1999 -2.12 (1.48) 1.2 % 0.12 [ 0.01, 2.18 ]
Carter 1999 -0.1625 (0.22) 25.1 % 0.85 [ 0.55, 1.31 ]
Castagna 2001 -0.47 (0.263) 21.0 % 0.63 [ 0.37, 1.05 ]
Nottage 2003 -0.1555 (0.401) 12.2 % 0.86 [ 0.39, 1.88 ]
Total (95% CI) 100.0 % 0.67 [ 0.48, 0.92 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 9.13, df = 6 (P = 0.17); I2 =34%
Test for overall effect: Z = 2.50 (P = 0.013)
0.02 0.1 1 10 50
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A D D I T I O N A L T A B L E S
Table 1. Outcome categories where only one study provided data - active versus placebo/no treatment
Experimental Control RR (95%CI) P value
Mucositis
category
Events/ Mean
(SD)
Total Events/ Mean
(SD)
Total
Aciclovir ver-
sus placebo
Bubley 1989
Any 18 27 15 30 1.33 (0.85, 2.08) 0.21
Aloe vera ver-
sus placebo
Any
Puataweepong
2009
29 30 31 31 0.97 (0.88, 1.06) 0.46
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Table 1. Outcome categories where only one study provided data - active versus placebo/no treatment (Continued)
Severe
Su 2004
1 30 8 31 0.13 (0.02, 0.97) 0.05
BCoG antibi-
otic pastilles
El Sayed 2002
Any 62 69 60 68 1.02 (0.91, 1.15) 0.76
Moderate plus
severe
50 69 53 68 0.93 (0.77, 1.13) 0.46
Severe 31 69 34 68 0.90 (0.63, 1.28) 0.55
Benzydamine
versus placebo
Any
Prada 1987
12 19 16 17 0.67 (0.47, 0.97) 0.03
Severe
Kazemian
2009
17 39 33 42 0.55 (0.38, 0.82) 0.003
Beta carotene
ver-
sus no treat-
ment control
Severe
Mills 1988
3 10 8 10 0.38 (0.14, 1.02) 0.05
Camomile
versus placebo
Fidler 1996
Any 33 82 37 82 0.89 (0.62, 1.27) 0.53
Moderate plus
severe
12 82 19 82 0.63 (0.33, 1.22) 0.17
Severe 8 82 7 82 1.14 (0.43, 3.01) 0.79
Chewing
gum versus no
chewing gum
Gandemer
2007
Any 48 70 55 70 0.87 (0.71, 1.07) 0.18
Severe 36 70 31 70 1.16 (0.82, 1.64) 0.40
Clar-
ithromycin
(systemic an-
tibiotic) versus
no treatment
Yuen 2001
Moderate plus
severe
18 35 26 35 0.69 (0.48, 1.01) 0.06
Den-
tal stent ver-
sus no treat-
ment control
Moderate plus
severe
14 19 21 24 0.84 (0.62, 1.15) 0.27
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Table 1. Outcome categories where only one study provided data - active versus placebo/no treatment (Continued)
Qin 2007
Severe 5 19 9 24 0.70 (0.28, 1.75) 0.45
Epidermal
growth factor
versus placebo
Wu 2009
Moderate plus
severe
32 76 17 27 0.67 (0.45, 0.99) 0.04
G-CSF versus
placebo Su
2006
Moderate plus
severe
11 19 15 21 0.81 (0.51, 1.30) 0.38
Histamine gel
versus placebo
Elad 2006
Any 17 20 12 19 1.35 (0.91, 1.99) 0.14
Severe 2 20 2 19 0.95 (0.15, 6.08) 0.96
Hydrolytic
enzymes (pa-
pain, trypsin,
chy-
motrypsin,
pancreatin,
brome-
lain) versus no
treatment
Kaul 1999
Severe 0 25 2 25 0.20 (0.01, 3.97) 0.29
Indomethacin
versus placebo
Pillsbury 1986
Moderate plus
severe
10 10 8 8 1.00 (0.82, 1.23) 1.00
Indigo
wood root ver-
sus saline
(placebo) You
2009
Moderate to
severe
8 11 9 9 0.75 (0.50, 1.10) 0.14
Severe 1 11 6 9 0.14 (0.02, 0.93) 0.04
Intestinal tre-
foil factor ver-
sus placebo
Peterson 2009
Any 23 66 22 33 0.52 (0.35, 0.79) 0.002
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Table 1. Outcome categories where only one study provided data - active versus placebo/no treatment (Continued)
Moderate plus
severe
7 66 16 33 0.22 (0.10, 0.48) 0.0001
Severe 1 66 0 33 1.52 (0.06, 36.39) 0.80
Oral care pro-
tocol versus
none
Any
Shieh 1997
12 20 10 10 0.62 (0.43, 0.91) 0.01
Moderate plus
se-
vere Borowski
1994
64 75 70 75 0.91 (0.82, 1.02) 0.12
Severe
Borowski
1994
49 75 58 75 0.84 (0.69, 1.04) 0.11
Pentox-
ifylline versus
no treatment
Attal 1993
Moderate plus
severe
30 70 30 70 1.00 (0.68, 1.47) 1.00
Pilocarpine
versus placebo
Lockhart
2005
Severe 12 18 12 16 0.89 (0.58, 1.37) 0.59
Prednisone
versus placebo
Leborgne
1997
Any 28 32 29 34 1.03 (0.85, 1.24) 0.79
Moderate plus
severe
16 32 24 34 0.71 (0.47, 1.07) 0.10
Severe 3 32 5 34 0.64 (0.17, 2.45) 0.51
Prostaglandin
versus placebo
(Veness 2006)
Moderate plus
severe
36 42 37 41 0.95 (0.81, 1.11) 0.53
Propantheline
versus placebo
Ahmed 1993
Any 2 6 5 6 0.40 (0.12, 1.31) 0.13
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Table 1. Outcome categories where only one study provided data - active versus placebo/no treatment (Continued)
PTA an-
tibiotic paste (
Wijers 2001)
Moderate plus
severe
26 39 28 38 0.90 (0.68, 1.21) 0.5
Shenqi-
fanghou ver-
sus no
treatment Hu
2005
Any 60 70 67 70 0.90 (0.80, 1.00) 0.04
Moderate plus
severe
30 70 59 70 0.51 (0.38, 0.68) 0.00001
Severe 10 70 50 70 0.20 (0.11, 0.36) 0.00001
Superoxide
dismutase ver-
sus placebo Tu
1998
Any 59 119 17 40 1.17 (0.78, 1.75) 0.45
Sucralfate
mouth-
wash plus gel
on skin
versus placebo
mouthwash
plus gel on
skin (Evensen
2001)
Any 30 30 28 30 1.07 (0.96, 1.20) 0.24
Moderate plus
severe
29 30 24 30 1.21 (1.00, 1.46) 0.05
Severe 26 30 23 30 1.13 (0.89, 1.44) 0.32
Traumeel ver-
sus placebo
Oberbaum
2001
Any 10 15 14 15 0.71 (0.49, 1.05) 0.08
Zinc sulphate
versus placebo
Ertekin 2004
Any 13 15 12 12 0.88 (0.69, 1.11) 0.28
Moderate plus
severe
5 15 12 12 0.36 (0.18, 0.71) 0.003
Severe 0 15 8 12 0.05 (0.00, 0.75) 0.03
CI = confidence interval; RR = risk ratio; SD = standard deviation.
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Table 2. Text only inclusions
Intervention Study Text
Amifostine versus no treatment Vacha 2003 CTC mucositis index used. Results presented as weekly means for
both arms with standard deviations. Text indicated statistically sig-
nificant difference in favour of amifostine at 2 weeks but does not
mention overall result
Benzydamine versus placebo Epstein 1989 Signs of mucositis were recorded by area of involvement, severity of
inflammation, severity of ulceration andmaximum size of ulceration
for each region of the oral cavity. Results in Table 3 indicate bor-
derline statistically significant differences in favour of benzydamine.
Maximum size of ulcerations (P = 0.04); total area of ulcerations (P
= 0.05); average area of mucositis (P = 0.050)
Benzydamine versus placebo Epstein 2001 Area under the curve of mean mucositis cores presented for different
radiotherapy intervals. Overall there was a statistically significant
difference in favour of benzydamine (P = 0.006), Table 4
Chlorhexidine versus placebo McGaw 1985 Hickey (0-3 scale) index for mucositis used over 4-week period.
During the third and fourth weeks the average mucositis scores were
significantly higher in the control group
Chlorhexidine versus povidone-iodine,
salt/soda versus water
Madan 2008 After 4 weeks there was a statistically significant decrease in mean
mucositis scores in each of the active treatment groups compared to
placebo
Cryotherapy versus no treatment control Svanberg 2007 “The results demonstrated that oral cryotherapy alleviated the devel-
opment of mucositis and oral pain, which resulted in a reduction in
the number of days of iv opioids for patients treated with autologous
BMT.”
GM-CSF versus no treatment control Chi 1995 Cross-over study showing period effect but indicating GM-CSF sig-
nificantly prevents mucositis (P < 0.001)
Laser versus placebo light treatment Bensadoun 1999 Parallel group study mucositis measured on 0-4 scale. Mean calcu-
lated for each patient over 7 weeks. Quote “the mean grade of mu-
cositis during radiotherapy was 2.1 +/ 0.26 for the group without
laser and 1.7 +/- 0.26 for the group with laser (P = 0.01).”
Laser versus sham laser treatment Schubert 2007 OMI appropriate index (Schubert 1992).
Quote: “Figure 1 shows the mean OMI over time by treatment
group. The placebo patient scores are higher on average than the
laser patient scores at nearly every time point, signifying more severe
mucositis over the course of the study..” The authors then present
day 11 data and statistical test for that day (P = 0.06)
“The peak severity of mucositis that generally occurs during the
second week of transplant was reduced in the 650 nm laser group.”
The results of the overall burden over time in Table 2 showed the
266Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Text only inclusions (Continued)
differences in the unadjusted model to be non-significant. Only one
difference comparing low-level laser with placebo was significant in
the adjusted model (P = 0.03)
Prostaglandin versus placebo Hanson 1995 Data from2centres reported separately.Overall ANOVA for 1 centre
showed no significant difference. The other centre found statistically
significant differences for weeks 4 and 5 with less mucositis in the
intervention group (P < 0.05)
Sucralfate versus placebo Epstein 1994 Signs of mucositis were recorded by area of involvement, severity of
inflammation, severity of ulceration andmaximum size of ulceration
for each regionof the oral cavity.No statistically significant difference
was seen in mucositis ulceration or the composite mucositis score
(Table 3).
Total mucositis score:
Placebo (n = 17) mean = 18.7 +/- 21.3
Sucralfate (n = 16) mean = 22.3 +/- 31.2
Total mucosal ulceration:
Placebo (n = 17) mean = 15.3 +/- 17.6
Sucralfate (n = 16) mean = 19.4 +/- 19.8.
Sucralfate versus placebo Lievens 1998 Mucositis scores on 0-6 ECOG scale. Graph (fig 1) displays mean
mucositis scores for each week 1-7. Quote: “Comparing the time
course of the mean scores for . . .mucositis . . . no statistically signif-
icant differences between the two treatment arms were observed.”
Quote: “At 5 week when the mucosal reaction tends to be most
severe a clear but not statistically significant advantage is seen for
sucralfate as opposed to placebo.”
Zinc versus placebo Lin 2006 RTOG mucositis index used. Results presented as graphs. Quote:
“This study no significant difference was found in the improvement
of radiation mucositis and dermatitis during the 2 weeks between
the patients with zinc supplement and those without.”
ANOVA = analysis of variance; BMT = bone marrow transplant; CTC = Common Toxicity Criteria; ECOG = Eastern Cooperative
Oncology Group; GM-CSF = granulocyte/macrophage colony-stimulating factor; OMI = oral mucositis index; RTOG = Radiation
Therapy Oncology Group.
Table 3. Outcome categories where only one study provided data - two active interventions
Experimental RR (95%CI) RR (95%CI) P value
Mucositis
category
Events/ Mean
(SD)
Total Events/ Mean
(SD)
Total
Chinese
herbs (coastal
glenhnia,
Moderate 23 52 47 49 0.46 (0.34, 0.63) 0.00001
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Table 3. Outcome categories where only one study provided data - two active interventions (Continued)
dwarf lilyturf
tuber root,
rehmannia
dried root,
figwort root,
spreading
hedyotis herb,
belamcaude
rhizome,
platycodom
root, shinyleaf
pricklyoash
root, honey-
suckle flower,
licorice root,
lalang grass
rhizome)
versus Do-
bell’s solution
Huang 2003 Severe 5 52 30 49 0.16 (0.07, 0.37) 0.0001
Chinese herbs
(cork-
tree bark, Chi-
nese gall, Eu-
ropean vebena
herb, cat-
echu, weeping
forsythia fruit
and burneol)
versus Do-
bell’s solution
Wang 2002
Any 8 76 17 71 0.44 (0.20, 0.95) 0.04
Moderate plus
severe
4 76 14 71 0.27 (0.09, 0.77) 0.01
Severe 0 76 5 71 0.09 (0.00, 1.51) 0.09
Chlorhexi-
dine ver-
sus cryother-
apy Sorensen
2008
Any 39 70 34 63 1.03 (0.76, 1.41) 0.84
Moderate plus
severe
20 70 16 63 1.13 (0.64, 1.97) 0.68
Severe 9 70 7 63 1.16 (0.46, 2.92) 0.76
Cryother-
apy 30 versus
60 minutes
Rocke 1993
Any 33 89 37 89 0.89 (0.62, 1.29) 0.54
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Table 3. Outcome categories where only one study provided data - two active interventions (Continued)
Moderate plus
severe
13 89 19 89 0.68 (0.36, 1.30) 0.25
Severe 6 89 10 89 0.60 (0.23, 1.58) 0.30
GM-CSF ver-
sus sucralfate
Saarilahti
2002
Moderate plus
severe
19 21 18 19 0.96 (0.80, 1.14) 0.61
Severe 6 21 10 19 0.54 (0.24, 1.21) 0.13
Keratinocyte
50 versus 25
mg Freytes
2004
Moderate plus
severe
7 14 9 14 0.78 (0.40, 1.49) 0.45
Severe 1 14 3 14 0.33 (0.04, 2.83) 0.31
Laser ver-
sus povidone
Arun Maiya
2006
Moderate plus
severe
7 25 25 25 0.29 ( 0.16, 0.54) < 0.0001
Severe 0 25 25 25 0.02 (0.00, 0.31) 0.005
Polaprez-
inc versus azu-
lene oral rinse
Watanabe
2010
Any 13 16 15 15 0.82 (0.63, 1.06) 0.13
Moderate plus
severe
6 16 13 15 0.43 (0.22, 0.84) 0.01
Severe 1 16 10 15 0.09 (0.01, 0.65) 0.02
Radio-
therapy morn-
ing versus af-
ternoon Goyal
2009
Moderate plus
severe
29 88 42 89 0.70 (0.48, 1.01) 0.06
Yangyin humo
decoctal-
ion versus ’tra-
ditional West-
ern medicine’
(lidocaine (iv),
dexam-
ethasone, gen-
tamycin, vita-
Moderate 11 21 17 21 0.65 (0.41, 1.02) 0.06
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Table 3. Outcome categories where only one study provided data - two active interventions (Continued)
min B12, bi-
carbonate)
Dai 2009
Severe 4 21 7 21 0.57 (0.20, 1.66) 0.30
CI = confidence interval; RR = risk ratio; SD = standard deviation.
A P P E N D I C E S
Appendix 1. Cochrane Oral Health Group Trials Register search strategy
((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR “histiocytosis malignant” OR retic-
uloendotheliosis OR “sarcoma mast cell” OR “Letterer Siwe disease” OR “immunoproliferative small intestine disease” OR “Hodgkin
disease” OR “histiocytosis malignant” OR “bone marrow transplant*” OR cancer* Or tumor* OR tumour* OR malignan* OR neu-
tropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemo*) AND (stomatitis
OR “Stevens Johnson syndrome” OR “candidiasis oral” OR mucositis OR (oral AND (cand* OR mucos* OR fung*)) OR mycosis
OR mycotic OR thrush))
Appendix 2. CENTRAL search strategy
1. Exp NEOPLASMS
2. Exp LEUKEMIA
3. Exp LYMPHOMA
4. Exp RADIOTHERAPY
5. Exp BONE MARROW TRANSPLANTATION
6. neoplasm* or cancer* or carcino* or malignan*
7. leukemi* or leukaemia*
8. tumour* or tumor*
9. neutropeni*
10. adenocarcinoma*
11. lymphoma*
12. (radioth* or radiat* or irradiat* or radiochemo*)
13. (bone next marrow next transplant*)
14. chemo* or radiochemo*
15. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14)
16. Exp STOMATITIS
17. MUCOSITIS
18. CANDIDIASIS ORAL
19. stomatitis
20. (stevens next johnson next syndrome)
21. mucositis
22. oral near cand*
23. mouth near cand*
24. oral and fung*
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25. mouth and fung*
26. (mycosis or mycotic or thrush)
27. #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
28. #15 AND #27
Appendix 3. MEDLINE via OVID search strategy
1. exp NEOPLASMS/
2. exp LEUKEMIA/
3. exp LYMPHOMA/
4. exp RADIOTHERAPY/
5. Bone Marrow Transplantation/
6. neoplasm$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
7. cancer$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
8. (leukaemi$ or leukemi$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug
manufacturer name, device trade name]
9. (tumour$ or tumor$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manu-
facturer name, device trade name]
10. malignan$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drugmanufacturer name,
device trade name]
11. neutropeni$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name, device trade name]
12. carcino$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
13. adenocarcinoma$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drugmanufacturer
name, device trade name]
14. lymphoma$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name, device trade name]
15. (radioth$ or radiat$ or irradiat$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer,
drug manufacturer name, device trade name]
16. (bone adj marrow adj5 transplant$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer,
drug manufacturer name, device trade name]
17. chemo$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
18. or/1-17
19. exp STOMATITIS/
20. Candidiasis, Oral/
21. stomatitis.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
22. mucositis.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
23. (oral and cand$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name, device trade name]
24. (oral adj6mucos$).mp. [mp=title, abstract, subject headings, drug trade name, original title, devicemanufacturer, drugmanufacturer
name, device trade name]
25. (oral and fung$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name, device trade name]
26. (mycosis or mycotic).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manu-
facturer name, device trade name]
27. or/19-26
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28. 18 and 27
Search filter for MEDLINE via OVID
Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity maximising version
(September 2009 revision) as referenced in Chapter 6 and detailed in box 6.4.c of the Cochrane Handbook for Systematic Reviews of
Interventions version 5.0.2 (updated September 2008):
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. animals.sh. not (humans.sh. and animals.sh.)
11. 9 not 10
Appendix 4. EMBASE via OVID search strategy
1. exp NEOPLASM/
2. exp LEUKEMIA/
3. exp LYMPHOMA/
4. exp RADIOTHERAPY/
5. exp bone marrow transplantation/
6. (neoplasm$or cancer$ or leukemi$or leukaemi$ or tumour$ or tumor$ ormalignan$ or neutropeni$ or carcino$ or adenocarcinoma$
or lymphoma$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name]
7. (radioth$ or radiat$ or irradiat$ or radiochemo$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device
manufacturer, drug manufacturer name]
8. (bone marrow adj3 transplant$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug
manufacturer name]
9. chemo$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]
10. or/1-9
11. exp Stomatitis/
12. Thrush/
13. (stomatitis or mucositis or (oral and candid$) or (oral adj4 mucositis) or (oral and fung$) or mycosis or mycotic or thrush).mp.
[mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]
14. or/11-13
15. 10 and 14
Filter for EMBASE via OVID
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
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9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/
16. HUMAN/
17. 16 and 15
18. 15 not 17
19. 14 not 18
Appendix 5. CANCERLIT (PubMed Cancer Subset) search strategy
((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR “histiocytosis malignant” OR retic-
uloendotheliosis OR “sarcoma mast cell” OR “Letterer Siwe disease” OR “immunoproliferative small intestine disease” OR “Hodgkin
disease” OR “histiocytosis malignant” OR “bone marrow transplant*” OR cancer* Or tumor* OR tumour* OR malignan* OR neu-
tropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemotherap*) AND (stom-
atitis OR “Stevens Johnson syndrome” OR “candidiasis oral” OR mucositis OR (oral AND (candid* OR mucos* OR fung*)) OR
mycosis OR mycotic OR thrush))
AND
(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh]
OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw]
OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw] )) OR (placebos [mh] OR placebo*
[tw] OR random* [tw] OR research design [mh:noexp]) NOT (animals [mh] NOT human [mh]))
Appendix 6. SIGLE search strategy
((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR histiocytosis malignant OR reticu-
loendotheliosis OR sarcoma mast cell OR Letterer Siwe disease OR immunoproliferative small intestine disease OR Hodgkin disease
OR histiocytosis malignant OR bone marrow transplant* OR cancer* Or tumor* OR tumour* OR malignan* OR neutropeni* OR
carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemo*)
AND
(stomatitis OR Stevens Johnson syndrome OR candidiasis oral OR mucositis OR (oral AND (cand* OR mucos* OR fung*)) OR
mycosis OR mycotic OR thrush)
Not updated after 2005
Appendix 7. LILACS search strategy
(www.bireme.org)
((Pt randomized controlled trial OR Pt controlled clinical trial ORMh randomized controlled trials ORMh random allocation ORMh
double-blind method ORMh single-blind method) ANDNOT (Ct animals AND NOT (Ct human and Ct animal)) OR (Pt clinical
trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$))
OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR
Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) ORMh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR
Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animals AND NOT (Ct human
and Ct animals)) OR (Ct comparative study OR Ex E05.337$ ORMh follow-up studies ORMh prospective studies OR Tw control$
OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animals AND NOT (Ct human and Ct animals)))
AND
Mh NEOPLASMS OR Tw neoplasm$ OR Tw cancer$ OR Tw carcinoma$ OR Tw tumour$ OR Tw tumor$ OR Tw malignan$
OR Tw carcino$ OR Tw nuetropeni$ OR Tw adenocarcinoma$ OR Mh leukemia OR Tw leukaemia$ OR Tw leukemi$ OR Tw
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lymphoma$ OR Tw “bone marrow transplantation” OR Tw “bone marrow transplant$” OR Tw radiotherapy OR Tw radioth$ OR
Tw radiat$ OR Tw irradiat$ OR Tw radiochemo$ OR Tw chemo$
AND
Mh stomatitis OR Tw stomatitis OR Mh Candidiasis-Oral OR Tw “oral candidiasis” OR (Tw candida$ AND (Tw mouth OR Tw
oral)) OR Tw mucositis OR ((Tw oral OR mouth) AND Tw fung$) OR (Tw oral AND Tw candidiasis$)
Appendix 8. CINAHL via EBSCO search strategy
S1 (MH “Neoplasms+”)
S2 (MH “Leukemia+”)
S3 (MH “Lymphoma+”)
S4 (MH “Radiotherapy+”)
S5 (MH “Bone Marrow Transplantation”)
S6 neoplasm*
S7 cancer*
S8 (leukemi* or leukaemi*)
S9 (tumour* or tumor*)
S10 malignan*
S11 neutropeni*
S12 carcino*
S13 adenocarcinoma*
S14 lymphoma*
S15 (radioth* or radiat* or irradiat*)
S16 (bone N1 marrow N5 transplant*)
S17 chemo*
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17
S19 MH “Stomatitis+”
S20 MH “Candidiasis, Oral”
S21 stomatitis
S22 mucositis
S23 (oral and cand*)
S24 (oral N6 mucos*)
S25 (oral and fung*)
S26 (mycosis or mycotic)
S27 S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26
S28 S18 AND S27
Filter for CINAHL search
S1 MH Random Assignment or MH Single-blind Studies or MHDouble-blind Studies or MHTriple-blind Studies or MHCrossover
design or MH Factorial Design
S2 TI (“multicentre study” or “multicenter study” or “multi-centre study” or “multi-center study”) or AB (“multicentre study” or
“multicenter study” or “multi-centre study” or “multi-center study”) or SU (“multicentre study” or “multicenter study” or “multi-
centre study” or “multi-center study”)
S3 TI random* or AB random*
S4 AB “latin square” or TI “latin square”
S5 TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)
S6 MH Placebos
S7 AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)
S8 TI blind* or AB mask* or AB blind* or TI mask*
S9 S7 and S8
S10 TI Placebo* or AB Placebo* or SU Placebo*
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S11 MH Clinical Trials
S12 TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)
S13 S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12
WH A T ’ S N E W
Last assessed as up-to-date: 7 March 2011.
Date Event Description
8 March 2011 New citation required and conclusions have changed Results and conclusions changed and five summary of find-
ings tables added
8 March 2011 New search has been performed Updated search.
H I S T O R Y
Protocol first published: Issue 1, 1998
Review first published: Issue 1, 2000
Date Event Description
10 November 2010 New search has been performed 42 new studies and 14 new interventions added. Risk
of bias assessments incorporated
10 November 2010 New citation required and conclusions have changed Nine interventions found to be beneficial for the pre-
vention of mucositis. Conclusions changed
16 June 2008 Amended Converted to new review format.
21 August 2007 New citation required and conclusions have changed Substantive amendment. This substantial update with
a search only 14months after the previous one includes
18 new included studies, bringing the total of number
of studies up to 89. There are four new interventions
included, bringing the total number of interventions
to 33
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C O N T R I B U T I O N S O F A U T H O R S
Helen Worthington (HW) and Jan Clarkson (JC) wrote the protocol and 2000, 2003, 2006 and 2007 updates of the review.
The 2010 update was co-ordinated byGemmaBryan (GB) andHW.GB,HW, JC independently and in duplicate assessed the eligibility
of the trials. GB, HW, JC, Susan Furness (SF), Anne-Marie Glenny (A-MG), and Anne Littlewood (AL) independently and in duplicate
extracted the information to complete the characteristics of included studies, and assessed the risk of bias of the trials. Data extraction
was done by HW, GB, JC and AL and HW conducted the statistical analysis. GB, HW, JC, SF, A-MG, AL, Martin McCabe (MMcC)
wrote the review. MMcC, StefanMeyer (SM) and Tasneem Khalid (TK) provided a clinical perspective on the cancer, cancer treatments
and interventions for preventing mucositis.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• The University of Manchester, UK.
• Chief Scientists Office, Scottish Executive, UK.
• NHS Education for Scotland, UK.
• University of Dundee, UK.
• Manchester Academic Health Sciences Centre (MAHSC) and NIHR Manchester Biomedical Research Centre, UK.
External sources
• NIDCR grant ref 1 DE016950-01, USA.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Clarification of the reason for exclusion of trials which report only multicomponent oral health indices.
N O T E S
The title of the protocol was originally ’Oral care for patients with cancer treated with chemotherapy (excluding head and neck cancer).’
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Antineoplastic Agents [∗adverse effects]; Candidiasis, Oral [etiology; ∗prevention & control]; Neoplasms [∗therapy]; Oral Ulcer [eti-
ology; ∗prevention & control]; Randomized Controlled Trials as Topic; Stomatitis [etiology; ∗prevention & control]
MeSH check words
Humans
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